Dynavax

DYNAVAX
2019 PROXY STATEMENT
& 2018 ANNUAL REPORT

DYNAVAX TECHNOLOGIES CORPORATION

2929 Seventh Street, Suite 100
Berkeley, California 94710

NOTICE OF 2019 ANNUAL MEETING OF STOCKHOLDERS

May 30, 2019

Dear Stockholder:

You are cordially invited to attend the 2019 Annual Meeting of Stockholders of Dynavax Technologies
Corporation, a Delaware corporation, or the Company. The meeting will be held on May 30, 2019, at 9:00 a.m.
Pacific Time, at the Company’s executive offices at 2929 Seventh Street, Suite 100, Berkeley, California 94710 for
the following purposes:

1.

2.

3.

4.

To elect our nominees for Class I directors to hold office until the 2022 Annual Meeting of Stockholders
or until their respective successors are duly elected and qualified.

To approve an amendment and restatement of the Dynavax Technologies Corporation 2018 Equity
Incentive Plan to, among other things, increase the aggregate number of shares of common stock
authorized for issuance under the plan by 2,300,000.

To approve, on an advisory basis, the compensation of the Company’s named executive officers, as
disclosed in the Proxy Statement accompanying this Notice.

To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the
Company for its fiscal year ending December 31, 2019.

5.

To conduct any other business properly brought before the meeting or any adjournment(s) thereof.

These items of business are more fully described in the Proxy Statement accompanying this Notice.

The record date for the 2019 Annual Meeting is April 9, 2019. Only stockholders of record at the close of

business on that date may vote at the meeting or any adjournment thereof.

Important Notice Regarding the Availability of Proxy Materials for the Stockholders’ Meeting to Be Held at
9:00 a.m., Pacific Time, on May 30, 2019 at 2929 Seventh Street, Suite 100, Berkeley, California 94710.

The proxy statement and annual report to stockholders
are available at http://investors.dynavax.com/annuals-proxies.cfm.

The Board of Directors recommends that you vote FOR the proposals identified above.

By Order of the Board of Directors

/s/ Steven N. Gersten
Steven N. Gersten
Secretary

Berkeley, California
April 22, 2019

Your vote is very important, regardless of the number of shares you own. Whether or not you
expect to attend the meeting, please complete, date, sign and return the enclosed proxy as promptly as
possible in order to ensure your representation at the meeting. A return envelope (which is postage
prepaid if mailed in the United States) is enclosed for your convenience. Even if you have voted by proxy,
you may still vote in person if you attend the meeting. Please note, however, that if your shares are held
of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a
proxy issued in your name from that record holder.

DYNAVAX TECHNOLOGIES CORPORATION
2929 Seventh Street, Suite 100
Berkeley, California 94710

PROXY STATEMENT
FOR THE 2019 ANNUAL MEETING OF STOCKHOLDERS

May 30, 2019

QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING

Why am I receiving these materials?

We have sent you this proxy statement and the enclosed proxy card because the Board of Directors, or Board,
of Dynavax Technologies Corporation, or the Company or Dynavax, or we or us, is soliciting your proxy to vote at
the 2019 Annual Meeting of Stockholders, or Annual Meeting. You are invited to attend the Annual Meeting to vote
on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting to vote
your shares. Instead, you may simply complete, sign and return the enclosed proxy card.

We intend to mail this proxy statement and accompanying proxy card on or about April 25, 2019, to all

stockholders of record entitled to vote at the Annual Meeting.

How do I attend the Annual Meeting?

The Annual Meeting will be held on May 30, 2019 at 9:00 a.m. Pacific Time, at our executive offices at 2929

Seventh Street, Suite 100, Berkeley, California 94710. Directions to the Annual Meeting may be found at
http://www.dynavax.com/contact. Information on how to vote in person at the Annual Meeting is discussed below.
For admission to the Annual Meeting, stockholders may be asked to present proof of identification and a statement
from their bank, broker or other nominee reflecting their beneficial ownership of our common stock as of April 9,
2019, as well as a proxy from the record holder to the stockholder.

Who can vote at the Annual Meeting?

Only stockholders of record at the close of business on April 9, 2019, will be entitled to vote at the Annual

Meeting. On this record date, there were 65,063,889 shares of common stock outstanding and entitled to vote.

Stockholder of Record: Shares Registered in Your Name

If on April 9, 2019, your shares were registered directly in your name with our transfer agent, then you are a

stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy.
Whether or not you plan to attend the Annual Meeting, we urge you to fill out and return the enclosed proxy card to
ensure your vote is counted.

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If on April 9, 2019, your shares were held, not in your name, but rather in an account at a brokerage firm, bank,

dealer or other similar organization, then you are the beneficial owner of shares held in “street name” and these
proxy materials are being forwarded to you by that organization. The organization holding your account is
considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you
have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also
invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your
shares in person at the Annual Meeting unless you request and obtain a valid proxy from your broker or other agent.

1

What am I voting on?

We are asking you to vote on four proposals:

1.

2.

3.

4.

To elect our nominees for Class I directors to hold office until the 2022 Annual Meeting of Stockholders or
until their respective successors are duly elected and qualified.

To approve an amendment and restatement of the Dynavax Technologies Corporation 2018 Equity Incentive
Plan (the “2018 EIP”) to, among other things, increase the aggregate number of shares of common stock
authorized for issuance under the plan by 2,300,000.

To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed
in this proxy statement.

To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the
Company for its fiscal year ending December 31, 2019.

What is the Board’s recommendation?

The Board recommends that you vote “For” each of the four proposals.

What if another matter is properly brought before the Annual Meeting?

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any

other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the
accompanying proxy to vote on those matters in accordance with her or his best judgment.

How do I vote?

You may either vote “For” all the nominees to the Board or you may “Withhold” your vote for any nominee

you specify. For each of the other matters to be voted on, you may vote “For” or “Against” or abstain from voting.
The procedures for voting are fairly simple:

Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy using the
enclosed proxy card. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure
your vote is counted. You may still attend the Annual Meeting and vote in person even if you have already voted by
proxy.

• To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive. Directions

to the Annual Meeting may be found at http://www.dynavax.com/contact.

• To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it

promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting,
we will vote your shares as you direct.

• To vote using the telephone, simply follow the instructions on the enclosed proxy card. Voting by

telephone has the same effect as voting by mail. You may vote by telephone until 11:59 p.m., Eastern
Time, May 29, 2019.

• To vote using the internet, simply follow the instructions on the enclosed proxy card. You may vote by

using the internet until 11:59 p.m., Eastern Time, May 29, 2019.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should

have received a proxy card and voting instructions with these proxy materials from that organization rather than

2

from Dynavax. Simply complete and mail the proxy card to ensure that your vote is counted. To vote in person at
the Annual Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions
from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other
agent to request a proxy form.

We provide internet proxy voting to allow you to vote your shares online, with procedures designed
to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that
you must bear any costs associated with your internet access, such as usage charges from internet access
providers and telephone companies.

How many votes do I have?

On each matter to be voted upon, you have one vote for each share of common stock you own as of April 9,

2019.

What happens if I do not vote?

Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record and do not vote by completing your proxy card, by telephone, through the

internet or in person at the Annual Meeting, your shares will not be voted.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If you are a beneficial owner and do not instruct your broker, bank, or other agent how to vote your shares, the
question of whether your broker or nominee will still be able to vote your shares depends on whether the applicable
stock exchange deems the particular proposal to be a “routine” matter. Brokers and nominees can use their
discretion to vote “uninstructed” shares with respect to matters that are considered to be “routine,” but not with
respect to “non-routine” matters. Under the rules and interpretations of the NYSE, “non-routine” matters are matters
that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals,
elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on
executive compensation and on the frequency of stockholder votes on executive compensation), and certain
corporate governance proposals, even if management-supported. Accordingly, your broker or nominee may not vote
your shares on Proposals 1, 2, or 3 without your instructions, but may vote your shares on Proposal 4.

What if I return a proxy card but do not make specific choices?

If you return a signed and dated proxy card without marking any voting selections, your shares will be voted:

1.

2.

3.

4.

Proposal 1: “For” election of our nominees for Class I directors.

Proposal 2: “For” approval of the amendment and restatement of the 2018 EIP to, among other things,
increase the aggregate number of shares of common stock authorized for issuance under the plan by
2,300,000;

Proposal 3: “For” advisory approval of executive compensation; and

Proposal 4: “For” ratification of the selection of Ernst & Young LLP as the independent registered public
accounting firm of the Company for its fiscal year ending December 31, 2019.

If any other matter is properly presented at the Annual Meeting, your proxyholder (one of the individuals

named on your proxy card) will vote your shares using his or her best judgment.

3

Who is paying for this proxy solicitation?

We will pay for the entire cost of soliciting proxies. In addition to mailing these proxy materials, our directors
and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and
employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage
firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.

What does it mean if I receive more than one proxy card?

If you receive more than one proxy card, your shares are registered in more than one name or are registered in

different accounts. Please complete, sign and return each proxy card to ensure that all of your shares are voted.

Can I change my vote after submitting my proxy?

Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record

holder of your shares, you may revoke your proxy in any one of three ways:

• You may submit another properly completed proxy card with a later date.

• You may send a timely written notice that you are revoking your proxy to Dynavax Technologies

Corporation, Attention: Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710.

• You may attend the Annual Meeting and vote in person. Simply attending the Annual Meeting will not, by

itself, revoke your proxy.

Your proxy card with the most recent date is the one that will be counted.

If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions

provided by your broker or bank.

When are stockholder proposals due for next year’s Annual Meeting?

To be considered for inclusion in next year’s proxy materials, your proposal must be submitted in writing by
December 24, 2019 to Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh Street,
Suite 100, Berkeley, California 94710, if mailed prior to June 1, 2019, or to 5959 Horton Street, Suite 700,
Emeryville, California 94608, if mailed on or after June 1, 2019. However, if our 2020 Annual Meeting of
Stockholders is not held between April 30, 2020, and June 29, 2020, then the deadline will be a reasonable time
before we begin to print and send our proxy materials. If you wish to submit a proposal (including a director
nomination) that is not to be included in next year’s proxy materials or nominate a director, you must do so no later
than the close of business on March 1, 2020, and no earlier than the close of business on January 31, 2020.
However, if our 2020 Annual Meeting of Stockholders is not held between April 30, 2020, and June 29, 2020, then
you must submit your proposal (or director nomination) not earlier than the close of business on the 120th day prior
to such annual meeting and not later than the close of business on the 90th day prior to such annual meeting or the
10th day following the day on which public announcement of the date of such meeting is first made.

How many votes are needed to approve each proposal?

•

Proposal 1, to elect our nominees for Class I directors, the three nominees receiving the most “For” votes
from the holders of shares present (either in person or represented by proxy) and cast for the election of
directors will be elected. Only votes “For” will affect the outcome of the vote; “Withhold” votes will have
no effect on the outcome of the vote. However, if a nominee receives a greater number of “Withhold”
votes than “For” votes, such nominee will submit his or her offer of resignation for consideration by our
Nominating and Corporate Governance Committee in accordance with our Majority Vote Policy discussed
in more detail on page 58 of this proxy statement.

4

•

•

•

Proposal 2, to approve the amendment and restatement of the 2018 EIP to, among other things, increase
the aggregate number of shares of common stock authorized for issuance under the 2018 EIP by
2,300,000, must receive “For” votes from the holders of a majority of shares present (either in person or
by proxy) and entitled to vote on the matter at the meeting. If you return your proxy and select “Abstain,”
it will have the same effect as an “Against” vote. Broker non-votes will have no effect.

Proposal 3, advisory approval of the compensation of the Company’s named executive officers, will be
considered to be approved if it receives “For” votes from the holders of a majority of shares present
(either in person or by proxy) and entitled to vote on the matter at the meeting. If you return your proxy
and select “Abstain” from voting, it will have the same effect as an “Against” vote. Broker non-votes will
have no effect.

Proposal 4, to ratify the selection of Ernst & Young LLP as the Company’s independent registered public
accounting firm for our fiscal year ending December 31, 2019, must receive “For” votes from the holders
of a majority of shares present (either in person or by proxy) and entitled to vote on the matter at the
meeting. If you return your proxy and select “Abstain” from voting, it will have the same effect as an
“Against” vote. Broker non-votes will have no effect, however, as Proposal 4 is considered a “routine”
matter, we do not expect to receive any broker non-votes.

What is the quorum requirement?

A quorum of stockholders is necessary to hold a valid Annual Meeting. A quorum will be present if

stockholders holding at least a majority of the outstanding shares entitled to vote are present at the Annual Meeting
in person or represented by proxy. On the record date, there were 65,063,889 shares outstanding and entitled to vote.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your

behalf by your broker, bank or other nominee) or if you vote in person at the Annual Meeting. Abstentions and
broker non-votes will be counted towards the quorum requirement. If there is no quorum, the holders of a majority
of shares present at the Annual Meeting in person or represented by proxy may adjourn the Annual Meeting to
another date.

How can I find out the results of the voting at the Annual Meeting?

Preliminary voting results will be announced at the Annual Meeting. Final voting results will be published in a
current report on Form 8-K within four business days following the voting. If we are unable to obtain final results in
that time, we will announce the preliminary results and subsequently file a second current report on Form 8-K with
the final results.

What proxy materials are available on the internet?

The 2019 proxy statement and 2018 Annual Report on Form 10-K are available at

http://investors.dynavax.com/annuals-proxies.cfm.

Householding of Proxy Materials

The Securities and Exchange Commission, or SEC, has adopted rules that permit companies and intermediaries

(e.g., brokers) to satisfy the delivery requirements for Annual Meeting materials with respect to two or more
stockholders sharing the same address by delivering a single set of Annual Meeting materials addressed to those
stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience
for stockholders and cost savings for companies. A number of brokers with account holders who are Dynavax
stockholders will be “householding” our proxy materials. A single set of Annual Meeting materials will be delivered
to multiple stockholders sharing an address unless contrary instructions have been received from the affected
stockholders. Once you have received notice from your broker that they will be “householding” communications to

5

your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If you
no longer wish to participate in “householding” and would prefer to receive a separate set of Annual Meeting
materials, please notify your broker and we will promptly deliver to you a separate set of our Annual Meeting
materials. direct your written request to Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929
Seventh Street, Suite 100, Berkeley, California 94710, if mailed prior to June 1, 2019, or to 5959 Horton Street,
Suite 700, Emeryville, California 94608, if mailed on or after June 1, 2019, or contact Dynavax’s Corporate
Secretary at (510) 848-5100. Stockholders who currently receive multiple copies of the Annual Meeting materials at
their addresses and would like to request “householding” of their communications should contact their brokers.

6

PROPOSAL 1

ELECTION OF DIRECTORS

Our Board is divided into three classes, and each class has a three-year term. Vacancies on the Board may be

filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a
vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the
remainder of the full term of that class and until the director’s successor is elected and qualified.

Our Board presently has eight members. There are three directors in the class whose term of office expires in

2019: Dennis A. Carson, M.D., Eddie Gray, and Laura Brege, each of whom is a nominee for director and currently
a director of the Company. Dr. Carson, Mr. Gray and Ms. Brege were previously elected by the stockholders in
2016. If each nominee is elected at the Annual Meeting, each of these nominees will serve until the 2022 Annual
Meeting and until his or her successor is elected and has qualified, or, if sooner, until the director’s death,
resignation or removal. We have a policy encouraging our directors’ attendance at our annual meetings. There were
six directors in attendance at our 2018 Annual Meeting.

Directors are elected by a plurality of the votes of the holders of shares present in person or represented by

proxy and entitled to vote on the election of directors. The three nominees receiving the highest number of
affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not
withheld, for the election of the nominees named below. Although the election of directors at the Annual Meeting is
uncontested and directors are elected by a plurality of votes cast, and we therefore anticipate that each of the named
nominees for director will be elected at the Annual Meeting, under our Corporate Governance Guidelines, any
nominee for director is required to submit an offer of resignation for consideration by the Nominating and Corporate
Governance Committee if such nominee for director (in an uncontested election) receives a greater number of
“Withhold” votes than “For” votes. In such case, the Nominating and Corporate Governance Committee will then
consider all of the relevant facts and circumstances and recommend to the Board the action to be taken with respect
to such offer of resignation. For more information on this policy see the section entitled “Corporate Governance.” If
any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for
the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve
if elected. Our Board has no reason to believe that any nominee will be unable to serve.

THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF EACH NAMED NOMINEE.

Set forth below is certain biographical information as of April 9, 2019, for the nominees and each person

whose term as a director will continue after the Annual Meeting.

Name

Age

Position

Arnold L. Oronsky, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Francis R. Cano, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dennis A. Carson, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Laura Brege . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Eddie Gray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Daniel L. Kisner, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Peggy V. Phillips . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Natale Ricciardi

78 Chairperson of the Board
74 Director
72 Director
61 Director
60 Chief Executive Officer (“CEO”) and Director
72 Director
65 Director
70 Director

7

CLASS I DIRECTORS NOMINEES

Dennis A. Carson, M.D.

Dr. Carson has been a member of our Board since December 1997. Dr. Carson is a noted researcher in the

fields of autoimmune and immunodeficiency diseases and is co-discoverer with Dr. Eyal Raz of the
immunostimulatory sequences (ISS) that form the basis of our technology. He has played key roles in the founding
of Vical, Inc., a gene therapy company, IDEC Pharmaceuticals, a biopharmaceutical company, and Triangle
Pharmaceuticals, a pharmaceutical company. Dr. Carson is former director of the Rebecca and John Moores Cancer
Center at the University of California, San Diego and has been a professor in the Department of Medicine at the
University of California, San Diego since 1990. The Board believes that Dr. Carson’s significant experience in
research and development provides important insights for the strategy of the Company, particularly with regard to
scientific opportunities for development by the Company, and qualifies Dr. Carson to be nominated as a director. He
is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of
Medicine, as well as the American Association for Cancer Research, the American Society for Clinical
Investigation, the American Society of Hematology and the Association of American Physicians. He received his
M.D. from Columbia University and his B.A. from Haverford College. Dr. Carson completed his residency in
internal medicine and a postdoctoral fellowship at the University of California, San Diego.

Eddie Gray – CEO and Director

Mr. Gray joined Dynavax as Chief Executive Officer and was appointed to our Board in May 2013. Most
recently, Mr. Gray served as the President of Pharmaceuticals Europe and a member of the corporate executive team
at GlaxoSmithKline plc (GSK) from 2008 until 2013 and as Senior Vice President and General Manager of
Pharmaceuticals UK from 2001 through 2007. Prior to the formation of GSK, Mr. Gray was with SmithKline
Beecham from 1988 through 2000 serving in various positions of increasing responsibility, including Vice President
and Director of Anti-Infectives Marketing in the U.S., Vice President and Director of the Vaccines Business Unit in
the U.S., and Vice President and General Manager of Pharmaceuticals in Canada. Our Board believes that
Mr. Gray’s more than 30 years of pharmaceutical industry experience, including, most recently, as the President of
Pharmaceuticals Europe at GSK, a leading pharmaceutical company, and other senior management roles at GSK
and its predecessor, where he was responsible for the launch, commercialization and strategic development of
vaccines and other products, enables him to provide commercial and strategic leadership to the Company and
qualifies Mr. Gray to be nominated as a director. Mr. Gray received a Bachelor of Science degree in Chemistry and
Management Studies from the University of London and an MBA from the Cranfield School of Management in the
UK.

Laura Brege

Ms. Brege has been a member of our Board since February 2015. Since September 2015, she has served as

managing director of Cervantes Life Science Partners, LLC, a consulting firm providing integrated business
solutions to life sciences companies. She has over 20 years of executive management experience in the
pharmaceutical, biotechnology and venture capital industries. From September 2012 to July 2015, Ms. Brege was
President and Chief Executive Officer of Nodality Inc., a life sciences company focused on innovative personalized
medicine. Prior to joining Nodality in 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals,
Inc., a biopharmaceutical and biotherapeutics company, from 2006 until 2012, including positions as Executive Vice
President and Chief Operating Officer. While at Onyx she led multiple functions, including commercialization,
strategic planning, corporate development, and medical, scientific and government affairs. Prior to Onyx, Ms. Brege
was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing
for technology companies. Previously Ms. Brege was Senior Vice President and Chief Financial Officer at COR
Therapeutics, where she helped build the company from an early stage R&D company through commercial launch
of a successful cardiovascular product. Earlier in her career, she served as Chief Financial Officer at Flextronics,
Inc. and Treasurer of The Cooper Companies. She serves on the board of directors of the following public
pharmaceutical companies: Acadia Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Portola Pharmaceuticals,

8

Inc. and HLS Therapeutics, Inc., a pharmaceutical company. During the past five years, Ms. Brege also served on
the boards of directors of Angiotech Pharmaceuticals, Inc., a biotechnology company, Delcath Systems, Inc., a
pharmaceutical company, and Aratana Therapeutics Inc., a pharmaceutical company. Our Board believes that
Ms. Brege’s background in finance and management of biotechnology companies and her participation as a member
of the audit committees of other public companies provides important strategic insights for the Board in setting
strategy and reviewing the operations of the Company, as well as qualifies Ms. Brege to be nominated as a director.
Ms. Brege attended all Board and Audit Committee meetings of the Company and all meetings of the boards and
committees on which she sits at other companies during the past year. Ms. Brege earned her undergraduate degrees
from Ohio University (Honors Tutorial College) and her MBA degree from the University of Chicago.

CLASS II DIRECTORS CONTINUING IN OFFICE UNTIL THE 2020 ANNUAL MEETING

Daniel L. Kisner, M.D.

Dr. Kisner has been a member of our Board since July 2010. From 2003 to 2010, Dr. Kisner served as a partner

at Aberdare Ventures and prior to that as President and CEO of Caliper Technologies, leading its evolution from a
start-up focused on microfluidic lab-on-chip technology to a publicly traded, commercial organization. Prior to
Caliper, he was the President and Chief Operating Officer of Isis Pharmaceuticals, Inc., a biomedical
pharmaceutical company. Previously, Dr. Kisner was Division Vice President of Pharmaceutical Development for
Abbott Laboratories and Vice President of Clinical Research and Development at SmithKline Beckman
Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San
Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and
Medical Oncology. Additionally, he is currently serving on the boards of Conatus Pharmaceuticals, Inc., a
biotechnology company and Zynerba Pharmaceuticals, a biotechnology company. Dr. Kisner previously served as
Chairman of the board for Tekmira Pharmaceuticals, a biopharmaceutical company, until March 2015, and as a
director of Lpath, Inc., a medical device company. Our Board believes that Dr. Kisner’s background with larger,
complex technology-based organizations as well as his significant experience with corporate transactions, including
investing in venture-backed life science companies provides the Board with insights for setting strategy of the
Company and qualifies him to serve as a director. He holds a B.A. from Rutgers University and an M.D. from
Georgetown University.

Natale (“Nat”) Ricciardi

Mr. Ricciardi has been a member of our Board since June 2013. Mr. Ricciardi spent his entire 39-year career at

Pfizer Inc., a biopharmaceutical company, retiring in 2011 as a member of the Pfizer Executive Leadership Team.
While holding the positions of President, Pfizer Global Manufacturing, and Senior Vice President of Pfizer Inc.
from 2004 until 2011, Mr. Ricciardi was directly responsible for all of Pfizer’s internal and external supply
organization, a global enterprise that grew to more than 100 manufacturing facilities supplying small and large
molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products. Mr. Ricciardi maintained
responsibility for global manufacturing activities from 2004 through 2011. Previously, from 1999 to 2004, he had
oversight for Pfizer’s U.S. manufacturing operations and from 1995 to 1999 was Vice President of Manufacturing
for Pfizer’s Animal Health Group. Mr. Ricciardi is currently a member of the board of directors of Rapid Micro
Biosystems, Inc., a technology company focused on microbiology automation, and Prestige Consumer Healthcare,
Inc., a healthcare company. Mr. Ricciardi also serves as a member of the board of directors of the 21st Century
Foundation of The City College of New York and as a member of the Advisory Board of HealthCare Royalty
Partners. Our Board believes Mr. Ricciardi’s 39-year career at Pfizer Inc., a leading pharmaceutical company,
including as a member of the Pfizer Executive Leadership Team and direct responsibility for all of Pfizer’s internal
supply organization, including global manufacturing, provides the Board with insights for reviewing the operations
of the Company and qualifies him to serve as a director. Mr. Ricciardi earned a degree in Chemical Engineering
from The City College of New York and an MBA in Finance and International Business from Fordham University.

9

CLASS III DIRECTORS CONTINUING IN OFFICE UNTIL THE 2021 ANNUAL MEETING

Arnold L. Oronsky, Ph.D.

Dr. Oronsky has been a member of our Board since November 1996 and became Chairperson of the Board in

February 2006. Dr. Oronsky has been a managing director with InterWest Partners, a venture capital firm, since
2009. Prior to joining InterWest Partners in 1994, Dr. Oronsky was Vice President of Discovery Research for the
Lederle Laboratories division of American Cyanamid, a pharmaceutical company. From 1973 until 1976,
Dr. Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy
Pharmaceutical Company. Dr. Oronsky also serves as a senior lecturer in the Department of Medicine at The Johns
Hopkins Medical School. Dr. Oronsky has won numerous grants and awards and has published over 125 scientific
articles. Dr. Oronsky currently serves on the board of directors of KalVista Pharmaceuticals, Inc., a biotechnology
company. Dr. Oronsky also served on the board of directors of MacroGenics, Inc., a biopharmaceutical company,
from 2000 to 2014, Applied Genetic Technologies Corporation, a biotechnology company, from November 2003
until August 2017, and Tesaro, Inc., an oncology-focused biopharmaceutical company from June 2011 until May
2018. The Board believes that Dr. Oronsky’s significant experience in growing and developing life sciences
companies, particularly in the immunology area, provides significant leadership and insights for the Board in
defining the strategy of the Company and qualifies him to serve as a director. He received his Ph.D. from Columbia
University, College of Physicians and Surgeons and his A.B. from New York University.

Francis R. Cano, Ph.D.

Dr. Cano was appointed to our Board in November 2009. Dr. Cano has been President and Founder of Cano

Biotech Corp., a consulting firm focusing on the vaccine business, since 1996 and also serves on the board of
Biomerica, Inc., a developer and manufacturer of diagnostic products. Previously, Dr. Cano served on the board of
Arbor Vita Corporation, a biopharmaceutical company. From 1993 to 1996, Dr. Cano was President and Chief
Operating Officer for Aviron, a biopharmaceutical company, which was later acquired by MedImmune in 2001. As
a Co-Founder of Aviron, he completed two rounds of venture financing, a licensing agreement with SmithKline
Biologicals and in-licensed Flu-Mist influenza vaccine from the National Institutes of Health. For 21 years,
Dr. Cano worked with the Lederle Laboratories Division of American Cyanamid, including as its Vice President and
General Manager of the Biologicals unit. The Board believes that Dr. Cano’s experience as a founder of and advisor
to established vaccine businesses provides significant insights for the strategy of the Company with respect to key
technical and operational issues in vaccine development and qualifies him to serve as a director. He earned a Ph.D.
in Microbiology from Pennsylvania State University, served as a Research Associate at Rutgers Institute of
Microbiology, and holds a M.S. in Microbiology and a B.S. in Biology from St. John’s University.

Peggy V. Phillips

Ms. Phillips has been a member of our Board since August 2006. Ms. Phillips served on the board of directors
of several biopharmaceutical companies: PhaseRx, Inc. from 2016 to 2018, Tekmira Pharmaceuticals from 2014 to
2015, Portola Pharmaceuticals from 2006 to 2013, as well as the Naval Academy Foundation from 2003 to 2011.
From 1996 until 2002, she served on the board of directors of Immunex Corporation, a biotechnology company,
and, from 1999, she served as its Chief Operating Officer until the company was acquired by Amgen in 2002.
During her career at Immunex, she held positions of increasing responsibility in research, development,
manufacturing, sales and marketing. As Senior Vice President for Pharmaceutical Development and General
Manager for Enbrel® from 1994 until 1998, she was responsible for clinical development and regulatory affairs as
well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles
Laboratories. The Board believes that Ms. Phillips provides significant experience in development and
commercialization of biotechnology products. Her background and experience with larger, complex organizations
provides significant operational and strategic insights in assessing the strategy of the Company and qualifies her to
serve as a director. Ms. Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho.

10

PROPOSAL 2

APPROVAL OF AN AMENDMENT AND RESTATEMENT OF THE 2018 EQUITY INCENTIVE PLAN

The Board is requesting stockholder approval of an amendment and restatement of the Dynavax Technologies
Corporation 2018 Equity Incentive Plan (the “2018 EIP”). We refer to such amendment and restatement of the 2018
EIP in this proxy statement as the “Amended 2018 EIP”.

The Amended 2018 EIP contains the following material changes from the 2018 EIP:

•

Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our
common stock that may be issued under the Amended 2018 EIP will not exceed 7,440,250 shares (plus the
Prior Plans’ Returning Shares (as defined below), as such shares become available from time to time),
which is an increase of 2,300,000 shares over the aggregate number of shares of our common stock that
may be issued under the 2018 EIP.

• The 2018 EIP contains a “fungible share counting” structure, whereby the number of shares of our

common stock available for issuance under the 2018 EIP will be reduced by: (i) one share for each share
issued pursuant to a stock option or stock appreciation right with an exercise price that is at least 100% of
the fair market value of our common stock on the date of grant (an “Appreciation Award”) granted under
the 2018 EIP; and (ii) 1.28 shares for each share issued pursuant to a stock award that is not an
Appreciation Award (a “Full Value Award”) granted under the 2018 EIP. The Amended 2018 EIP retains
such fungible share counting structure, except that the number of shares of our common stock available
for issuance under the Amended 2018 EIP will be reduced by 1.40 shares for each share issued pursuant to
a stock award that is a Full Value Award granted under the Amended 2018 EIP on or after May 30, 2019.
As part of such fungible share counting structure, the number of shares of our common stock available for
issuance under the Amended 2018 EIP will be increased by: (i) one share for each share that becomes
available again for issuance under the terms of the Amended 2018 EIP subject to an Appreciation Award
and (ii) 1.40 shares for each share that becomes available again for issuance under the terms of the
Amended 2018 EIP subject to a Full Value Award on or after May 30, 2019.

• The 2018 EIP provides that if a corporate transaction or change in control (each, a “Transaction”) occurs

and the surviving or acquiring corporation (or its parent company) does not assume or continue
outstanding awards under the 2018 EIP and/or any Prior Plan (i.e., the Dynavax Technologies Corporation
2011 Equity Incentive Plan (the “2011 EIP”) or the Dynavax Technologies Corporation 2017 Inducement
Award Plan), or substitute similar stock awards for such outstanding awards, then with respect to any such
awards that have not been assumed, continued or substituted and that are held by participants whose
continuous service has not terminated prior to the Transaction, the vesting of such awards will be
accelerated in full to a date prior to the Transaction (contingent upon the closing or completion of the
Transaction). The Amended 2018 EIP retains such provision, but specifies that for purposes of such
acceleration, with respect to performance stock awards, vesting will be deemed to be satisfied at the target
level of performance.

Why We Are Asking Our Stockholders to Approve the Amended 2018 EIP

We are seeking stockholder approval of the Amended 2018 EIP to increase the number of shares available for
the grant of stock options, restricted stock unit awards and other awards by 2,300,000 shares, which will enable us
to have a competitive equity incentive program to compete with our peer group for key talent.

Our stockholders’ approval of the Amended 2018 EIP will allow us to continue to grant stock options,

restricted stock unit awards and other awards at levels determined appropriate by the Board or Compensation
Committee. The Amended 2018 EIP will also allow us to further utilize a broad array of equity incentives in order
to secure and retain the services of our employees and directors, and to continue to provide long-term incentives that
align the interests of our employees and directors with the interests of our stockholders.

11

Stockholder Approval

If this Proposal 2 is approved by our stockholders, the Amended 2018 EIP will become effective as of the date

of the Annual Meeting. In the event that our stockholders do not approve this Proposal 2, the Amended 2018 EIP
will not become effective and the 2018 EIP will continue in its current form.

The Amended 2018 EIP Combines Compensation and Governance Best Practices

Why You Should Vote for the Amended 2018 EIP

The Amended 2018 EIP includes provisions that are designed to protect our stockholders’ interests and to

reflect corporate governance best practices including:

•

Stockholder approval is required for additional shares. The Amended 2018 EIP does not contain an
annual “evergreen” provision. The Amended 2018 EIP authorizes a fixed number of shares, so that
stockholder approval is required to issue any additional shares.

• Repricing is not allowed. The Amended 2018 EIP prohibits the repricing of stock options and stock

appreciation rights without prior stockholder approval.

• No discounted stock options or stock appreciation rights. All stock options and stock appreciation rights
granted under the Amended 2018 EIP must have an exercise price equal to or greater than the fair market
value of our common stock on the date the stock option or stock appreciation right is granted.

• Reasonable share counting provisions.

In general, when awards granted under the Amended 2018 EIP

lapse or are canceled, the shares reserved for those awards will be returned to the share reserve and be
available for future awards. However, any shares received from the exercise of stock options or withheld
for taxes will not be returned to our share reserve.

• Minimum vesting requirements. The Amended 2018 EIP provides that no award may vest until at least
12 months following the date of grant of such award, except that shares up to 5% of the share reserve of
the Amended 2018 EIP may be issued pursuant to awards that do not meet such vesting requirements.

•

Limit on non-employee director compensation. The aggregate value of all cash and equity-based
compensation granted or paid by us to any individual for service as a non-employee director of the Board
with respect to any fiscal year of the Company will not exceed (i) a total of $200,000 with respect to any
such cash compensation and (ii) $800,000 in total value with respect to any such equity-based
compensation (including awards granted under the Amended 2018 EIP and any other equity-based
awards), calculating the value of any such awards based on the grant date fair value of such awards for
financial reporting purposes.

• Restrictions on dividends. The Amended 2018 EIP provides that (i) no dividends or dividend equivalents
may be paid with respect to any shares of our common stock subject to an award before the date such
shares have vested, (ii) any dividends or dividend equivalents that are credited with respect to any such
shares will be subject to all of the terms and conditions applicable to such shares under the terms of the
applicable award agreement (including any vesting conditions), and (iii) any dividends or dividend
equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares
are forfeited to or repurchased by us due to a failure to vest.

12

Overhang

The following table provides certain information regarding our equity incentive program.

Total number of shares of common stock subject to outstanding stock options

Weighted-average exercise price of outstanding stock options

Weighted-average remaining term of outstanding stock options

Total number of shares of common stock subject to outstanding full value awards

Total number of shares of common stock available for grant under the 2018 EIP(1)

Total number of shares of common stock outstanding

Per-share closing price of common stock as reported on NASDAQ Capital Market

As of April 9, 2019

7,293,909

$

16.22

5.60 years

2,189,334

1,554,878

65,063,889

$

6.99

(1) As of April 9, 2019, there were no shares of common stock available for grant under any of our other equity incentive plans.

We Manage Our Equity Incentive Award Use Carefully and Dilution Is Reasonable

We continue to believe that equity incentive awards such as stock options and restricted stock unit awards are a

vital part of our overall compensation program. Our compensation philosophy reflects broad-based eligibility for
equity incentive awards, and we grant awards to substantially all of our employees. However, we recognize that
equity incentive awards dilute existing stockholders, and, therefore, we must responsibly manage the growth of our
equity compensation program. We are committed to effectively monitoring our equity compensation share reserve,
including our “burn rate,” to ensure that we maximize stockholders’ value by granting the appropriate number of
equity incentive awards necessary to attract, reward, and retain employees. In addition, the vesting of some of our
equity awards granted to our named executive officers are contingent on meeting pre-defined performance criteria,
thereby ensuring alignment with value creation.

The following table shows our responsible historical dilution and burn rate percentages.

As of December 31

2018

2017

2016

Full Dilution(1)
Gross Burn Rate (as discussed in greater detail below)(2)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .

16.31% 14.92% 16.90%
4.75% 5.23% 5.90%

(1)

Full Dilution is calculated as (shares available for grant + shares subject to outstanding equity incentive awards)/(weighted average common
stock outstanding + shares available for grant + shares subject to outstanding equity incentive awards).

(2) Gross Burn Rate is calculated as (shares subject to options granted + shares subject to other equity incentive awards granted)/weighted

average common stock outstanding.

The Size of Our Share Reserve Increase Request Is Reasonable

If this Proposal 2 is approved by our stockholders, we will have 2,300,000 new shares available for grant after

our Annual Meeting for a total of approximately 3,854,878 shares available for grant after our Annual Meeting (plus
the Prior Plans’ Returning Shares (as defined below), as such shares become available from time to time), and
absent any unforeseen circumstances, we anticipate returning to stockholders for additional shares in 2020.

13

Burn Rate

The following table provides detailed information regarding the activity related to our equity incentive plans

for fiscal years 2018, 2017 and 2016.

Fiscal Year 2018

Fiscal Year 2017

Fiscal Year 2016

Total number of shares of common stock subject to stock options

granted

2,502,817

535,497

1,414,262

Total number of shares of common stock subject to full value

awards granted

457,542

2,217,303

856,258

Weighted-average number of shares of common stock

outstanding

Burn Rate

62,361,828

52,613,215

38,505,856

4.75%

5.23%

5.90%

A summary of the principal features of the Amended 2018 EIP follows below. The summary is qualified by the

full text of the Amended 2018 EIP that is attached as Appendix A to this proxy statement.

Description of the Amended 2018 EIP

Purpose

The Amended 2018 EIP is designed to secure and retain the services of our employees and directors, provide

incentives for our employees and directors to exert maximum efforts for the success of the Company and its
affiliates, and provide a means by which our employees and directors may be given an opportunity to benefit from
increases in the value of our common stock.

Types of Awards

The Amended 2018 EIP provides for the grant of incentive stock options, nonstatutory stock options, stock
appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and other stock
awards.

Shares Available for Awards

Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common

stock that may be issued under the Amended 2018 EIP will not exceed 7,440,250 shares (which is the sum of (i)
140,250 shares (the number of unallocated shares that were available for grant under the 2011 EIP as of the effective
date of the 2018 EIP), (ii) 5,000,000 additional shares that were reserved as of the effective date of the 2018 EIP,
and (iii) 2,300,000 newly requested shares), plus the Prior Plans’ Returning Shares (as defined below), as such
shares become available from time to time.

The term “Prior Plans’ Returning Shares” refers to the following shares of our common stock subject to any
outstanding stock award granted under either of the Prior Plans: (i) any shares subject to such stock award that are
not issued because such stock award expires or otherwise terminates without all of the shares covered by such stock
award having been issued; (ii) any shares subject to such stock award that are not issued because such stock award is
settled in cash; and (iii) any shares issued pursuant to such stock award that are forfeited back to or repurchased by
us because of a failure to vest.

The following shares of our common stock (collectively, the “Amended 2018 EIP Returning Shares”) will also

become available again for issuance under the Amended 2018 EIP: (i) any shares subject to a stock award granted
under the Amended 2018 EIP that are not issued because such stock award expires or otherwise terminates without
all of the shares covered by such stock award having been issued; (ii) any shares subject to a stock award granted

14

under the Amended 2018 EIP that are not issued because such stock award is settled in cash; and (iii) any shares
issued pursuant to a stock award granted under the Amended 2018 EIP that are forfeited back to or repurchased by
us because of a failure to vest.

The following shares of our common stock will not become available again for issuance under the Amended

2018 EIP: (i) any shares that are reacquired or withheld (or not issued) by us to satisfy the exercise, strike or
purchase price of a stock award granted under the Amended 2018 EIP or any Prior Plan (including any shares
subject to such award that are not delivered because such award is exercised through a reduction of shares subject to
such award); (ii) any shares that are reacquired or withheld (or not issued) by us to satisfy a tax withholding
obligation in connection with a stock award granted under the Amended 2018 EIP or any Prior Plan; (iii) any shares
repurchased by us on the open market with the proceeds of the exercise, strike or purchase price of a stock award
granted under the Amended 2018 EIP or any Prior Plan; and (iv) in the event that a stock appreciation right granted
under the Amended 2018 EIP or any Prior Plan is settled in shares, the gross number of shares subject to such
award.

The number of shares of our common stock available for issuance under the Amended 2018 EIP will be

reduced by: (i) one share for each share issued pursuant to an Appreciation Award granted under the Amended 2018
EIP; (ii) 1.28 shares for each share issued pursuant to a Full Value Award granted under the Amended 2018 EIP
prior to May 30, 2019; and (iii) 1.40 shares for each share issued pursuant to a Full Value Award granted under the
Amended 2018 EIP on or after May 30, 2019.

The number of shares of our common stock available for issuance under the Amended 2018 EIP will be
increased by: (i) one share for each Prior Plans’ Returning Share or Amended 2018 EIP Returning Share subject to
an Appreciation Award; (ii) 1.28 shares for each Prior Plans’ Returning Share or Amended 2018 EIP Returning
Share subject to a Full Value Award that returns to the Amended 2018 EIP prior to May 30, 2019; and (iii) 1.40
shares for each Prior Plans’ Returning Share or Amended 2018 EIP Returning Share subject to a Full Value Award
that returns to the Amended 2018 EIP on or after May 30, 2019.

Eligibility

All of our (including our affiliates’) employees and non-employee directors are eligible to participate in the

Amended 2018 EIP and may receive all types of awards other than incentive stock options. Incentive stock options
may be granted under the Amended 2018 EIP only to our (including our affiliates’) employees.

As of April 9, 2019, we (including our affiliates) had approximately 298 employees and seven non-employee

directors.

Non-Employee Director Compensation Limit

The aggregate value of all cash and equity-based compensation granted or paid by us to any individual for
service as a non-employee director of the Board with respect to any fiscal year of the Company will not exceed (i) a
total of $200,000 with respect to any such cash compensation and (ii) $800,000 in total value with respect to any
such equity-based compensation (including awards granted under the Amended 2018 EIP and any other equity-
based awards), calculating the value of any such awards based on the grant date fair value of such awards for
financial reporting purposes.

Administration

The Amended 2018 EIP will be administered by our Board, which may in turn delegate authority to administer

the Amended 2018 EIP to a committee. Our Board has delegated concurrent authority to administer the Amended
2018 EIP to our Compensation Committee, but may, at any time, re-vest in itself some or all of the power delegated
to our Compensation Committee. Our Board and Compensation Committee are each considered to be a Plan
Administrator for purposes of this Proposal 2.

15

Subject to the terms of the Amended 2018 EIP, the Plan Administrator may determine the recipients, the types
of awards to be granted, the number of shares of our common subject to or the cash value of awards, and the terms
and conditions of awards granted under the Amended 2018 EIP, including the period of their exercisability and
vesting. The Plan Administrator also has the authority to provide for accelerated exercisability and vesting of
awards. Subject to the limitations set forth below, the Plan Administrator also determines the fair market value
applicable to a stock award and the exercise or strike price of stock options and stock appreciation rights granted
under the Amended 2018 EIP.

The Plan Administrator may also delegate to one or more officers the authority to designate employees who are

not officers to be recipients of certain stock awards and the number of shares of our common stock subject to such
stock awards. Under any such delegation, the Plan Administrator will specify the total number of shares of our
common stock that may be subject to the stock awards granted by such officer. The officer may not grant a stock
award to himself or herself.

Repricing; Cancellation and Re-Grant of Stock Awards

Under the Amended 2018 EIP, the Plan Administrator does not have the authority to reprice any outstanding

stock option or stock appreciation right by reducing the exercise or strike price of the stock option or stock
appreciation right or to cancel any outstanding stock option or stock appreciation right that has an exercise or strike
price greater than the then-current fair market value of our common stock in exchange for cash or other stock
awards without obtaining the approval of our stockholders. Such approval must be obtained within 12 months prior
to such an event.

Minimum Vesting Requirements

Under the Amended 2018 EIP, no award may vest until at least 12 months following the date of grant of such

award, except that shares up to 5% of the share reserve of the Amended 2018 EIP may be issued pursuant to awards
that do not meet such vesting requirements.

Dividends and Dividend Equivalents

The Amended 2018 EIP provides that dividends or dividend equivalents may be paid or credited with respect
to any shares of our common stock subject to an award, as determined by the Plan Administrator and contained in
the applicable award agreement; provided, however, that (i) no dividends or dividend equivalents may be paid with
respect to any such shares before the date such shares have vested, (ii) any dividends or dividend equivalents that
are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such
shares under the terms of the applicable award agreement (including any vesting conditions), and (iii) any dividends
or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such
shares are forfeited to or repurchased by us due to a failure to vest.

Stock Options

Stock options may be granted under the Amended 2018 EIP pursuant to stock option agreements. The
Amended 2018 EIP permits the grant of stock options that are intended to qualify as incentive stock options, or
ISOs, and nonstatutory stock options, or NSOs.

The exercise price of a stock option granted under the Amended 2018 EIP may not be less than 100% of the
fair market value of our common stock on the date of grant and, in some cases (see “Limitations on Incentive Stock
Options” below), may not be less than 110% of such fair market value.

The term of stock options granted under the Amended 2018 EIP may not exceed seven years from the date of
grant and, in some cases (see “Limitations on Incentive Stock Options” below), may not exceed five years from the

16

date of grant. Except as otherwise provided in a participant’s stock option agreement or other written agreement
with us or one of our affiliates, if a participant’s service relationship with us or any of our affiliates (referred to in
this Proposal 2 as “continuous service”) terminates (other than for cause and other than upon the participant’s death
or disability), the participant may exercise any vested stock options for up to three months following the
participant’s termination of continuous service. Except as otherwise provided in a participant’s stock option
agreement or other written agreement with us or one of our affiliates, if a participant’s continuous service terminates
due to the participant’s disability or death (or the participant dies within a specified period, if any, following
termination of continuous service), the participant, or his or her beneficiary, as applicable, may exercise any vested
stock options for up to 12 months following the participant’s termination due to the participant’s disability or for up
to 18 months following the participant’s death. Except as explicitly provided otherwise in a participant’s stock
option agreement or other written agreement with us or one of our affiliates, if a participant’s continuous service is
terminated for cause (as defined in the Amended 2018 EIP), all stock options held by the participant will terminate
upon the participant’s termination of continuous service and the participant will be prohibited from exercising any
stock option from and after such termination date. Except as otherwise provided in a participant’s stock option
agreement or other written agreement with us or one of our affiliates, the term of a stock option may be extended if
the exercise of the stock option following the participant’s termination of continuous service (other than for cause
and other than upon the participant’s death or disability) would be prohibited by applicable securities laws or if the
sale of any common stock received upon exercise of the stock option following the participant’s termination of
continuous service (other than for cause) would violate our insider trading policy. In no event, however, may a stock
option be exercised after its original expiration date.

Acceptable forms of consideration for the purchase of our common stock pursuant to the exercise of a stock
option under the Amended 2018 EIP will be determined by the Plan Administrator and may include payment: (i) by
cash, check, bank draft or money order payable to us; (ii) pursuant to a program developed under Regulation T as
promulgated by the Federal Reserve Board; (iii) by delivery to us of shares of our common stock (either by actual
delivery or attestation); (iv) by a net exercise arrangement (for NSOs only); or (v) in other legal consideration
approved by the Plan Administrator.

Stock options granted under the Amended 2018 EIP may vest and become exercisable in cumulative

increments, as determined by the Plan Administrator at the rate specified in the stock option agreement (subject to
the limitations described in “Minimum Vesting Requirements” above). Shares covered by different stock options
granted under the Amended 2018 EIP may be subject to different vesting schedules as the Plan Administrator may
determine.

The Plan Administrator may impose limitations on the transferability of stock options granted under the

Amended 2018 EIP in its discretion. Generally, a participant may not transfer a stock option granted under the
Amended 2018 EIP other than by will or the laws of descent and distribution or, subject to approval by the Plan
Administrator, pursuant to a domestic relations order or an official marital settlement agreement. However, the Plan
Administrator may permit transfer of a stock option in a manner that is not prohibited by applicable tax and
securities laws. In addition, subject to approval by the Plan Administrator, a participant may designate a beneficiary
who may exercise the stock option following the participant’s death. Notwithstanding the foregoing, no option may
be transferred to any financial institution without prior stockholder approval.

Limitations on Incentive Stock Options

The aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to
ISOs that are exercisable for the first time by a participant during any calendar year under all of our stock plans may
not exceed $100,000. The stock options or portions of stock options that exceed this limit or otherwise fail to qualify
as ISOs are treated as NSOs. No ISO may be granted to any person who, at the time of grant, owns or is deemed to

17

own stock possessing more than 10% of our total combined voting power or that of any affiliate unless the
following conditions are satisfied:

•

•

the exercise price of the ISO must be at least 110% of the fair market value of our common stock on the
date of grant; and

the term of the ISO must not exceed five years from the date of grant.

Subject to adjustment for certain changes in our capitalization, the aggregate maximum number of shares of

our common stock that may be issued pursuant to the exercise of ISOs under the Amended 2018 EIP is 10,000,000
shares.

Stock Appreciation Rights

Stock appreciation rights may be granted under the Amended 2018 EIP pursuant to stock appreciation right
agreements. Each stock appreciation right is denominated in common stock share equivalents. The strike price of
each stock appreciation right will be determined by the Plan Administrator, but will in no event be less than 100%
of the fair market value of our common stock on the date of grant. The term of stock appreciation rights granted
under the Amended 2018 EIP may not exceed seven years from the date of grant. The Plan Administrator may also
impose restrictions or conditions upon the vesting of stock appreciation rights that it deems appropriate (subject to
the limitations described in “Minimum Vesting Requirements” above). The appreciation distribution payable upon
exercise of a stock appreciation right may be paid in shares of our common stock, in cash, in a combination of cash
and stock, or in any other form of consideration determined by the Plan Administrator and set forth in the stock
appreciation right agreement. Stock appreciation rights will be subject to the same conditions upon termination of
continuous service and restrictions on transfer as stock options under the Amended 2018 EIP.

Restricted Stock Awards

Restricted stock awards may be granted under the Amended 2018 EIP pursuant to restricted stock award
agreements. A restricted stock award may be granted in consideration for cash, check, bank draft or money order
payable to us, the participant’s services performed for us or any of our affiliates, or any other form of legal
consideration acceptable to the Plan Administrator. Shares of our common stock acquired under a restricted stock
award may be subject to forfeiture to or repurchase by us in accordance with a vesting schedule to be determined by
the Plan Administrator (subject to the limitations described in “Minimum Vesting Requirements” above). Rights to
acquire shares of our common stock under a restricted stock award may be transferred only upon such terms and
conditions as are set forth in the restricted stock award agreement; provided, however, that no restricted stock award
may be transferred to any financial institution without prior stockholder approval. Upon a participant’s termination
of continuous service for any reason, any shares subject to restricted stock awards held by the participant that have
not vested as of such termination date may be forfeited to or repurchased by us.

Restricted Stock Unit Awards

Restricted stock unit awards may be granted under the Amended 2018 EIP pursuant to restricted stock unit
award agreements. Payment of any purchase price may be made in any form of legal consideration acceptable to the
Plan Administrator. A restricted stock unit award may be settled by the delivery of shares of our common stock, in
cash, in a combination of cash and stock, or in any other form of consideration determined by the Plan
Administrator and set forth in the restricted stock unit award agreement. Restricted stock unit awards may be subject
to vesting in accordance with a vesting schedule to be determined by the Plan Administrator (subject to the
limitations described in “Minimum Vesting Requirements” above). Except as otherwise provided in a participant’s
restricted stock unit award agreement or other written agreement with us or one of our affiliates, restricted stock
units that have not vested will be forfeited upon the participant’s termination of continuous service for any reason.

18

Performance Stock Awards

A performance stock award is a stock award that is payable (including that may be granted, may vest, or may
be exercised) contingent upon the attainment of pre-determined performance goals during a performance period. A
performance stock award may require the completion of a specified period of continuous service. The length of any
performance period, the performance goals to be achieved during the performance period, and the measure of
whether and to what degree such performance goals have been attained will be determined by the Plan
Administrator (subject to the limitations described in “Minimum Vesting Requirements” above). In addition, to the
extent permitted by applicable law and the performance stock award agreement, the Plan Administrator may
determine that cash may be used in payment of performance stock awards.

Performance goals under the Amended 2018 EIP will be based on any one or more of the following

performance criteria: (i) earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes
and depreciation; (iii) earnings before interest, taxes, depreciation and amortization (EBITDA); (iv) total
stockholder return; (v) return on equity or average stockholder’s equity; (vi) return on assets, investment, or capital
employed; (vii) stock price or stock price performance; (viii) margin (including gross margin); (ix) net income
(before or after taxes); (x) operating income; (xi) operating income after taxes; (xii) pre-tax profit; (xiii) operating
cash flow; (xiv) sales or revenue targets; (xv) increases in revenue or product revenue; (xvi) expenses and cost
reduction goals; (xvii) improvement in or attainment of working capital levels; (xviii) economic value added (or an
equivalent metric); (xix) market share; (xx) cash flow; (xxi) cash flow per share; (xxii) share price performance;
(xxiii) debt reduction; (xxiv) implementation or completion of projects or processes; (xxv) customer satisfaction;
(xxvi) stockholders’ equity; (xxvii) capital expenditures; (xxviii) debt levels; (xxix) operating profit or net operating
profit; (xxx) workforce diversity; (xxxi) growth of net income or operating income; (xxxii) billings; (xxxiii)
submission to, or approval by, a regulatory body (including but not limited to the U.S. Food and Drug
Administration) of an applicable filing for a product candidate or other product development milestones;
(xxxiv) acquisitions, divestitures, joint ventures, strategic alliances, licenses or collaborations; (xxxv) spin-offs,
split-ups, reorganizations, recapitalizations, restructurings, financings (debt or equity) or refinancings;
(xxxvi) manufacturing or process development, clinical trial, regulatory, intellectual property, compliance or
research objectives; and (xxxvii) any other measures of performance selected by the Plan Administrator.

Performance goals may be based on a company-wide basis, with respect to one or more business units,

divisions, affiliates or business segments, and in either absolute terms or relative to the performance of one or more
comparable companies or the performance of one or more relevant indices. The Plan Administrator is authorized to
make appropriate adjustments in the method of calculating the attainment of performance goals for a performance
period as follows: (i) to exclude restructuring and/or other nonrecurring charges; (ii) to exclude exchange rate
effects, as applicable, for non-U.S. dollar denominated performance goals; (iii) to exclude the effects of changes to
generally accepted accounting principles; (iv) to exclude the effects of any statutory adjustments to corporate tax
rates; (v) to exclude the effects of items that are “unusual” in nature or occur “infrequently” as determined under
generally accepted accounting principles; (vi) to exclude the dilutive effects of acquisitions or joint ventures; (vii) to
assume that any business divested by the Company achieved performance objectives at targeted levels during the
balance of a performance period following such divestiture; (viii) to exclude the effect of any change in the
outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization,
recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate
change, or any distributions to common stockholders other than regular cash dividends; (ix) to exclude the effects of
stock based compensation and/or the award of an annual cash incentive under our Annual Incentive Program; (x) to
exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary item; and (xi) to make
other appropriate adjustments selected by the Plan Administrator.

In addition, the Plan Administrator retains the discretion to reduce or eliminate the compensation or economic
benefit due upon the attainment of any performance goals and to define the manner of calculating the performance
criteria it selects to use for a performance period.

19

Other Stock Awards

Other forms of stock awards valued in whole or in part by reference to, or otherwise based on, our common
stock may be granted either alone or in addition to other stock awards under the Amended 2018 EIP. Subject to the
terms of the Amended 2018 EIP (including the limitations described in “Minimum Vesting Requirements” above),
the Plan Administrator will have sole and complete authority to determine the persons to whom and the time or
times at which such other stock awards will be granted, the number of shares of our common stock to be granted and
all other terms and conditions of such other stock awards.

Clawback/Recoupment

Awards granted under the Amended 2018 EIP will be subject to recoupment in accordance with any clawback

policy that we are required to adopt pursuant to the listing standards of any national securities exchange or
association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and
Consumer Protection Act or other applicable law. In addition, the Plan Administrator may impose other clawback,
recovery or recoupment provisions in an award agreement, including a reacquisition right in respect of previously
acquired shares or other cash or property upon the occurrence of cause.

Changes to Capital Structure

In the event of certain capitalization adjustments, the Plan Administrator will appropriately adjust: (i) the
class(es) and maximum number of securities subject to the Amended 2018 EIP; (ii) the class(es) and maximum
number of securities that may be issued pursuant to the exercise of ISOs; and (iii) the class(es) and number of
securities and price per share of stock subject to outstanding stock awards.

Corporate Transaction and Change in Control

The following provisions will apply to outstanding awards under the Amended 2018 EIP and any Prior Plan in

the event of a corporate transaction (as defined in the Amended 2018 EIP and described below) or a change in
control (as defined in the Amended 2018 EIP and described below) unless otherwise provided in the instrument
evidencing the award, in any other written agreement between us or one of our affiliates and the participant, or in
our director compensation policy. For purposes of this Proposal 2, the term “Transaction” will mean such corporate
transaction or change in control.

In the event of a Transaction, any surviving or acquiring corporation (or its parent company) may assume or

continue any or all outstanding awards under the Amended 2018 EIP and/or any Prior Plan, or may substitute
similar stock awards for such outstanding awards (including, but not limited to, awards to acquire the same
consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or
repurchase rights held by the Company in respect of shares issued pursuant to any outstanding awards under the
Amended 2018 EIP and/or any Prior Plan may be assigned by the Company to the surviving or acquiring
corporation (or its parent company). The terms of any such assumption, continuation or substitution will be set by
the Plan Administrator.

In the event of a Transaction in which the surviving or acquiring corporation (or its parent company) does not

assume or continue outstanding awards under the Amended 2018 EIP and/or any Prior Plan, or substitute similar
stock awards for such outstanding awards, then with respect to any such awards that have not been assumed,
continued or substituted and that are held by participants whose continuous service has not terminated prior to the
effective time of the Transaction (the “Current Participants”), the vesting (and exercisability, if applicable) of such
awards will be accelerated in full (and with respect to performance stock awards, vesting will be deemed to be
satisfied at the target level of performance) to a date prior to the effective time of the Transaction (contingent upon
the closing or completion of the Transaction) as the Plan Administrator will determine (or, if the Plan Administrator
does not determine such a date, to the date that is five days prior to the effective time of the Transaction), and such
awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction in accordance

20

with the exercise procedures determined by the Plan Administrator, and any reacquisition or repurchase rights held
by the Company with respect to such awards will lapse (contingent upon the closing or completion of the
Transaction).

In the event of a Transaction in which the surviving or acquiring corporation (or its parent company) does not

assume or continue outstanding awards under the Amended 2018 EIP and/or any Prior Plan, or substitute similar
stock awards for such outstanding awards, then with respect to any such awards that have not been assumed,
continued or substituted and that are held by participants other than the Current Participants, such awards will
terminate if not exercised (if applicable) prior to the effective time of the Transaction in accordance with the
exercise procedures determined by the Plan Administrator; provided, however, that any reacquisition or repurchase
rights held by the Company with respect to such awards will not terminate and may continue to be exercised
notwithstanding the Transaction.

Notwithstanding the foregoing, in the event any outstanding award under the Amended 2018 EIP and/or any
Prior Plan held by a participant will terminate if not exercised prior to the effective time of a Transaction, the Plan
Administrator may provide that the participant may not exercise such award but instead will receive a payment, in
such form as may be determined by the Plan Administrator, equal in value to the excess, if any, of (i) the value of
the property the participant would have received upon the exercise of such award immediately prior to the effective
time of the Transaction, over (ii) any exercise price payable by the participant in connection with such exercise.

Unless provided otherwise in the participant’s award agreement, in any other written agreement or plan with us

or one of our affiliates, or in our director compensation policy, outstanding awards under the Amended 2018 EIP
and any Prior Plan will not be subject to additional acceleration of vesting and exercisability upon or after a change
in control.

For purposes of the Amended 2018 EIP, a corporate transaction generally will be deemed to occur in the event
of the consummation of: (i) a sale or other disposition of all or substantially all of our consolidated assets; (ii) a sale
or other disposition of at least 90% of our outstanding securities; (iii) a merger, consolidation or similar transaction
following which we are not the surviving corporation; or (iv) a merger, consolidation or similar transaction
following which we are the surviving corporation but the shares of our common stock outstanding immediately prior
to the transaction are converted or exchanged into other property by virtue of the transaction.

For purposes of the Amended 2018 EIP, a change in control generally will be deemed to occur in the event:

(i) a person, entity or group acquires, directly or indirectly, our securities representing more than 50% of the
combined voting power of our then outstanding securities, other than by virtue of a merger, consolidation, or similar
transaction; (ii) there is consummated a merger, consolidation, or similar transaction and, immediately after the
consummation of such transaction, our stockholders immediately prior thereto do not own, directly or indirectly,
more than 50% of the combined outstanding voting power of the surviving entity or the parent of the surviving
entity in substantially the same proportions as their ownership of our outstanding voting securities immediately prior
to such transaction; (iii) there is consummated a sale or other disposition of all or substantially all of our
consolidated assets, other than a sale or other disposition to an entity in which more than 50% of the entity’s
combined voting power is owned by our stockholders in substantially the same proportions as their ownership of our
outstanding voting securities immediately prior to such sale or other disposition; or (iv) over a period of 12 months
or less, a majority of our Board becomes comprised of individuals whose nomination, appointment, or election was
not approved by a majority of the Board members or their approved successors.

Plan Amendments and Termination

The Plan Administrator has the authority to amend or terminate the Amended 2018 EIP at any time. However,
except as otherwise provided in the Amended 2018 EIP or an award agreement, no amendment or termination of the
Amended 2018 EIP may materially impair a participant’s rights under his or her outstanding awards without the
participant’s consent.

21

We will obtain stockholder approval of any amendment to the Amended 2018 EIP as required by applicable
law and listing requirements. No incentive stock options may be granted under the Amended 2018 EIP after April 8,
2028, which is the tenth anniversary of the date the 2018 EIP was originally adopted by the Board.

U.S. Federal Income Tax Consequences

The following is a summary of the principal United States federal income tax consequences to participants and
us with respect to participation in the Amended 2018 EIP. This summary is not intended to be exhaustive and does
not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The
information is based upon current federal income tax rules and therefore is subject to change when those rules
change. Because the tax consequences to any participant may depend on his or her particular situation, each
participant should consult the participant’s tax adviser regarding the federal, state, local and other tax consequences
of the grant or exercise of an award or the disposition of stock acquired the Amended 2018 EIP. The Amended 2018
EIP is not qualified under the provisions of Section 401(a) of the Internal Revenue Code of 1986, as amended (the
“Code”), and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974. Our
ability to realize the benefit of any tax deductions described below depends on our generation of taxable income as
well as the requirement of reasonableness, the provisions of Section 162(m) of the Code and the satisfaction of our
tax reporting obligations.

Nonstatutory Stock Options

Generally, there is no taxation upon the grant of an NSO if the stock option is granted with an exercise price

equal to the fair market value of the underlying stock on the grant date. Upon exercise, a participant will recognize
ordinary income equal to the excess, if any, of the fair market value of the underlying stock on the date of exercise
of the stock option over the exercise price. If the participant is employed by us or one of our affiliates, that income
will be subject to withholding taxes. The participant’s tax basis in those shares will be equal to their fair market
value on the date of exercise of the stock option, and the participant’s capital gain holding period for those shares
will begin on that date.

We will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the

participant.

Incentive Stock Options

The Amended 2018 EIP provides for the grant of stock options that are intended to qualify as “incentive stock

options,” as defined in Section 422 of the Code. Under the Code, a participant generally is not subject to ordinary
income tax upon the grant or exercise of an ISO. If the participant holds a share received upon exercise of an ISO
for more than two years from the date the stock option was granted and more than one year from the date the stock
option was exercised, which is referred to as the required holding period, the difference, if any, between the amount
realized on a sale or other taxable disposition of that share and the participant’s tax basis in that share will be long-
term capital gain or loss.

If, however, a participant disposes of a share acquired upon exercise of an ISO before the end of the required
holding period, which is referred to as a disqualifying disposition, the participant generally will recognize ordinary
income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value of the share
on the date of exercise of the stock option over the exercise price. However, if the sales proceeds are less than the
fair market value of the share on the date of exercise of the stock option, the amount of ordinary income recognized
by the participant will not exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying
disposition exceeds the fair market value of the share on the date of exercise of the stock option, that excess will be
short-term or long-term capital gain, depending on whether the holding period for the share exceeds one year.

For purposes of the alternative minimum tax, the amount by which the fair market value of a share of stock
acquired upon exercise of an ISO exceeds the exercise price of the stock option generally will be an adjustment

22

included in the participant’s alternative minimum taxable income for the year in which the stock option is exercised.
If, however, there is a disqualifying disposition of the share in the year in which the stock option is exercised, there
will be no adjustment for alternative minimum tax purposes with respect to that share. In computing alternative
minimum taxable income, the tax basis of a share acquired upon exercise of an ISO is increased by the amount of
the adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the
stock option is exercised.

We are not allowed a tax deduction with respect to the grant or exercise of an ISO or the disposition of a share
acquired upon exercise of an ISO after the required holding period. If there is a disqualifying disposition of a share,
however, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the
participant, provided that either the employee includes that amount in income or we timely satisfy our reporting
requirements with respect to that amount.

Restricted Stock Awards

Generally, the recipient of a restricted stock award will recognize ordinary income at the time the stock is
received equal to the excess, if any, of the fair market value of the stock received over any amount paid by the
recipient in exchange for the stock. If, however, the stock is not vested when it is received (for example, if the
employee is required to work for a period of time in order to have the right to sell the stock), the recipient generally
will not recognize income until the stock becomes vested, at which time the recipient will recognize ordinary
income equal to the excess, if any, of the fair market value of the stock on the date it becomes vested over any
amount paid by the recipient in exchange for the stock. A recipient may, however, file an election with the Internal
Revenue Service, within 30 days following his or her receipt of the stock award, to recognize ordinary income, as of
the date the recipient receives the award, equal to the excess, if any, of the fair market value of the stock on the date
the award is granted over any amount paid by the recipient for the stock.

The recipient’s basis for the determination of gain or loss upon the subsequent disposition of shares acquired
from a restricted stock award will be the amount paid for such shares plus any ordinary income recognized either
when the stock is received or when the stock becomes vested.

We will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient

of the restricted stock award.

Restricted Stock Unit Awards

Generally, the recipient of a restricted stock unit award structured to comply with the requirements of

Section 409A of the Code or an exemption to Section 409A of the Code will recognize ordinary income at the time
the stock is delivered equal to the excess, if any, of the fair market value of the stock received over any amount paid
by the recipient in exchange for the stock. To comply with the requirements of Section 409A of the Code, the stock
subject to a restricted stock unit award may generally only be delivered upon one of the following events: a fixed
calendar date (or dates), separation from service, death, disability or a change in control. If delivery occurs on
another date, unless the restricted stock unit award otherwise complies with or qualifies for an exemption to the
requirements of Section 409A of the Code, in addition to the tax treatment described above, the recipient will owe
an additional 20% federal tax and interest on any taxes owed.

The recipient’s basis for the determination of gain or loss upon the subsequent disposition of shares acquired

from a restricted stock unit award will be the amount paid for such shares plus any ordinary income recognized
when the stock is delivered.

We will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient

of the restricted stock unit award.

23

Stock Appreciation Rights

Generally, if a stock appreciation right is granted with an exercise price equal to the fair market value of the
underlying stock on the grant date, the recipient will recognize ordinary income equal to the fair market value of the
stock or cash received upon such exercise. We will generally be entitled to a tax deduction equal to the taxable
ordinary income realized by the recipient of the stock appreciation right.

Section 162(m) Limitations

Under Section 162(m) of the Code (“Section 162(m)”), compensation paid to any publicly held corporation’s

“covered employees” that exceeds $1 million per taxable year for any covered employee is generally
non-deductible. Awards granted under the Amended 2018 EIP will be subject to the deduction limit under
Section 162(m) and will not be eligible to qualify for the performance-based compensation exception under
Section 162(m) pursuant to the transition relief provided by the Tax Cuts and Jobs Act. For further information
regarding the deduction limit under Section 162(m) and such transition relief, see the section entitled
“Compensation Discussion and Analysis – Other Executive Compensation Matters – Tax Effects of Executive
Compensation.”

Name and Position

Number of Shares

New Plan Benefits under Amended 2018 EIP

Eddie Gray(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

CEO and Director

Michael S. Ostrach(1)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Senior Vice President, Chief Financial Officer and Chief Business Officer

Robert L. Coffman, Ph.D.(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Senior Vice President and Chief Scientific Officer

Robert Janssen, M.D.(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Chief Medical Officer and Senior Vice President, Clinical Development, Medical

and Regulatory Affairs

David F. Novack(1)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Senior Vice President, Operations and Quality

All current executive officers as a group(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . .
All current directors who are not executive officers as a group(2)
All employees, including all current officers who are not executive officers, as a

group(1)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—

—

—

—

—

—
105,000 per calendar year

—

(1) Awards granted under the Amended 2018 EIP to our executive officers and other employees are discretionary and are not subject to set
benefits or amounts under the terms of the Amended 2018 EIP, and our Board and our Compensation Committee have not granted any
awards under the Amended 2018 EIP subject to stockholder approval of this Proposal 2. Accordingly, the benefits or amounts that will be
received by or allocated to our executive officers and other employees under the Amended 2018 EIP are not determinable.

(2) Awards granted under the Amended 2018 EIP to our non-employee directors are discretionary and are not subject to set benefits or amounts
under the terms of the Amended 2018 EIP. However, pursuant to our current compensation program for non-employee directors, each of our
current non-employee directors is eligible to receive an annual grant of a stock option to purchase 15,000 shares of our common stock. On
and after the date of the Annual Meeting, any such stock options will be granted under the Amended 2018 EIP if this Proposal 2 is approved
by our stockholders. For additional information regarding our current compensation program for non-employee directors, please see
“Director Compensation” below.

24

The following table sets forth, for each of the individuals and various groups indicated, the total number of

shares of our common stock subject to awards that have been granted under the 2018 EIP as of April 9, 2019.

Awards Granted under the 2018 EIP

2018 Equity Incentive Plan

Name and Position

As of
April 9, 2019
Number of Shares

Eddie Gray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

350,000

CEO and Director

Michael S. Ostrach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

110,000

Senior Vice President, Chief Financial Officer and Chief Business Officer

Robert L. Coffman, Ph.D.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

110,000

Senior Vice President and Chief Scientific Officer

Robert Janssen, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chief Medical Officer and Senior Vice President, Clinical Development, Medical and

130,000

Regulatory Affairs

David F. Novack . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

130,000

Senior Vice President, Operations and Quality

All current executive officers as a group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
All current directors who are not executive officers as a group . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Each non-employee nominee for election as a director:

Laura Brege . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dennis A. Carson, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Each associate of any executive officers, current directors or director nominees . . . . . . . . . . . . . . .
Each other person who received or is to receive 5% of awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
All employees, including all current officers who are not executive officers, as a group . . . . . . . . .

830,000
105,000

15,000
15,000
—
—
2,609,608

Vote Required

The affirmative vote of the holders of a majority of shares present (either in person or by proxy) and entitled to

vote on the matter at the Annual Meeting will be required to approve this Proposal 2. Abstentions will be counted
toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as
negative votes. Broker non-votes are counted towards a quorum but are not counted for any purpose in determining
whether this Proposal 2 has been approved.

THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF PROPOSAL 2.

25

PROPOSAL 3

ADVISORY VOTE ON EXECUTIVE COMPENSATION

Under the Dodd-Frank Wall Street Reform and Consumer Protection Act and Section 14A of the Exchange

Act, Dynavax stockholders are being asked to approve, on an advisory basis, the compensation of our named
executive officers as disclosed in this proxy statement, which is commonly referred to as a “say-on-pay vote.” This
vote is not intended to address any specific item of compensation, but rather the overall compensation of our named
executive officers, which results from our compensation philosophy, policies and practices as discussed in this
proxy statement. The compensation of our named executive officers subject to the say-on-pay vote is described in
the Compensation Discussion and Analysis, the accompanying tables, and the related narrative disclosure contained
in this proxy statement.

Our Compensation Committee is responsible for designing and administering our executive compensation
programs. Our Compensation Committee firmly believes that Dynavax’s executive compensation programs should
reward our named executive officers for performance, and that when key performance objectives are not achieved,
the compensation of our named executive officers should reflect as much. We believe that the compensation of our
named executive officers, as disclosed in this proxy, reflects this philosophy. In addition, our Compensation
Committee believes that the compensation programs for our named executive officers have been instrumental in
helping Dynavax be able to attract, retain and motivate our executive team, thereby enabling our company to be in a
position to move forward with our business strategy.

Our Board of Directors is now asking our stockholders to indicate their support for the compensation of our

named executive officers as described in this proxy statement by casting a non-binding advisory vote “For” the
following resolution:

“RESOLVED, that the compensation paid to Dynavax’s named executive officers, as disclosed pursuant to
Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and
narrative discussion, is hereby APPROVED.”

Although this vote is advisory and the outcome is not binding on our Board of Directors, the views expressed
by our stockholders, whether through this vote or otherwise, are important to us. As a result, the Board of Directors
and the Compensation Committee will carefully review the results of this vote, and they will consider these results
in making future decisions about our executive compensation programs and arrangements.

Unless our Board of Directors modifies its policy on the frequency of future advisory votes on the

compensation of our named executive officers, the next advisory vote on the compensation of our named executive
officers will be held at the 2020 annual meeting of stockholders.

Approval of this advisory proposal requires the affirmative vote of the holders of a majority of shares present
(either in person or by proxy) and entitled to vote on the matter at the Annual Meeting. Abstentions will be counted
toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as
negative votes. Broker non-votes are counted towards a quorum but are not counted for any purpose in determining
whether this Proposal 3 has been approved.

THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF PROPOSAL 3.

26

PROPOSAL 4

RATIFICATION OF SELECTION OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Audit Committee has selected Ernst & Young LLP, or Ernst & Young, as our independent registered
public accounting firm for the fiscal year ending December 31, 2019. Ernst & Young has audited our financial
statements since 2002. Representatives of Ernst & Young are expected to be present at the Annual Meeting. Ernst &
Young will have an opportunity to make a statement if it so desires and will be available to respond to appropriate
questions.

If the stockholders fail to ratify the selection of Ernst & Young, the Audit Committee will reconsider whether

or not to retain that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the
appointment of a different independent registered public accounting firm at any time during the year if it determines
that such a change would be in the best interests of the Company and its stockholders.

The affirmative vote of the holders of a majority of the shares present (either in person or by proxy) and
entitled to vote on the matter at the Annual Meeting will be required to ratify the selection of Ernst & Young.
Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will
have the same effect as negative votes. Broker non-votes are counted towards a quorum but are not counted for any
purpose in determining whether this matter has been approved; however, Proposal 4 is considered a “routine”
matter, and therefore no broker non-votes are expected to exist in connection with this Proposal 4.

THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF PROPOSAL 4.

AUDIT FEES

In connection with the audit of our 2018 financial statements, we entered into an engagement agreement with

Ernst & Young which sets forth the terms by which Ernst & Young will perform audit services for us.

The following table represents aggregate fees billed to the Company for the fiscal years ended December 31,

2018 and 2017 by Ernst & Young, our principal auditors. The Audit Committee pre-approved all service fees
described below.

Fiscal Year Ended

2018

2017

Audit Fees(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tax Fees(2)
All Other Fees(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,442,681
79,200
1,995

$1,203,801
40,500
1,995

Total Fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,523,876

$1,246,296

(1) Audit fees include fees for the audit of our consolidated financial statements and interim reviews of our quarterly financial statements,

including compliance with the provisions of Section 404 of the Sarbanes-Oxley Act as well as fees related to registration statements,
consents and other services related to SEC matters. In each of 2017 and 2018, audit fees included fees related to a comfort letter in
connection with an equity offering.

(2)

Tax fees include Section 382 study and other tax advisory services.

(3) All other fees represent subscription fees for an online accounting research tool and related database.

PRE-APPROVAL POLICIES AND PROCEDURES

Our Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services

rendered by our independent registered public accounting firm, Ernst & Young. Under the policy, the Audit

27

Committee pre-approves specified services in the defined categories of audit services, audit-related services, tax
services and all other services up to specified amounts. Pre-approval may be given as part of the Audit Committee’s
approval of the scope of the engagement of the independent registered public accounting firm or on an interim basis
by the Audit Committee Chair, as needed and on a case-by-case basis before the independent registered public
accounting firm is engaged to provide each service.

The Audit Committee has determined that services rendered by Ernst & Young are compatible with

maintaining the principal auditors’ independence.

28

EXECUTIVE OFFICERS

The following table sets forth certain information with respect to our executive officers as of April 9, 2019:

Name

Eddie Gray(1) . . . . . . . . . . . . . . . . . . . . . . . .
Michael S. Ostrach . . . . . . . . . . . . . . . . . . .

Robert L. Coffman, Ph.D. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .
Robert Janssen, M.D.

Age

60
67

72
65

David F. Novack . . . . . . . . . . . . . . . . . . . . .

57

Position

Chief Executive Officer and Director
Senior Vice President, Chief Financial Officer and Chief
Business Officer
Senior Vice President and Chief Scientific Officer
Chief Medical Officer and Senior Vice President, Clinical
Development, Medical and Regulatory Affairs
Senior Vice President, Operations and Quality

(1)

Please see “Proposal 1 – Election of Directors” in this proxy statement for more information about Mr. Gray.

Michael S. Ostrach – Senior Vice President, Chief Financial Officer and Chief Business Officer

Mr. Ostrach is our Senior Vice President, Chief Financial Officer and Chief Business Officer. Mr. Ostrach

joined Dynavax in October 2006 as Vice President, Chief Business Officer and General Counsel, and became
Principal Financial Officer in September 2013, Chief Financial Officer in March 2015 and Senior Vice President in
February 2016. Mr. Ostrach held the position of Dynavax’s General Counsel from October 2006 to September 2015.
From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold
Pharmaceuticals. From 1997 to 2004, Mr. Ostrach was at Kosan Biosciences, most recently as President and Chief
Operating Officer. Mr. Ostrach began his corporate career at Cetus Corporation, where he served in several
capacities between 1981 and 1991, initially as General Counsel and finally as Senior Vice President of Corporate
Affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr. Ostrach
became President of Chiron Technologies. He holds a B.A. from Brown University and a J.D. from Stanford Law
School.

Robert L. Coffman, Ph.D. – Senior Vice President and Chief Scientific Officer

Dr. Coffman was appointed Senior Vice President and Chief Scientific Officer of Dynavax in February 2014,

and prior to that he was Vice President and Chief Scientific Officer of Dynavax since December 2000. Prior to
joining Dynavax in 2000, Dr. Coffman was a founding member of the DNAX Research Institute in Palo Alto,
California. Dr. Coffman has authored over 200 scientific publications, is a member of the National Academy of
Sciences and the American Academy of Microbiology, and has received a number of prestigious awards for his
work. With colleague Dr. Tim Mosmann, he defined the two principal subtypes of helper T cells, termed Th1 and
Th2 cells, and demonstrated the central relationship between their differences in cytokine expression and function.
Dr. Coffman defined basic mechanisms of T-cell regulation in asthma and infectious and parasitic diseases, and
demonstrated the central role of regulatory CD4+ T cells in preventing inflammatory bowel disease. At Dynavax,
Dr. Coffman has pioneered the development of agonists and antagonists for Toll-Like Receptors (“TLRs”), key
recognition receptors in innate immunity. Dr. Coffman received an A.B. in Microbiology from Indiana University
and a Ph.D. in Immunology from the University of California, San Diego.

Robert Janssen, M.D. – Chief Medical Officer and Senior Vice President, Clinical Development, Medical and
Regulatory Affairs

Dr. Janssen was appointed Chief Medical Officer and Senior Vice President, Clinical Development, Medical

and Regulatory Affairs in January 2018. Dr. Janssen was appointed Chief Medical Officer and Vice President,
Clinical Development and Regulatory Affairs in July 2013. He served as Dynavax’s Vice President, Medical Affairs
since November 2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 through
2012, during which time he was extensively involved with Phase 3 clinical development of HEPLISAV-B and its

29

U.S. and European licensing applications. Prior to joining Dynavax, Dr. Janssen was Vice President, Medical
Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health care provider
education focused on HIV and hepatitis B therapies. Until 2008, Dr. Janssen spent 23 years at the U.S. Centers for
Disease Control and Prevention (“CDC”), most recently as the Director of the Division of HIV/AIDS Prevention
from 2000 to 2008. Under his leadership, the CDC first explored HIV treatment as a mode of HIV prevention and
launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV. Dr. Janssen received a Bachelor
of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of
Southern California. He is a neurologist with training in virology received at the University of Pennsylvania.
Dr. Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 130
scientific articles in a variety of journals and has served as a reviewer for leading scientific journals.

David F. Novack – Senior Vice President, Operations and Quality

Mr. Novack joined Dynavax in March 2013 as Senior Vice President, Operations and Quality. Mr. Novack was

formerly with Novartis Vaccines & Diagnostics where he served since 2009 as the Global Head of Technical
Operations and Supply Chain for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine
Manufacturing Strategy. Prior to Novartis, Mr. Novack was the Vice President, Business Development for Vaxin,
Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr. Novack worked at MedImmune, formerly
Aviron, serving in several capacities including business development, manufacturing, contract operations and most
recently as Senior Director, Supply Chain Operations. Previously, from 1989 to 1993, Mr. Novack was with
American Cyanamid Company in various roles. Mr. Novack received a B.S. in Biology from State University of
New York and an M.B.A. from Columbia University.

Overview

COMPENSATION DISCUSSION AND ANALYSIS

This Compensation Discussion and Analysis discusses our executive compensation philosophy and practices

and provides an overview of the Compensation Committee’s 2018 decisions for the following named executive
officers (“NEOs”) whose compensation is set forth in the Summary Compensation Table and other related tables
contained in this proxy statement:

• Eddie Gray, Chief Executive Officer and Director;

• Michael S. Ostrach, Senior Vice President, Chief Financial Officer and Chief Business Officer;

• Robert L. Coffman, Ph.D., Senior Vice President and Chief Scientific Officer;

• Robert Janssen, M.D., Chief Medical Officer and Senior Vice President, Clinical Development, Medical

and Regulatory Affairs; and

• David F. Novack, Senior Vice President, Operations and Quality.

We present this Compensation Discussion and Analysis in the following sections:

1.

2.

3.

Executive Summary. Provides an overview of our 2018 and early 2019 corporate performance and
certain governance aspects of our executive compensation program.

Executive Compensation Program. Describes the Company’s executive compensation philosophy and
process and the material elements of our executive compensation program.

2018 Executive Compensation Decisions. Provides a synopsis of the Compensation Committee’s
executive compensation decisions for 2018 and certain actions taken before or after 2018 when doing
so enhances the understanding of our executive compensation program.

4. Other Executive Compensation Matters. Reviews the accounting and tax treatment of compensation

and the relationship between our compensation program and risk.

p. 31

p. 34

p. 38

p. 45

30

Executive Summary

Business Overview, Corporate Developments in 2018 and Early 2019 and Relationship to Executive
Compensation

We are a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate

and adaptive immune responses through toll-like receptor (“TLR”) stimulation. Our first commercial product,
HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted), was approved by the United States Food and
Drug Administration (“FDA”) in November 2017 for prevention of infection caused by all known subtypes of
hepatitis B virus in adults age 18 years and older. We commenced commercial shipments of HEPLISAV-B in
January 2018 and deployed our field sales force in February 2018. In March 2018, we received regulatory approval
of the pre-filled syringe (“PFS”) presentation of HEPLISAV-B. Our development efforts are primarily focused on
stimulating the innate immune response to treat cancer in combination with other immunomodulatory agents.
Our lead investigational immuno-oncology product candidates are SD-101, currently being evaluated in Phase 2
clinical studies, and DV281, in a Phase 1 safety study. Given the long product development cycles in our business,
we believe delivery of long term value to our stockholders is the best measure of our performance.

Heading into 2018, we had worked to diversify our portfolio such that our focus for the year was balanced
between ongoing manufacturing, quality, commercialization and market adoption efforts for HEPLISAV-B and
advancing our oncology program. As a result of this diversification, we viewed our success in 2018 and beyond as
being based on our commercialization progress for HEPLISAV-B and achievements in our oncology program.
Thus, we designed our 2018 executive compensation program to reward achievement of the specific related
objectives we believed would advance our business strategy and create long-term value for our stockholders. In
particular, our 2018 annual incentive program was aligned with our corporate objectives by selecting and weighting
corporate goals as follows:

• Commercialization, dosage volume sold and manufacturing goals for HEPLISAV-B were weighted at

42.5%;

• Objectives specific to advancing our oncology pipeline were weighted at 42.5%; and

• Business plan goals that supported advancing our business and portfolio strategies were weighted at 15%.

Committed to achieving these corporate goals in 2018, our NEOs were focused on executing our

HEPLISAV-B business strategy by working to successfully commercialize it, deploy a field sales force, develop a
distribution network, obtain reimbursement coverage, develop and implement a healthcare compliance program to
support compliant product-related business practices, and ensure that we achieved sufficient manufacturing
capability to successfully meet demand and that such manufacturing was done in accordance with applicable quality
requirements. Our NEOs were also focused on advancing a robust pipeline of immuno-oncology clinical stage
development programs and discovering other cutting-edge TLR-based vaccines and immunotherapies. We believe
that we have balanced the diverse needs of being a fully-operational commercial company with continuing to
advance our scientific progress in research and development in our immuno-oncology program, including reporting
significant results relating to SD-101 in combination with Keytruda® (pembrolizumab), an anti-PD-1 therapy, and
initiating a Phase 1 safety study of DV281 in combination with another anti-PD-1 therapy.

Propelled by our diversification strategy and the performance of our NEOs, we believe 2018 was a year of
many positive developments for our company. For HEPLISAV-B, we not only commercialized the product and
made significant strides advancing it through the multiple-step decision-making process employed by institutional
hepatitis B vaccine purchasers, but we also gained regulatory approval of the PFS presentation of the vaccine—we
believe this was an important accomplishment, as it increased our ability to achieve faster adoption of our product
by physicians and other key decision-makers. HEPLISAV-B also received a recommendation from the Centers for
Disease Control Advisory Committee on Immunization Practices (“ACIP”) and additional payer and policy review
and approval. Each of these developments served to lay a foundation for future sales growth for HEPLISAV-B
through advocacy and adoption efforts.

31

We also successfully delivered certain key corporate goals related to advancing our immuno-oncology
programs. In particular, we announced results associated with SD-101 and advanced DV281 into the clinical stage.
We also achieved certain business plan goals that supported advancing our business and portfolio strategies.

Certain key events that took place for our company involving HEPLISAV-B and our immuno-oncology

pipeline in 2018 are summarized below:

•

•

•

•

•

•

•

•

•

In January, we announced that HEPLISAV-B was available to adults in the United States, becoming the
first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B
vaccine for adults. Commercial sales followed immediately after availability.

In February, we deployed our field sales force for HEPLISAV-B, and the sales force members
immediately began meeting with institutional decision-makers about HEPLISAV-B and commencing
other selling efforts. In addition, we announced that ACIP voted unanimously in favor of including
HEPLISAV-B on its list of ACIP-recommended products for use to vaccinate adults against hepatitis B.
The ACIP recommendation is required by many insurance plans and institutions in order to cover or make
available HEPLISAV-B, and was an essential step in providing patients with broad access to
HEPLISAV-B going forward.

In March, we received FDA approval of the PFS presentation of HEPLISAV-B, enabling us to meet the
preferred means of physicians, institutions and payers in delivering the only two-dose adult hepatitis B
vaccine in the United States.

In April, we presented durability of response data in advanced melanoma patients from the ongoing Phase
1b/2 study investigating SD-101 in combination with pembrolizumab. This data showed that 86% of
initial responses were ongoing after a median of 18 months of follow-up in patients that were naïve to
anti-PD-1/L1 monotherapy. We also, presented interim data for SD-101 in combination with
pembrolizumab for patients with advanced squamous cell carcinoma of the head and neck, indicating,
among other things, an overall response rate (“ORR”) of 33%, and that SD-101 was well-tolerated with no
dose-limiting toxicities. The data was presented at the 2018 American Association for Cancer Research
Annual Meeting.

In April, we also announced the CDC’s publication of ACIP’s recommendation for the use of
HEPLISAV-B for adults in the United States in the Morbidity and Mortality Weekly Report (“MMWR”).
Publication in the MMWR is the final endorsement of HEPLISAV-B that was required by many
institutional policies for reimbursement.

In June, we announced the presentation of updated findings in patients with advanced melanoma in the
ongoing Phase 1b/2 study investigating SD-101 in combination with pembrolizumab. The data showed a
70% ORR in patients who received the ≤ 2 mg dose of SD-101 and a 6-month progression free survival
rate of 76% in patients naïve to anti-PD-1 treatment in patients who received the ≤ 2 mg dose of SD-101.
The data was presented at the 2018 American Society of Clinical Oncology Annual Meeting.

In June, we also announced results of a post hoc analysis of data from HBV 23, the pivotal Phase 3 trial of
HEPLISAV B evaluating data for participants with type 2 diabetes aged 60 to 70. The per protocol
analysis showed that the seroprotection rate at week 28 for HEPLISAV-B was 85.8% compared to 58.5%
for Engerix-B®, that HEPLISAV-B induced higher geometric mean concentration at week 24 than
Engerix-B at week 28, and that HEPLISAV-B had a similar safety profile compared to Engerix-B,
regardless of study subgroup. The data were presented at the 2018 American Diabetes Association Annual
Meeting.

In August, we announced that 100% of Medicare-insured lives, 94% of commercially-insured lives, and
74% of lives under state Medicaid plans were now covered for HEPLISAV-B, ensuring a strong
reimbursement environment as we continue to seek market share.

In August, we also announced that two peer-reviewed papers reporting clinical studies of SD-101 were
published by Cancer Discovery, a journal publication from the American Association of Cancer

32

•

•

•

•

Research (“AACR”). The investigators reported clinical activity and broad immune activation in the
tumor microenvironment when SD-101 is administered in combination with either low dose radiation in
patients with indolent lymphoma or in combination with PD-1 blockade in patients with unresectable or
metastatic melanoma.

In September, we announced publication of a preclinical study demonstrating that inhalation of a TLR9
agonist, such as DV281, can stimulate effective immunity against lung tumors and complement the
actions of PD-1 blockade to generate durable, systemic anti-tumor immunity.

In October, we announced that the combination of SD-101 and pembrolizumab would be evaluated in a
new randomized, investigational treatment arm for the ongoing I-SPY 2 Trial™ for neoadjuvant treatment
of locally advanced breast cancer, expanding SD-101’s potential use in the field of neoadjuvant
immunotherapy.

In October, we also presented interim data from our ongoing Phase 1b/2 SYNERGY-001 study
investigating SD-101 in combination with pembrolizumab in patients with advanced melanoma naïve to
anti-PD-1/L1 therapy. The interim data showed a 70% ORR in advanced melanoma patients naïve to
anti-PD-1/L1 therapy who received the ≤ 2 mg dose of SD-101 and a 48% ORR in the group receiving the
8 mg dose of SD-101. The data was presented at the European Society for Medical Oncology 2018
Congress.

In November, we announced significant progress on HEPLISAV-B’s commercialization, including
obtaining Pharmacy and Therapeutics (“P&T”) committee approval from six of the top 10 integrated
delivery networks, and that 402 of our largest targeted customers have received P&T committee approval,
of whom 200 have progressed to purchase HEPLISAV-B and 68 have implemented HEPLISAV-B
throughout their system, indicating continuing adoption of HELPISAV-B as the standard of care for
hepatitis B vaccination in adults in the U.S. This progress is critical to our achievement of HEPLISAV-B
in 2019 and beyond.

Compensation Governance Highlights

È Design executive compensation program to align

È No excessive change in control or severance

What we do

What we do not do

pay with performance

payments (no cash severance multiplier greater
than 2x base + target bonus)

È Majority of pay is variable and not guaranteed

È No repricing of underwater stock options without

(over 86% for our CEO in 2018)

È Prohibit hedging and discourage pledging by
executive officers and directors (no pledging
occurred in 2018)

stockholder approval

È No tax gross-ups

È Grant equity awards with performance-based

È No perquisites

vesting

È Conduct an annual say-on-pay vote
È Seek input from, listen to and respond to

stockholders

È No guaranteed bonuses

Consideration of Our Prior Say-on-Pay Votes and Related Stockholder Engagement

In 2016, our Board of Directors adopted, and our stockholders approved, a policy that we would hold a

say-on-pay vote on a yearly basis. Since adjusting to an annual say-on-pay practice, we have experienced continued
favorable voting results with our say-on-pay practices. The results of the past three years’ voting have been over

33

70%, 85%, and 95% in fiscal years 2016, 2017, and 2018, respectively, of stockholders voting in favor of our pay
practices.

Because of its importance, we continue to solicit feedback from our stockholders regarding our executive

compensation program as part of our stockholder outreach. We view the stockholder feedback process as a year-
round activity, and we have incorporated stockholder feedback into our pay practices, such as implementing
performance-based equity measures for our NEOs. As a result, we obtained feedback from our stockholders in the
spring and fall of 2018, and plan to do so again in 2019. As part of our annual stockholder feedback program, we
contacted 12 of our largest 20 institutional stockholders in early fall 2018, and we spoke with 100% of the
stockholders that wanted to provide us with feedback at that time about our corporate governance and executive
compensation practices. During these discussions, which included an opportunity for detailed questions, none of our
stockholders expressed any concerns about our corporate governance or executive compensation practices. The bulk
of the stockholders, while appreciating the outreach, did not feel a need to talk at the time.

Executive Compensation Program

Philosophy and Objectives

We believe our NEOs’ compensation should align our executives’ success with that of our stockholders over

the long-term through achievement of strategic corporate objectives that are fundamental to our business model and
that will create long-term stockholder value. Our executive compensation programs are designed to be competitive
with our peer group to enable us to attract, motivate, reward, and retain outstanding talent. Our compensation
programs are based on the following key principles:

• A significant component of pay is linked with performance and the achievement of our strategic goals;

• Alignment of our executives’ interests with those of our stockholders through equity compensation;

• Overall compensation that is competitive in the industry in which we compete for executive talent; and

• Recognition of individual contributions, teamwork and corporate performance.

Compensation-Setting Process

Role of the Compensation Committee and Management

The Compensation Committee oversees and administers our executive compensation programs. The
Compensation Committee acts pursuant to a charter adopted by our Board, which can be found at our website,
www.dynavax.com. The Compensation Committee generally determines the compensation to be paid to the
executive officers, including our NEOs. Either the Compensation Committee or the independent members of our
Board, upon recommendation from the Compensation Committee, approve certain compensation of our CEO, and
references in this Compensation Discussion and Analysis to our Board approving our CEO’s compensation refer to
the independent members of our Board.

The Compensation Committee (and the board of directors, with respect to our CEO) approves our corporate
goals and the individual goals of our NEOs after considering the Company’s recommendations on these matters.
The Compensation Committee annually reviews the base salaries, cash incentives and equity compensation of our
NEOs and periodically reviews other elements of our compensation. Compensation decisions are based primarily on
the following:

• Peer and Industry Data – The Compensation Committee uses peer and industry data provided by its
consultant, Arnosti Consulting Inc. (“Arnosti”), as a reference in setting base salaries and target cash
compensation, determining appropriate levels and mix of equity compensation and determining the type
and portion of compensation tied to performance goals.

• Annual Performance Reviews – The Chair of the Compensation Committee conducts annual performance
reviews of our CEO taking into consideration feedback obtained during the course of the year from the

34

independent members of our Board and the CEO’s direct reports. Our CEO conducts and presents the
performance reviews of the other NEOs to the Compensation Committee after the end of each fiscal year.
In reviewing and determining the compensation of each NEO, the Compensation Committee also
considers individual factors, such as potential for future contributions to Company growth, industry
experience and retention concerns.

• CEO Recommendations – The Compensation Committee seeks input from our CEO for setting the salary

and target cash compensation levels for the other NEOs, and also for purposes of setting annual
performance metrics and target amounts under our annual incentive program.

Role of Compensation Consultant

Arnosti has been the Compensation Committee’s independent compensation consultant since 2010, and the
Compensation Committee meets regularly with Arnosti, both with and without management present, depending
upon the topic being discussed.

In January 2018 and again in February 2019, the Compensation Committee reviewed whether the work of
Arnosti as a compensation consultant raised any conflict of interest, taking into consideration the following factors:

• The provision of other services to the Company;

• The amount of fees paid to Arnosti by the Company;

• Arnosti’s policies and procedures that are designed to prevent conflicts of interest;

• Any business or personal relationship of Arnosti or the individual compensation advisors employed by

Arnosti with an executive officer of the Company; and

• Any Company stock owned by Arnosti or the individual compensation advisors employed by Arnosti.

Based on the Compensation Committee’s review of this information, it determined the work of Arnosti and the

individual compensation advisors employed by Arnosti as compensation consultant to the Compensation
Committee, did not create any conflict of interest. The Compensation Committee has the sole authority to direct,
terminate or continue Arnosti’s services, although the Company pays the cost for Arnosti’s services.

In 2018, Arnosti provided advice to the Compensation Committee on several different aspects of its

responsibilities related to our compensation programs and practices. Specifically, during 2018, Arnosti assisted the
Compensation Committee as follows:

• Reviewed and analyzed compensation levels of our NEOs in comparison to those of our peer companies;

•

•

•

•

Provided general information concerning executive compensation trends and developments;

Provided recommendations to the Compensation Committee on refining our peer group;

Provided an assessment of the annual meeting voting results;

Provided the Board with a review of competitive data from the peer group on Board compensation; and

• Reviewed the Compensation Discussion and Analysis for inclusion in our proxy statement.

2018 Peer Group

Our Compensation Committee uses a peer group for a general understanding of market compensation practices

and our positioning within the peer group. Our Compensation Committee believes that over-reliance on
benchmarking could result in compensation that is unrelated to the value delivered by the NEOs because
compensation benchmarking does not take the specific performance of the NEOs, or the performance of the
Company, into account.

35

Our Compensation Committee does not have a specific target compensation level for the NEOs or otherwise

use a formulaic approach to setting pay at a particular positioning within the market data; rather, the Compensation
Committee reviews a range of market data reference points of the Company’s peer group with respect to total target
cash compensation (including both base salary and the annual target performance bonus) and equity compensation
(valued based on an approximation of grant date fair value and also considered as shares as a percentage of total
common shares outstanding) to support its compensation decisions.

For 2018 compensation decisions, our Compensation Committee approved a peer group of biotechnology
companies at a similar stage of product development with which we compete for executive talent that were of
similar size to the Company in terms of market capitalization, product portfolio, pipeline and number of employees.
To align with our strategic plan, which included commercialization of HEPLISAV-B and expansion of our pipeline
with early clinical development in cancer immunotherapy, our peer group included companies that were:

• Commercial-stage (italicized in the list below and representing approximately 32% of the companies in

our peer group);

• Both oncology and non-oncology focused; and

• Companies that had their own manufacturing operations.

The change in our peer group from 2017 to 2018 included removing five companies for various reasons
including market caps that were out of range or because the company had been acquired. The companies that were
removed were Ariad Biotech Inc., Celldex Therapeutics, Inc., Exelixis, Inc., Kite Pharma, Inc. and NewLink
Genetics Corporation. As of September 2017, which was shortly before the 2018 peer group was approved, the
companies in the 2018 peer group had market capitalizations between ranging from $296 million to $3.9 billion and
the median market capitalization of our peer group was $870 million. At that time, our market capitalization was
$1.258 billion. The following table lists our 2018 peer group.

• Aduro Biotech, Inc.

• Amicus Therapeutics, Inc.

• Array Biopharma, Inc.

•

ImmunoGen, Inc.

• MacroGenics, Inc.

• Nektar Therapeutics, Inc.

• BioCryst Pharmaceuticals, Inc.

• Novavax, Inc.

• ChemoCentryx, Inc.

• Cytokinetics, Inc.

• Clovis Oncology, Inc.

• Depomed, Inc.

• Demira, Inc.

• Eagle Pharmaceuticals, Inc.

• Emergent BioSolutions, Inc.

• Epizyme, Inc.

• Heron Therapeutics, Inc.

•

Puma Biotechnology, Inc.

• Repligen Corp.

• Rigel Pharmaceuticals, Inc.

•

•

Sarepta Therapeutics, Inc.

Supernus Pharmaceuticals, Inc.

• TG Therapeutics, Inc.

• Xenocor, Inc.

• Ziopharm Oncology, Inc.

Elements of Executive Compensation

Our executive team continues to manage a changing and increasingly complex business. We strive to recognize

these efforts by compensating our NEOs for the demands and risks associated with our business through three
primary elements that are designed to reward performance in a simple and straightforward manner—base salaries,
annual performance-based cash incentives and long-term equity awards. During our annual stockholder outreach,

36

our key stockholders expressed support for the elements of our executive compensation program, including our
continued use of stock options as one portion of long-term equity awards and continuing to grant a portion of long-
term equity awards with performance-based vesting. As reflected in the chart below, we utilized performance-based
vesting for a portion of our 2018 long-term equity awards.

The table below summarizes the purpose and key characteristics of each of our compensation elements.

Element

Base Salary

Purpose

Key Characteristics

Provides a fixed level of compensation for
performing the essential day-to-day elements
of the job; gives executives a degree of
certainty in light of having a majority of their
compensation at risk.

Fixed compensation that is reviewed annually
and adjusted if and when appropriate; reflects
each NEO’s performance, experience, skills,
level of responsibility and the breadth, scope
and complexity of the position as well as the
competitive marketplace for executive talent
specific to our industry.

Annual cash incentive based on corporate and
individual performance compared to
pre-established goals. Our CEO’s annual
incentive is based entirely on corporate goals.

Corporate goals focus on overarching
objectives for the Company which will
support long-term value, while individual
objectives represent key performance
expectations at the departmental or individual
level.

Corporate goals are aligned with our business
strategy and weighted by relative importance
so that achievement can be objectively
measured.

Stock options with an exercise price equal to
the fair market value on the date of grant
vesting over three years; the ultimate value
realized, if any, depends on the appreciation
of our common stock price and if our stock
price does not appreciate, there is no value
realized. In determining the aggregate size of
equity grants in any given year, the
Compensation Committee generally
considers the same factors described above
under “Base Salaries” as well as the
criticality of the executive to the long-term
achievement of corporate goals.

In March 2018, 20% of our NEO’s annual
grants were performance-based stock option
awards vesting upon the Compensation
Committee’s certification of achievement of
pre-established performance goals discussed
below.

Annual
Incentive
Program

Motivates executive officers to achieve
corporate and individual business goals,
which we believe increase stockholder value,
while providing flexibility to respond to
opportunities and changing market
conditions.

Long-Term
Equity
Incentives
(Stock Options)

Motivates executive officers to achieve our
business objectives by tying incentives to the
appreciation of our common stock over the
long term.

37

Element

Purpose

Key Characteristics

Long-Term
Equity
Incentives
(RSUs)

Other
Compensation

Motivates executive officers to achieve our
corporate objectives by tying compensation
to the performance of our common stock over
the long term and/or the achievement of
business and clinical development goals over
the long term; motivates our executive
officers to remain with the Company by
mitigating swings in incentive values during
periods when market volatility weighs on our
stock price.

Our executive officers participate in the same
benefits offered to all other employees, which
promote employee health and welfare and
assist in attracting and retaining our executive
officers.

Severance and
Change in
Control
Benefits

Serves our retention objectives by helping our
named executive officers maintain continued
focus and dedication to their responsibilities
to maximize stockholder value, including in
the event of a transaction that could result in
a change in control of our Company.

From time to time, we may also use special
grants of stock options for purposes of
retention or to reward continuous service
within the company, as was done in 2018 in
the case of two of our NEOs.

Restricted stock unit awards may vest based
on continued service over a specified period
of time and/or achievement of performance
goals; the ultimate value realized varies with
our common stock price.

From time to time, we may also use special
RSU awards for purposes of retention or to
reward continuous service within the
company. No such RSUs were granted to
NEOs in 2018.

Indirect compensation element consisting of
programs such as medical, vision, dental, life
and accidental death, long-term care and
disability insurance as well as a 401(k) plan
with a Company matching contribution, and
other plans and programs made available to
all eligible employees.

Provides protection in the event of a
termination of employment under specified
circumstances, including following a change
in control of our Company as described
below under “Potential Payments Upon
Change in Control or Involuntary
Termination.”

2018 Executive Compensation Decisions

Total Target Cash Compensation – Base Salaries and Target Bonus Percentages

When determining 2018 base salary and target bonus percentage adjustments, the Compensation Committee
considered each individual’s performance and Company performance, each individual’s industry experience and
tenure, internal pay equity, and retention concerns. The Compensation Committee also reviewed a range of market
data reference points (the 10th, 25th, 50th, 60th, 75th and 90th percentiles of peer group data) with respect to total
target cash compensation (including both base salary and the annual target performance bonus).

38

The Compensation Committee (and the board of directors, with respect to our CEO) decided that for 2018 each

NEO’s target bonus percentage would remain the same as in 2017 (which has not increased for any of our NEOs
since 2013) and base salaries would be increased as shown in the table below. In determining NEO compensation,
the Compensation Committee takes into account peer group data; each NEO’s industry experience, expertise, and
tenure with the Company; internal pay equity and the Company’s annual salary budget.

Name

Eddie Gray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Michael S. Ostrach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert L. Coffman, Ph.D.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert Janssen, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
David F. Novack . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2018 Base
Salary

$621,000
$439,875
$483,134
$438,000
$401,700

% Increase
from Prior
Year(1)

2018
Target
Bonus

3.5%
3.5%
3.5%
9.5%
4.0%

60%
50%
50%
50%
50%

(1) Dr. Janssen was promoted to his current position of Chief Medical Officer and Senior Vice President, Clinical Development, Medical and

Regulatory Affairs in 2018.

Long-Term Equity Incentive Awards

In making annual long-term equity incentive awards to NEOs in early 2018, the Compensation Committee

considered each NEO’s total options outstanding as of December 31, 2017, his performance during 2017, the
potential amount that could be realized at different hypothetical stock prices upon exercise of those awards and each
NEO’s percentage of ownership of the Company. The Compensation Committee also reviewed peer group data
reference points (the 10th, 25th, 50th, 60th, 75th and 90th percentiles of the market data) with respect to an
approximation of grant date fair value and shares as a percentage of total common shares outstanding. Additionally,
the Compensation Committee considered the mix of stock options and RSUs granted in 2017. The Compensation
Committee made final determinations based on its judgment in accordance with our pay-for-performance
philosophy and the need to retain and motivate these highly experienced and essential members of our management
team.

The Compensation Committee (and the board of directors, with respect to our CEO) determined to grant each

NEO’s annual long-term incentive compensation with a blend of both time-based options and performance-based
options in 2018. The Compensation Committee’s determination to only grant stock options to each NEO in 2018
was partially based upon the Compensation Committee’s grant of both time-and performance-based RSUs in 2017
as part of each NEO’s annual long-term incentive compensation, as well one-time retention grants of RSUs to our
NEOs that were made in 2017. As a result, the Compensation Committee determined that a blend of time-based and
performance-based stock options was most appropriate.

In 2018, the Compensation Committee approved annual grants in the form of stock options. Eighty percent of

each NEO’s 2018 annual grant was in the form of a time-based option, subject to each individual’s continuous
service, one-third of the shares subject to each grant vested on February 1, 2019 and the remainder vests in equal
monthly installments thereafter.

The remaining 20% of the NEO’s 2018 annual grant were performance-based stock options that vest solely

upon the Compensation Committee’s certification of achievement of the following equally weighted performance
goals:

• Achieve approval by the FDA of Pre-filled Syringe (“PFS”) and “potency assay” applications;

•

Sales of at least 200,000 doses of HEPLISAV-B;

• Release 720,000 doses of HEPLISAV-B PFS;

• Complete SD-101 and DV281 development plans;

39

•

Initiate expanded SD-101 clinical trial program; and

• Achieve financing to ensure certain cash-on-hand goals.

In February 2019, the Compensation Committee (and the Board, with respect to our CEO) affirmed the
achievement of the performance goals at the 90% level and the vesting of these stock options at such level. The
table below describes the aggregate grant date fair value of these stock options granted in fiscal year 2018.

Name

Grant Date Fair Value
of February 2018
Time-Based Stock
Option Awards

Grant Date Fair Value
of March 2018
Performance-Based
Stock Option Awards

Eddie Gray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Michael S. Ostrach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert L. Coffman, Ph.D.
Robert Janssen, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
David F. Novack . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$3,032,400
$ 866,400
$ 866,400
$ 866,400
$ 866,400

$758,100
$216,600
$216,600
$216,600
$216,600

Additionally, in March 2018, the Compensation Committee made a special time-based stock option grant to
Mr. Ostrach and Dr. Coffman of 150,000 shares each, of which 50% will vest in March 2020, and the remainder
will vest in March 2021. Our Compensation Committee determined that it was necessary to grant these retention
equity awards to Mr. Ostrach and Dr. Coffman during this critical time so as to secure their continued leadership,
including, for Mr. Ostrach, oversight of accounting, finance, business development and intellectual property, in
connection with integration of the HEPLISAV-B field sales team as Dynavax employees and our continued
commercialization efforts, and as we make decisions to advance our immuno-oncology program, and for
Dr. Coffman, with respect to our immuno-oncology program, including his key scientific role in advancing SD-101
and DV281.

In February 2019, our Board (with respect to our CEO and upon the recommendation of the Compensation
Committee) and the Compensation Committee (with respect to our other NEOs) approved annual long-term equity
incentive awards to our NEOs. These awards consisted of 80% time-based stock option awards, and 20%
performance-based RSU awards. The stock option grants vest over three years, with one-third of the shares subject
to each portion vesting 12 months after the grant date, and the remainder vesting in equal monthly installments
thereafter. The performance-based RSUs will vest, if at all, upon the Compensation Committee’s determination that
certain performance goals are met.

2018 Annual Incentive Program – Structure, Goals and Payout Decision

Structure. Our CEO does not have individual goals separate from the Company’s corporate objectives. For

our other NEOs, their total cash incentive payout is typically based on a weighting of 50% corporate and 50%
individual goals. Our CEO recommends individual goals for each NEO, which are aligned with our business
strategy and linked with corporate goals, and our Compensation Committee approves these goals. The individual
goals for the NEOs are in addition to the general responsibilities each officer has for managing his respective
functional or operational area.

2018 Corporate Goals.

In early 2018, the Compensation Committee established the corporate and individual

goals described below. While we now are a fully-integrated biopharmaceutical company with a marketed product
and robust development programs, at the time our marketed product was very newly introduced to the market, and
so our corporate goals were directly aligned with the specific strategic objectives, including completing important
foundational elements for HEPLISAV-B, such as restarting the Dusseldorf manufacturing facility, obtaining FDA
approval of the PFS application and deploying the field sales team, and advancing the development programs that
we continue to believe will create long-term value for stockholders. In February 2019, the Compensation Committee
evaluated the accomplishments and performance of the Company against such corporate goals. With respect to each
of the categories of Corporate Goals (that is, HEPLISAV-B Advancement; Oncology: Advance the Pipeline; and
Sustain the Dynavax Business Plan), the Committee took into consideration each of the goals identified and the

40

level of completion in making an overall determination of goal completion for each category. We have omitted
details about the 2018 goals or achievement of goals in the table below only where we believe disclosing such
details would result in competitive harm. After its consideration of the Company’s performance, as more
specifically described in the following chart, the Compensation Committee rated our 2018 corporate achievement at
90% of our 2018 corporate goals.

Corporate
Achievement
Percentage

85%

Corporate Goal

Weighting

Corporate Achievement

HEPLISAV-B Advancement

• Obtain ACIP recommendation.

•

•

Post-marketing study and “first
patient in.”

FDA approval of PFS and “potency
assay” applications.

• Engage, train and deploy field sales

organization.

• Minimum 90% reimbursement

coverage of commercial lives 90 days
post-ACIP recommendation.

• Minimum of 200,000 doses sold.

•

720,000 doses of PFS doses released.

• Execute re-start plan for Dusseldorf
manufacturing facility and release 2
hepatitis B surface antigen batches.

• Develop and implement healthcare
compliance program to ensure
compliant HEPLISAV-B operations.

42.5% The Compensation Committee determined
that we achieved the goals in this category
at an overall percentage of 85%. In
determining this percentage, the
Compensation Committee considered
several factors, including:

• Obtaining the ACIP recommendation.

• Achieving the first patient enrolled in

post-marketing study.

• Obtaining FDA approval of PFS and

“potency assay”.

•

Successful deployment of field sales
organization.

• Achievement of reimbursement

coverage of commercial lives goal.

•

•

•

•

•

Positioning us for increasing
HEPLISAV-B sales in 2019 and
beyond by advancing through the
lengthy institutional decision-making
process in 2018.

100,000 doses of HEPLISAV-B sold.

Introduction of PFS to market and
rapid customer uptake of this
presentation.

Successfully restarting the Dusseldorf
manufacturing facility.

Successful implementation of a
healthcare compliance program
associated with status as a
commercial company.

Oncology: Advance the Pipeline

• Advance oncology programs that are
in clinical studies, including initiating
enrollment in various studies for
SD-101 and advance intra-tumoral
vaccination studies for 2019
initiation.

• Complete SD-101 and DV281

development plans.

42.5% The Compensation Committee determined
that we achieved the goals in this category
at an overall percentage of 95%. In
determining this percentage, the
Compensation Committee considered
several factors, including:

95%

• Advancement of SD-101 in

melanoma and squamous cell head
and neck cancer and data presentation
of results at key oncology meetings.

41

Corporate Goal

Weighting

Corporate Achievement

Corporate
Achievement
Percentage

•

•

Select lead compound TLR 7/8
agonists and develop and explore
production and collaboration
strategies.
Identify and execute oncology-
specific meeting presentation/
publication timetable.

Sustain the DVAX Business Plan
• At least one year of cash at year end

2018.

• Control net cash usage within budget.
• Establish and implement necessary
financial reports and controls to
deliver compliant commercial
organization.
Implement quality systems
automation.

•

• Complete preparations for

pharmacovigilance inspection.
• Develop and implement investor

relations and corporate
communications program, including
regular investor engagement.
• Recruit key leadership positions.
• Develop strategic plan document and

update Board of Directors on a
bi-annual basis.

• The selection of SD-101 and

pembrolizumab in combination for
advanced breast cancer in the
on-going I-SPY 2 trial.
•
Initiation of DV281 Phase 1 study.
• Completion of SD-101 and DV281

Development Plans.

15% The Compensation Committee determined
that we achieved the goals in this category
at an overall percentage of 90%. In
determining this percentage, the
Compensation Committee considered
several factors, including:
• Maintaining one year of cash at year

90%

end.

• Controlling net cash usage.
• Establishing and implementing
financial reports and controls.
Successful pharmacovigilance
inspection.

•

• Hiring VPs of Quality and Investor

Relations & Corporate
Communications.

Total

100%

90%

The terms used, but not defined above, have the following definitions:

•

•

“ACIP” is the Centers for Disease Control and Prevention’s Advisory Committee on Immunization
Practices.

“I-SPY 2” is the “Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging
And moLecular Analysis 2” study.

2018 Individual Goals. As described above, our CEO does not have individual goals separate from the
Company’s corporate objectives. For our other NEOs, the total cash incentive payout for 2018 was based on a
weighting of 50% corporate and 50% individual goals. Our CEO recommends individual goals for each NEO, which
are aligned with our business strategy and linked with corporate goals, and our Compensation Committee approves
these goals. The individual goals for our NEOs relate to critical responsibilities of each NEO that go beyond the
corporate goals and are significant to our success. The 2018 individual goals for the NEOs include those listed
below. These specific goals were in addition to the general responsibilities each officer had for managing his
respective functional operational area.

Our Compensation Committee, in recognition of the fact that 50% of the incentive payout for each NEO is
based on corporate goal achievement, believes it is of equal importance to assess the individual achievement portion

42

of the goal grading in a manner that is reflective of performance against the individual goals. Thus, as is the case
with respect to the 2018 individual goals, there may be circumstances where the individual goal grading exceeds the
corporate goal grading, and there may be instances where the corporate goal grading will surpass the individual goal
grading. In early 2019, based on the recommendation of our CEO, as well as the observations by Compensation
Committee members of these officers and its own assessment of each NEO’s effectiveness, the Compensation
Committee determined the level of achievement of each NEO’s individual performance goals as follows:

Individual
Achievement
Percentage

107%

Name

Individual Goals

Individual Achievement

Michael S.
Ostrach

1. Meet key financial objectives,

including securing adequate
financing to support business
operations, establish and
implement accounting policies
and controls related to
HEPLISAV-B commercialization,
complete implementation of major
IT requirements, optimize
processes for managing financial
reporting.

2. Develop business and

communications strategies that are
implementable and target the right
opportunities.

3. Optimize internal IP function and
file strategic patents related to
oncology assets.

Mr. Ostrach exceeded his individual
goals by, among other things:

• Managing our financial strategy,
implementing new processes and
securing debt financing which was
critical to funding the launch of
HEPLISAV-B and our clinical
trials;

•

Implementing accounting policies
and controls to support
commercialization of
HEPLISAV-B;

• Hiring and integrating a VP of

Investor Relations and Corporate
Communications to enable
expanding and deepening both
investor relations and corporate
communications; and

•

Securing patents, including
pertaining to Heplisav-B (method
of use) and DV281 (composition
of matter) and development
function and IP needs.

Robert L.

Coffman, Ph.D.

1.

Evaluate combinations for
possible 2019 DV281 studies.

Dr. Coffman exceeded his individual
goals by, among other things:

108%

2. Advance preclinical and clinical
vaccine and oncology programs.

3. Develop and implement strategies

that will continue to broaden our
scientific platform.

4. Advance business development

initiatives.

• Making significant progress with
evaluations of combinations for
possible DV281 studies;

• Overseeing the on-going Phase 1
study of DV281 for lung cancer;
and

• Contributing significant time and
effort on a wide range of business
development initiatives, including
finalizing a finalizing a full
license agreement to access of
TLR7/8.

43

Name

Individual Goals

Individual Achievement

Individual
Achievement
Percentage

108%

Robert Janssen,

1.

M.D.

Lead efforts to obtain ACIP
recommendation and initiation
and continuation of various
studies to enhance HEPLISAV-B
adoption across indications.

2. Develop and implement clinical,
regulatory and medical affairs
strategies to advance immuno-
oncology and vaccine programs in
the clinic, including initiation of
I-SPY-2 neoadjuvant study and
developing DV281 combinations
clinical plan for initiation.

3. Develop and advance Company’s

David Novack

1.

immuno-oncology presence and
profile, including supporting
business development goals and
recruitment of key medical
leadership positions.

Ensure and execute against goals
relating to commercial supply and
distribution of HEPLISAV-B and
process development and
continuous improvement of
HEPLISAV-B manufacturing.

2. Develop and implement

manufacturing and quality
strategies for advancing our
immuno-oncology programs in the
clinic.

3. Continue to implement quality

assurance strategies required for a
commercial organization.

4.

Enhance efforts to grow the
Company’s overall vaccine
business and vaccine collaborative
efforts.

Dr. Janssen exceeded his individual
goals by, among other things:

• Obtaining ACIP recommendation
for HEPLISAV-B and initiation of
post-marketing studies;

• Advancing development activities

for further vaccines;

• Contributing to the selection of
SD-101 to inclusion in the
I-SPY-2 neoadjuvant clinical
study for breast cancer; and

• Recruiting a VP of Clinical
Operations with extensive
oncology development
experience.

Mr. Novack exceeded his individual
goals by, among other things:

120%

•

Successfully transitioning
manufacturing at our Dusseldorf
site to full commercial operations
after being put on hold prior to
FDA approval of HEPLISAV-B;

• Leading the company’s successful
effort to obtain FDA approval of
the PFS presentation of
HEPLISAV-B, resulting in
increased customer and
practitioner uptake;

•

Successfully completing process
development and manufacturing
of clinical and registration batches
to advance various oncology
programs; and

• Completing implementation of
quality system automation and
other improvements to support
commercial product and
advancing/expanding
development portfolio.

After making these determinations regarding levels of corporate and individual performance achieved against

the pre-established performance goals, the Compensation Committee (and the Board with respect to the CEO)

44

reviewed and approved the cash incentive payouts noted below. As noted above, for the NEOs other than the CEO,
the cash incentive payouts are based 50% on achievement of corporate goals and 50% on achievement of individual
goals. There were no changes to the NEOs’ target annual cash incentive percentages between 2017 and 2018.

2018 Actual Annual Cash Incentive Paid

2018 Target Annual
Cash Incentive

Achievement of
Corporate Goals

Achievement of
Individual Goals

Name

% of
Base
Salary

$

% of
Target
Annual
Cash
Incentive

$*

Eddie Gray . . . . . . . . . . . . . . . . . . . . . . .
Michael S. Ostrach . . . . . . . . . . . . . . . . .
. . . . . . . . . . .
Robert L. Coffman, Ph.D.
Robert Janssen, M.D. . . . . . . . . . . . . . . .
David F. Novack . . . . . . . . . . . . . . . . . .

60% $372,600
50% $219,938
50% $241,567
50% $219,000
50% $200,850

90% $335,340
45% $ 98,972
45% $108,705
45% $ 98,550
45% $ 90,383

*

Amounts are rounded to the nearest dollar

Other Executive Compensation Matters

Equity Compensation Policies

% of
Target
Annual
Cash
Incentive

N/A

$*

Total*

54% $117,667
54% $130,446
54% $118,260
60% $120,510

N/A $335,340
$216,639
$239,151
$216,810
$210,893

Our Compensation Committee approves equity awards for NEOs and authorizes the CEO to approve equity

awards for all other employees based on approved pools for annual and new hire grants. NEO awards are approved
either at a regularly-scheduled meeting of the Compensation Committee or by unanimous written consent. The
effective date of the grant is generally the date of the meeting, or the date the last person executes the unanimous
written consent.

The exercise price of stock options is not less than the closing price of our common stock on the Nasdaq
Capital Market on the grant date of the stock option. We have no practice of timing grants of stock options or
restricted stock awards to coordinate with the release of material non-public information, and we have not timed the
release of material non-public information for purposes of affecting the value of the compensation awarded to our
NEOs or any other employee.

We encourage our NEOs to hold a significant equity interest in our Company, but we have not set specific

stock ownership guidelines.

We have a policy that prohibits our executive officers, directors and other members of management from
engaging in short sales, transactions in put or call options, hedging transactions or other inherently speculative
transactions with respect to our stock.

Tax Effects of Executive Compensation

Under Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”), compensation paid to

any publicly held corporation’s “covered employees” that exceeds $1 million per taxable year for any covered
employee is generally non-deductible.

Prior to the enactment of the Tax Cuts and Jobs Act, Section 162(m) of the Code (“Section 162(m)”) provided
a performance-based compensation exception, pursuant to which the deduction limit under Section 162(m) did not
apply to any compensation that qualified as “performance-based compensation” under Section 162(m). Pursuant to
the Tax Cuts and Jobs Act, the performance-based compensation exception under Section 162(m) was repealed with
respect to taxable years beginning after December 31, 2017, except that certain transition relief is provided for
compensation paid pursuant to a written binding contract which was in effect on November 2, 2017 and which is not
modified in any material respect on or after such date.

45

Compensation paid to each of the Company’s “covered employees” in excess of $1 million per taxable year

generally will not be deductible unless it qualifies for the performance-based compensation exception under
Section 162(m) pursuant to the transition relief described above. Because of certain ambiguities and uncertainties as
to the application and interpretation of Section 162(m), as well as other factors beyond the control of the
Compensation Committee, no assurance can be given that any compensation paid by the Company will be eligible
for such transition relief and be deductible by the Company in the future. Although the Compensation Committee
will continue to consider tax implications as one factor in determining executive compensation, the Compensation
Committee also looks at other factors in making its decisions and retains the flexibility to provide compensation for
the Company’s named executive officers in a manner consistent with the goals of the Company’s executive
compensation program and the best interests of the Company and its stockholders, which may include providing for
compensation that is not deductible by the Company due to the deduction limit under Section 162(m). The
Compensation Committee also retains the flexibility to modify compensation that was initially intended to be
exempt from the deduction limit under Section 162(m) if it determines that such modifications are consistent with
the Company’s business needs.

The Compensation Committee also considers the impact of Section 409A of the Code, and in general, our
executive plans and programs are designed to comply with the requirements of that section so as to avoid possible
adverse tax consequences that may result from non-compliance.

Accounting Considerations

The accounting impact of our compensation programs is one of many factors that the Compensation

Committee considers in determining the structure and size of our executive compensation programs. In general, the
Company accounts for equity compensation paid to our employees under the Financial Accounting Standards Board
Accounting Standards Codification Topic 718, Compensation—Stock Compensation, or ASC 718, which requires
us to estimate and record an expense over the service period of the equity award, and our cash compensation is
recorded as an expense at the time the obligation is accrued.

Compensation Recovery Policy

Amounts paid and awards granted under our 2011 and 2018 Plans will be subject to recoupment in accordance

with the Dodd-Frank Wall Street Reform and Consumer Protection Act and any applicable regulations under the
Act, any clawback policy the Company adopts or as is required by applicable law. In addition, as a public company
subject to the provisions of Section 304 of the Sarbanes-Oxley Act of 2002, if we are required as a result of
misconduct to restate our financial results due to our material noncompliance with any financial reporting
requirements under the federal securities laws, our chief executive officer and chief financial officer may be legally
required to reimburse us for any bonus or other incentive-based or equity-based compensation they receive. In
addition, we will comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection
Act once the SEC final regulations on the subject become effective.

Compensation Risk Analysis

During fiscal 2018, our Compensation Committee reviewed our compensation policies as generally applicable

to our employees in order to determine whether any such programs were likely to present a material risk to the
Company. As part of its assessment, the Compensation Committee considered, among other things, the allocation of
compensation among base salary and short- and long-term compensation, our approach to establishing Company-
wide and individual financial, operational and other performance targets, and the nature of our key performance
metrics. As a result of this review and analysis, the Compensation Committee’s determined that our policies and
programs do not encourage excessive or inappropriate risk taking, and that the level of risk that they do encourage is
not reasonably likely to have a material adverse effect on the Company.

46

Report of the Compensation Committee of the Board of Directors on Executive Compensation

In early 2019, the Compensation Committee discussed with management the Compensation Discussion and
Analysis, contained in this proxy statement. Based on this review and discussion, the Compensation Committee has
recommended to the Board that the Compensation Discussion and Analysis be included in this proxy statement and
incorporated into our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

The material in this report is not “soliciting material,” is furnished to, but not deemed “filed” with, the SEC

and is not deemed to be incorporated by reference in any filing of the Company under the Securities Act or the
Exchange Act, other than the Company’s Annual Report on Form 10-K, where it shall be deemed to be “furnished,”
whether made before or after the date hereof and irrespective of any general incorporation language in any such
filing.

Ms. Peggy V. Phillips, Chairperson
Dr. Francis R. Cano, Ph.D.
Dr. Daniel Kisner, M.D.

SUMMARY COMPENSATION TABLE

The following table shows for the fiscal years ended December 31, 2018, 2017 and 2016, compensation

awarded to or paid to, or earned by, NEOs.

Name and Principal Position

Year

Salary

Eddie Gray . . . . . . . . . . . . . . . . . . . . . .
CEO and Director

Michael S. Ostrach . . . . . . . . . . . . . . . .
Senior Vice President, Chief Financial
Officer, Chief Business Officer

Robert L. Coffman, Ph.D. . . . . . . . . . . .
Senior Vice President and Chief

Scientific Officer

Robert Janssen, M.D.
. . . . . . . . . . . . . .
Chief Medical Officer and Senior Vice
President, Clinical Development,
Medical and Regulatory Affairs

David F. Novack . . . . . . . . . . . . . . . . . .
Senior Vice President, Operations and

Quality

2018
2017
2016

2018
2017
2016

2018
2017
2016

2018
2017
2016

2018
2017
2016

$621,000
$600,000
$600,000

$439,875
$425,000
$425,000

$483,134
$466,796
$466,796

$438,000
$400,000
$400,000

$401,700
$386,250
$386,250

Stock
Awards(1)

Option
Awards(2)

Non-Equity
Incentive
Compensation(3)

All Other
Compensation(4)

$
$2,094,113
$

— $3,790,500
—
— $2,345,840

$

$
$1,126,060
$

— $2,904,000
—
— $ 703,752

$

$
$1,223,041
$

— $2,904,000
—
— $ 703,752

$

$
$1,068,056
$

— $1,083,000
—
— $ 670,240

$

$
$1,036,148
$

— $1,083,000
—
— $ 536,192

$

$335,340
$450,000
$ —

$216,639
$265,625
$ —

$239,151
$297,582
$ —

$216,810
$260,000
$ —

$210,893
$241,406
$ —

$2,000
$2,000
$2,000

$2,000
$2,000
$2,000

$2,000
$2,000
$2,000

$2,000
$2,000
$2,000

$2,000
$2,000
$2,000

Total

$4,748,840
$3,146,113
$2,947,840

$3,562,514
$1,818,685
$1,130,752

$3,628,285
$1,989,419
$1,172,548

$1,739,810
$1,730,056
$1,072,240

$1,697,593
$1,665,804
$ 924,442

(1) Represents the aggregate grant date fair value of RSUs granted in the fiscal year in accordance with ASC 718. See note 15 of our “Notes to

Consolidated Financial Statements” in our annual report on Form 10-K filed with the SEC on February 27, 2019 for a discussion of
assumptions we made in determining the compensation costs included in this column. With regard to RSUs with performance-based vesting,
the grant date fair value included in the table above assumes the highest level of achievement had been met.

(2)

Except as otherwise set forth in this footnote, represents the aggregate grant date fair value of option awards granted in the fiscal year in
accordance with ASC 718. A portion of the options granted in fiscal year 2018 are subject to performance-based vesting, as described in the
“Compensation Discussion and Analysis.” The grant date fair value for such options with performance-based vesting is based on the
probable outcome of the performance conditions as of the grant date. The maximum potential value of such options with performance-based
vesting, assuming the highest level of performance achievement is as follows:

Name

Eddie Gray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Michael S. Ostrach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert L. Coffman, Ph.D.
Robert Janssen, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
David F. Novack . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

47

Options with
Performance-
Based Vesting

2018

$758,100
$216,600
$216,600
$216,600
$216,600

For a further discussion of assumptions we made in determining the compensation costs included in this column, see note 15 of our “Notes to
Consolidated Financial Statements” in our annual report on Form 10-K filed with the SEC on February 27, 2019..

(3) Represents the annual incentive bonuses earned pursuant to our annual incentive bonus plan for services rendered in the fiscal year. For

further discussion see the section entitled “Compensation Discussion and Analysis – 2018 Executive Compensation Decisions – 2018
Annual Incentive Program – Structure, Goals and Payout Decision.”

(4) Represents $2,000 401(k) matching contribution for each NEO made by the Company in the fiscal year.

GRANTS OF PLAN BASED AWARDS

The following table shows certain information regarding grants of plan-based awards to NEOs during the fiscal

year ended December 31, 2018.

Name

Grant Date

Estimated
Future
Payouts
Under
Non-Equity
Incentive
Plan
Awards
Target(1)
($)

Estimated
Future
Payouts
Under
Equity
Incentive
Plan
Awards
Target(2)
(#)

All Other
Option
Awards:
Number of
Securities
Underlying
Options
(#)

Exercise
or Base
Price of
Option
Awards
($/Share)

Grant Date
Fair Value
of RSU and
Option
Awards(3) ($)

Eddie Gray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

— $372,600

2/1/2018
2/1/2018

Michael S. Ostrach . . . . . . . . . . . . . . . . . . . . . . . .

— $219,938

2/1/2018
2/1/2018
3/21/2018

Robert L. Coffman, Ph.D. . . . . . . . . . . . . . . . . . . .

— $241,567

2/1/2018
2/1/2018
3/21/2018

Robert Janssen, M.D.

. . . . . . . . . . . . . . . . . . . . . .

— $219,000

David F. Novack . . . . . . . . . . . . . . . . . . . . . . . . . .

— $200,850

2/1/2018
2/1/2018

2/1/2018
2/1/2018

70,000
—
—
20,000

—
—
— 280,000

—

—

—

—
$16.45 $3,032,400
— $16.45 $ 758,100
—
—
$16.45 $ 866,400
80,000
— $16.45 $ 216,600
$18.40 $1,821,000
—
$16.45 $ 866,400
— $16.45 $ 216,600
$18.40 $1,821,000
—
$16.45 $ 866,400
— $16.45 $ 216,600
—
—
$16.45 $ 866,400
80,000
— $16.45 $ 216,600

—

—

— 150,000
—
—
—
80,000
20,000

— 150,000
—
—
—
80,000
20,000
—
—
20,000

(1) Represents the target cash incentive award in fiscal year 2018 as further described under “Compensation Discussion and Analysis –

Elements of Executive Compensation”; our annual incentive program does not specify minimum or maximum levels.

(2) Represents the number of options granted in the fiscal year that are subject to performance-based vesting, as described in the “Compensation

Discussion and Analysis,” and do not include minimum or maximum levels.

(3) Represents the aggregate grant date fair value of options granted in fiscal year 2018 in accordance with ASC 718. See Note 15 of our “Notes
to Consolidated Financial Statements” in our annual report on Form 10-K filed with the SEC on February 27, 2019 for a discussion of the
assumptions we made in determining the compensation costs included in this column. With regard to options with performance-based
vesting, the grant date fair value assumes the probable outcome of the conditions, as reported in the “Summary Compensation Table.” For
further discussion of these performance-based options, see the section entitled “Compensation Discussion and Analysis – 2018 Executive
Compensation Decisions – Long-Term Equity Incentive Awards.”

48

NARRATIVE DISCLOSURE TO SUMMARY COMPENSATION TABLE AND GRANTS OF PLAN BASED AWARDS
TABLE

The material terms of NEOs’ annual compensation and the explanations of the amounts of base salary, annual

cash-based incentives, and equity-based awards in proportion to total compensation are described under
“Compensation Discussion and Analysis” in this proxy statement. Our severance and change in control benefits are
described under “Summary of Change in Control and Involuntary Termination Arrangements” in this proxy
statement.

As discussed in the “Compensation Discussion and Analysis,” the fiscal year 2018 cash incentive amounts

were paid pursuant to the annual cash incentive compensation program, based on the achievement of certain
corporate and individual performance goals. Equity-based awards were granted in 2018 under our 2018 Plan and
represent a mix of time based and performance based options, as described in the “Compensation Discussion and
Analysis.”

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END

The following table shows certain information regarding outstanding equity awards for NEOs as of

December 31, 2018.

Option Awards

Stock Awards

Name

Eddie Gray . . . . . .

Michael S.

Ostrach . . . . . . .

Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)

Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable

Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable

150,000
75,001
150,000
215,624
264,444
—
—
—
—
—

3,750
2,673
25,000
18,000
20,000
27,000
64,208
24,166
79,333
—
—
—
—
—
—

(2)

(3)

(4)

(5)

(6)

(3)

(7)

(2)

(2)

(3)

(4)

(5)

(6)

(3)

(7)

(8)

—
—
—
9,376
15,556
—
—
—
280,000
—

—
—
—
—
—
—
2,792
4,834
4,667
—
—
—
80,000
—
150,000

—
—
—
—
—
—
—
—
—
70,000

—
—
—
—
—
—
—
—
—
—
—
—
—
20,000
—

Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares or
Other
Rights
that Have
Not
Vested (#)

Equity
Incentive
Plan
Awards:
Market
or Payout
Value of
Unearned
Shares
or Other
Rights
that Have
Not
Vested ($)

Number
of
Shares
or Units
that
Have
Not
Vested
(#)

Market
Value
of Stock
that
Have
Not
Vested
($)(1)

Option
Exercise
Price
($)

Vesting
Commencement
Date

Option
Expiration
Date

5/1/2013
1/31/2014
2/4/2014
2/9/2015
2/4/2016

—
—
—

4/30/2023
1/30/2024
2/3/2024
2/8/2025
2/3/2023

— 75,000 $686,250
— 74,000 $677,100
— 75,000 $686,250

2/1/2018

—

1/31/2025
1/31/2025

3/10/2009
2/19/2010
1/6/2011
1/31/2012
2/5/2013
2/4/2014
2/9/2015
8/27/2015
2/4/2016

—
—
—

3/9/2019
2/18/2020
1/5/2021
1/30/2022
2/4/2023
2/3/2024
2/8/2025
8/26/2025
2/3/2023

— 49,804 $455,707
— 17,000 $155,550
— 49,804 $455,707

2/1/2018

—

3/21/2018

1/31/2025
1/31/2025
3/20/2025

$22.10
$17.40
$17.10
$16.00
$21.99
—
—
—
16.45
16.45

$ 5.40
$15.80
$31.40
$34.80
$30.80
$17.10
$16.00
$28.45
$21.99
—
—
—
16.45
16.45
18.4

49

Option Awards

Stock Awards

Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)

Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable

Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable

Option
Exercise
Price
($)

Vesting
Commencement
Date

Option
Expiration
Date

Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares or
Other
Rights
that Have
Not
Vested (#)

Equity
Incentive
Plan
Awards:
Market
or Payout
Value of
Unearned
Shares
or Other
Rights
that Have
Not
Vested ($)

Number
of
Shares
or Units
that
Have
Not
Vested
(#)

Market
Value
of Stock
that
Have
Not
Vested
($)(1)

10,000
30,000
18,000
18,000
71,874
13,751
79,333
—
—
—
—
—
—

6,000
2,250
2,500
15,000
18,000
53,666
75,555
—
—
—
—
—

30,000
22,000
71,874
60,444
—
—
—
—
—

(2)

(2)

(3)

(4)

(5)

(6)

(3)

(7)

(8)

(2)

(2)

(3)

(4)

(5)

(6)

(3)

(7)

(2)

(2)

(3)

(4)

(5)

(6)

(3)

(7)

—
—
—
—
3,126
2,750
4,667
—
—
—
80,000
—
150,000

—
—
—
—
—
2,334
4,445
—
—
—
80,000
—

—
—
3,126
3,556
—
—
—
80,000
—

—
—
—
—
—
—
—
—
—
—
—
20,000
—

—
—
—
—
—
—
—
—
—
—
—
20,000

—
—
—
—
—
—
—
—
20,000

$15.80
$31.40
$34.80
$30.80
$16.00
$28.45
$21.99
—
—
—
16.45
16.45
18.4

$13.60
$31.40
$36.80
$41.40
$17.10
$16.00
$21.99
—
—
—
16.45
16.45

$21.40
$17.10
$16.00
$21.99
—
—
—
16.45
16.45

2/19/2010
1/6/2011
1/31/2012
2/5/2013
2/9/2015
8/27/2015
2/4/2016

—
—
—

2/18/2020
1/5/2021
1/30/2022
2/4/2023
2/8/2025
8/26/2025
2/3/2023

— 54,702 $500,523
— 17,000 $155,550
— 54,702 $500,523

2/1/2018

—

3/21/2018

1/31/2025
1/31/2025
3/20/2025

4/7/2010
1/6/2011
2/1/2012
10/31/2012
2/4/2014
2/9/2015
2/4/2016

4/6/2020
1/5/2021
1/31/2022
10/30/2022
2/3/2024
2/8/2025
2/3/2023

—
—
—

— 46,875 $428,906
— 17,000 $155,550
— 46,875 $428,906

2/1/2018

—

1/31/2025
1/31/2025

3/25/2013
2/4/2014
2/9/2015
2/4/2016

3/24/2023
2/3/2024
2/8/2025
2/3/2023

—
—
—

— 45,263 $414,156
— 17,000 $155,550
— 45,263 $414,156

2/1/2018

—

1/31/2025
1/31/2025

Name

Robert L.

Coffman,
Ph.D. . . . . . . . . .

Robert Janssen,

M.D.

. . . . . . . . .

David F.

Novack . . . . . . .

(1) Represents the aggregate fair value of RSUs in accordance with ASC 718, based on the last closing price per share as of December 31, 2018

of $9.15.

(2) Options vest at the rate of 1/4th of the shares on the first anniversary of the vesting commencement date, with 1/48th of the total number of

shares vesting each month thereafter.

(3) Options vests at the rate of 1/3rd of the shares on the first anniversary of the vesting commencement date, with 1/36th of the total number of

shares vesting each month thereafter.

(4) RSU vested 50% on February 22, 2018 and 50% on February 22, 2019.

(5) RSU vested one-third on February 22, 2018, one-third vested on February 22, 2019 and the remainder will vest on February 22, 2020.

(6) RSU vested 50% on June 2, 2018 and the remainder will vest on June 2, 2019.

(7) Represents the number of options granted in the fiscal year that are subject to performance-based vesting, as described in the “Compensation

Discussion and Analysis.”

(8) Options vest 50% on March 21, 2020 and the remainder will vest on March 21, 2021.

50

OPTION EXERCISES AND STOCK VESTED

The following table provides information on stock awards that vested, including the number of shares acquired

upon vesting and the value realized, determined as described below, for the named executive officers in the fiscal
year ended December 31, 2018.

Name

Option Awards

Stock Awards

Number of Shares
Acquired on
Exercise (#)

Value Realized
on Exercise
($)

Number of Shares
Acquired on
Vesting (#)

Value Realized
on Vesting
($)(1)

Eddie Gray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Michael S. Ostrach . . . . . . . . . . . . . . . . . . . . . . . .
Robert L. Coffman, Ph.D. . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . .
Robert Janssen, M.D.
David F. Novack . . . . . . . . . . . . . . . . . . . . . . . . . .

—
—
—
—
—

—
—
—
—
—

214,750
114,485
124,281
108,625
105,403

3,626,363
1,914,582
2,077,196
1,817,306
1,763,821

(1)

The value realized on vesting is determined by multiplying the number of shares of stock by the market value of the underlying shares as
reported by the Nasdaq Capital Market on the vesting date.

PENSION BENEFITS

None of the NEOs participates in or has an account balance under any pension or qualified or non-qualified

defined benefit retirement plans sponsored by the Company.

NON -QUALIFIED DEFERRED COMPENSATION

None of the NEOs participates in or has an account balance under any non-qualified defined contribution plans

or other non-qualified deferred compensation plans maintained by the Company.

POTENTIAL PAYMENTS UPON CHANGE IN CONTROL OR INVOLUNTARY TERMINATION

Summary of Change in Control and Involuntary Termination Arrangements.

To promote retention of certain key executives, our Board has authorized the Company to enter into
Management Continuity and Severance Agreements with each NEO. We refer to the agreements in effect as of
December 31, 2018 as the “Management Agreements.” In order to be eligible to receive benefits under the
Management Agreements, our NEOs and other officers must execute a general waiver and release of claims, and
such release must become effective in accordance with its terms.

Change in Control.

The Management Agreement with Mr. Gray provides that, as of immediately prior to the effective date of a

Change in Control (as described below), all of Mr. Gray’s then-outstanding equity awards (including stock options
and RSUs) under the 2011 Plan or the 2018 Plan shall automatically accelerate and fully vest, subject to Mr. Gray’s
execution and delivery of a release. Upon a Change in Control, Mr. Gray would have 598,932 aggregate equity
awards subject to accelerated vesting, with a value of $2,049,600, assuming the event occurred on December 31,
2018. This amount represents the value of stock and accelerated stock option and award vesting if the event took
place on December 31, 2018. The value for RSUs is calculated in accordance with ASC 718, based on the closing
price per share on December 31, 2018. The value for stock option awards is calculated based on the “spread”
between the closing price per share on December 31, 2018 of $9.15 and the exercise price of the vested awards, to
the extent such vested awards were “in the money.”

The other NEOs do not receive an equity acceleration benefit in the event of a Change in Control (without

termination of employment) of the Company.

51

Qualifying Termination in Connection with a Change in Control.

Under the Management Agreements, if, on or during the two-year period following a Change in Control (as
described below), the NEO’s employment is involuntarily terminated, the NEO will, subject to the execution of a
release of claims, be entitled to receive:

•

•

•

•

•

a lump-sum cash payment equal to a specified number of months (24 months for Mr. Gray and 12 months
for our other NEOs) of the executive’s then-effective annual base salary;

a lump-sum cash payment equal to the NEO’s target annual variable cash compensation (200% of such
target for Mr. Gray and 100% of such target for our other NEOs) for the year of termination;

cash payments equal to the applicable COBRA premiums for up to the same number of months as the
NEO receives in base salary, as set forth in the first bullet (the “COBRA Payment”);

acceleration of vesting of all outstanding equity awards at the time of such termination (provided,
however, that Mr. Gray will receive accelerated vesting for only those grants that (i) were issued under the
2011 Plan (or any equity plan of a successor company) and (ii) are subject to time-based vesting criteria if
issued after the Change of Control); and

the extension of exercisability of all stock options to purchase the Company’s common stock for a period
of 3 years following termination of employment (but in any event not beyond each option’s expiration
date).

In addition, if any payments or benefits would constitute a “parachute payment” within the meaning of
Section 280G of the Code and such payments would be subject to the excise tax imposed by Section 4999 of the
Code, then such payments will either be (1) provided to the NEO in full or (2) reduced to such lesser amount that
would result in no portion of such payments being subject to the excise tax, whichever amount after taking into
account all applicable taxes, including the excise tax, would result in the NEO’s receipt, on an after-tax basis, of the
greatest amount of such payments.

The Management Agreements generally define a Change in Control to mean the occurrence of a change in the

majority ownership of the voting securities of the Company; a merger that results in change in the majority
ownership of the voting securities of the Company; the sale of all or substantially all of the assets; or (for all of our
NEOs except Mr. Gray) over a period of 12 months or less, when a majority of our Board becomes comprised of
individuals who were not serving on our Board as of a specified date, or whose nomination, appointment, or election
was not approved by a majority of the directors who were serving on our Board as such specified date.

The table below outlines the potential payments and benefits payable to each NEO in the event such

executive’s termination in connection with a Change in Control of the Company, assuming such event had occurred
on December 31, 2018.

Name

Severance
Payment

Continuation
of Benefits

Eddie Gray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Michael S. Ostrach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert L. Coffman, Ph.D.
Robert Janssen, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
David F. Novack . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,987,200
$ 659,813
$ 724,701
$ 657,000
$ 602,550

$59,253
$35,047
$29,726
$29,726
$35,047

Value of
Accelerated
Stock
Awards(1)

$2,049,600
$1,066,963
$1,156,597
$1,013,363
$ 983,863

Total

$4,096,053
$1,761,823
$1,911,024
$1,700,089
$1,621,460

(1) Represents the value of accelerated vesting of equity awards if the event took place on December 31, 2018. The value for RSUs is calculated
in accordance with ASC 718, based on the closing price per share on December 31, 2018. The value for stock option awards is calculated
based on the “spread” between the closing price per share on December 31, 2018 of $9.15 and the exercise price of the vested awards, to the
extent such vested awards were “in the money.”

52

Involuntary Termination.

Under the terms of the Management Agreements, upon an “involuntary” termination without “cause” or, if
applicable, upon a resignation for “good reason” (as defined below), the NEO will, subject to the execution of a
release of claims, be entitled to receive:

•

•

•

•

a lump-sum cash payment equal to the specified number of months (ranging from 6 to 24) of the
executive’s then-effective annual base salary;

the COBRA Payment;

accelerated vesting of all equity awards that are held by Mr. Gray on the effective date of termination and
subject to time-based vesting criteria; and

for Mr. Gray, the extension of exercisability of all vested stock options to purchase the Company’s
common stock for a period of 3 years following termination of employment (but in any event not beyond
each option’s expiration date).

Under the terms of the Management Agreements:

• Mr. Gray will receive 24 months of base salary, 200% of his target annual cash incentive, the COBRA

Payment, accelerated vesting of his then-outstanding employee stock options and restricted stock awards,
and up to 3 years to exercise the vested options; and

• Our other NEOs will receive 6 months of base salary and the COBRA Payment.

The table below outlines the potential payments and benefits payable to each NEO in the event of such NEO’s

involuntary termination had occurred on December 31, 2018.

Name

Severance
Payment

Continuation
of Benefits

Value of
Accelerated
Stock Awards(1)

Total

Eddie Gray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Michael S. Ostrach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert L. Coffman, Ph.D.
. . . . . . . . . . . . . . . . . . . . . . . . . .
Robert Janssen, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
David F. Novack . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,987.200
$ 219,938
$ 241,567
$ 219,000
$ 200,850

$59,253
$17,524
$14,863
$14,863
$17,524

$2,049,600
$
$
$
$

$4,096,053
— $ 237,461
— $ 256,430
— $ 233,863
— $ 218,374

(1) Represents the value of accelerated vesting of equity awards that are subject to time-based vesting criteria if the event took place on

December 31, 2018. The value for RSUs is calculated in accordance with ASC 718, based on the closing price per share on December 31,
2018. The value for stock option awards is calculated based on the “spread” between the closing price per share on December 31, 2018 of
$9.15 and the exercise price of the vested awards, to the extent such vested awards were “in the money.”

For purposes of the Management Agreements, “cause” generally means (1) gross negligence or willful
misconduct in the performance of duties to the Company, where such gross negligence or willful misconduct has
resulted or is likely to result in substantial and material damage to the Company or its subsidiaries; (2) repeated
unexplained or unjustified absence from the Company; (3) a material and willful violation of any federal or state
law; (4) commission of any act of fraud with respect to the Company; or (5) conviction of a felony or a crime
involving moral turpitude causing material harm to the standing and reputation of the Company, in each case as
determined in good faith by the Board.

For purposes of the Management Agreements, “good reason” generally means the NEO’s voluntary
termination following (1) a material reduction or change in job duties, responsibilities, and requirements
inconsistent with the NEO’s position with the Company and his or her prior duties, responsibilities, and
requirements, or a material change in the level of management to which the NEO reports; (2) any material reduction
of base compensation (other than in connection with a general decrease in base salaries for most officers of the
successor corporation); or (3) the refusal to relocate to a facility or location more than 35 miles from the Company’s
current location. The NEO must provide 90 days’ notice of the event giving rise to good reason, give the Company

53

30 days to cure (if curable), and any resignation for good reason must occur within 180 days after the occurrence of
the event giving rise to such resignation right.

PAY RATIO DISCLOSURE

Under SEC rules, we are required to calculate and disclose the annual total compensation of our median
employee, as well as the ratio of the annual total compensation of our median employee as compared to the annual
total compensation of our CEO (“CEO Pay Ratio”). To identify our median employee, we used the following
methodology:

• To determine our total population of employees, we included all full-time, part-time, and temporary

employees as of December 31, 2018.

• To identify our median employee from our employee population, we calculated the aggregate amount of

each employee’s 2018 base salary (using a reasonable estimate of the hours worked and overtime actually
paid during 2018 for hourly employees and actual salary paid for our remaining employees), the target
value of annual cash incentive awards, and the value of equity awards granted in 2018 using the same
methodology we use for estimating the value of the equity awards granted to our named executive officers
and reported in our Summary Compensation Table.

•

In making this determination, we annualized the compensation elements listed above of employees who
were employed by us for less than the entire calendar year.

• Compensation paid in foreign currencies was converted to U.S. dollars based on exchange rates in effect

on December 31, 2018.

Using this approach, we determined our median employee. Once the median employee was identified, we then

calculated the annual total compensation of this employee for 2018 in accordance with the requirements of the
Summary Compensation Table.

For 2018, the median of the annual total compensation of our employees (other than our CEO) was $162,137

and the annual total compensation of our CEO, as reported in the Summary Compensation Table included in this
Proxy Statement, was $4,748,840. Based on this information, the ratio of the annual total compensation of our CEO
to the median of the annual total compensation of all employees was 29 to 1.

The CEO Pay Ratio above represents our reasonable estimate calculated in a manner consistent with SEC rules

and applicable guidance. SEC rules and guidance provide significant flexibility in how companies identify the
median employee, and each company may use a different methodology and make different assumptions particular to
that company. As a result, and as explained by the SEC when it adopted these rules, in considering the pay ratio
disclosure, stockholders should keep in mind that the rule was not designed to facilitate comparisons of pay ratios
among different companies, even companies within the same industry, but rather to allow stockholders to better
understand and assess each particular company’s compensation practices and pay ratio disclosures.

Neither the Compensation Committee nor our management used our CEO Pay Ratio measure in making

compensation decisions.

54

DIRECTOR COMPENSATION

NON-EMPLOYEE DIRECTOR COMPENSATION PHILOSOPHY

Our non-employee director compensation philosophy is based on the following guiding principles:

• Aligning the long-term interests of stockholders and directors; and

• Compensating directors appropriately and adequately for their time, effort and experience

The elements of director compensation consist of annual cash retainers and equity awards, as well as customary

and usual expense reimbursement in attending Board and committee meetings. In an effort to align the long-term
interests of our stockholders and non-employee directors, the mix of cash and equity compensation has historically
been, and is currently, weighted more heavily to equity.

The Compensation Committee determines non-employee director compensation, which the full Board reviews
and approves upon recommendation from the Compensation Committee. When considering non-employee director
compensation decisions, the Compensation Committee believes it is important to be informed as to current
compensation practices of comparable publicly-held companies in the life sciences industry, especially to
understand the demand and competitiveness for attracting and retaining an individual with each non-employee
director’s specific expertise and experience. Thus, the Compensation Committee considers recommendations from
Arnosti based on an analysis of peer group Board compensation. Our compensation arrangements for our
non-employee directors are set forth in our Non-Employee Director Compensation Policy (the “Director
Compensation Policy”). The Director Compensation Policy outlines cash and equity compensation automatically
payable to non-employee members of the Board, unless such non-employee director declines receipt of such cash or
equity compensation by written notice to us. The Compensation Committee reviews our non-employee director
compensation relative to industry practices at least every other year, and the last review was done in February 2019.
No changes to Director compensation were made in 2019.

In 2018, our stockholders approved a limit on the amount of non-employee director compensation under our
2018 Equity Incentive Plan. The aggregate value of all cash and equity-based compensation granted or paid by us to
any individual for service as a non-employee director of the Board with respect to any fiscal year of the Company
may not exceed (i) a total of $200,000 with respect to any such cash compensation and (ii) $800,000 in total value
with respect to any such equity-based compensation (including awards granted under our 2018 Equity Incentive
Plan and any other equity-based awards), calculating the value of any such awards based on the grant date fair value
of such awards for financial reporting purposes. This limit was not intended to serve as an increase in the annual
amount of non-employee director compensation; rather, this action was approved for the purpose of limiting the
amount of compensation the Board can approve for non-employee directors each year.

CASH COMPENSATION ARRANGEMENTS

During 2018, each member of our Board who was not an employee or officer of the Company received the

following cash compensation for Board services:

• A $65,000 annual retainer for service as chairman of the Board and a $40,000 annual retainer for service

as a member of the Board.

• A $20,000 annual retainer for the Chair of the Audit Committee and a $10,000 annual retainer for each

additional member of the Audit Committee.

• A $15,000 annual retainer for the Chair of the Compensation Committee and a $7,000 annual retainer for

each additional member of the Compensation Committee.

• A $10,000 annual retainer for the Chair of the Nominating and Governance Committee and $5,000 annual

retainer for each additional member of the Nominating and Governance Committee.

We also reimburse our non-employee directors for their reasonable expenses incurred in attending meetings of

our Board and committees of our Board.

55

EQUITY AWARDS

Our compensation program for non-employee directors, was modified in February 2018 to increase of the size
of the Subsequent Grant described below from 7,500 shares to 15,000 shares. The compensation program currently
provides that:

• Each director and the chairman of the Board automatically receives an initial equity award, or Initial
Grant, consisting of a non-qualified stock option to purchase 15,000 shares and 25,000 shares,
respectively, of Dynavax common stock upon the date each such person is elected or appointed to the
Board.

• On the date of each annual meeting of the Company’s stockholders, each non-employee director also
automatically receives a subsequent equity award, or Subsequent Grant, consisting of a non-qualified
stock option to purchase 15,000 shares of Dynavax common stock. However, the non-employee director’s
first Subsequent Grant shall be reduced to 75% of the Subsequent Grant, or 11,250 shares, if the service
period from the non-employee director’s initial election date to the annual meeting is between 7 and 10
months, 50% of the Subsequent Grant, or 7,500 shares, if the service period from the non-employee
director’s initial election date to the annual meeting is between 4 and 7 months, and 25% of the
Subsequent Grant, or 3,750 shares, if the service period from the non-employee director’s initial election
date to the annual meeting is between 1 and 4 months.

Effective as of the 2016 Annual Meeting, each Initial Grant vests in equal annual installments over three years

on the anniversary of the grant date. Each Subsequent Grant vests in full on the one-year anniversary of the grant
date. The exercise price per share of each Initial Grant and Subsequent Grant shall be one hundred percent of the
fair market value per share on the date of grant.

Our Board may approve additional cash and equity awards for our non-employee directors.

DIRECTOR COMPENSATION TABLE

The following table shows for the fiscal year ended December 31, 2018, certain information with respect to the

compensation of all non-employee directors of the Company:

Name

Fees Earned
or Paid in
Cash(1)

Option
Awards(2)(3)

Total

Arnold L. Oronsky, Ph.D.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Laura Brege . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Francis R. Cano, Ph.D.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dennis A. Carson, M.D.
Daniel L. Kisner, M.D.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Peggy V. Phillips . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stanley A. Plotkin, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Natale Ricciardi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$75,000
$60,000
$52,000
$40,000
$57,000
$65,000
$20,000
$45,000

$156,767
$156,767
$156,767
$156,767
$156,767
$156,767

$231,767
$216,767
$208,767
$196,767
$213,767
$221,767
— $ 20,000
$201,767

$156,767

(1) Consists of fees earned or paid in 2018 for Board and committee meeting membership as described above. Dr. Plotkin voluntarily resigned

from the Board effective as of May 31, 2018, and was only eligible for cash fees in fiscal year 2018.

(2) Represents the aggregate grant date fair value of stock options granted in the fiscal year in accordance with ASC 718. See note 15 of our

“Notes to Consolidated Financial Statements” in our annual report on Form 10-K filed with the SEC on February 27, 2019, for a discussion
of assumptions we made in determining the compensation costs included in this column.

(3) As of December 31, 2018, each non-employee director held stock options to purchase the following numbers of shares of our common stock:
Dr. Oronsky held options to purchase 58,950 shares of our common stock; Ms. Brege held options to purchase 42,675 shares of our common
stock; Dr. Cano held options to purchase 55,050 shares of our common stock; Dr. Carson held options to purchase 48,750 shares of our
common stock; Dr. Kisner held options to purchase 58,450 shares of our common stock; Ms. Phillips held options to purchase 58,950 shares
of our common stock; and Mr. Ricciardi held options to purchase 42,750 shares of our common stock.

56

EQUITY COMPENSATION PLANS

The following table shows activity under our equity compensation plans as of the fiscal year ended

December 31, 2018.

Number of
securities to
be issued upon exercise
of outstanding options,
warrants and rights

Weighted-average
exercise price of
outstanding
options, warrants
and rights

Number
of securities remaining
available for future
issuance under
equity compensation
plans (excluding
securities reflected in
the first column)

Plan Category

Equity compensation plans approved by security

holders:

2004 Stock Incentive Plan . . . . . . . . . . . . . . . . .
2011 Equity Incentive Plan . . . . . . . . . . . . . . . . .
2014 Employee Stock Purchase Plan . . . . . . . . .
2018 Equity Incentive Plan . . . . . . . . . . . . . . . . .
Equity compensation plans not approved by security

holders:

39,223
4,740,931
—
474,000

2010 Employment Inducement Award Plan(2)
2017 Inducement Award Plan(3)

. . . . . .
. . . . . . . . . . . . . . . . .

11,450
484,800

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

5,750,404

$13.71
$18.76
$ —
$13.78

$16.55
$17.46

$18.20

—
—

573,034(1)

4,810,112

—
—

5,383,146

(1) As of December 31, 2018, an aggregate of 573,034 shares remained available for future issuance under the 2014 Employee Stock Purchase

Plan, and as of April 9, 2019, up to a maximum of 498,472 shares may be purchased in the current purchase period.

(2)

(3)

In order to induce qualified individuals to join our Company, our Board adopted the 2010 Employment Inducement Award Plan, or the 2010
Inducement Plan, effective January 8, 2010, which provided for the issuance of up to 150,000 shares of Company common stock to new
employees of the Company. Stockholder approval of the 2010 Inducement Plan was not required under Nasdaq Marketplace Rule
5635(c)(4). Upon the effectiveness of the Amended 2011 Plan, no additional awards were granted under either the 2004 Stock Incentive Plan
or the 2010 Inducement Plan. All shares currently subject to awards outstanding under the 2004 Stock Incentive Plan or 2010 Inducement
Plan, which awards expire or are forfeited, will be included in the reserve for the Amended 2011 Plan to the extent such shares would
otherwise return to such plans. Awards granted under the 2010 Inducement Plan have a term of 10 years. Exercisability, option price and
other terms are determined by the plan administrator, but the option price cannot be less than 100% of fair market value of those shares on
the date of grant. Stock options granted under the 2010 Inducement Plan generally vest over a period of four years, with the exception of
performance based awards which will vest upon achievement of certain performance conditions.

In order to induce qualified individuals to join our Company, on November 28, 2017, our Board adopted the 2017 Inducement Award Plan,
or the 2017 Inducement Plan, which provided for the issuance of up to 1,200,000 shares of Company common stock to new employees of the
Company. Stockholder approval of the 2017 Inducement Plan was not required under Nasdaq Marketplace Rule 5635(c)(4). Upon the
effectiveness of the 2018 Equity Incentive Plan, no additional awards were granted under the 2017 Inducement Plan. All shares currently
subject to awards outstanding under the 2017 Inducement Plan, which awards expire or are forfeited, are included in the reserve for the 2018
Equity Incentive Plan to the extent such shares would otherwise return to such plan. Awards granted under the 2017 Inducement Plan have a
term of 10 years. Exercisability, option price and other terms are determined by the plan administrator, but the option price cannot be less
than 100% of fair market value of those shares on the date of grant. Stock options granted under the 2017 Inducement Plan generally vest
over a period of four years, with the exception of performance based awards which will vest upon achievement of certain performance
conditions.

57

CORPORATE GOVERNANCE

CORPORATE GOVERNANCE GUIDELINES

In February 2016, our Board adopted Corporate Governance Guidelines that set forth key principles to guide

the Board in its exercise of responsibilities and serve the interests of the Company and our stockholders. The
Corporate Governance Guidelines were reviewed and updated by the Board in February 2018. Our Corporate
Governance Guidelines can be found on the Corporate Governance page under the Investors and Media – Corporate
Governance section of our website at www.dynavax.com. In addition, these guidelines are available in print to any
stockholder who requests a copy. Please direct all requests to our Corporate Secretary, Dynavax Technologies
Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, if mailed prior to June 1, 2019, or to 5959
Horton Street, Suite 700, Emeryville, California 94608, if mailed on or after June 1, 2019.

STOCKHOLDER OUTREACH AND ENGAGEMENT

Our Board of Directors and management team value the views of our stockholders and we proactively engage

with our major stockholders on a regular basis. We believe our outreach efforts help ensure that our stockholders are
aware of our governance initiatives and provide us with valuable feedback in order to enhance our governance
practices and disclosure to stockholders. In early spring 2018, and again in fall 2018, we contacted 12 of our 20
largest stockholders and we spoke with 100% of the stockholders that wanted to provide us with feedback at that
time. The bulk of the stockholders, while appreciating the outreach, did not feel a need to talk at the time. During
these discussions we solicited feedback from our stockholders on our corporate governance and executive
compensation practices, and provided an opportunity for each stockholder with whom we spoke to ask questions
concerning our corporate governance and executive compensation practices. During these conversations, none of
our stockholders expressed any concerns about our about our corporate governance or executive compensation
practices.

MAJORITY VOTE POLICY

Our Corporate Governance Guidelines include a provision whereby any nominee for director in an uncontested

election would submit an offer of resignation for consideration by the Nominating and Corporate Governance
Committee of the Board, if such nominee receives a greater number of “Withhold” votes than “For” votes. The
Nominating and Corporate Governance Committee would then consider all of the relevant facts and circumstances
and recommend to the Board the action to be taken with respect to such offer of resignation. Promptly following the
Board’s decision, we would disclose that decision and an explanation of such decision in a filing with the SEC or a
press release.

INDEPENDENCE OF THE BOARD OF DIRECTORS

As required under the Nasdaq Stock Market, or Nasdaq listing standards, and our Corporate Governance
Guidelines, a majority of the members of a listed company’s board of directors must qualify as “independent,” as
affirmatively determined by the board of directors. In addition, applicable Nasdaq rules require that, subject to
specified exceptions, each member of a listed company’s audit, compensation and nominating committees be
independent within the meaning of applicable Nasdaq rules. Audit committee members must also satisfy the
independence criteria set forth in Rule 10A-3 under the Exchange Act.

Consistent with these considerations, our Board undertook a review of the independence of each director and

considered whether any director has a material relationship that could compromise his or her ability to exercise
independent judgment in carrying out his or her responsibilities. After review of all relevant transactions or
relationships between each director, or any of his or her family members, and the Company, its senior management
and its independent registered public accounting firm, the Board has affirmatively determined that the following
directors are independent directors within the meaning of the applicable Nasdaq listing standards: Ms. Phillips,
Ms. Brege and Mr. Ricciardi as well as Drs. Carson, Cano, Kisner and Oronsky. In making these determinations, the
Board found that none of these directors has a material or other disqualifying relationship with the Company.

58

In determining the independence of Dr. Carson, the Board took into account his role as the university-
nominated representative on the evaluation committee to oversee aspects of the agreement between the Regents of
the University of California and Dynavax and determined that this relationship would not interfere with
Dr. Carson’s exercise of independent judgment in carrying out his responsibilities as a director.

By virtue of his employment with the Company, Eddie Gray, our Chief Executive Officer is not an independent

director.

BOARD LEADERSHIP STRUCTURE

Our Board is currently chaired by Dr. Oronsky. The duties of the chairman include presiding over all meetings

of the Board; preparing the agenda for Board meetings in consultation with the CEO and other members of our
Board; calling and presiding over meetings of non-employee directors; and managing the Board’s process for annual
evaluation of the CEO. Accordingly, the chairman has substantial ability to shape the work of our Board. Our Board
currently believes that separation of the positions of chairman and CEO reinforces the independence of our Board in
its oversight of our business and affairs. In addition, such separation helps create an environment that is more
conducive to objective evaluation and oversight of management’s performance, increasing management
accountability and improving the ability of our Board to monitor whether management’s actions are in the best
interests of our Company and its stockholders.

Our Board also believes there may be advantages to having an independent chairman for matters such as
communications and relations between our Board, the CEO and other senior management and in assisting our Board
in reaching consensus on particular strategies and policies. Having a chairman separate from the CEO also allows
the chairman to focus on assisting the CEO and other senior management in seeking and adopting successful
business strategies and risk management policies and in making successful choices in management succession.

BOARD’S ROLE IN RISK OVERSIGHT

Risk assessment and oversight are an integral part of our governance and management processes. Our Board

encourages management to promote a culture that incorporates risk management into our corporate strategy and
day-to-day business operations. Management discusses strategic and operational risks at regular management
meetings, and conducts specific strategic planning and review sessions during the year that include a focused
discussion and analysis of the risks facing the Company. Throughout the year, senior management reviews these
risks with the Board at regular Board meetings as part of management presentations that focus on particular business
functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.

Our Board does not have a standing risk management committee but rather administers this oversight function

directly through our Board as a whole as well as through various standing committees of our Board that address
risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and
assessing strategic risk exposure, including overseeing our healthcare compliance program pertaining to healthcare
laws, regulations and industry standards applicable to pharmaceutical companies. Our Audit Committee has the
responsibility to oversee our major financial risk exposures and the steps our management has taken to monitor and
control these exposures as well as oversight of our enterprise risk management program. The Audit Committee also
monitors compliance with legal and regulatory requirements, oversees the performance of our internal audit function
and approves or disapproves any related-persons transactions. Our Nominating and Governance Committee
monitors the effectiveness of our corporate governance guidelines and manages the process for annual director self-
assessment and evaluation of the Board. Our Compensation Committee assesses and monitors whether any of our
compensation policies and programs has the potential to encourage excessive risk-taking.

MEETINGS OF THE BOARD OF DIRECTORS

Our Board met five times during fiscal year 2018. All Board members attended at least 75% or more of the
aggregate of the meetings of the Board and of the committees on which the member served held during the period of
service as a director or committee member.

59

COMMITTEES OF THE BOARD OF DIRECTORS

Our Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating
and Governance Committee. The following table provides membership and meeting information for fiscal year 2018
for each of the Board committees:

Name

Audit Compensation Nominating

Arnold L. Oronsky, Ph.D.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Francis R. Cano, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Laura Brege . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Daniel L. Kisner, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Peggy V. Phillips . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Natale Ricciardi
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

X

X*

X

3
4

X

X
X*

3
4

X

X*

X
3
2

*

Committee Chairperson

Below is a description of each committee of our Board. Each of the committees has authority to engage legal

counsel or other experts or consultants as it deems appropriate to carry out its responsibilities. Our Board has
determined that each member of each committee meets the applicable Nasdaq listing standards and related rules and
regulations regarding “independence” and that each member is free of any relationship that would impair his or her
individual exercise of independent judgment with regard to the Company.

Audit Committee

The Audit Committee for 2018 was comprised of three directors: Ms. Brege (Chairperson), Dr. Oronsky and

Ms. Phillips. In addition to determining that all members of the Audit Committee are independent (as independence
is currently defined in Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq listing standards), the Board determined that
Ms. Brege qualified as an “audit committee financial expert,” as defined in applicable SEC rules. The Board made a
qualitative assessment of Ms. Brege’s level of knowledge and experience based on a number of factors, including
Ms. Brege’s formal education and experience as a chief financial officer. The Audit Committee was established by
the Board in accordance with Section 3(a)(58)(A) of the Exchange Act to oversee the Company’s corporate
accounting and financial reporting processes and audits of its financial statements. The Audit Committee operates
under a written charter that is available on the Company’s website at http://investors.dynavax.com/corporate-
governance.

Among other things, the charter specifically requires our Audit Committee to:

•

•

•

•

•

•

review and monitor the policies and procedures adopted by the Company to fulfill its responsibilities
regarding the fair and accurate presentation of the Company’s financial statements;

appoint, compensate, and oversee the work of the Company’s independent registered public accounting
firm;

approve and monitor all audit and non-audit services performed by the Company’s independent registered
public accounting firm;

investigate, review and report the propriety and ethical implications of any transactions between the
Company and any related persons;

consult and discuss with management and the independent registered public accounting firm regarding the
effectiveness of the Company’s internal controls over financial reporting;

establish procedures, as required under applicable law, for the receipt, retention and treatment of
complaints received by the Company regarding accounting, internal controls or auditing matters and the
confidential and anonymous submission by employees of concerns regarding questionable accounting or
auditing matters;

60

•

•

review and evaluate the Company’s accounting principles and systems of internal controls; and

review and discuss the disclosure of the Company’s annual audited financial statements and quarterly
financial statements, including reviewing the Company’s disclosures under “Management’s Discussion
and Analysis of Financial Condition and Results of Operations.”

Management is responsible for the financial reporting process, including the system of internal controls and for
the preparation of consolidated financial statements in accordance with accounting principles generally accepted in
the United States. Ernst & Young, the Company’s independent registered public accounting firm, is responsible for
auditing or reviewing those financial statements. The Audit Committee monitors and reviews these processes.

Report of the Audit Committee of the Board of Directors

During 2018, the Audit Committee met on four occasions. During these meetings the Committee met with
Ernst & Young, without the presence of the Company’s management. During the course of these meetings, we:

•

•

•

•

•

•

discussed with management and Ernst & Young management’s continued testing and evaluation of its
system of internal control over financial reporting. We also reviewed Ernst & Young’s Report of
Independent Registered Public Accounting Firm included in the Annual Report on Form 10-K, or Annual
Report, related to its audit of the effectiveness of the Company’s internal control over financial reporting;

reviewed and discussed with management and Ernst & Young the annual audited financial statements
before filing the Annual Report with the SEC, addressing the acceptability of the Company’s accounting
principles and such other matters as applicable auditing standards require us to discuss; the Audit
Committee has discussed with the independent registered public accounting firm the matters required to
be discussed by Auditing Standard No. 1301, Communications with Audit Committees (“AS 1301”), as
adopted by the Public Company Accounting Oversight Board (“PCAOB”) and recommended to the Board
that the financial statements should be included in the Annual Report;

reviewed and discussed with management and Ernst & Young the Company’s quarterly unaudited
financial statements before the issuance of its quarterly financial results press releases and the filing of its
Quarterly Reports on Form 10-Q with the SEC;

discussed with management and Ernst & Young significant financial reporting matters, including liquidity
and capital requirements, and the accounting for significant transactions;

appointed and oversaw the work and compensation of Ernst & Young, including the review of
engagement agreement terms;

reviewed and provided guidance with respect to the external audit and the Company’s relationship with
Ernst & Young by (1) reviewing Ernst & Young’s proposed audit scope, approach, compensation and
independence; (2) obtaining written statements and disclosures from Ernst & Young regarding
relationships and services with the Company which may impact independence as required by Ethics and
Independence Rule 3526, “Communications with Audit Committees Concerning Independence”;
(3) discussing with Ernst & Young the financial statements and audit findings, including any significant
adjustments, management judgments and accounting estimates, significant new accounting policies and
whether there were disagreements with management; and (4) obtaining assurance from Ernst & Young
that the requirements of Section 10A of the Exchange Act have been met; and

•

reviewed, in conjunction with the Company’s legal counsel, all legal matters that could have a significant
impact on the Company’s financial statements or compliance policies.

Based on our reviews and discussions as described above, and based on the report of Ernst & Young, we

recommended to the Board, and the Board approved, that the audited financial statements be included in the
Company’s Annual Report for the year ended December 31, 2018, filed with the SEC. We also approved, subject to
stockholder ratification, the selection of Ernst & Young as the Company’s independent registered public accounting

61

firm for 2019. In making this recommendation, we considered whether Ernst & Young’s provision of services other
than audit services is compatible with maintaining independence of our independent registered public accounting
firm. Although we have the sole authority to appoint the independent registered public accounting firm, we
continued the long-standing practice of recommending that the Board ask the stockholders at their Annual Meeting
to ratify the appointment of Ernst & Young as the Company’s independent registered public accounting firm.

The material in this report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be
incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made
before or after the date hereof and irrespective of any general incorporation language in any such filing.

Ms. Laura Brege, Chairperson
Dr. Arnold L. Oronsky, Ph.D.
Ms. Peggy V. Phillips

Compensation Committee

Our Compensation Committee is composed of three directors: Ms. Phillips (Chairperson) and Drs. Kisner and

Cano. All members of the Compensation Committee are independent as required by Nasdaq Rule 5605(d) (as
independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards), are “outside directors” for
purposes of Section 162(m) of the Code and are “non-employee directors” for purposes of Rule 16b-3 under the
Exchange Act.

The Compensation Committee acts on behalf of the Board to review, recommend for adoption, and oversee the

Company’s compensation strategy, policies, plans and programs. The Compensation Committee operates under a
written charter that is available on the Company’s website at http://investors.dynavax.com/corporate-governance.
Among other things, the charter specifically requires our Compensation Committee to:

• Annually review and approve the Company’s corporate goals and objectives relevant to CEO

compensation, evaluate the CEO’s performance in light of such goals and objectives, and recommend to
the Board the CEO’s compensation level based on this evaluation. In determining the long-term incentive
component of the CEO’s compensation, the Compensation Committee will consider the Company’s
performance and relative stockholder return, the value of similar incentive awards to CEOs at comparable
companies, and the awards given to the Company’s CEO in past years;

•

•

•

•

annually review and make recommendations to the Board with respect to incentive compensation plans
and equity-based plans;

annually review Director compensation and make recommendation to the Board;

administer the Company’s incentive-compensation plans and equity-based plans as in effect and as
adopted from time to time by the Board provided that the Board shall retain the authority to interpret such
plans;

annually review and approve for the Company’s executive officers as defined in Rule 16a-1(f) of the
Exchange Act: i) annual base salary levels; ii) annual incentive compensation levels; iii) long-term
incentive compensation levels; and iv) employment agreements, severance agreements, change of control
agreements/provisions and any other compensatory arrangements, in each case as, when and if
appropriate;

• make regular reports to the Board; and

•

perform such other functions and have such other powers consistent with the Compensation Committee
Charter, the Company’s Bylaws and governing laws as the Compensation Committee or the Board may
deem appropriate.

62

Under its charter, our Compensation Committee may form, and delegate authority to, subcommittees, as
appropriate. Our Compensation Committee has authorized and delegated authority to our CEO to grant stock
options to employees and consultants who are not officers of the Company from pre-approved pools and in
accordance with guidelines designated for new hire and annual grants. The purpose of this delegation is to enhance
the flexibility of option administration within the Company and to facilitate the timely grant of options to
non-executive employees, particularly new employees, within specified limits and values approved by our
Compensation Committee.

Compensation Committee Interlocks and Insider Participation

During the fiscal year ended December 31, 2018, Ms. Phillips and Drs. Cano and Kisner, each served as a
member of the Compensation Committee. None of the members of our Compensation Committee at any time has
been one of our officers or employees or an officer or employee of one of our subsidiaries at any time during the
fiscal year ended December 31, 2018. None of our executive officers currently serve, or in the past year has served,
as a member of the board of directors or compensation committee of any entity that has one or more executive
officers on our Board or Compensation Committee.

Nominating and Governance Committee

Our Nominating and Governance Committee is composed of three directors: Drs. Kisner (Chairperson) and

Cano, and Mr. Ricciardi. All members of the Nominating and Governance Committee are independent (as
independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards). The Nominating and
Governance Committee is responsible for identifying, reviewing and evaluating candidates to serve as directors of
the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent directors and
identifying with the CEO candidates for appointment or election to the Board.

In identifying potential director candidates, the Nominating and Governance Committee considers Board
candidates through a variety of methods and sources. These include suggestions from current Board members,
senior management, stockholders, professional search firms and other sources. At this time, the Nominating and
Governance Committee does not have a policy with regard to the consideration of director candidates recommended
by stockholders. While the Nominating and Governance Committee does not have such a formal policy, it will
consider such a recommendation, as reflected by its decision to recommend Mr. Ricciardi to the Board following a
stockholder recommendation. Our Board believes that it is appropriate that the Nominating and Corporate
Governance Committee does not have such a policy because the Nominating and Corporate Governance Committee
reviews all candidates in the same manner regardless of the source of the recommendation. In the case of a new
director candidate, the Nominating and Governance Committee also determines whether the nominee is independent
based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if
necessary. Among the qualifications to be considered in the selection of candidates are broad experience in business,
finance or administration, familiarity with the Company’s industry, and prominence and reputation. Since
prominence and reputation in a particular profession or field of endeavor are what bring most persons to the Board’s
attention, there is further consideration of whether the individual has the time available to devote to the work of the
Board and one or more of its committees. In addition, our Nominating and Governance Committee will consider
whether the candidate assists in achieving a mix of members that represents a diversity of backgrounds and
experience, including with respect to age, gender, international background, race and specialized experience. Each
year, our Nominating and Governance Committee reviews its Board membership criteria and assesses the
composition of the Board against the criteria.

The Nominating and Governance Committee discussed committee business a number of times during the year

and held three formal meetings. The Nominating and Governance Committee has adopted a written charter that is
available to stockholders on the Company’s website at http://investors.dynavax.com/corporate-governance.

63

STOCKHOLDER COMMUNICATIONS WITH THE BOARD OF DIRECTORS

Stockholders may communicate with our Board by directing comments, concerns, and questions to the
Corporate Secretary at Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California
94710, if mailed prior to June 1, 2019, or to 5959 Horton Street, Suite 700, Emeryville, California 94608, if mailed
on or after June 1, 2019. Communications will be distributed to the Board, or to any individual directors as
appropriate, depending on the facts and circumstances outlined in the communication. In that regard, our Board has
requested that certain items that are unrelated to the duties and responsibilities of the Board be filtered, including
product complaints or inquiries, new product suggestions, résumés and other forms of job inquiries, surveys, or
business solicitations or advertisements. In addition, material that is unduly hostile, threatening, illegal or similarly
unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to
any non-employee director upon request. Stockholders may also communicate with our Board as a group through
our website at http://investors.dynavax.com/confirmation/contact-board. All communications directed to the Audit
Committee in accordance with our whistleblower policy that relate to questionable accounting or auditing matters
involving the Company will be promptly and directly forwarded to the chairperson of the Audit Committee. Every
effort has been made to ensure that the views of stockholders are heard by the Board or individual directors, as
applicable, and that appropriate responses are provided to stockholders in a timely manner. We believe our
responsiveness to stockholder communications to the Board has been excellent.

64

CERTAIN TRANSACTIONS

There has not been, nor is there currently proposed, any transaction or series of similar transactions to which

the Company was or is to be a party in which the amount involved exceeds $120,000 and in which any current
director, executive officer, holder of more than 5% of our common stock or any immediate family member of any of
the foregoing persons had or will have a direct or indirect material interest other than compensation arrangements,
described under the sections entitled “Executive Compensation” and “ Director Compensation,” other than with
respect to the indemnification agreements described below.

Related Persons Transactions and Indemnification

Policies and Procedures for Related Person Transactions

Our Audit Committee is responsible for reviewing and approving all related party transactions, which would

include a transaction, arrangement or relationship (or any series of similar transactions, arrangements or
relationships) in which we and any “related person” are participants involving an amount that exceeds $120,000, not
including transactions involving compensation for services provided to Dynavax as an employee, director,
consultant or similar capacity by a related person. Related parties include any of our directors or executive officers,
certain of our stockholders and their immediate family members. This obligation is set forth in writing in the Audit
Committee charter. A copy of the Audit Committee charter is available on the Company’s website at http://
investors.dynavax.com/corporate-governance.

Where a transaction has been identified as a related-person transaction, management would present information

regarding the proposed related-person transaction to the Audit Committee (or, where Audit Committee approval
would be inappropriate, to another independent body of the Board) for consideration and approval or ratification.
The presentation would include a description of, among other things, the material facts, the interests, direct and
indirect, of the related persons, the benefits to Dynavax of the transaction and whether any alternative transactions
were available. To identify related-person transactions in advance, the Audit Committee relies on information
supplied by our executive officers and directors. In considering related-person transactions, the Audit Committee
takes into account the relevant available facts and circumstances including, but not limited to (a) the risks, costs and
benefits to Dynavax, (b) the impact on a director’s independence in the event the related person is a director,
immediate family member of a director or an entity with which a director is affiliated, (c) the terms of the
transaction, (d) the availability of other sources for comparable services or products and (e) the terms available to or
from, as the case may be, unrelated third parties or to or from employees generally. In the event a director has an
interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.
In determining whether to approve, ratify or reject a related-person transaction, the Audit Committee considers, in
light of known circumstances, whether the transaction is in, or is not inconsistent with, the best interests of Dynavax
and our stockholders, as the Audit Committee determines in the good faith exercise of its discretion.

Transactions With Related Persons

We have no related person transactions to report.

Indemnity Agreements

We have entered into indemnity agreements with some of our officers and directors so that they will be free

from undue concern about personal liability in connection with their service to the Company. The indemnity
agreements provide, among other things, that the Company will indemnify such officer or director, under the
circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or
she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or
her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under
Delaware law.

65

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Exchange Act requires the Company’s directors and executive officers, and persons who

own more than ten percent of a registered class of the Company’s equity securities, to file with the SEC initial
reports of ownership and reports of changes in ownership of common stock and other equity securities of the
Company. Officers, directors and greater-than-ten-percent stockholders are required by SEC regulation to furnish
the Company with copies of all Section 16(a) forms they file.

To the Company’s knowledge, based solely on a review of the copies of such reports furnished to the Company
and written representations that no other reports were required, during the fiscal year ended December 31, 2018, all
Section 16(a) filing requirements applicable to its officers, directors and greater-than-ten-percent beneficial owners
were in compliance.

CODE OF BUSINESS CONDUCT AND ETHICS

We have adopted the Dynavax Code of Business Conduct and Ethics that applies to all officers, directors and
employees. Our Code of Business Conduct and Ethics is available on our website at http://investors.dynavax.com/
corporate-governance and upon written request. We will provide a written copy of the Dynavax Code of Business
Conduct and Ethics to anyone without charge, upon request written to Dynavax Technologies Corporation,
Attention: Chief Compliance Officer, 2929 Seventh Street, Suite 100, Berkeley, California 94710, if mailed prior to
June 1, 2019, or to 5959 Horton Street, Suite 700, Emeryville, California 94608, if mailed on or after June 1, 2019,
or contact Dynavax’s Chief Compliance Officer at (510) 848-5100. If we make any substantive amendments to or
grant any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director,
we will promptly disclose the nature of the amendment or waiver on our website. There have been no waivers under
the Code of Business Conduct and Ethics as of April 9, 2019.

66

SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the ownership of the Company’s common stock as

of January 31, 2019 by: (i) each director and nominee for director; (ii) the NEOs; (iii) all executive officers and
directors of the Company as a group; and (iv) all those known by the Company to be beneficial owners of more than
five percent of its common stock.

Name and Address of Beneficial Holder

5% Stockholders:

Number of
Shares(2)

Percent of Shares
Beneficially
Owned(3)

BlackRock, Inc.(4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4,128,600

6.51%

55 East 52nd Street
New York, New York 10055

HealthCor Management, L.P.(5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4,613,280

7.28%

55 Hudson Yards, 28th Floor
New York, New York 10001

Franklin Resources, Inc.(6)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,199,278

5.05%

One Franklin Parkway
San Mateo, California 94403-1906

Senvest Management, L.L.C.(7)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,173,112

5.01%

540 Madison Avenue, 32nd Floor
New York, New York 10022

Federated Investors, Inc.(8) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,661,600

5.78%

Federated Investors Tower
Pittsburgh, Pennsylvania 15222-3779

NEOs and Directors (1)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Eddie Gray(9)
Michael S. Ostrach(10) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert L. Coffman, Ph.D.(11)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert Janssen, M.D.(12) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
David F. Novack(13)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Arnold L. Oronsky, Ph.D.(14)
Laura Brege(15) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Francis R. Cano, Ph.D.(16)
Dennis A. Carson, M.D.(17)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Daniel L. Kisner, M.D.(18)
Peggy V. Phillips(19) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Natale Ricciardi(20) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . .
All executive officers and directors as a group (12 persons)(21)

1,329,823
451,527
437,769
379,614
318,366
81,456
27,675
40,050
40,562
44,950
57,752
27,750
3,237,294

2.06%
*
*
*
*
*
*
*
*
*
*
*
4.90%

*

(1)

(2)

Less than one percent.

The address of each of the NEOs and directors is, prior to June 1, 2019, c/o Dynavax Technologies Corporation, 2929 Seventh Street, Suite
100, Berkeley, California 94710, or on or after June 1, 2019, c/o Dynavax Technologies Corporation, 5959 Horton Street, Suite 700,
Emeryville, California 94608.

To our knowledge, except as set forth in the footnotes to this table, and subject to applicable community property laws, each person named in
this table has sole voting and investment power with respect to the shares set forth opposite such person’s name.

(3) Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect

to the securities. Shares of our common stock subject to options currently exercisable or that will become exercisable within 60 days after
January 31, 2019, are deemed outstanding for computing the percentage of the person holding such options but are not deemed outstanding
for computing the percentage of any other person. Applicable percentages are based on 63,378,738 shares of our common stock outstanding
as of January 31, 2019, adjusted as required by the rules of the SEC.

67

(4)

(5)

(6)

(7)

(8)

This information is based solely on a Schedule 13G/A filed by BlackRock, Inc., on February 4, 2019, with the SEC. BlackRock beneficially
owns and has sole dispositive power over 4,128,600 shares of common stock, of which 3,996,747 are held with sole voting power. The
address of the principal business and office of BlackRock, Inc. and its affiliates is BlackRock Inc., 55 East 52nd Street, New York, NY
10055. The Schedule 13G/A provides information only as of December 31, 2018, and, consequently, the beneficial ownership of the above-
mentioned reporting person may have changed between December 31, 2018 and January 31, 2019.

This information is based solely on Schedule 13G/A filed by HealthCor Management, L.P. on February 14, 2019, with the SEC. HealthCor
Management, L.P. beneficially owns 4,613,280 shares and has no sole dispositive or sole voting power. The address of the principal business
and office of HealthCor Management, L.P. is, 55 Hudson Yards, 28th Floor, New York, NY 10001. The Schedule 13G/A provides
information only as of December 31, 2018 and consequently, the beneficial ownership of the above-mentioned reporting person may have
changed between December 31, 2018 and January 31, 2019.

This information is based solely on Schedule 13G/A filed by Franklin Resources, Inc. on January 25, 2019, with the SEC. Franklin
Resources, Inc. beneficially owns and has sole dispositive and voting power over 3,199,278 shares. The address of the principal business and
office of Franklin Resources, Inc. is, One Franklin Parkway, San Mateo, CA 94403-1906. The Schedule 13G/A provides information only as
of December 31, 2018 and consequently, the beneficial ownership of the above-mentioned reporting person may have changed between
December 31, 2018 and January 31, 2019.

This information is based solely on Schedule 13G filed by Sunvest Management, LLC on January 8, 2019, with the SEC. Sunvest
Management, LLC beneficially owns 3,173,112 shares and has no sole dispositive or sole voting power. The address of the principal
business and office of Sunvest Management, LLC is, 540 Madison Avenue, 32nd Floor, New York, NY 10022. The Schedule 13G provides
information only as of January 7, 2019 and consequently, the beneficial ownership of the above-mentioned reporting person may have
changed between January 7, 2019 and January 31, 2019.

This information is based solely on Schedule 13G/A filed by Federated Investors, Inc. on February 13, 2019, with the SEC. Federated
Investors, Inc. beneficially owns 3,661,600 shares and has sole dispositive and sole voting power over such shares. The address of the
principal business and office of Federated Investors, Inc. is, Federated Investors Tower, Pittsburgh, PA 15222-3779. The Schedule 13G/A
provides information only as of December 31, 2018 and consequently, the beneficial ownership of the above-mentioned reporting person
may have changed between December 31, 2018 and January 31, 2019.

(9) Consists of 158,934 shares of common stock owned directly by Mr. Gray, restricted stock awards to be converted into 112,000 shares of

common stock within 60 days of January 31, 2019 and options to purchase 1,058,889 shares of common stock exercisable within 60 days of
January 31, 2019.

(10) Consists of 76,554 shares of common stock owned directly by Mr. Ostrach, restricted stock awards to be converted into 58,304 shares of

common stock within 60 days of January 31, 2019 and options to purchase 316,669 shares of common stock exercisable within 60 days of
January 31, 2019.

(11) Consists of 77,768 shares of common stock owned directly by Dr. Coffman, restricted stock awards to be converted into 63,202 shares of
common stock within 60 days of January 31, 2019 and options to purchase 296,799 shares of common stock exercisable within 60 days of
January 31, 2019.

(12) Consists of 93,378 shares of common stock owned directly by Dr. Janssen, 948 of which were purchased through the employee stock

purchase plan; restricted stock awards to be converted into 55,375 shares of common stock within 60 days of January 31, 2019 and options
to purchase 230,861 shares of common stock exercisable within 60 days of January 31, 2019.

(13) Consists of 22,492 shares of common stock owned directly by Mr. Novack, restricted stock awards to be converted into 53,763 shares of

common stock within 60 days of January 31, 2019 and options to purchase 242,111 shares of common stock exercisable within 60 days of
January 31, 2019.

(14) Consists of 37,506 shares of common stock owned directly by Dr. Oronsky and options to purchase 43,950 shares of common stock

exercisable within 60 days of January 31, 2019.

(15) Consists of options to purchase 27,675 shares of common stock exercisable within 60 days of January 31, 2019.

(16) Consists of options to purchase 40,050 shares of common stock exercisable within 60 days of January 31, 2019.

(17) Consists of 6,812 shares of common stock owned directly by Dr. Carson and options to purchase 33,750 shares of common stock exercisable

within 60 days of January 31, 2019.

(18) Consists of 1,500 shares of common stock owned directly by Dr. Kisner and options to purchase 43,450 shares of common stock exercisable

within 60 days of January 31, 2019.

(19) Consists of 13,802 shares of common stock owned directly by Ms. Phillips and options to purchase 43,950 shares of common stock

exercisable within 60 days of January 31, 2019.

(20) Consists of options to purchase 27,750 shares of common stock exercisable within 60 days of January 31, 2019.

(21) Total number of shares includes 488,746 shares of common stock in aggregate held as of January 31, 2019, by our executive officers and

directors and entities affiliated with such executive officers and directors. Also includes restricted stock awards to be converted into 342,644

68

shares of common stock within 60 days of January 31, 2019 and options to purchase 2,405,904 shares of common stock exercisable within
60 days of January 31, 2019.

PERFORMANCE GRAPH

The chart below compares total stockholder return on an investment of $100 in cash on December 31, 2013,
for: our common stock, The Nasdaq Stock Market (U.S. companies), and the Nasdaq Pharmaceutical Preparation
Index. All values assume reinvestment of the full amount of all dividends.

Note: Dynavax management cautions that the stock price performance shown in the graph below should not be

considered indicative of potential future stock price performance.

COMPARISON OF 5 -YEAR CUMULATIVE TOTAL RETURN
AMONG DYNAVAX TECHNOLOGIES, NASDAQ MARKET INDEX, AND SIC CODE INDEX

$450

$400

$350

$300

$250

$200

$150

$100

$50

$0
Dec-13

Dec-14

Dec-15

Dec-16

Dec-17

Dec-18

DYNAVAX TECHNOLOGIES CORPORATION

NASDAQ U.S.

NASDAQ Pharmaceutical

ASSUMES $100 INVESTED ON DECEMBER 31, 2013
ASSUMES DIVIDENDS REINVESTED 
FISCAL YEAR ENDING DECEMBER 31, 2018

This Section is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by

reference in any filing of Dynavax Technologies Corporation under the Securities Act, or the Exchange Act,
whether made before or after the date hereof and irrespective of any general incorporation language in any such
filing.

69

OTHER MATTERS

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any

other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the
accompanying proxy to vote on such matters in accordance with their best judgment.

By Order of the Board of Directors

/s/ Steven N. Gersten

Steven N. Gersten
Secretary

April 22, 2019

A copy of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, is
available without charge upon written request to: Dynavax Technologies Corporation, Attention: Corporate
Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710.

70

DYNAVAX TECHNOLOGIES CORPORATION

2018 EQUITY INCENTIVE PLAN

ADOPTED BY THE BOARD OF DIRECTORS: APRIL 8, 2018
APPROVED BY THE STOCKHOLDERS: MAY 31, 2018
AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: APRIL 9, 2019
APPROVED BY THE STOCKHOLDERS: [MAY 30, 2019]

Appendix A

1. GENERAL.

(a) Successor to and Continuation of 2011 Plan. The Plan is intended as the successor to and continuation of

the Dynavax Technologies Corporation 2011 Equity Incentive Plan (the “2011 Plan”). Following the Effective
Date, no additional awards may be granted under the 2011 Plan or the Dynavax Technologies Corporation 2017
Inducement Award Plan (the “2017 Inducement Plan”) (each of the 2011 Plan and 2017 Inducement Plan, a “Prior
Plan”). Any unallocated shares remaining available for grant under the 2011 Plan as of 12:01 a.m. Pacific Time on
the Effective Date (the “2011 Plan’s Available Reserve”) will cease to be available under the 2011 Plan at such
time and will be added to the Share Reserve (as defined in Section 3(a)(i)) and be then immediately available for
grant and issuance pursuant to Awards granted under this Plan. From and after 12:01 a.m. Pacific Time on the
Effective Date, except as provided in Sections 9(c), 9(d) and 9(e), all outstanding stock awards granted under either
of the Prior Plans (each, a “Prior Plan Award”) will remain subject to the terms of the applicable Prior Plan;
provided, however, that the following shares of Common Stock subject to any outstanding Prior Plan Award
(collectively, the “Prior Plans’ Returning Shares”) will immediately be added to the Share Reserve (as defined in
Section 3(a)(i)) as and when such shares become Prior Plans’ Returning Shares and will become available for grant
and issuance pursuant to Awards granted under this Plan: (i) any shares subject to such stock award that are not
issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares
covered by such stock award having been issued; (ii) any shares subject to such stock award that are not issued
because such stock award or any portion thereof is settled in cash; and (iii) any shares issued pursuant to such stock
award that are forfeited back to or repurchased by the Company because of the failure to meet a contingency or
condition required for the vesting of such shares. All Awards granted on or after 12:01 a.m. Pacific Time on the
Effective Date will be subject to the terms of this Plan.

(b) Eligible Award Recipients. Subject to Section 4, Employees and Directors are eligible to receive Awards.

(c) Available Awards. The Plan provides for the grant of the following types of Awards: (i) Incentive Stock

Options; (ii) Nonstatutory Stock Options; (iii) Stock Appreciation Rights; (iv) Restricted Stock Awards;
(v) Restricted Stock Unit Awards; (vi) Performance Stock Awards; and (vii) Other Stock Awards.

(d) Purpose. The Plan, through the granting of Awards, is intended to help the Company and any Affiliate

secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum
efforts for the success of the Company and any Affiliate and provide a means by which such persons may benefit
from increases in value of the Common Stock.

2. ADMINISTRATION.

(a) Administration by Board. The Board will administer the Plan. The Board may delegate administration of

the Plan to a Committee or Committees, as provided in Section 2(c).

(b) Powers of Board. The Board will have the power, subject to, and within the limitations of, the express

provisions of the Plan:

(i) To determine (A) who will be granted Awards, (B) when and how each Award will be granted,

(C) what type of Award will be granted, (D) the provisions of each Award (which need not be identical), including

A-1

when a Participant will be permitted to exercise or otherwise receive cash or Common Stock under the Award,
(E) the number of shares of Common Stock subject to, or the cash value of, an Award, and (F) the Fair Market
Value applicable to an Award.

(ii) To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke
rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may
correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent
it will deem necessary or expedient to make the Plan or Award fully effective.

(iii) To settle all controversies regarding the Plan and Awards granted under it.

(iv) To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or at which

cash or shares of Common Stock may be issued in settlement thereof).

(v) To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan (including

Section 2(b)(viii)) or an Award Agreement, suspension or termination of the Plan will not materially impair a
Participant’s rights under an outstanding Award without his or her written consent.

(vi) To amend the Plan in any respect the Board deems necessary or advisable, including, without

limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred
compensation under Section 409A of the Code and/or to make the Plan or Awards granted under the Plan compliant
with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for
nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable
law. However, if required by applicable law or listing requirements, and except as provided in Section 9(a) relating
to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that
(A) materially increases the number of shares of Common Stock available for issuance under the Plan,
(B) materially expands the class of individuals eligible to receive Awards under the Plan, (C) materially increases
the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common
Stock may be issued or purchased under the Plan, or (E) materially expands the types of Awards available for
issuance under the Plan. Except as otherwise provided in the Plan (including Section 2(b)(viii)) or an Award
Agreement, no amendment of the Plan will materially impair a Participant’s rights under an outstanding Award
without his or her written consent.

(vii) To submit any amendment to the Plan for stockholder approval, including, but not limited to,

amendments to the Plan intended to satisfy the requirements of (A) Section 422 of the Code regarding incentive
stock options or (B) Rule 16b-3.

(viii) To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or

more outstanding Awards, including, but not limited to, amendments to provide terms more favorable to the
Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not
subject to Board discretion; provided, however, that except as otherwise provided in the Plan (including this
Section 2(b)(viii)) or an Award Agreement, no amendment of an outstanding Award will materially impair a
Participant’s rights under such Award without his or her written consent.

Notwithstanding the foregoing or anything in the Plan to the contrary, unless prohibited by applicable law,

the Board may amend the terms of any outstanding Award or the Plan, or may suspend or terminate the Plan,
without the affected Participant’s consent, (A) to maintain the qualified status of the Award as an Incentive Stock
Option under Section 422 of the Code, (B) to change the terms of an Incentive Stock Option, if such change results
in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option
under Section 422 of the Code, (C) to clarify the manner of exemption from, or to bring the Award or the Plan into
compliance with, Section 409A of the Code or (D) to comply with other applicable laws or listing requirements.

A-2

(ix) Generally, to exercise such powers and to perform such acts as the Board deems necessary or
expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or
Awards.

(x) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the

Plan by Employees or Directors who are foreign nationals or employed outside the United States (provided that
Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are
required for compliance with the laws of the relevant foreign jurisdiction).

(c) Delegation to Committee.

(i) General. The Board may delegate some or all of the administration of the Plan to a Committee or

Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with
the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the
Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers
the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee
or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not
inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).
The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to
the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and
may, at any time, revest in the Board some or all of the powers previously delegated.

(ii) Rule 16b-3 Compliance. The Committee may consist solely of two or more Non-Employee Directors

in accordance with Rule 16b-3.

(d) Delegation to an Officer. The Board may delegate to one or more Officers the authority to do one or both

of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the
extent permitted by applicable law, other Awards) and, to the extent permitted by applicable law, the terms of such
Awards; and (ii) determine the number of shares of Common Stock to be subject to such Awards granted to such
Employees; provided, however, that the Board resolutions regarding such delegation will specify the total number of
shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not
grant an Award to himself or herself. Any such Awards will be granted on the form of Award Agreement most
recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the
delegation of authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of
an Officer (and not also as a Director) to determine the Fair Market Value of the Common Stock pursuant to
Section 13(w)(iii).

(e) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in

good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

(f) Cancellation and Re-Grant of Awards. Neither the Board nor any Committee will have the authority to

(i) reduce the exercise or strike price of any outstanding Option or SAR or (ii) cancel any outstanding Option or
SAR that has an exercise or strike price (per share) greater than the then-current Fair Market Value of the Common
Stock in exchange for cash or other Awards under the Plan, unless the stockholders of the Company have approved
such an action within 12 months prior to such an event.

(g) Minimum Vesting Requirements. No Award may vest (or, if applicable, be exercisable) until at least 12
months following the date of grant of the Award; provided, however, that shares of Common Stock up to 5% of the
Share Reserve (as defined in Section 3(a)(i)) may be issued pursuant to Awards that do not meet such vesting (and,
if applicable, exercisability) requirements.

(h) Dividends and Dividend Equivalents. Dividends or dividend equivalents may be paid or credited, as
applicable, with respect to any shares of Common Stock subject to an Award, as determined by the Board and

A-3

contained in the applicable Award Agreement; provided, however, that (i) no dividends or dividend equivalents may
be paid with respect to any such shares before the date such shares have vested under the terms of such Award
Agreement, (ii) any dividends or dividend equivalents that are credited with respect to any such shares will be
subject to all of the terms and conditions applicable to such shares under the terms of such Award Agreement
(including, but not limited to, any vesting conditions), and (iii) any dividends or dividend equivalents that are
credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are
forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such
Award Agreement.

3.

SHARES SUBJECT TO THE PLAN.

(a) Share Reserve.

(i) Subject to Section 3(a)(iii) and Section 9(a) relating to Capitalization Adjustments, the aggregate

number of shares of Common Stock that may be issued pursuant to Awards from and after the Effective Date will
not exceed (A) 7,440,250 shares (which number is the sum of (i) the number of shares (140,250) subject to the 2011
Plan’s Available Reserve, (ii) an additional 5,000,000 shares that were approved at the Company’s 2018 Annual
Meeting of Stockholders, and (iii) an additional 2,300,000 shares that were approved at the Company’s 2019 Annual
Meeting of Stockholders), plus (B) the Prior Plans’ Returning Shares, if any, which become available for issuance
under this Plan from time to time (such aggregate number of shares described in (A) and (B), the “Share Reserve”).

(ii) Subject to Section 3(b), the number of shares of Common Stock available for issuance under the Plan

will be reduced by: (A) one share for each share of Common Stock issued pursuant to an Appreciation Award
granted under the Plan; (B) 1.28 shares for each share of Common Stock issued pursuant to a Full Value Award
granted under the Plan prior to May 30, 2019; and (C) 1.40 shares for each share of Common Stock issued pursuant
to a Full Value Award granted under the Plan on or after May 30, 2019.

(iii) Subject to Section 3(b), the number of shares of Common Stock available for issuance under the Plan
will be increased by: (A) one share for each Prior Plans’ Returning Share or 2018 Plan Returning Share (as defined
in Section 3(b)(i)) subject to an Appreciation Award; (B) 1.28 shares for each Prior Plans’ Returning Share or 2018
Plan Returning Share subject to a Full Value Award that returns to the Plan prior to May 30, 2019; and (C) 1.40
shares for each Prior Plans’ Returning Share or 2018 Plan Returning Share subject to a Full Value Award that
returns to the Plan on or after May 30, 2019.

(iv) For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common
Stock that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Awards
except as provided in Section 7(a). Shares may be issued in connection with a merger or acquisition as permitted by
NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX
Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares
available for issuance under the Plan.

(b) Reversion of Shares to the Share Reserve.

(i) Shares Available for Subsequent Issuance. The following shares of Common Stock (collectively, the

“2018 Plan Returning Shares”) will become available again for issuance under the Plan: (A) any shares subject to
an Award that are not issued because such Award or any portion thereof expires or otherwise terminates without all
of the shares covered by such Award having been issued; (B) any shares subject to an Award that are not issued
because such Award or any portion thereof is settled in cash; and (C) any shares issued pursuant to an Award that
are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition
required for the vesting of such shares.

(ii) Shares Not Available for Subsequent Issuance. The following shares of Common Stock will not

become available again for issuance under the Plan: (A) any shares that are reacquired or withheld (or not issued) by

A-4

the Company to satisfy the exercise, strike or purchase price of an Award or a Prior Plan Award (including any
shares subject to such award that are not delivered because such award is exercised through a reduction of shares
subject to such award (i.e., “net exercised”)); (B) any shares that are reacquired or withheld (or not issued) by the
Company to satisfy a tax withholding obligation in connection with an Award or a Prior Plan Award; (C) any shares
repurchased by the Company on the open market with the proceeds of the exercise, strike or purchase price of an
Award or a Prior Plan Award; and (D) in the event that a Stock Appreciation Right granted under the Plan or a stock
appreciation right granted under either of the Prior Plans is settled in shares of Common Stock, the gross number of
shares of Common Stock subject to such award.

(c) Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to Capitalization

Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the
exercise of Incentive Stock Options will be 10,000,000 shares.

(d) Non-Employee Director Compensation Limit. The aggregate value of all cash and equity-based
compensation granted or paid, as applicable, by the Company to any individual for service as a Non-Employee
Director with respect to any fiscal year of the Company will not exceed (i) a total of $200,000 with respect to any
such cash compensation and (ii) $800,000 in total value with respect to any such equity-based compensation
(including Awards and any other equity-based awards), calculating the value of any such awards based on the grant
date fair value of such awards for financial reporting purposes.

(e) Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired

Common Stock, including shares repurchased by the Company on the open market or otherwise.

4. ELIGIBILITY.

(a) Eligibility for Specific Awards. Incentive Stock Options may be granted only to employees of the

Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e)
and 424(f) of the Code). Awards other than Incentive Stock Options may be granted to Employees and Directors;
provided, however, that Awards may not be granted to Employees and Directors who are providing Continuous
Service only to any “parent” of the Company, as such term is defined in Rule 405, unless (i) the stock underlying
such Awards is treated as “service recipient stock” under Section 409A of the Code (for example, because the
Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii) the Company, in
consultation with its legal counsel, has determined that such Awards are otherwise exempt from or alternatively
comply with Section 409A of the Code.

(b) Ten Percent Stockholders. A Ten Percent Stockholder will not be granted an Incentive Stock Option
unless the exercise price (per share) of such Option is at least 110% of the Fair Market Value of the Common Stock
on the date of grant of such Option and the Option is not exercisable after the expiration of five years from the date
of grant.

5.

PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.

Each Option or SAR Agreement will be in such form and will contain such terms and conditions as the Board

deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock
Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for
shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as
an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the
Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof)
will be a Nonstatutory Stock Option. The terms and conditions of separate Option or SAR Agreements need not be
identical; provided, however, that each Award Agreement will conform to (through incorporation of the provisions
hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following
provisions:

A-5

(a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will

be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the
Award Agreement.

(b) Exercise or Strike Price. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the
exercise or strike price (per share) of each Option or SAR will be not less than 100% of the Fair Market Value of the
Common Stock on the date the Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted
with an exercise or strike price (per share) less than 100% of the Fair Market Value of the Common Stock on the
date the Award is granted if such Award is granted pursuant to an assumption of, or substitution for, another option
or stock appreciation right pursuant to a Transaction and in a manner consistent with the provisions of Section 409A
of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Common
Stock equivalents.

(c) Payment of Exercise Price for Options. The exercise price of an Option may be paid, to the extent
permitted by applicable law and as determined by the Board in its sole discretion, by one or more of the methods of
payment set forth below that are specified in the Option Agreement. The Board has the authority to grant Options
that do not permit all of the following methods of payment (or that otherwise restrict the ability to utilize certain
methods) and to grant Options that require the consent of the Company to utilize a particular method of payment.

(i) By cash (including electronic funds transfers), check, bank draft or money order payable to the

Company;

(ii) Pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board

that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check)
by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from
the sales proceeds;

(iii) By delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;

(iv) If an Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the
Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number
of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the
Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the
aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of
Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that
(A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are
delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding
obligations; or

(v) In any other form of legal consideration that may be acceptable to the Board and specified in the

applicable Award Agreement.

(d) Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written

notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such
SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the
excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of
Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such
SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike
price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on
such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in
any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing
such SAR.

A-6

(e) Transferability of Options and SARs. The Board may, in its sole discretion, impose such limitations on
the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the
Board to the contrary, the restrictions set forth in this Section 5(e) on the transferability of Options and SARs will
apply. Notwithstanding the foregoing or anything in the Plan or an Award Agreement to the contrary, no Option or
SAR may be transferred to any financial institution without prior stockholder approval.

(i) Restrictions on Transfer. An Option or SAR will not be transferable, except by will or by the laws of

descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below), and will be exercisable during the
lifetime of the Participant only by the Participant. Subject to the foregoing paragraph, the Board may, in its sole
discretion, permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities
laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.

(ii) Domestic Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an
Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement
agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2). If
an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result
of such transfer.

(iii) Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a

Participant may, by delivering written notice to the Company, in a form approved by the Company (or the
designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to
exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In
the absence of such a designation, upon the death of the Participant, the executor or administrator of the
Participant’s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other
consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any
time, including due to any conclusion by the Company that such designation would be inconsistent with the
provisions of applicable laws.

(f) Vesting. The total number of shares of Common Stock subject to an Option or SAR may vest and become
exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other
terms and conditions on the time or times when it may or may not be exercised (which may be based on the
satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of
individual Options or SARs may vary. The provisions of this Section 5(f) are subject to Section 2(g) and any Option
or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may
be exercised.

(g) Termination of Continuous Service. Except as otherwise provided in the applicable Award Agreement or

other written agreement between a Participant and the Company or an Affiliate, if a Participant’s Continuous
Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant
may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or
SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier
of (i) the date that is three months following such termination of Continuous Service (or such longer or shorter
period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in
the Award Agreement. If, after such termination of Continuous Service, the Participant does not exercise his or her
Option or SAR (as applicable) within the applicable time period, the Option or SAR (as applicable) will terminate.

(h) Extension of Termination Date. Except as otherwise provided in the applicable Award Agreement or
other written agreement between a Participant and the Company or an Affiliate, if the exercise of an Option or SAR
following the termination of a Participant’s Continuous Service (other than for Cause and other than upon the
Participant’s death or Disability) would be prohibited at any time solely because the issuance of shares of Common
Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on
the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-

A-7

termination exercise period after the termination of the Participant’s Continuous Service during which the exercise
of the Option or SAR would not be in violation of such registration requirements or (ii) the expiration of the term of
the Option or SAR as set forth in the applicable Award Agreement. In addition, except as otherwise provided in the
applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if
the sale of any Common Stock received upon exercise of an Option or SAR following the termination of a
Participant’s Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then
the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be
consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s
Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR
would not be in violation of the Company’s insider trading policy or (ii) the expiration of the term of the Option or
SAR as set forth in the applicable Award Agreement.

(i) Disability of Participant. Except as otherwise provided in the applicable Award Agreement or other

written agreement between a Participant and the Company or an Affiliate, if a Participant’s Continuous Service
terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the
extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous
Service), but only within such period of time ending on the earlier of (i) the date that is 12 months following such
termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the
expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after such termination of
Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable
time period, the Option or SAR (as applicable) will terminate.

(j) Death of Participant. Except as otherwise provided in the applicable Award Agreement or other written

agreement between a Participant and the Company or an Affiliate, if (i) a Participant’s Continuous Service
terminates as a result of the Participant’s death, or (ii) a Participant dies within the period (if any) specified in the
Award Agreement for exercisability after the termination of the Participant’s Continuous Service (for a reason other
than death), then the Participant’s Option or SAR may be exercised (to the extent that the Participant was entitled to
exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right
to exercise the Option or SAR by bequest or inheritance, or by a person designated to exercise the Option or SAR
upon the Participant’s death, but only within such period of time ending on the earlier of (i) the date that is 18
months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the
expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after the Participant’s death,
the Option or SAR (as applicable) is not exercised within the applicable time period, the Option or SAR (as
applicable) will terminate.

(k) Termination for Cause. Except as explicitly provided otherwise in the applicable Award Agreement or

other individual written agreement between a Participant and the Company or an Affiliate, if a Participant’s
Continuous Service is terminated for Cause, the Participant’s Option or SAR will terminate immediately upon such
termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR
from and after the time of such termination of Continuous Service.

(l) Non-Exempt Employees. If an Option or SAR is granted to an Employee who is a non-exempt employee
for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable
for any shares of Common Stock until at least six months following the date of grant of the Option or SAR
(although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic
Opportunity Act, (i) if such non-exempt employee dies or suffers a Disability, (ii) upon a Transaction in which such
Option or SAR is not assumed, continued or substituted, (iii) upon a Change in Control, or (iv) upon the
Participant’s retirement (as such term may be defined in the Participant’s Award Agreement, in another written
agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the
Company’s or Affiliate’s then current employment policies and guidelines), the vested portion of any Options and
SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to
operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an

A-8

Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for
compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt
employee in connection with the exercise, vesting or issuance of any shares under any other Award will be exempt
from the employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Awards and are hereby
incorporated by reference into such Award Agreements.

6.

PROVISIONS OF AWARDS OTHER THAN OPTIONS AND SARS.

(a) Restricted Stock Awards. Each Restricted Stock Award Agreement will be in such form and will contain
such terms and conditions as the Board deems appropriate. To the extent consistent with the Company’s bylaws, at
the Board’s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry
form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse, or
(ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.
The terms and conditions of separate Restricted Stock Award Agreements need not be identical; provided, however,
that each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by
reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:

(i) Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash (including

electronic funds transfers), check, bank draft or money order payable to the Company, (B) past services to the
Company or an Affiliate or (C) any other form of legal consideration (including future services) that may be
acceptable to the Board, in its sole discretion, and permissible under applicable law.

(ii) Vesting. Subject to Section 2(g), shares of Common Stock awarded under a Restricted Stock Award
Agreement may be subject to forfeiture to or repurchase by the Company in accordance with a vesting schedule to
be determined by the Board.

(iii) Termination of Continuous Service. If a Participant’s Continuous Service terminates, the Company

may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by
the Participant that have not vested as of the date of such termination under the terms of the Participant’s Restricted
Stock Award Agreement.

(iv) Transferability. Rights to acquire shares of Common Stock under a Restricted Stock Award
Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the
Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock
awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award
Agreement. Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the
contrary, no Restricted Stock Award may be transferred to any financial institution without prior stockholder
approval.

(b) Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement will be in such form and

will contain such terms and conditions as the Board deems appropriate. The terms and conditions of separate
Restricted Stock Unit Award Agreements need not be identical; provided, however, that each Restricted Stock Unit
Award Agreement will conform to (through incorporation of the provisions hereof by reference in the applicable
Award Agreement or otherwise) the substance of each of the following provisions:

(i) Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the

consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the
Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common
Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be
acceptable to the Board, in its sole discretion, and permissible under applicable law.

(ii) Vesting. Subject to Section 2(g), at the time of the grant of a Restricted Stock Unit Award, the Board

may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole
discretion, deems appropriate.

A-9

(iii) Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock,

their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board
and contained in the Restricted Stock Unit Award Agreement.

(iv) Additional Restrictions. At the time of the grant of a Restricted Stock Unit Award, the Board, as it

deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common
Stock (or their cash equivalent) subject to the Restricted Stock Unit Award to a time after the vesting of the
Restricted Stock Unit Award.

(v) Termination of Continuous Service. Except as otherwise provided in the applicable Restricted Stock

Unit Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a
Participant’s Continuous Service terminates, any portion of the Participant’s Restricted Stock Unit Award that has
not vested as of the date of such termination will be forfeited upon such termination.

(c) Performance Stock Awards.

(i) General. A Performance Stock Award is an Award that is payable (including that may be granted, vest

or be exercised) contingent upon the attainment during a Performance Period of specified Performance Goals. A
Performance Stock Award may, but need not, require the Participant’s completion of a specified period of
Continuous Service. Subject to Section 2(g), the length of any Performance Period, the Performance Goals to be
achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals
have been attained will be conclusively determined by the Board, in its sole discretion. In addition, to the extent
permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used
in payment of Performance Stock Awards.

(ii) Board Discretion. With respect to any Performance Stock Award, the Board retains the discretion to
(A) reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goals
on the basis of any considerations as the Board, in its sole discretion, may determine and (B) define the manner of
calculating the Performance Criteria it selects to use for a Performance Period.

(d) Other Stock Awards. Other forms of Awards valued in whole or in part by reference to, or otherwise
based on, Common Stock, including the appreciation in value thereof (e.g., options or stock appreciation rights with
an exercise or strike price (per share) less than 100% of the Fair Market Value of the Common Stock on the date of
grant) may be granted either alone or in addition to Awards granted under Section 5 and this Section 6. Subject to
the provisions of the Plan (including, but not limited to, Sections 2(g) and 2(h)), the Board will have sole and
complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will
be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such
Other Stock Awards and all other terms and conditions of such Other Stock Awards.

7. COVENANTS OF THE COMPANY.

(a) Availability of Shares. The Company will keep available at all times the number of shares of Common

Stock reasonably required to satisfy then-outstanding Awards.

(b) Securities Law Compliance. The Company will seek to obtain from each regulatory commission or
agency having jurisdiction over the Plan the authority required to grant Awards and to issue and sell shares of
Common Stock upon exercise of the Awards; provided, however, that this undertaking will not require the Company
to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any
such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such
regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful
issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to
issue and sell Common Stock upon exercise of such Awards unless and until such authority is obtained. A
Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock
pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.

A-10

(c) No Obligation to Notify or Minimize Taxes. The Company will have no duty or obligation to any
Participant to advise such holder as to the time or manner of exercising an Award. Furthermore, the Company will
have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an
Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to
minimize the tax consequences of an Award to the holder of such Award.

8. MISCELLANEOUS.

(a) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock issued

pursuant to Awards will constitute general funds of the Company.

(b) Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Company
of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise
determined by the Board, regardless of when the instrument, certificate or letter evidencing the Award is
communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g.,
Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g.,
exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or
related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant
documents, the corporate records will control and the Participant will have no legally binding right to the incorrect
term in the Award Agreement or related grant documents.

(c) Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a
holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has
satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to
its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and
records of the Company.

(d) No Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other

instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any
Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award
was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee
with or without notice and with or without cause, or (ii) the service of a Director pursuant to the bylaws of the
Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or
the Affiliate is incorporated, as the case may be.

(e) Change in Time Commitment. In the event a Participant’s regular level of time commitment in the
performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation,
if the Participant is an Employee of the Company and the Employee has a change in status from a full-time
Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to
the Participant, the Board has the right in its sole discretion to (i) make a corresponding reduction in the number of
shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the
date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the
vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have
no right with respect to any portion of the Award that is so reduced or extended.

(f) Incentive Stock Option Limitation. To the extent that the aggregate Fair Market Value (determined at the
time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by
any Participant during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or
such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock
Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted)
or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any
contrary provision of the applicable Option Agreement(s).

A-11

(g) Investment Assurances. The Company may require a Participant, as a condition of exercising or acquiring

Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant’s
knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably
satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or
she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising
the Award and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring
Common Stock subject to the Award for the Participant’s own account and not with any present intention of selling
or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to
such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common
Stock under the Award has been registered under a then currently effective registration statement under the
Securities Act or (B) as to any particular requirement, a determination is made by counsel for the Company that
such requirement need not be met in the circumstances under the then applicable securities laws. The Company
may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such
counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not
limited to, legends restricting the transfer of the Common Stock.

(h) Withholding Obligations. Unless prohibited by the terms of an Award Agreement, the Company may, in
its sole discretion, satisfy any federal, state, local or foreign tax withholding obligation relating to an Award by any
of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment;
(ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the
Participant in connection with the Award; (iii) withholding cash from an Award settled in cash; (iv) withholding
payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in
the Award Agreement.

(i) Electronic Delivery. Any reference herein to a “written” agreement or document will include any

agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or
posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the
Participant has access).

(j) Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine that

the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of
any Award may be deferred and may establish programs and procedures for deferral elections to be made by
Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with
Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or
otherwise providing services to the Company or an Affiliate. The Board is authorized to make deferrals of Awards
and determine when, and in what annual percentages, Participants may receive payments, including lump sum
payments, following the Participant’s termination of Continuous Service, and implement such other terms and
conditions consistent with the provisions of the Plan and in accordance with applicable law.

(k) Section 409A. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award
Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards
granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with
Section 409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is
therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the
terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the
extent an Award Agreement is silent on terms necessary for compliance with Section 409A of the Code, such terms
are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this
Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly
traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the
Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount
under such Award that is due because of a “separation from service” (as defined in Section 409A of the Code
without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one

A-12

day following the date of such Participant’s “separation from service” or, if earlier, the date of the Participant’s
death, unless such distribution or payment may be made in a manner that complies with Section 409A of the Code,
and any amounts so deferred will be paid in a lump sum on the day after such six-month period elapses, with the
balance paid thereafter on the original schedule.

(l) Clawback/Recovery. All Awards granted under the Plan will be subject to recoupment in accordance with

any clawback policy that the Company is required to adopt pursuant to the listing standards of any national
securities exchange or association on which the Company’s securities are listed or as is otherwise required by the
Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may
impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines
necessary or appropriate, including, but not limited to, a reacquisition right in respect of previously acquired shares
of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such
a clawback policy will be an event giving rise to a right to resign for “good reason” or “constructive termination”
(or similar term) under any agreement with the Company or an Affiliate.

9. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.

(a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately and

proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to
Section 3(a); (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of
Incentive Stock Options pursuant to Section 3(c); and (iii) the class(es) and number of securities and price per share
of stock subject to outstanding Awards. The Board will make such adjustments and its determination will be final,
binding and conclusive.

(b) Dissolution or Liquidation. Except as otherwise provided in the applicable Award Agreement or other
written agreement between a Participant and the Company or an Affiliate, in the event of a dissolution or liquidation
of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of
Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) will terminate
immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to a
forfeiture condition or the Company’s right of repurchase may be reacquired or repurchased by the Company
notwithstanding the fact that the holder of such Award is providing Continuous Service.

(c) Transactions. In the event of a Transaction, the provisions of this Section 9(c) will apply to each

outstanding Award and Prior Plan Award, in each case unless otherwise provided in the instrument evidencing the
Award or Prior Plan Award (as applicable), in any other written agreement between the Company or any Affiliate
and the Participant, or in any director compensation policy of the Company.

(i) Awards May Be Assumed. In the event of a Transaction, any surviving corporation or acquiring

corporation (or the surviving or acquiring corporation’s parent company) may assume or continue any or all
outstanding Awards and/or Prior Plan Awards or may substitute similar stock awards for any or all outstanding
Awards and/or Prior Plan Awards (including, but not limited to, awards to acquire the same consideration paid to
the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the
Company in respect of Common Stock issued pursuant to any outstanding Awards and/or Prior Plan Awards may be
assigned by the Company to the surviving corporation or acquiring corporation (or the surviving or acquiring
corporation’s parent company). For clarity, in the event of a Transaction, any surviving corporation or acquiring
corporation (or the surviving or acquiring corporation’s parent company) may choose to assume or continue only a
portion of an outstanding Award or Prior Plan Award, to substitute a similar stock award for only a portion of an
outstanding Award or Prior Plan Award, or to assume or continue, or substitute similar stock awards for, the
outstanding Awards and/or Prior Plan Awards held by some, but not all, Participants. The terms of any such
assumption, continuation or substitution will be set by the Board.

(ii) Awards Held by Current Participants. In the event of a Transaction in which the surviving
corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) does not assume

A-13

or continue outstanding Awards and/or Prior Plan Awards, or substitute similar stock awards for outstanding
Awards and/or Prior Plan Awards, then with respect to any such Awards and/or Prior Plan Awards that have not
been assumed, continued or substituted and that are held by Participants whose Continuous Service has not
terminated prior to the effective time of the Transaction (referred to as the “Current Participants”), the vesting (and
exercisability, if applicable) of such Awards and Prior Plan Awards will be accelerated in full (and with respect to
Performance Stock Awards, vesting will be deemed to be satisfied at the target level of performance) to a date prior
to the effective time of the Transaction (contingent upon the closing or completion of the Transaction) as the Board
will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective
time of the Transaction), and such Awards and Prior Plan Awards will terminate if not exercised (if applicable) prior
to the effective time of the Transaction in accordance with the exercise procedures determined by the Board, and
any reacquisition or repurchase rights held by the Company with respect to such Awards and Prior Plan Awards will
lapse (contingent upon the closing or completion of the Transaction).

(iii) Awards Held by Participants other than Current Participants. In the event of a Transaction in

which the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent
company) does not assume or continue outstanding Awards and/or Prior Plan Awards, or substitute similar stock
awards for outstanding Awards and/or Prior Plan Awards, then with respect to any such Awards and/or Prior Plan
Awards that have not been assumed, continued or substituted and that are held by Participants other than Current
Participants, such Awards and Prior Plan Awards will terminate if not exercised (if applicable) prior to the effective
time of the Transaction in accordance with the exercise procedures determined by the Board; provided, however,
that any reacquisition or repurchase rights held by the Company with respect to such Awards and Prior Plan Awards
will not terminate and may continue to be exercised notwithstanding the Transaction.

(iv) Payment for Awards in Lieu of Exercise. Notwithstanding the foregoing, in the event any

outstanding Award or Prior Plan Award held by a Participant will terminate if not exercised prior to the effective
time of a Transaction, the Board may provide that the Participant may not exercise such Award or Prior Plan Award
but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if
any, of (A) the value of the property the Participant would have received upon the exercise of such Award or Prior
Plan Award immediately prior to the effective time of the Transaction, over (B) any exercise price payable by the
Participant in connection with such exercise. For clarity, such payment may be zero if the value of such property is
equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that
payment of consideration to the holders of the Common Stock in connection with the Transaction is delayed as a
result of escrows, earn outs, holdbacks or any other contingencies.

(d) Change in Control. Unless provided otherwise in the Award Agreement for an Award or award agreement
for a Prior Plan Award (as applicable), in any other written agreement or plan between the Company or any Affiliate
and the Participant, or in any director compensation policy of the Company, an Award or Prior Plan Award will not
be subject to additional acceleration of vesting and exercisability upon or after a Change in Control.

(e) Prior Plan Awards. For clarity, with respect to any Prior Plan Award, the terms set forth in Sections 9(c)
and 9(d) will supersede any terms set forth in the applicable Prior Plan regarding the treatment of such Prior Plan
Award in the event of a Corporate Transaction (as defined in the applicable Prior Plan) or Change in Control (as
defined in the applicable Prior Plan).

(f) Parachute Payments. Except as otherwise provided in the applicable Award Agreement or other written
agreement between a Participant and the Company or an Affiliate, if any payment or benefit the Participant would
receive pursuant to a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a
“parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to
the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the
Reduced Amount. The “Reduced Amount” will be either (x) the largest portion of the Payment that would result in
no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of
the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes,

A-14

income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant’s
receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the
Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments”
is necessary so that the Payment equals the Reduced Amount, reduction will occur in the following order:
(A) reduction of cash payments; (B) cancellation of accelerated vesting of equity awards other than stock options;
(C) cancellation of accelerated vesting of stock options; and (D) reduction of other benefits paid to the Participant.
Within any such category of payments and benefits (that is, (A), (B), (C) or (D)), a reduction will occur first with
respect to amounts that are not “deferred compensation” within the meaning of Section 409A of the Code and then
with respect to amounts that are. In the event that acceleration of compensation from a Participant’s equity awards is
to be reduced, such acceleration of vesting will be canceled, subject to the immediately preceding sentence, in the
reverse order of the date of grant. The accounting firm engaged by the Company for general audit purposes as of the
day prior to the effective date of the Change in Control will perform the foregoing calculations. If the accounting
firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the
Change in Control, the Company will appoint a nationally recognized accounting firm to make the determinations
required hereunder. The Company will bear all expenses with respect to the determinations by such accounting firm
required to be made hereunder. The accounting firm engaged to make the determinations hereunder will provide its
calculations, together with detailed supporting documentation, to the Participant and the Company within 15
calendar days after the date on which the Participant’s right to a Payment is triggered (if requested at that time by
the Participant or the Company) or such other time as reasonably requested by the Participant or the Company. Any
good faith determinations of the accounting firm made hereunder will be final, binding and conclusive upon the
Participant and the Company.

10. TERMINATION OR SUSPENSION OF THE PLAN.

(a) Termination or Suspension. The Board may suspend or terminate the Plan at any time. No Incentive

Stock Option may be granted after the tenth anniversary of the earlier of (i) the Adoption Date or (ii) the date the
Plan is approved by the stockholders of the Company. No Awards may be granted under the Plan while the Plan is
suspended or after it is terminated.

(b) No Impairment of Rights. Suspension or termination of the Plan will not materially impair rights and
obligations under any Award granted while the Plan is in effect except with the written consent of the affected
Participant or as otherwise permitted in the Plan (including Section 2(b)(viii)) or an Award Agreement.

11. EFFECTIVE DATE OF PLAN.

This Plan will become effective on the Effective Date.

12. CHOICE OF LAW.

The laws of the State of Delaware will govern all questions concerning the construction, validity and

interpretation of this Plan, without regard to that state’s conflict of laws rules.

13. DEFINITIONS. As used in the Plan, the following definitions will apply to the capitalized terms indicated

below:

(a) “Adoption Date” means April 8, 2018, which is the date the Plan was adopted by the Board.

(b) “Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms

are defined in Rule 405. The Board will have the authority to determine the time or times at which “parent” or
“subsidiary” status is determined within the foregoing definition.

(c) “Appreciation Award” means (i) a stock option or stock appreciation right granted under any of the Prior

Plans or (ii) an Option or Stock Appreciation Right, in each case with respect to which the exercise or strike price is

A-15

at least 100% of the Fair Market Value of the Common Stock subject to the stock option or stock appreciation right,
or Option or Stock Appreciation Right, as applicable, on the date of grant.

(d) “Award” means an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a
Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award.

(e) “Award Agreement” means a written agreement between the Company and a Participant evidencing the

terms and conditions of an Award.

(f) “Board” means the Board of Directors of the Company.

(g) “Capitalization Adjustment” means any change that is made in, or other events that occur with respect to,

the Common Stock subject to the Plan or subject to any Award after the Adoption Date without the receipt of
consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation,
stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock
split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar
equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards No. 123
(revised). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be
treated as a Capitalization Adjustment.

(h) “Cause” will have the meaning ascribed to such term in any written agreement between a Participant and

the Company or an Affiliate defining such term and, in the absence of such agreement, such term means, with
respect to a Participant, the occurrence of one or more of the following: (i) the Participant’s theft, dishonesty, willful
misconduct, breach of fiduciary duty for personal profit, or falsification of any Company or Affiliate documents or
records; (ii) the Participant’s material failure to abide by the code of conduct or other policies (including, without
limitation, policies relating to confidentiality and reasonable workplace conduct) of the Company or an Affiliate;
(iii) the Participant’s unauthorized use, misappropriation, destruction or diversion of any tangible or intangible asset
or corporate opportunity of the Company or an Affiliate (including, without limitation, the Participant’s improper
use or disclosure of confidential or proprietary information of the Company or an Affiliate); (iv) any intentional act
by the Participant which has a material detrimental effect on the reputation or business of the Company or an
Affiliate; (v) the Participant’s repeated failure or inability to perform any reasonable assigned duties after written
notice from the Company or an Affiliate, and a reasonable opportunity to cure, such failure or inability; (vi) any
material breach by the Participant of any employment or service agreement between the Participant and the
Company or an Affiliate, which breach is not cured pursuant to the terms of such agreement; or (vii) the
Participant’s conviction (including any plea of guilty or nolo contendere) of any criminal act involving fraud,
dishonesty, misappropriation or moral turpitude, or which impairs the Participant’s ability to perform his or her
duties. The determination that a termination of a Participant’s Continuous Service is either for Cause or without
Cause will be made by the Company, in its sole discretion. Any determination by the Company that the Continuous
Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by the
Participant will have no effect upon any determination of the rights or obligations of the Company or the Participant
for any other purpose.

(i) “Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of

any one or more of the following events:

(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company

representing more than 50% of the combined voting power of the Company’s then outstanding securities other than
by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will
not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company,
(B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other
Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the
primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or

A-16

(C) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the
designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition
of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in
Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the
Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting
securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change
in Control will be deemed to occur;

(ii) there is consummated a merger, consolidation or similar transaction involving (directly or

indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar
transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either
(A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the
surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined
outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction,
in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the
Company immediately prior to such transaction;

(iii) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of
the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of
all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of
the combined voting power of the voting securities of which are Owned by stockholders of the Company in
substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such sale, lease, license or other disposition; or

(iv) over a period of 12 months or less, individuals who, on the Adoption Date, are members of the Board

(the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board;
provided, however, that if the appointment or election (or nomination for election) of any new Board member was
approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new
member will, for purposes of this Plan, be considered as a member of the Incumbent Board.

Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control will not
include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of
the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written
agreement between a Participant and the Company or an Affiliate will supersede the foregoing definition with
respect to Awards and/or Prior Plan Awards (as applicable) subject to such agreement; provided, however, that (1) if
no definition of Change in Control (or any analogous term) is set forth in such an individual written agreement, the
foregoing definition will apply; and (2) no Change in Control (or any analogous term) will be deemed to occur with
respect to Awards and/or Prior Plan Awards (as applicable) subject to such an individual written agreement without
a requirement that the Change in Control (or any analogous term) actually occur.

If required for compliance with Section 409A of the Code, in no event will an event be deemed a Change in
Control if such event is not also a “change in the ownership of” the Company, a “change in the effective control of”
the Company or a “change in the ownership of a substantial portion of the assets of” the Company, each as
determined under Treasury Regulations Section 1.409A-3(i)(5) (without regard to any alternative definition
thereunder). The Board may, in its sole discretion and without a Participant’s consent, amend the definition of
“Change in Control” to conform to the definition of a “change in control event” under Section 409A of the Code and
the regulations thereunder.

(j) “Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and

guidance thereunder.

A-17

(k) “Committee” means a committee of one or more Directors to whom authority has been delegated by the

Board in accordance with Section 2(c).

(l) “Common Stock” means the common stock of the Company.

(m) “Company” means Dynavax Technologies Corporation, a Delaware corporation.

(n) “Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an

Employee or Director, is not interrupted or terminated. A change in the capacity in which the Participant renders
service to the Company or an Affiliate as an Employee or Director or a change in the Entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant’s service
with the Company or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if
the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board,
in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such
Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a
Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the
chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service
will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive
officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an
Affiliate or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous
Service for purposes of vesting in an Award only to such extent as may be provided in the Company’s or Affiliate’s
leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the
Participant, or as otherwise required by law.

(o) “Corporate Transaction” means the occurrence, in a single transaction or in a series of related transactions,

of any one or more of the following events:

(i) the consummation of a sale or other disposition of all or substantially all, as determined by the Board,

in its sole discretion, of the consolidated assets of the Company and its Subsidiaries;

(ii) the consummation of a sale or other disposition of at least 90% of the outstanding securities of the

Company;

(iii) the consummation of a merger, consolidation or similar transaction following which the Company is

not the surviving corporation; or

(iv) the consummation of a merger, consolidation or similar transaction following which the Company is

the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger,
consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar
transaction into other property, whether in the form of securities, cash or otherwise.

If required for compliance with Section 409A of the Code, in no event will an event be deemed a Corporate
Transaction if such event is not also a “change in the ownership of” the Company, a “change in the effective control
of” the Company or a “change in the ownership of a substantial portion of the assets of” the Company, each as
determined under Treasury Regulations Section 1.409A-3(i)(5) (without regard to any alternative definition
thereunder). The Board may, in its sole discretion and without a Participant’s consent, amend the definition of
“Corporate Transaction” to conform to the definition of a “change in control event” under Section 409A of the Code
and the regulations thereunder.

(p) “Director” means a member of the Board.

(q) “Disability” means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment that can be

A-18

expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12
months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on
the basis of such medical evidence as the Board deems warranted under the circumstances.

(r) “Effective Date” means the effective date of this Plan, which is the date of the Annual Meeting of
Stockholders of the Company held in 2018, provided that this Plan is approved by the Company’s stockholders at
such meeting.

(s) “Employee” means any person employed by the Company or an Affiliate. However, service solely as a

Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for
purposes of the Plan.

(t) “Entity” means a corporation, partnership, limited liability company or other entity.

(u) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations

promulgated thereunder.

(v) “Exchange Act Person” means any natural person, Entity or “group” (within the meaning of Section 13(d)

or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any
Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or
any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary
of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such
securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same
proportions as their Ownership of stock of the Company, or (v) any natural person, Entity or “group” (within the
meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or
indirectly, of securities of the Company representing more than fifty percent 50% of the combined voting power of
the Company’s then outstanding securities.

(w) “Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

(i) Unless otherwise provided by the Board, if the Common Stock is listed on any established stock

exchange or traded on any established market, then the Fair Market Value of a share of Common Stock will be the
closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest
volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems
reliable.

(ii) Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on

the date of determination, then the Fair Market Value of a share of Common Stock will be the closing sales price for
such stock on the last preceding date for which such quotation exists.

(iii) In the absence of such markets for the Common Stock, the Fair Market Value of a share of Common
Stock will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of
the Code.

(x) “Full Value Award” means (i) a stock award granted under any of the Prior Plans or (ii) an Award, in each

case that is not an Appreciation Award.

(y) “Incentive Stock Option” means an option granted pursuant to Section 5 that is intended to be, and that

qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code.

(z) “Non-Employee Director” means a Director who either (i) is not a current employee or officer of the
Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an

A-19

Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to
which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities
Act (“Regulation S-K”)), does not possess an interest in any other transaction for which disclosure would be
required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure
would be required pursuant to Item 404(b) of Regulation S-K, or (ii) is otherwise considered a “non-employee
director” for purposes of Rule 16b-3.

(aa) “Nonstatutory Stock Option” means an option granted pursuant to Section 5 that does not qualify as an

Incentive Stock Option.

(bb) “Officer” means a person who is an officer of the Company within the meaning of Section 16 of the

Exchange Act.

(cc) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common

Stock granted pursuant to the Plan.

(dd) “Option Agreement” means a written agreement between the Company and a holder of an Option
evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and
conditions of the Plan.

(ee) “Other Stock Award” means an award based in whole or in part by reference to the Common Stock which

is granted pursuant to the terms and conditions of Section 6(d).

(ff) “Other Stock Award Agreement” means a written agreement between the Company and a holder of an

Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award
Agreement will be subject to the terms and conditions of the Plan.

(gg) “Own,” “Owned,” “Owner,” “Ownership” A person or Entity will be deemed to “Own,” to have

“Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or
indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power,
which includes the power to vote or to direct the voting, with respect to such securities.

(hh) “Participant” means (i) with respect to any Award, a person to whom such Award is granted pursuant to
the Plan or, if applicable, such other person who holds an outstanding Award, and (ii) with respect to any Prior Plan
Award, a person to whom such Prior Plan Award is granted pursuant to any Prior Plan or, if applicable, such other
person who holds an outstanding Prior Plan Award.

(ii) “Performance Criteria” means the one or more criteria that the Board will select for purposes of

establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to
establish such Performance Goals may be based on any one of, or combination of, the following, as determined by
the Board: (i) earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes and
depreciation; (iii) earnings before interest, taxes, depreciation and amortization (EBITDA); (iv) total stockholder
return; (v) return on equity or average stockholder’s equity; (vi) return on assets, investment, or capital employed;
(vii) stock price or stock price performance; (viii) margin (including gross margin); (ix) net income (before or after
taxes); (x) operating income; (xi) operating income after taxes; (xii) pre-tax profit; (xiii) operating cash flow;
(xiv) sales or revenue targets; (xv) increases in revenue or product revenue; (xvi) expenses and cost reduction goals;
(xvii) improvement in or attainment of working capital levels; (xviii) economic value added (or an equivalent
metric); (xix) market share; (xx) cash flow; (xxi) cash flow per share; (xxii) share price performance; (xxiii) debt
reduction; (xxiv) implementation or completion of projects or processes; (xxv) customer satisfaction;
(xxvi) stockholders’ equity; (xxvii) capital expenditures; (xxviii) debt levels; (xxix) operating profit or net operating
profit; (xxx) workforce diversity; (xxxi) growth of net income or operating income; (xxxii) billings; (xxxiii)
submission to, or approval by, a regulatory body (including but not limited to the U.S. Food and Drug

A-20

Administration) of an applicable filing for a product candidate or other product development milestones;
(xxxiv) acquisitions, divestitures, joint ventures, strategic alliances, licenses or collaborations; (xxxv) spin-offs,
split-ups, reorganizations, recapitalizations, restructurings, financings (debt or equity) or refinancings;
(xxxvi) manufacturing or process development, clinical trial, regulatory, intellectual property, compliance or
research objectives; and (xxxvii) any other measures of performance selected by the Board. Partial achievement of
the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified
in the applicable Award Agreement.

(jj) “Performance Goals” means, for a Performance Period, the one or more goals established by the Board for
the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide
basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute
terms or relative to the performance of one or more comparable companies or the performance of one or more
relevant indices. The Board is authorized to make appropriate adjustments in the method of calculating the
attainment of Performance Goals for a Performance Period as follows: (i) to exclude restructuring and/or other
nonrecurring charges; (ii) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated
Performance Goals; (iii) to exclude the effects of changes to generally accepted accounting principles; (iv) to
exclude the effects of any statutory adjustments to corporate tax rates; (v) to exclude the effects of items that are
“unusual” in nature or occur “infrequently” as determined under generally accepted accounting principles; (vi) to
exclude the dilutive effects of acquisitions or joint ventures; (vii) to assume that any business divested by the
Company achieved performance objectives at targeted levels during the balance of a Performance Period following
such divestiture; (viii) to exclude the effect of any change in the outstanding shares of common stock of the
Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger,
consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to
common stockholders other than regular cash dividends; (ix) to exclude the effects of stock based compensation
and/or the award of an annual cash incentive under the Company’s Annual Incentive Program; (x) to exclude the
effect of any other unusual, non-recurring gain or loss or other extraordinary item; and (xi) to make other
appropriate adjustments selected by the Board.

(kk) “Performance Period” means the period of time selected by the Board over which the attainment of one

or more Performance Goals will be measured for the purpose of determining a Participant’s right to and the payment
of a Performance Stock Award. Performance Periods may be of varying and overlapping duration, at the sole
discretion of the Board.

(ll) “Performance Stock Award” means an Award granted under the terms and conditions of Section 6(c).

(mm) “Plan” means this Dynavax Technologies Corporation 2018 Equity Incentive Plan.

(nn) “Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to the

terms and conditions of Section 6(a).

(oo) “Restricted Stock Award Agreement” means a written agreement between the Company and a holder of a

Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted
Stock Award Agreement will be subject to the terms and conditions of the Plan.

(pp) “Restricted Stock Unit Award” means a right to receive shares of Common Stock which is granted

pursuant to the terms and conditions of Section 6(b).

(qq) “Restricted Stock Unit Award Agreement” means a written agreement between the Company and a holder
of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each
Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.

(rr) “Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as

in effect from time to time.

A-21

(ss) “Rule 405” means Rule 405 promulgated under the Securities Act.

(tt) “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated

thereunder.

(uu) “Stock Appreciation Right” or “SAR” means a right to receive the appreciation on Common Stock that is

granted pursuant to the terms and conditions of Section 5.

(vv) “Stock Appreciation Right Agreement” or “SAR Agreement” means a written agreement between the

Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation
Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.

(ww) “Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the

outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such
corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or
might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly,
Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company
has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of
more than 50%.

(xx) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d)

of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the
Company or any Affiliate.

(yy) “Transaction” means a Corporate Transaction or a Change in Control.

A-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549 

Form 10-K 

(Mark One)
(cid:3) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

(cid:31)

For the fiscal year ended December 31, 2018 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the transition period from                        to                        

Commission file number: 001-34207 

Dynavax Technologies Corporation 

(Exact name of registrant as specified in its charter) 

Delaware
(State or other jurisdiction of
incorporation or organization)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100 
Berkeley, CA 94710-2753 
(510) 848-5100 
(Address, including Zip Code, and telephone number, including area code, of the registrant’s principal executive offices) 

Securities registered pursuant to Section 12(b) of the Act: 

Title of Each Class:
Common Stock, $0.001 Par Value

Name of Each Exchange on Which Registered:
The Nasdaq Stock Market LLC

Securities Registered Pursuant to Section 12(g) of the Act: 
None 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities 

Act.    Yes  (cid:3)    No  (cid:4)

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the 

Act.    Yes  (cid:4)    No  (cid:3) 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities 

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and 
(2) has been subject to such filing requirements for the past 90 days.    Yes  (cid:3)   No  (cid:4) 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted 
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the 
registration was required to submit such files).    Yes  (cid:3)    No  (cid:4) 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not 
be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of 
this Form 10-K or any amendment to this Form 10-K.  (cid:3) 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller 
reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting 
company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
Large accelerated filer (cid:3)
Emerging growth company (cid:31) 

Non-accelerated filer (cid:31)   

   Accelerated filer (cid:31)   

Smaller reporting company (cid:31)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for 

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. (cid:31)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  (cid:31)    No  (cid:3) 
The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant, based upon the closing sale 

price of the common stock on June 30, 2018 as reported on the Nasdaq Capital Market, was approximately $760,000,000. Shares of 
common stock held by each officer and director and by each person known to the Company who owns 5% or more of the outstanding 
common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not 
necessarily a conclusive determination for other purposes. 

As of February 22, 2019, the registrant had outstanding 63,996,911 shares of common stock. 
DOCUMENTS INCORPORATED BY REFERENCE 

Portions of the Definitive Proxy Statement for the registrant’s 2019 Annual Meeting of Stockholders are incorporated by reference 

into Part III, Items 10-14 of this Form 10-K. The Definitive Proxy Statement will be filed no later than 120 days after the close of the 
registrant’s fiscal year ended December 31, 2018.

 
 
INDEX 

DYNAVAX TECHNOLOGIES CORPORATION 

PART I

   Page No.

Item 1.

 BUSINESS......................................................................................................................................................  

Item 1A. RISK FACTORS ............................................................................................................................................  

Item 1B.  UNRESOLVED STAFF COMMENTS .........................................................................................................  

Item 2.

Item 3.

Item 4.

 PROPERTIES .................................................................................................................................................  

 LEGAL PROCEEDINGS ...............................................................................................................................  

 MINE SAFETY DISCLOSURE.....................................................................................................................  

PART II

Item 5.

MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER 

MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES...................................................  

Item 6.

Item 7.

 SELECTED FINANCIAL DATA ..................................................................................................................  

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS 
OF OPERATIONS.....................................................................................................................................  

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK...............................  

Item 8.

 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ...............................................................  

Item 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND 

FINANCIAL DISCLOSURE ....................................................................................................................  

Item 9A. CONTROLS AND PROCEDURES...............................................................................................................  

Item 9B.  OTHER INFORMATION ..............................................................................................................................  

PART III

Item 10.  

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE .......................................  

Item 11.  EXECUTIVE COMPENSATION..................................................................................................................  

Item 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND 

RELATED STOCKHOLDER MATTERS ...............................................................................................  

Item 13.  

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR 

INDEPENDENCE .....................................................................................................................................  

Item 14.  PRINCIPAL ACCOUNTING FEES AND SERVICES.................................................................................  

PART IV

Item 15.  

EXHIBITS, FINANCIAL STATEMENT SCHEDULES ..............................................................................  

Item 16.  

FORM 10-K SUMMARY ..............................................................................................................................  

SIGNATURES................................................................................................................................................  

2

4

19

35

36

36

37

38

39

40

51

52

80

80

82

83

83

83

83

83

84

90

91

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FORWARD-LOOKING STATEMENTS 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the 

Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 which are subject to a number of risks and 
uncertainties. All statements that are not historical facts are forward-looking statements, including statements about our 
ability to successfully commercialize HEPLISAV-B® and our anticipated level of sales of HEPLISAV-B, our ability to 
develop and timely achieve regulatory approval for SD-101, DV281 and our other early stage compounds, our business, 
collaboration and regulatory strategy, changes in our sales organization, our intellectual property position, our product 
development efforts, our ability to manufacture commercial supply and meet regulatory requirements, the timing of the 
introduction of our products, uncertainty regarding our capital needs and future operating results and profitability, 
anticipated sources of funds, including additional borrowings under our loan agreement, as well as our plans, objectives, 
strategies, expectations and intentions. These statements appear throughout our document and can be identified by the use of 
forward-looking language such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” 
“predict,” “future,” or “intend,” or the negative of these terms or other variations or comparable terminology. In addition, 
statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements 
are based upon information available to us as of the date of this Form 10-K, and while we believe such information forms a 
reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read 
to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. 
These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

Actual results may vary materially from those in our forward-looking statements as a result of various factors that are 

identified in “Item 1A—Risk Factors” and “Item 7—Management’s Discussion and Analysis of Financial Condition and 
Results of Operations” and elsewhere in this document. No assurance can be given that the risk factors described in this 
Annual Report on Form 10-K are all of the factors that could cause actual results to vary materially from the forward-
looking statements. All forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Readers 
should not place undue reliance on these forward-looking statements and are cautioned that any such forward-looking 
statements are not guarantees of future performance. We assume no obligation to update any forward-looking statements. 

This Annual Report on Form 10-K includes trademarks and registered trademarks of Dynavax Technologies 
Corporation. Products or service names of other companies mentioned in this Annual Report on Form 10-K may be 
trademarks or registered trademarks of their respective owners. References herein to “we,” “our,” “us,” “Dynavax” or the 
“Company” refer to Dynavax Technologies Corporation and its subsidiary.

3

ITEM 1.

BUSINESS 

OVERVIEW

PART I

We are a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and 
adaptive immune responses through toll-like receptor (“TLR”) stimulation. Our first commercial product, HEPLISAV-B® 
(Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved by the United States Food and Drug Administration (“FDA”) 
for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. We 
commenced commercial shipments of HEPLISAV-B in January 2018. In March 2018, we received regulatory approval of the 
pre-filled syringe (“PFS”) presentation of HEPLISAV-B. Our development efforts are primarily focused on stimulating the 
innate immune response to treat cancer in combination with other immunomodulatory agents. Our lead investigational 
immuno-oncology product candidates are SD-101, currently being evaluated in Phase 2 clinical studies, and DV281, in a 
Phase 1 safety study. 

OUR TECHNOLOGY

Toll-like Receptor Immune Modulation Platform

Toll-like receptors are a family of transmembrane proteins that play a vital role in innate immunity and subsequent 

adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated 
molecules and is essential to generation of innate immunity. The innate immune response is, in effect, the first line of defense 
against viruses, bacteria and other potential pathogens. The innate response also initiates and regulates the generation of an 
adaptive immune response composed of highly specific antibodies and T cells. Our research is focused primarily on 
stimulation of a subset of TLRs that have evolved to recognize bacterial and viral nucleic acids.

Our research has resulted in the identification of proprietary synthetic oligonucleotides (short segments of DNA), that 
mimic the activity of microbial DNA and selectively activate one of these important receptors, TLR9. These are called CpG 
oligonucleotides – CpGs for short – referring to the presence of specific nucleotide sequences containing the CG base pair. In 
addition, we are developing compounds that activate two other important innate receptors, TLR7 and TLR8. These TLR 
agonists are able to stimulate or modify immune responses as single agents and can synergize with other classes of 
immunotherapeutic agents. In combination with tumor antigens or vaccines, these TLR agonists can substantially enhance 
and prolong protective immune responses. Thus, this portfolio of novel and potent activators opens multiple potential 
opportunities for expanding the scope of cancer immunotherapy, enhancing the efficiency of vaccines and modulating 
allergic diseases. 

OUR STRATEGY

•

Commercialize HEPLISAV-B, initially in the United States, to generate cash flows to support continued 
development of TLR-based immuno-oncology therapeutics and new vaccines

• Demonstrate the versatility of our immuno-oncology platform by assessing efficacy in multiple tumor types and in 

combination with a range of modalities through clinical development of product candidates in three areas:

o

Intratumoral SD-101 in combination with anti-PD-1 therapies in melanoma, head and neck squamous cell 
carcinoma (“HNSCC”) and additional tumor types

o Combinations of SD-101, DV281 or our other TLR agonists in combination with agents other than anti-PD-

1/L-1 alone, including other immuno-modulatory agents or chemotherapy 

o TLR9 or TLR7/8 agonists designed for targeted delivery beyond intratumoral injection 

HEPLISAV-B 

The Company's first commercial product, HEPLISAV-B (Hepatitis B Vaccine, (Recombinant), Adjuvanted), is 
approved by the FDA for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and 
older.  

4

HEPLISAV-B combines 1018, our proprietary TLR9 agonist adjuvant, and recombinant hepatitis B surface antigen 
(“rHBsAg” or “HBsAg”) that is manufactured by Dynavax GmbH, our wholly-owned subsidiary, in Düsseldorf, Germany. In 
Phase 3 trials, HEPLISAV-B demonstrated higher rates of protection with fewer doses than another currently approved 
hepatitis B vaccine and a similar adverse event profile. HEPLISAV-B is the only two-dose hepatitis B vaccine for adults 
approved in the U.S.

About Hepatitis B

Hepatitis B is a viral disease of the liver that can become chronic and lead to cirrhosis of the liver, liver cancer and 
death. Hepatitis B virus is an extremely infectious and potentially deadly virus. It can be spread through the exchange of body 
fluids such as semen or blood, and is 50 to 100 times more infectious than HIV.

Hepatitis B can be either acute or chronic. Acute hepatitis B virus infection is a short-term illness that occurs within the 

first six months after exposure to the hepatitis B virus. Acute infection can — but does not always — lead to chronic 
infection. Chronic hepatitis B virus infection is a long-term illness that occurs when the hepatitis B virus remains in a 
person’s body. 

There is no cure for hepatitis B, but the disease can be prevented through effective vaccination. The World Health 

Organization (“WHO”) and Centers for Disease Control and Prevention (“CDC”) have set a goal to eliminate all viral 
hepatitis infections, including hepatitis B, globally by 2030, and are calling for a continued commitment to increase services 
to eliminate hepatitis. 

Worldwide, an estimated 257 million people are living with hepatitis B, including at least 850,000 in the United States, 

where an estimated 21,000 new infections occur each year.

In adults, sexual transmission of hepatitis B may occur, particularly in unvaccinated men who have sex with men and 
heterosexual persons who have multiple sex partners or contact with sex workers. Transmission of the virus may also occur 
through the reuse of needles and syringes either in healthcare settings or among persons who inject drugs. Infection also can 
occur during medical, surgical and dental procedures, through tattooing or the use of razors contaminated with infected blood. 

Prevention in Adults with Effective Vaccination 

Adult vaccination to prevent hepatitis B is recommended by the CDC Advisory Committee on Immunization Practices 

(“ACIP”) for many at-risk populations, including certain healthcare and public safety workers, people with diabetes and 
travelers. The ACIP recommendation includes adults with the following risks:

•

•

•

Environmental Related Risk - Health care and first responders, travelers, persons who are in close contact with 
hepatitis B infected patients, residents and staff of facilities for developmentally disabled and those who work with 
HBV-infected primates or HBV in the lab;

Increased Risk or Severity of Disease due to Chronic Conditions - Adults with diabetes, end stage renal disease, 
HIV and chronic liver disease;

Behavioral Risk – Men who have sex with men, persons with multiple sex partners, STD clinic patients, inmates, 
IV drug users. 

Protection Against Hepatitis B

The approval of HEPLISAV-B was based on data from three Phase 3 non-inferiority trials of nearly 10,000 adult 
participants who received HEPLISAV-B. These pivotal studies compared HEPLISAV-B administered in two doses over one 
month to Engerix-B® administered in three doses over a six-month schedule. Results from HBV-23, the largest Phase 3 trial, 
which included 6,665 participants, showed that HEPLISAV-B demonstrated a statistically significantly higher rate of 
protection of 95% compared with 81% for Engerix-B. Across the three clinical trials, the most common local reaction was 
injection site pain (23% to 39%). The most common systemic reactions were fatigue (11% to 17%) and headache (8% to 
17%). 

5

Commercialization of HEPLISAV-B in the United States

Dynavax has worldwide commercial rights to HEPLISAV-B. There are three other vaccines approved for the 
prevention of hepatitis B in the U.S.: Engerix-B and Twinrix® from GlaxoSmithKline plc (“GSK”) and Recombivax-HB® 
from Merck & Co. (“Merck”).

We commenced shipments of HEPLISAV-B in January 2018. Currently, total U.S. gross sales for adult hepatitis B 

vaccines is approximately $300 million annually. We are currently targeting approximately 25% of the total vaccine outlets, 
which we believe represent approximately 75% of hepatitis B vaccine sales in the U.S., with our field sales force team of 
approximately 60 people across 10 regions. We plan on converting our independent contractor field sales force team into 
Dynavax employees in the second quarter of 2019.

In late 2012 the ACIP expanded its recommendation for adults who should be vaccinated against hepatitis B to include 
people with diabetes mellitus (type 1 and type 2). According to the CDC there are 20 million adults diagnosed with diabetes 
and another 1.5 million new cases diagnosed each year. This population represents a significant increase in the number of 
adults recommended for vaccination against hepatitis B in the U.S. 

DEVELOPMENT PROGRAMS 

Our pipeline of product candidates includes the following. Each named clinical stage program is discussed below. 

Product Candidate

Indication(s)

Stage of 
Development

Vaccine

1018 adjuvant

Immuno-oncology

Pertussis

Preclinical

 SD-101 + Pembrolizumab* 

Melanoma, anti-PD-1 Naive 

Phase 2

SD-101 + Pembrolizumab*

SD-101 + Pembrolizumab*

Melanoma, anti-PD-1 
Resistant/Refractory
Head and Neck Squamous Cell 
Carcinoma

Phase 2

Phase 2

SD-101 + Pembrolizumab

Neoadjuvant breast cancer (I-SPY2)

Phase 2

Inhaled DV281  + Nivolumab

Non-small Cell Lung Cancer

Additional Programs:

Additional Programs:

Cancer Vaccine

TLR7/8 agonists for Oncology

Phase 1 

Research

Research

* Clinical collaboration with Merck; Dynavax maintains all commercial rights to SD-101

Immuno-oncology

Immuno-oncology is a rapidly advancing field that focuses on modulating the immune system to develop or enhance 

anti-tumor activities in order to control growth or eliminate tumors. The industry is exploring multiple strategies and 
technologies aimed at enhancing and prolonging anti-tumor immune responses and inhibiting the actions of multiple immune 
checkpoints that limit the effectiveness of anti-tumor responses. Agents that inhibit two of these immune checkpoints, CTLA-
4 and the PD-1/PD-L1 interaction, have been approved for a number of cancer indications. These checkpoint inhibitors 
represent a major advance in cancer treatment, yet a majority of patients fail to respond to these inhibitors used as single 
agents. In many instances, it appears that the failure to respond correlates with anti-tumor activity that remains inadequate 
even with checkpoint blockade. Thus, a major opportunity in immuno-oncology is the development of immunostimulatory 
approaches that increase the number, location and functional state of tumor-reactive cytotoxic T cells, enabling remission and 
durable control of tumor growth.

6

Through our expertise in TLR biology we have designed compounds that stimulate multiple innate mechanisms, 
activating a cascade of anti-tumor activities including stimulating the tumor microenvironment, generating tumor specific T 
cells and initiating a systemic distribution of those cells to all tumor sites. These compounds were specifically designed to 
stimulate multiple pathways of tumor killing through type 1 interferon induction and highly efficient stimulation of antigen 
presenting functions of plasmacytoid dendritic cells.

Our clinical development strategy for immuno-oncology applications is based on two key principles. The first is that 

immune activation by TLR agonists will be significantly more effective when focused on the tumor than when administered 
as a systemic therapy. This has been shown in many studies with mouse tumor models and has been confirmed in pioneering 
academic studies of intratumoral injection of CpGs in lymphoma patients. These studies indicate TLR9 stimulation applied 
locally allows optimal concentrations of the CpG to be achieved at the site of highest concentrations of tumor antigens and T 
cells that recognize those antigens. Local stimulation of innate anti-tumor mechanisms, such as Natural Killer cells, should 
enhance release of tumor antigens and locally induced chemokine gradients can lead to enhanced recruitment of additional 
tumor-reactive T cells.

The second principle is the development of combinations that have complementary mechanisms of action and have the 

potential for synergistic, rather than additive clinical effects. An example is our development of combination treatment of 
intra-tumoral SD-101 with the PD-1 inhibitor, pembrolizumab. Pembrolizumab releases anti-tumor T cells from one of the 
most potent of the immune checkpoints, while intratumoral SD-101 generates both greater numbers and more highly 
functional cytotoxic T cells directed against tumor cells. We have published studies showing the mechanisms of this synergy 
in mouse tumor models.

We are developing our initial immuno-oncology product candidates, SD-101 and DV281, to eventually be combined 

with a variety of immunotherapies when activation of an anti-tumor immune response is desirable. We are targeting 
combinations with checkpoint inhibitors that offer activities synergistic with TLR9 stimulation, with an initial focus on 
approved checkpoint inhibitors in indications that have generally low response rates and would provide a clear path to 
approval. As a result, in 2015, we began our first combination trial in metastatic melanoma with SD-101, our novel 
intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD1 therapy approved for 
metastatic melanoma, under a clinical collaboration with Merck. We have expanded this trial to include head and neck 
squamous cell carcinoma, another approved indication for KEYTRUDA. Under the terms of the agreement, Dynavax is 
sponsoring and funding the trial, Merck is supplying KEYTRUDA at no cost and the data and intellectual property are 
shared. Each party has agreed that during the term of the study, it will not conduct a combination study with any third party 
that involves the combination of the two classes of compounds. 

We also are conducting a study of DV281 in lung cancer in combination with an anti-PD-1 therapy and there are 
ongoing and planned studies to support our strategy to develop SD-101 and DV281 in combination with multiple checkpoint 
inhibitors and other agents in multiple indications. Studies sponsored by us include the following:

SD-101 – TLR9 Agonist for intratumoral injection

Our lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist that was selected for characteristics 
optimal for treatment of cancer, including high interferon induction. Directly injecting SD-101 into a tumor site optimizes its 
effect by ensuring proximity to tumor-specific antigens. In animal models, SD-101 demonstrated significant anti-tumor 
effects at both the injected site and at distant sites. 

SD-101 in combination with KEYTRUDA® (pembrolizumab) in Melanoma

In October 2015, we initiated a Phase 1/2 multicenter clinical trial to assess the safety and potential efficacy of 

intratumoral SD-101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with 
advanced or metastatic melanoma. The study includes patients who have disease that is progressing while receiving an anti-
PD-1 therapy and patients who are naïve to anti-PD-1 therapy. The primary endpoints of this dose-expansion/dose-finding 
study are safety and preliminary efficacy.

Results from SD-101 in combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma Patients Naïve to 

anti-PD-1/L1 therapy 

In October 2018, we reported results from the Phase 1b/2 study on a total of 87 intention to treat (ITT) patients with 

advanced melanoma naïve to anti-PD-1/L1 therapy. The study compared two different doses of SD-101. In the study, 47 
patients received (cid:3)2 mg of SD-101 in up to four lesions and 40 patients received 8 mg in a single lesion. The results showed a 

7

70% (33 out of 47 patients) overall response rate (ORR) in advanced melanoma patients who received the (cid:3) 2 mg dose of 
SD-101 and a 48% (19 out of 40 patients) ORR in the group receiving the 8 mg dose of SD-101. The ORR was similar for 
PD-L1 negative and PD-L1 positive tumors. The combination of SD-101 and KEYTRUDA remained well tolerated with 
adverse events related to SD-101 being transient, mild to moderate flu-like symptoms.

Results from SD-101 in combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma Patients Resistant/ 

Refractory to anti-PD-1/L1 therapy 

In October 2018, we reported results from the Phase 1b/2 study in patients with advanced melanoma 

resistant/refractory to anti-PD-1/PD-L1 therapy. The results showed a 21% (six out of 29 patients) ORR in patients who 
received 8 mg in a single lesion. Responses were observed in both SD-101 injected and non-injected lesions. The 
combination of SD-101 and KEYTRUDA remained well tolerated with adverse events related to SD-101 being transient, 
mild to moderate flu-like symptoms. Approximately 25 additional patients are being enrolled to receive 2 mg per injection.

SD-101 in combination with KEYTRUDA® (pembrolizumab) in Head and Neck Squamous Cell Carcinoma

Based on the initial results from the combination of SD-101 and KEYTRUDA in melanoma, we expanded the 
combination study with KEYTRUDA to include a Phase 2 trial in patients with recurrent or metastatic head and neck 
squamous cell cancers. 

In October 2018, we presented data from the Phase 1b/2 clinical trial. The results demonstrated a 27% (six out of 22 

patients) ORR who received 8 mg in a single lesion. Responses were observed in both SD-101 injected and non-injected 
lesions. The combination of SD-101 and KEYTRUDA remained well tolerated with adverse events related to SD-101 being 
transient, mild to moderate flu-like symptoms. Approximately 25 additional patients are being enrolled to receive 2 mg per 
injection.

SD-101 in combination with KEYTRUDA® (pembrolizumab) for Neoadjuvant Breast Cancer (I-SPY2)

In October 2018, we and Quantum Leap Healthcare Collaborative™ (QLHC) announced that the combination of SD-

101 and KEYTRUDA (pembrolizumab) will be evaluated in a new randomized, investigational treatment arm for the 
ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.

The I-SPY 2 TRIAL is a standing Phase 2 randomized, controlled, multicenter study with an innovative Bayesian 
adaptive design aimed to rapidly screen and identify promising new treatments in specific subgroups of women with newly-
diagnosed, high-risk (high likelihood of recurrence), locally-advanced breast cancer (Stage II/III). 

DV281 – Inhaled TLR 9 agonist for lung cancer

Although we continue to advance the strategy of focused delivery of a CpG in studies with intratumoral injection of 

SD-101, there are many tumor types for which direct, repeated injection is not feasible. Non-small cell lung cancer 
(“NSCLC”) represents one such challenge. This major type of lung cancer is known to respond to a variety of 
immunotherapy approaches and several inhibitors of the PD-1/PD-L1 checkpoint pathway have been approved for NSCLC. 
Yet response rates to these agents remain low. A strategy for focused delivery to lung tumors is direct administration to the 
lung by inhalation. To accomplish this, we have developed DV281, a novel investigational TLR9 agonist designed 
specifically for focused delivery to primary lung tumors and lung metastases. DV281 is similar in biological activity and 
mechanism of action to SD-101, but has been optimized for administration as an aerosol. 

Studies in preclinical animal models of lung cancer show that this direct delivery of DV281 to tumor-bearing lungs 

results in induction of interferons and cytokines and infiltration of T cells, responses similar to those observed after 
intratumoral injection of SD-101. Animal models also demonstrate synergy of inhaled DV281 with anti-PD1 antibodies in 
reducing tumor burden and generating a systemic and durable anti-tumor response. Inhaled DV281, delivered by a nebulizer, 
entered clinical trials for NSCLC, in combination with anti-PD-1 therapy, in October, 2017. We are conducting the Phase 1 
clinical study in subjects with advanced NSCLC to investigate the safety and tolerability of DV281 as monotherapy and in 
combination with an approved anti-PD-1 inhibitor (nivolumab), and to identify a recommended dose for the expansion part of 
the study.

8

AZD1419 for Asthma

AZD1419 is being developed for the treatment of asthma pursuant to a collaboration with AstraZeneca. AZD1419 is 

designed to change the basic immune response to environmental allergens, such as house dust and pollens, leading to 
prolonged reduction in asthma symptoms by converting the response from one primarily mediated by type-2 helper T cells to 
type-1 helper T cells. 

In November, 2018, we were informed by our collaborator, AstraZeneca, that initial high-level results from a Phase 2a 

study indicate AZD1419 treatment was not associated with a statistically significant improvement in the time to loss of 
asthma control and therefore did not meet the primary endpoint of the study. The treatment appeared to be safe and well 
tolerated and the study confirmed activation of the TLR9 pathway. The proposed mechanism of action of AZD1419 is 
distinct from that of the other TLR9 agonists being developed by Dynavax for immuno-oncology and vaccine applications. 
AstraZeneca is in the process of reviewing the full data before deciding on the next steps for the AZD1419 program.

Vaccine Adjuvants

Our vaccine research to date has focused on the use of TLR9 agonists as novel adjuvants. Different TLR9 agonist 
molecules are taken up within different endosomes within target cells, stimulating different signaling pathways. CpG B-Class 
TLR9 agonists, such as our 1018 vaccine adjuvant, are selectively taken up by late endosomes (more mature endosomes also 
known as multivesicular bodies), resulting in signaling that leads to release of cytokines necessary for T cell activation and 
establishing long-term immunity but with modest induction of interferon alpha. TLR9 stimulation also helps generate 
memory T Helper 1 (“Th1”) cells that can stimulate the immune system to induce long-lasting effects. As a result, TLR9 
adjuvanted vaccines induce a specific Th1 immune response and durable levels of protective antibodies. We are evaluating 
additional candidates to leverage our 1018 adjuvant in additional vaccines. We are also collaborating with the Serum Institute 
of India Pvt. Ltd. to develop adjuvanted vaccines using 1018. Our initial joint program is an improved pertussis vaccine.   

INTELLECTUAL PROPERTY

Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our drug 

candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others 
from infringing our proprietary rights. In addition to seeking patent protection in the U.S., we generally file patent 
applications in Australia, Canada, Europe, Japan and additional foreign countries on a selective basis to further protect the 
inventions that we or our partners consider important to the development of our business. We also rely on trade secrets and 
contracts to protect our proprietary information. 

As of December 31, 2018, our intellectual property portfolio included over 30 issued U.S. patents, over 235 issued or 

granted foreign patents and over 55 additional owned or co-owned pending U.S. and foreign patent applications claiming 
compositions containing TLR agonists or antagonists, methods of use, and/or methods of manufacture thereof.

We have two issued patents relating to certain uses of HEPLISAV-B that expire in 2032. We have issued patents 

expiring in 2023 and covering compositions such as SD-101 and their uses in the U.S. and in several major European and 
other countries. We anticipate we will be eligible for up to a five-year patent term extension with respect to SD-101. We own 
or have an exclusive license to U.S. and foreign patents and patent applications pending for each of our other product 
candidates and/or their uses. At present, it is not known or determinable whether patents will issue from any of these 
applications or what the specific expiration dates would be for any patents that do issue. 

Individual patents extend for varying periods depending on the date of filing of the patent application or the date of 
patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued in the U.S. 
are effective for: 

•

•

the longer of 17 years from the issue date or 20 years from the earliest effective filing date, if the patent application 
was filed prior to June 8, 1995; and 

20 years from the earliest effective filing date, if the patent application was filed on or after June 8, 1995. 

In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a 

result of the FDA regulatory review period. The duration of patents varies in accordance with provisions of applicable local 
law, but typically is 20 years from the filing date. Our patent estate, based on patents existing now and expected by us to 
issue based on pending applications, will expire on dates ranging from 2018 to 2038.

9

The actual protection afforded by a patent varies on a product-by-product basis, from country-to-country and depends 

upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory related extensions, 
the availability of legal remedies in a particular country and the validity and enforceability of the patents. 

Because patent applications in the U.S. and many foreign jurisdictions typically are not published until 18 months after 
filing and publications of discoveries in the scientific literature often lag behind actual discoveries, we cannot be certain that 
we were the first to make the inventions claimed in each of our issued patents or pending patent applications or that we were 
the first to invent and/or the first to file for protection of the inventions set forth in these patent applications. The U.S. Patent 
and Trademark Office (“PTO”) may declare interference proceedings to determine the priority of inventions with respect to 
our patent applications and those of other parties or reexamination or reissue proceedings to determine if the scope of a patent 
should be narrowed. 

Our commercial success depends significantly on our ability to operate without infringing patents and proprietary 
rights of third parties. A number of pharmaceutical companies and biotechnology companies, as well as universities and 
research institutions, may have filed patent applications or may have been granted patents that cover inventions similar to the 
inventions owned or licensed to us. We cannot determine with certainty whether patents or patent applications of other 
parties may materially affect our ability to make, use or sell any products. If another party controls patents or patent 
applications covering our products, we may not be able to obtain the rights we need to those patents or patent applications in 
order to commercialize our products. One of our competitors, Merck, is an exclusive licensee of a number of broad patents 
covering HBsAg, a component of HEPLISAV-B. We have a non-exclusive license to those patents controlled by Merck, 
which was obtained in 2018. 

Litigation may be necessary to enforce patents issued or licensed to us or to determine the scope or validity of another 
party’s proprietary rights. The existence of third-party patent applications and patents could significantly reduce the coverage 
of the patents owned by or licensed to us and limit our ability to obtain meaningful patent protection. For example, Pfizer, 
Inc. has issued U.S. and foreign patent claims as well as patent claims pending with the PTO and foreign patent offices that, 
if held to be valid, could require us to obtain a license in order to commercialize one or more of our formulations of TLR 
agonist other than with respect to HEPLISAV-B, for which we have a license. Litigation or any other proceedings, such as 
patent interferences, could result in substantial costs to and diversion of effort by us, and an adverse outcome in a court or 
patent office could subject us to significant liabilities, require disputed rights to be licensed from other parties, or require us 
to cease using some of our technology. We may not prevail in these actions or proceedings, if any. 

In addition, other parties may duplicate, design around or independently develop similar or alternative technologies to 

ours or our licensors. 

We may rely, in some circumstances, on trade secrets and confidentiality agreements to protect our technology. 
Although trade secrets are difficult to protect, wherever possible, we use confidential disclosure agreements to protect the 
proprietary nature of our technology. Our policy is to require each of our commercial partners, employees, consultants and 
advisors to enter into an agreement before beginning their employment, consulting or advisory relationship with us that in 
general provides that the individuals must keep confidential and not disclose to other parties any of our confidential 
information developed or learned by the individuals during the course of their relationship with us except in limited 
circumstances. These agreements also generally provide that we own all inventions conceived by the individuals in the course 
of rendering their employment or services to us. However, there can be no assurance that these agreements will not be 
breached, that we will have adequate remedies for any breach, or that our trade secrets and/or proprietary information will not 
otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants or 
contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights in related or 
resulting know-how and inventions.  

COMPETITION 

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense 
competition and a strong emphasis on proprietary products. Our products and development programs target a number of 
areas, including vaccine adjuvants, cancer immunotherapy and autoimmune and inflammatory diseases. There are many 
commercially available products for the prevention and treatment of these diseases. Many companies and institutions are 
making substantial investments in developing additional products to treat these diseases that could compete directly or 
indirectly with our products under development. 

HEPLISAV-B, a two-dose hepatitis B vaccine, competes directly with conventional three-dose marketed vaccines 
Engerix-B from GSK as well as Recombivax-HB marketed by Merck. There are also modified schedules of conventional 

10

hepatitis B vaccines for limited age ranges that are approved in the European Union and U.S. In addition, HEPLISAV-B 
competes against Twinrix, a bivalent vaccine marketed by GSK for protection against hepatitis B and hepatitis A.

Our cancer immunotherapy, SD-101, if developed, approved and commercialized will compete with a range of 

therapies being used or studied to treat blood cancers and solid tumor malignancies, including:

•

•

•

Chemotherapeutic agents;

Immuno-oncology agents, including immune checkpoint inhibitors such as anti- CTLA4 and anti-PD1 antibodies, 
cytokines such as anti-IL2, immune stimulation therapies including agonists of TLR, STING and other innate 
immune recognition receptors; and

Targeted therapies, such as BRAF inhibitors, MEK inhibitors and BTK inhibitors.

• Oncolytic viral therapies such as IMLYGIC®
•

Cancer vaccines such as mRNA for in vivo delivery

•

Cell therapies such as autologous tumor infiltrating lymphocytes and CAR-T products

Approved and late-stage investigational cancer immunotherapeutics are marketed or being developed by numerous 

companies, including AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Gilead, Roche/Genentech, Nektar, Pfizer, 
Amgen, GSK, Regeneron, Novartis, AbbVie and Merck.

We are in direct competition with a number of other companies developing TLR agonists as well as other mechanisms 

of action that are focused on stimulating the immune response. These companies include Aduro Biotech, Inc., Idera 
Pharmaceuticals, Inc., Immune Design Corp., Checkmate Pharmaceuticals, Inc. and Mologen AG/Oncologie International.

Many of the entities developing and marketing these competing products have significantly greater financial resources 
and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory 
approvals and marketing than we do. Smaller or early-stage companies may also prove to be significant competitors, 
particularly through collaborative agreements with large, established companies with access to capital. These entities may 
also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring 
technologies complementary to or necessary for our programs. 

REGULATORY CONSIDERATIONS 

Government Regulation

The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose extensive 

requirements upon the clinical development, pre-market approval, manufacture, labeling, marketing, promotion, pricing, 
import, export, storage and distribution of biopharmaceuticals. These agencies and other regulatory agencies regulate 
research and development activities and the testing, approval, manufacture, quality control, safety, effectiveness, labeling, 
storage, recordkeeping, advertising and promotion of drugs and biologics. Failure to comply with applicable FDA or foreign 
regulatory agency requirements may result in warning letters, fines, civil or criminal penalties, additional reporting 
obligations and/or agency oversight, suspension or delays in clinical development, recall or seizure of products, partial or 
total suspension of production or withdrawal of a product from the market. 

In the United States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act and its 
implementing regulations and biologics additionally under the Public Health Service Act. The process required by the FDA 
before biopharmaceuticals may be marketed in the United States generally involves the following: 

•

•

•

submission to the FDA of an IND, which must become effective before human clinical trials may begin and must 
be updated annually; 

completion of extensive pre-clinical laboratory tests and pre-clinical animal studies, all performed in accordance 
with the FDA’s Good Laboratory Practice, or GLP, regulations; 

performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the 
product for each proposed indication; 

11

•

•

•

•

submission to the FDA of a new drug application or a biologics license application, NDA or BLA, depending on 
the nature of the product after completion of all pivotal clinical trials to demonstrate the safety, purity and potency 
of the product for the indication for use; 

a determination by the FDA to accept the application for review; 

satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities to assess compliance 
with the FDA’s current good manufacturing practices regulations for pharmaceuticals, or cGMPs; and 

FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the product in the 
United States. 

The development and approval process requires substantial time, effort and financial resources, and we cannot be 

certain that any approvals for our product candidates will be granted on a timely basis, if at all. 

The results of pre-clinical tests (which include laboratory evaluation as well as GLP studies to evaluate toxicity in 

animals) for a particular product candidate, together with related manufacturing information and analytical data, are 
submitted as part of an IND to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless 
the FDA, within the thirty-day time period, raises concerns or questions about the conduct of the proposed clinical trial, 
including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND 
sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. IND submissions may not 
result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for 
each successive clinical trial conducted during product development. Further, an independent institutional review board, or 
IRB, for each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial 
before it commences at that center and it must monitor the study until completed. The FDA, the IRB or the sponsor may 
suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to 
an unacceptable health risk. Clinical testing also must satisfy extensive good clinical practice regulations and regulations for 
informed consent and privacy of individually identifiable information.

Clinical Trials. For purposes of an NDA or BLA submission and approval, clinical trials are typically conducted in the 

following sequential phases, which may overlap: 

•

•

•

•

Phase 1. Studies are initially conducted in a limited population to test the product candidate for safety, dose 
tolerance, absorption, distribution, metabolism, and excretion, typically in healthy humans, but in some cases in 
patients. 

Phase 2. Studies are generally conducted in a limited patient population to identify possible adverse effects and 
safety risks, explore the initial efficacy of the product for specific targeted indications and to determine dose range 
or pharmacodynamics. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior 
to beginning larger and more expensive Phase 3 clinical trials. 

Phase 3. These are commonly referred to as pivotal studies. When Phase 2 evaluations demonstrate that a dose 
range of the product is effective and has an acceptable safety profile, Phase 3 clinical trials are undertaken in large 
patient populations to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for 
safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial centers. 

Phase 4. The FDA may approve an NDA or BLA for a product candidate, but require that the sponsor conduct 
additional clinical trials to further assess the product after approval under a post-marketing commitment or post- 
marketing requirement. In addition, a sponsor may decide to conduct additional clinical trials after the FDA has 
approved a product. Post-approval trials are typically referred to as Phase 4 clinical trials. 

For certain products and indications, the FDA may agree to an abbreviated clinical trial program in order to obtain 
approval. That is determined on a case-by-case basis and there is no guarantee for any product and/or indication that the FDA 
will agree to an abbreviated clinical trial program.

12

The results of biologic development, pre-clinical studies and clinical trials are submitted to the FDA as part of an NDA 
or BLA. Applications also must contain extensive manufacturing and control information. Applications must be accompanied 
by a significant user fee. Once the submission has been accepted for filing, the FDA’s goal is to review applications within 
ten months of submission or, if the application relates to an unmet medical need in a serious or life-threatening indication, 
eight months from submission. The review process is often significantly extended by FDA requests for additional 
information or clarification. The FDA will typically conduct a pre-approval inspection of the manufacturer to ensure that the 
product can be reliably produced in compliance with cGMPs and will typically inspect certain clinical trial sites for 
compliance with good clinical practice, or GCP. The FDA may refer the application to an advisory committee for review, 
evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the 
recommendation of an advisory committee, but it typically follows such recommendations. The FDA may deny approval of 
an application by issuing a Complete Response Letter if the applicable regulatory criteria are not satisfied. A Complete 
Response Letter may require additional clinical data and/or trial(s), and/or other significant, expensive and time- consuming 
requirements related to clinical trials, pre-clinical studies or manufacturing. Approval may occur with boxed warnings on 
product labeling or Risk Evaluation and Mitigation Strategies, or REMS, which limit the labeling, distribution or promotion 
of a product. Once issued, the FDA may withdraw product approval if ongoing regulatory requirements are not met or if 
safety problems occur after the product reaches the market. In addition, the FDA may require testing, including Phase 4 
clinical trials, and surveillance programs to monitor the safety effects of approved products which have been commercialized 
and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing 
programs or other information. 

Other Regulatory Requirements. Products manufactured or distributed pursuant to FDA approvals are subject to 

continuing regulation by the FDA, including recordkeeping, annual product quality review, payment of program user fees 
and reporting requirements. Adverse event experience with the product must be reported to the FDA in a timely fashion and 
pharmacovigilance programs to proactively look for these adverse events are mandated by the FDA. Manufacturers and their 
subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to 
periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory 
requirements, including cGMPs, which impose certain procedural and documentation requirements upon us and our third-
party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible 
legal or regulatory action, such as suspension of manufacturing, seizure of product, injunctive action, additional reporting 
requirements and/or oversight by the agency, import alert or possible civil or criminal penalties. The FDA may also require 
us to recall a product from distribution or withdraw approval for that product. 

The FDA closely regulates the post-approval marketing and promotion of pharmaceuticals, including standards and 

regulations for direct-to-consumer advertising, dissemination of off-label information, industry-sponsored scientific and 
educational activities and promotional activities involving the Internet, including certain social media activities. Further, if 
there are any modifications to the product, including changes in indications, labeling, or manufacturing processes or facilities, 
we may be required to submit and obtain FDA approval of a new or supplemental application, which may require us to 
develop additional data or conduct additional pre-clinical studies and clinical trials. Failure to comply with these 
requirements can result in adverse publicity, warning letters, corrective advertising and potential administrative, civil and 
criminal penalties, as well as damages, fines, withdrawal of regulatory approval, the curtailment or restructuring of our 
operations, the exclusion from participation in federal and state healthcare programs, additional reporting requirements and/or 
oversight by the agency, and imprisonment, any of which could adversely affect our ability to sell our products or operate our 
business and also adversely affect our financial results.  

Physicians may, in their independent medical judgment, prescribe legally available pharmaceuticals for uses that are 

not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses 
are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many 
patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The 
FDA does, however, impose stringent restrictions on manufacturers’ communications regarding off-label use. Additionally, a 
significant number of pharmaceutical companies have been the target of inquiries and investigations by various U.S. federal 
and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for 
off-label uses and other sales practices. These investigations have alleged violations of various U.S. federal and state laws 
and regulations, including claims asserting antitrust violations, violations of the Food, Drug and Cosmetic Act, false claims 
laws, the Prescription Drug Marketing Act, or PDMA, anti-kickback laws, and other alleged violations in connection with the 
promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. If our promotional 
activities, including any promotional activities that a contracted sales force may perform on our behalf, fail to comply with 
these regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, 
our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to issue warning 
letters or untitled letters, suspend or withdraw an approved product from the market, require corrective advertising or a recall 

13

or institute fines or civil fines, additional reporting requirements and/or oversight or could result in disgorgement of money, 
operating restrictions, injunctions or criminal prosecution, any of which could harm our business. 

Outside the United States, the ability of our partners and us to market a product is contingent upon obtaining marketing 

authorization from the appropriate regulatory authorities. The requirements governing marketing authorization, pricing and 
reimbursement vary widely from country to country and region to region. 

Healthcare Fraud and Abuse Laws. As a pharmaceutical company, certain federal and state healthcare laws and 
regulations pertaining to fraud and abuse and patients’ rights may be applicable to our business. We may be subject to 
various federal and state laws targeting fraud and abuse in the healthcare industry. For example, in the United States, there 
are federal and state anti-kickback laws that prohibit the payment or receipt of kickbacks, bribes or other remuneration 
intended to induce the purchase or recommendation of healthcare products and services or reward past purchases or 
recommendations. These laws are applicable to manufacturers of products regulated by the FDA, such as us, and pharmacies, 
hospitals, physicians and other potential purchasers of such products. 

The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or 
paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or 
arranging for a good or service, for which payment may be made, in whole or in part, under a federal healthcare program, 
such as the Medicare and Medicaid programs. The term “remuneration” is defined as any remuneration, direct or indirect, 
overt or covert, in cash or in kind, and has been broadly interpreted to include anything of value, including for example, gifts, 
discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payment, ownership 
interests and providing anything at less than its fair market value. Several courts have interpreted the statute’s intent 
requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal 
healthcare covered business, the statute may have been violated, and enforcement will depend on the relevant facts and 
circumstances. The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education 
Reconciliation Act of 2010, or collectively the ACA, among other things, amended the intent requirement of the federal Anti-
Kickback Statute to state that a person or entity need not have actual knowledge of this statute or specific intent to violate it 
in order to have committed a violation. In addition, the ACA provides that the government may assert that a claim including 
items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for 
purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute, which imposes penalties 
against any person who is determined to have presented or caused to be presented a claim to a federal health program that the 
person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or to have 
offered improper inducements to federal health care program beneficiaries to select a particular provider or supplier. The 
federal Anti-Kickback Statute is broad, and despite a series of narrow statutory exceptions and regulatory safe harbors, 
prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Many states have 
also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare 
items or services reimbursed by any source, not only the Medicare and Medicaid programs, and do not contain identical safe 
harbors. In addition, where such activities involve foreign government officials, they may also potentially be subject to the 
Foreign Corrupt Practices Act. Because of the breadth of these laws and the narrowness of the statutory exceptions and 
regulatory safe harbors available, it is possible that some of our business activities, including our activities with physician 
customers, pharmacies, and patients, as well as our activities pursuant to partnerships with other companies and pursuant to 
contracts with contract research organizations, could be subject to challenge under one or more of such laws. 

The federal criminal and civil false claims laws, including the civil False Claims Act, which prohibits any person from 
knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, 
using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal 
government. A claim includes “any request or demand” for money or property presented to the U.S. government. In addition, 
the ACA specified that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute 
constitutes a false or fraudulent claim for purposes of the civil False Claims Act. The civil federal False Claims Act has been 
the basis for numerous enforcement actions and settlements by pharmaceutical and other healthcare companies in connection 
with various alleged financial relationships with customers. In addition, a number of pharmaceutical manufacturers have 
reached substantial financial settlements in connection with allegedly causing false claims to be submitted because of the 
companies’ marketing of products for unapproved, and thus non-reimbursable, uses. Certain marketing practices, including 
off-label promotion, may also violate false claims laws, as might violations of the federal physician self-referral laws, such as 
the Stark laws, which prohibit a physician from making a referral to certain designated health services with which the 
physician or the physician’s family member has a financial interest and prohibit submission of a claim for reimbursement 
pursuant to the prohibited referral. The “qui tam” provisions of the civil False Claims Act allow a private individual to bring 
civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal 
government, and to share in any monetary recovery. In addition, various states have enacted similar fraud and abuse statutes 

14

or regulations, including, without limitation, false claims laws analogous to the civil False Claims Act that apply to items and 
services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. 

Separately, there are a number of other fraud and abuse laws that pharmaceutical manufacturers must be mindful of, 
particularly after a product candidate has been approved for marketing in the United States. For example, a federal criminal 
law enacted as part of, the Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other 
things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party 
payors. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or 
making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare 
benefits, items or services. There are also federal and state consumer protection and unfair competition laws, which broadly 
regulate marketplace activities and activities that potentially harm consumers. 

Healthcare Privacy and Security Laws. We may be subject to, or our marketing activities may be limited by, HIPAA, 

as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their 
respective implementing regulations, which established uniform standards for certain “covered entities” (certain healthcare 
providers, health plans and healthcare clearinghouses) governing the conduct of certain electronic healthcare transactions and 
protecting the security and privacy of protected health information. Among other things, HIPAA’s privacy and security 
standards are directly applicable to “business associates” — independent contractors or agents of covered entities that create, 
receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a 
covered entity. In addition to possible civil and criminal penalties for violations, HITECH created new tiers of civil monetary 
penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state 
attorneys general authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek 
attorney’s fees and costs associated with pursuing federal civil actions. State laws also govern the privacy and security of 
health information in certain circumstances, many of which differ from each other in significant ways and may not have the 
same effect, thus complicating compliance efforts. Further, we are required to comply with international personal data 
protection laws and regulations, particularly as the result of our operations in Düsseldorf, Germany. Under the European 
General Data Protection Regulation, or GDPR (EU) 2016/679, personal information about European Union (“E.U.”) citizens 
can only be transferred from the E.U. to countries with adequate data protection.

“Sunshine” and Marketing Disclosure Laws. There are an increasing number of federal and state “sunshine” laws that 

require pharmaceutical manufacturers to make reports to states on pricing and marketing information. Several states have 
enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, 
file periodic reports with the state, and make periodic public disclosures on sales and marketing activities, and prohibiting 
certain other sales and marketing practices. In addition, a similar federal requirement, known as the Physician Payments 
Sunshine Act, requires manufacturers, including pharmaceutical manufacturers, to track and report annually to the federal 
government certain payments and other transfers of value made to physicians and other healthcare professionals and teaching 
hospitals and ownership or investment interests held by physicians and their immediate family members. The federal 
government discloses the reported information on a publicly available website. Certain states, such as Massachusetts, also 
make the reported information publicly available. In addition, there are state and local laws that require pharmaceutical 
representatives to be licensed and comply with codes of conduct, transparency reporting, and other obligations. These laws 
may adversely affect our sales, marketing, and other activities with respect to our products in the United States by imposing 
administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply 
with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities.

Government Price Reporting. For those marketed products which are covered in the United States by the Medicaid 

programs, we have various obligations, including government price reporting and rebate requirements, which generally 
require products be offered at substantial rebates/discounts to Medicaid and certain purchasers (including “covered entities” 
purchasing under the 340B Drug Discount Program). We are also required to discount such products to authorized users of 
the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply. 
These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory 
formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and 
the guidance governing such calculations is not always clear. Compliance with such requirements can require significant 
investment in personnel, systems and resources, but failure to properly calculate our prices, or offer required discounts or 
rebates could subject us to substantial penalties. One component of the rebate and discount calculations under the Medicaid 
and 340B programs, respectively, is the “additional rebate,” a complex calculation which is based, in part, on the rate at 
which a branded drug price increases over time more than the rate of inflation (based on the CPI-U). This comparison is 
based on the baseline pricing data for the first full quarter of sales associated with a branded drug’s NDA, and baseline data 
cannot generally be reset, even on transfer of the NDA to another manufacturer. This “additional rebate” calculation can, in 

15

some cases where price increase has been relatively high versus the first quarter of sales of the NDA, result in Medicaid 
rebates up to 100 percent of a drug’s “average manufacturer price” and 340B prices of one penny. 

In General. Because of the breadth of these laws and the narrowness of available statutory exception and regulatory 

safe harbors, it is possible that some of our business activities in the United States could be subject to challenge under one or 
more of such laws. Moreover, state governmental agencies may propose or enact laws and regulations that extend or 
contradict federal requirements. If we or our operations are found to be in violation of any of the state or federal laws 
described above or any other governmental regulations that apply to us, we may be subject to penalties, including significant 
civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from 
participation in U.S. federal or state healthcare programs, additional reporting requirements and/or oversight, if subject to a 
corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion from 
participation in federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, 
and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our 
operations could materially adversely affect our ability to operate our business and our financial results. Although 
compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be 
entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us 
to incur significant legal expenses and divert our management’s attention from the operation of our business. Moreover, 
achieving and sustaining compliance with applicable federal and state privacy, security, sunshine, government price 
reporting, and fraud laws may prove costly. 

Impact of Healthcare Reform and Recent Public Scrutiny of Specialty Drug Pricing on Coverage, Reimbursement, and 
Pricing. In the United States and other potentially significant markets for our products, federal and state authorities as well as 
third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for 
new and innovative products and therapies, which has resulted in lower average net selling prices. Further, there is increased 
scrutiny of prescription drug pricing practices by federal and state lawmakers and enforcement authorities. In addition, there 
is an emphasis on managed healthcare in the United States, which will put additional pressure on product pricing, 
reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can 
arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to 
Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. 

The U.S. and some foreign jurisdictions are considering or have enacted a number of additional legislative and 

regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. 
Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in 
healthcare systems with the stated goals of containing healthcare costs (including a number of proposals pertaining to 
prescription drugs, specifically), improving quality and/or expanding access. For example, in Massachusetts, the MassHealth 
program has requested permission from the federal government to use commercial tools, such as a closed formulary, to 
negotiate more favorable rebate agreements from drug manufactures. There also has been particular and increasing legislative 
and enforcement interest in the United States with respect to specialty drug pricing practices, particularly with respect to 
drugs that have been subject to relatively large price increases over relatively short time periods. Such interest has resulted in 
several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other 
things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, 
reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the 
federal level, the Trump administration’s budget proposal for fiscal year 2019 contains further drug price control measures 
that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to 
permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate 
drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Additionally, the Trump 
administration released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contains additional 
proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, 
incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by 
consumers. The U.S. Department of Health and Human Services, or HHS, has already started the process of soliciting 
feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. 
For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy 
for Part B drugs beginning January 1, 2019, in October 2018, CMS proposed a new rule that would require direct-to-
consumer television advertisements of prescription drugs and biological products, for which payment is available through or 
under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or 
biological product, and on January 31, 2019, the HHS Office of Inspector General proposed modifications to federal Anti-
Kickback Statute safe harbors which, among other things, may affect rebates paid by manufacturers to Medicare Part D plans, 
the purpose of which is to further reduce the cost of drug products to consumers. While some of these, and other proposed 
measures will require authorization through additional legislation to become effective, Congress and the Trump 

16

administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug 
costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control 
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on 
certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage 
importation from other countries and bulk purchasing. For example, in California, effective January 1, 2019, drug companies 
must notify insurers and government regulators of certain price increases and provide an explanation of the reasons for such 
increases. 

In the United States, the pharmaceutical industry has already been significantly affected by major legislative initiatives, 

including, for example, the ACA. The ACA, among other things, imposes a significant annual fee on companies that 
manufacture or import branded prescription drug products. It also contains substantial provisions intended to broaden access 
to health insurance, reduce or constrain the growth of healthcare spending, and impose additional health policy reforms, any 
or all of which may affect our business. 

Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional 
challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain 
aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to 
delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health 
insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace 
all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the 
implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, 
includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA 
on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as 
the “individual mandate”. On January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal 
year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called “Cadillac” tax on certain 
high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market 
share, and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, or the BBA, 
among other things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale 
discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and close the coverage gap in 
most Medicare drug plans, commonly referred to as the “donut hole.” In July 2018, CMS published a final rule permitting 
further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA 
risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to 
determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is 
unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Act. While the 
Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no 
immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to 
repeal and replace the ACA will impact the ACA. 

Other legislative changes have also been proposed and adopted since the ACA was enacted. For example, the Budget 
Control Act of 2011 resulted in aggregate reductions in Medicare payments to providers of up to two percent per fiscal year, 
starting in 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect 
through 2027 unless additional Congressional action is taken. In addition, the American Taxpayer Relief Act of 2012, among 
other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the 
government to recover overpayments to providers from three to five years. Such laws, and others that may affect our business 
that have been recently enacted or may in the future be enacted, may result in additional reductions in Medicare and other 
healthcare funding. 

Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to 
Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for 
certain patients to access certain investigational new drug products that have completed a Phase I clinical trial and that are 
undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without 
enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no 
obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to 
Try Act, and the Right to Try Act does not invalidate currently existing expanded access programs. 

MANUFACTURING

We rely on our facility in Düsseldorf, Germany and third parties to perform the multiple processes involved in 
manufacturing our product candidates, including the manufacturing of TLR agonists, antigens, and the formulation, fill and 

17

finish of the resultant products. We have relied on a limited number of suppliers to produce products for clinical trials and a 
single supplier to produce our 1018 for HEPLISAV-B. In order to successfully manufacture and commercialize HEPLISAV-
B, we have secured long term supply agreements with the key third party suppliers and vendors for supply of product for 
commercialization. To date, we have manufactured only small quantities of TLR agonists ourselves for development 
purposes. We currently manufacture the HBsAg for HEPLISAV-B at our Dynavax GmbH facility. 

COMMITMENT TO COMPLIANCE AND ENVIRONMENT

We are committed to conducting our business in compliance with all applicable legal and ethical standards. In addition, 

we are committed to helping to protect the environment.  

Our Ethics and Compliance program includes our Code of Business Conduct (“Code”), which sets forth our 

expectations of all Dynavax employees globally that they conduct their business activities in a legal and ethical manner. The 
Code can be found on Dynavax.com under the header “Investor Relations” and within that under the header “Corporate 
Governance and Compliance.” We have a Chief Ethics and Compliance Officer, a Compliance Steering Committee and 
policies, procedures and training addressing specific aspects of our business, including advertising and promotion; 
engagements with healthcare providers; and regarding our business activities outside the United States to ensure they comply 
with the U.S. Foreign Corrupt Practices Act and all other applicable anti-corruption laws. We certify on an annual basis to 
having a comprehensive compliance program that meets the standards set forth under California law. This certification, 
which sets forth all of the elements of our healthcare compliance program, can be found on our web-site.

We also care about the environment. To that end, the building we are moving into later this year is being designed to be 

scored as no less than a “Gold” level on the LEED Scorecard as set forth by the United States Green Building Committee. 
Additionally, the facility is located adjacent to an expansive public transit center, and the Company offers incentives to 
employees to utilize public transit in order to reduce traffic congestion and pollution. We also allow our employees to 
telecommute one or more days a week, depending on the nature of their role, which further helps reduce congestion and 
pollution. In addition, we have an active recycling program. We continue to consider other ways in which we can conduct our 
business in an environmentally friendly manner.

We have made, and will continue to make, expenditures for environmental compliance and protection. We do not 

expect that expenditures for compliance with environmental laws will have a material effect on our results of operations in 
the future. 

EMPLOYEES 

As of December 31, 2018, we had 249 full-time employees, including 169 employees in our headquarters in Berkeley, 

California and 80 employees in our office and manufacturing facility in Düsseldorf, Germany.

THE COMPANY AND BACKGROUND 

Dynavax Technologies Corporation was incorporated in California in August 1996 under the name Double Helix 
Corporation, and we changed our name to Dynavax Technologies Corporation in September 1996. We were reincorporated in 
Delaware in November 2000 and listed on the Nasdaq Capital Market under the ticker symbol “DVAX”.

Our principal executive offices are located at 2929 Seventh Street, Suite 100, Berkeley, California, 94710-2753. Our 
telephone number is (510) 848-5100. We make available, free of charge on our website located at www.dynavax.com, our 
annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those 
reports, as soon as reasonably practicable after filing such reports with the Securities and Exchange Commission. Our code of 
conduct, audit committee charter, nominating and corporate governance committee charter, compensation committee charter 
and audit committee complaint procedures are also posted on our website and are each available in print to any stockholder 
upon request by writing to: 2929 Seventh Street, Suite 100, Berkeley, California 94710-2753. The contents of our website are 
not incorporated by reference into this report.

18

ITEM 1A.

RISK FACTORS

Various statements in this Annual Report on Form 10-K are forward-looking statements concerning our future efforts 

to obtain regulatory approval, timing of development activities, commercialization efforts of the approved products, expenses, 
revenues, liquidity and cash needs, as well as our plans and strategies. These forward-looking statements are based on 
current expectations and we assume no obligation to update this information. Numerous factors could cause our actual 
results to differ significantly from the results described in these forward-looking statements, including the following risk 
factors. 

Risks Related to our Business and Capital Requirements

HEPLISAV-B has been launched in the United States and there is significant competition in the marketplace. Since this 
is our first marketed product, the timing of uptake and distribution efforts are unpredictable and there is a risk that we 
may not achieve and sustain commercial success for HEPLISAV-B.

We have established sales, marketing and distribution capabilities and commercialized HEPLISAV-B in the U.S. 
Successful commercialization of HEPLISAV-B will require significant resources and time and, while Dynavax personnel are 
experienced with respect to marketing of prescription drug products, because HEPLISAV-B is the company’s first marketed 
product, that the potential uptake of the product in distribution and the timing for growth in sales, if any, may be 
unpredictable and we may not be successful in commercializing HEPLISAV-B. In particular, successful commercialization 
of HEPLISAV-B will require that we continue to negotiate and enter into contracts with wholesalers, distributors, group 
purchasing organizations, and other parties, and that we maintain those contractual relationships. There is a risk that we may 
not complete or maintain all of these important contracts on favorable terms or that in a potentially evolving reimbursement 
environment our efforts can overcome established competition at favorable pricing.

We anticipate converting our contracted field sales team into full-time Dynavax employees in the second quarter of 

2019. The conversion of the field sales team to employees will require additional internal resources, both in the conversion 
process and for ongoing administrative and logistical support. We have not previously employed an in-house field sales team, 
and thus have limited experience in overseeing and managing an employed salesforce. In addition, retention of capable sales 
personnel may be more difficult with a single product offering and we must retain our salesforce in order for HEPLISAV-B 
to establish a commercial presence.  

Moreover, we expect that significant resources will need to be invested in order to successfully market, sell and 

distribute HEPLISAV-B for use with diabetes patients, one of our targeted patient populations. The Centers for Disease 
Control and Prevention (“CDC”) and the CDC’s Advisory Committee on Immunization Practices (“ACIP”) recommend that 
patients with diabetes receive hepatitis B vaccinations and while the potential number of recommended vaccine adult patients 
is larger than our initial targeted market, we are unable to predict how many of those patients may receive HEPLISAV-B. 

In addition to the risks with employing and maintaining our own commercial capabilities and with contracting, other 

factors that may inhibit our efforts to successfully commercialize HEPLISAV-B include:

• whether we are able to recruit and retain adequate numbers of effective sales and marketing personnel;
• whether we are able to access key health care providers to discuss HEPLISAV-B;
• whether we can compete successfully as a new entrant in established distribution channels for vaccine products; 

and

• whether we will maintain sufficient funding to cover the costs and expenses associated with creating and 

sustaining a capable sales and marketing organization and related commercial infrastructure.

If we are not successful, we may be required to collaborate or partner HEPLISAV-B with a third party pharmaceutical 
or biotechnology company with existing products. To the extent we collaborate or partner, the financial value will be shared 
with another party and we will need to establish and maintain a successful collaboration arrangement, and we may not be able 
to enter into these arrangements on acceptable terms or in a timely manner in order to establish HEPLISAV-B in the market. 
To the extent that we enter into co-promotion or other arrangements, any revenues we receive will depend upon the efforts of 
third parties, which may not be successful and are only partially in our control. In that event, our product revenues may be 
lower than if we marketed and sold our products directly with the highest priority, and we may be required to reduce or 
eliminate much of our commercial infrastructure and personnel as a result of such collaboration or partnership.

19

If we, or our partners, if any, are not successful in setting our marketing, pricing and reimbursement strategies, 

recruiting and maintaining effective sales and marketing personnel or in building and maintaining the infrastructure to 
support commercial operations, we will have difficulty successfully commercializing HEPLISAV-B, which would adversely 
affect our business and financial condition. 

We face uncertainty regarding coverage, pricing and reimbursement and the practices of third-party payors, which may 
make it difficult or impossible to sell our product or product candidates on commercially reasonable terms.

In both domestic and foreign markets, our ability to achieve profitability will depend in part on the negotiation of a 
favorable price, as well as the availability of coverage and adequate reimbursement, from third-party payors, in particular for 
HEPLISAV-B, where existing products are already marketed. In the U.S., pricing for hepatitis B vaccines is currently stable 
and reimbursement is favorable as private and public payors recognize the value of prophylaxis in this setting given the high 
costs of potential morbidity and mortality, and we have achieved coverage with most third-party payors. However, there is a 
risk that some payors may limit coverage to specific products on an approved list, also known as a formulary, which might 
not include HEPLISAV-B. Thus, there can be no assurance that HEPLISAV-B will achieve and sustain stable pricing and 
favorable reimbursement. Our ability to successfully obtain and retain market share and achieve and sustain profitability will 
be significantly dependent on the market’s acceptance of a price for HEPLSIAV-B sufficient to achieve profitability, and 
future acceptance of such pricing. 

Third-party payors are increasingly challenging the price and cost-effectiveness of medical products and services, and 

pricing, as well as coverage and reimbursement decisions may not allow our future products to compete effectively with 
existing competitive products. Because we intend to offer products, if approved, that involve new technologies and new 
approaches to treating disease, the willingness of third-party payors to reimburse for our products is uncertain. We will have 
to charge a price for our products that is sufficient to enable us to recover our considerable investment in product 
development and our operating costs. Adequate third-party payor reimbursement may not be available to enable us to 
maintain price levels sufficient to achieve profitability, and such unavailability could harm our future prospects and reduce 
our stock price.

Also, there has been heightened governmental scrutiny recently in the U.S. over pharmaceutical pricing practices in 

light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional 
inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to 
product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program 
reimbursement methodologies for products. At the federal level, the Trump administration’s budget proposal for fiscal year 
2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future 
legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under 
Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic 
drugs for low-income patients. Additionally, the Trump administration released a “Blueprint” to lower drug prices and reduce 
out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating 
power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce 
the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services, or HHS, 
has already started the process of soliciting feedback on some of these measures and, at the same, is immediately 
implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow 
Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January 1, 2019, and in October 2018, 
CMS proposed a new rule that would require direct-to-consumer television advertisements of prescription drugs and 
biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement 
the Wholesale Acquisition Cost, or list price, of that drug or biological product. On January 31, 2019, the HHS Office of 
Inspector General proposed modifications to federal Anti-Kickback Statute safe harbors which, among other things, may 
affect rebates paid by manufacturers to Medicare Part D plans, the purpose of which is to further reduce the cost of drug 
products to consumers. While a number of these, and other proposed measures will require authorization through additional 
legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new 
legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed 
legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or 
patient reimbursement constraints, discounts, and restrictions on certain product access. In some cases, such legislation and 
regulations have been designed to encourage importation from other countries and bulk purchasing. There have been, and 
likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening 
the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be 
adopted in the future or the effect any such initiatives may have on our business.

20

We are also dependent on the success of our development stage products including SD-101, which depend on regulatory 
approval. Failure to maintain or obtain regulatory approvals could require us to discontinue operations. 

In addition to the potential commercial success of HEPLISAV-B, we are dependent on our development stage immune-

oncology pipeline of early stage oncology product candidates, and early stage development is inherently risky. Even if we 
have early indications of success in clinical development, in order to be able to market our products in the U.S., we must 
obtain approval from the FDA, and corresponding applications to foreign regulatory agencies must be approved by those 
agencies before we may sell the product in their respective geographic area. Obtaining FDA marketing approval and 
corresponding foreign applications is highly uncertain and we may fail to obtain approval. The FDA review process is 
extensive, lengthy, expensive and uncertain, and the FDA or foreign regulatory agencies may delay, limit or deny approval of 
our application for many reasons, including: whether the data from our clinical trials or the development program are 
satisfactory to the FDA or foreign regulatory agency; disagreement with the number, design, size, conduct or implementation 
of our clinical trials or proposed post-marketing study, or a conclusion that the data fails to meet statistical or clinical 
significance or safety requirements; acceptability of data generated at our clinical trial sites that are monitored by third party 
contract research organizations (“CROs”); and deficiencies in our manufacturing processes or facilities or those of our third 
party contract manufacturers and suppliers, if any. For example, we received Complete Response Letters from the FDA for 
HEPLISAV-B in 2013 and 2016 before obtaining approval in November 2017. 

In the event that we determine to commercialize HEPLISAV-B outside the United States, such as in Europe, the 

product is not approved and our opportunity will depend upon our receiving regulatory approval, which can be costly and 
time consuming, and there is a risk that one or more regulatory bodies may require that we conduct additional clinical trials 
and/or take other measures which will take time and require that we incur significant additional expense. In addition, there is 
the risk that we may not receive approval in one or more jurisdictions.

In addition, we obtain guidance from regulatory authorities on certain aspects of our clinical development activities and 

seek to comply with written guidelines provided by the authorities. These discussions and written guidelines are not binding 
obligations on the part of the regulatory authorities and the regulatory authorities may require additional patient data or 
studies to be conducted. Regulatory authorities may revise or retract previous guidance during the course of a clinical trial or 
after completion of the trial. The authorities may also disqualify a clinical trial from consideration in support of approval of a 
potential product if they deem the guidelines have not been met. The FDA or foreign regulatory agencies may determine our 
clinical trials or other data regarding safety, efficacy or consistency of manufacture or compliance with GMP regulations are 
insufficient for regulatory approval.

We are subject to ongoing FDA post-marketing obligations concerning HEPLISAV-B, which may result in significant 
additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience 
unanticipated problems with HEPLISAV-B.

Our HEPLISAV-B regulatory approval is subject to certain post-marketing obligations and commitments to the FDA. 

We must conduct an observational comparative study of HEPLISAV-B to another hepatitis B vaccine to assess occurrence of 
acute myocardial infarction; must conduct an observational surveillance study to evaluate the incidence of new onset 
immune-mediated diseases, herpes zoster and anaphylaxis; and must establish a pregnancy registry to provide information on 
outcomes following pregnancy exposure to HEPLISAV-B. These studies will require significant effort and resources, and 
failure to timely conduct these studies to the satisfaction of FDA could result in withdrawal of our BLA approval. The results 
of post-marketing studies may also result in additional warnings or precautions for the HEPLISAV-B label or expose 
additional safety concerns that may result in product liability and withdrawal of the product from the market, which would 
have a material adverse effect on our business, results of operations, financial condition and prospects.  

In addition, the manufacturing processes, labelling, packaging, distribution, adverse event reporting, storage, 
advertising, promotion and recordkeeping for HEPLISAV-B are subject to extensive and ongoing regulatory requirements. 
These requirements include submissions of safety and other post-marketing information and reports, registration, as well as 
continued compliance with cGMPs, GCPs, ICH guidelines, and GLPs. If we are not able to meet and maintain regulatory 
compliance, we may lose marketing approval and be required to withdraw our product. As noted in the preceding paragraph, 
withdrawal would have a material adverse effect on our business.

21

We have incurred net losses in each year since our inception and anticipate that we will continue to incur significant 
losses for the foreseeable future unless we can successfully commercialize HEPLISAV-B, and if we are unable to achieve 
and sustain profitability, the market value of our common stock will likely decline.

We have generated limited revenue from the sale of products and have incurred losses in each year since we 
commenced operations in 1996. Our net losses for the years ended December 31, 2018 and 2017 were $158.9 million and 
$95.2 million, respectively. As of December 31, 2018, we had an accumulated deficit of $1.1 billion.

With our investment in the launch and commercialization of HEPLISAV-B in the U.S. in addition to our investment in 
our oncology product candidates, we expect to continue incurring significant expenses and increasing operating losses for the 
foreseeable future. Our expenses have increased substantially as we established and maintain our HEPLISAV-B commercial 
infrastructure, including investments in internal infrastructure to support our plans for converting our contracted field sales 
force to Dynavax employees and investments in manufacturing and supply chain commitments to maintain commercial 
supply of HEPLISAV-B. The timing for uptake of our product in the U.S. has further increased losses related to 
commercialization, and the advancement of our oncology pipeline has increased our costs as we conduct more and larger 
studies to invest in clinical development. Due to the numerous risks and uncertainties associated with developing and 
commercializing vaccine and pharmaceutical products, we are unable to predict the extent of any future losses or when, if 
ever, we will become profitable.  

Until we are able to generate significant revenues or achieve profitability through product sales, we will require 
substantial additional capital to finance our operations and continue development of our product candidates. 

We expect to incur significant expenses and operating losses for the foreseeable future as we continue to invest in 

commercialization of HEPLISAV-B, clinical trials and other development, manufacturing and regulatory activities for our 
immuno-oncology product candidates and discovery research and development. Until we can generate a sufficient amount of 
revenue, we will need to finance our operations through strategic alliance and licensing arrangements and/or public or private 
debt and equity financings. Adequate financing may not be available to us on acceptable terms, or at all. If adequate funds are 
not available when needed, we may need to delay, reduce the scope of or put on hold one or more programs while we seek 
strategic alternatives. 

Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a 
number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number 
of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise 
such additional capital at a price or on terms that are favorable to us. Raising additional funds through the issuance of equity 
or debt securities could result in dilution to our existing stockholders, increased fixed payment obligations, or both. In 
addition, these securities may have rights senior to those of our common stock and could include covenants that would 
restrict our operations. 

The FDA may require more clinical trials for our development stage product candidates than we currently expect or are 
conducting before granting regulatory approval, if regulatory approval is granted at all. Our clinical trials may be 
extended which may lead to substantial delays in the regulatory approval process for our product candidates and may 
impair our ability to generate revenues.

Our registration and commercial timelines depend on further discussions with the FDA and corresponding foreign 
regulatory agencies and requirements and requests they may make for additional data or completion of additional clinical 
trials. Any such requirements or requests could:

•

•

•

•

•

•

•

adversely affect our ability to timely and successfully commercialize or market these product candidates;

result in significant additional costs;

potentially diminish any competitive advantages for those products;

potentially limit the markets for those products;

adversely affect our ability to enter into collaborations or receive milestone payments or royalties from potential 
collaborators;

cause us to abandon the development of the affected product candidate; or

limit our ability to obtain additional financing on acceptable terms, if at all. 

22

Clinical trials for our product candidates are expensive and time consuming, may involve combinations with other agents, 
may take longer than we expect or may not be completed at all, and their outcomes are uncertain.

Clinical trials, including post-marketing studies, to generate sufficient data to meet FDA requirements can be expensive 

and time consuming. 

We are currently undertaking clinical trials of SD-101 and DV281, including combination studies with other oncology 

agents, and expect to commence clinical trials for other product candidates in our immuno-oncology pipeline in the future. 
Our strategy with respect to development of SD-101 and DV281 involves combination studies with other oncology agents. 
While we believe that this combination agent approach increases the potential for success, these clinical trials are dependent 
on continuing access to the other oncology agents, and for combination studies that are pursuant to a collaboration they are 
contingent on agreement with our combination agent study partners regarding the use of the other agents, concurrence on a 
protocol and supply of clinical materials. Most of our combination agent study partners, such as Merck & Co. (“Merck”), are 
significantly larger than we are and are conducting various other combination studies with other immuno-oncology agents 
and collaborators. We are not certain these clinical trials will be successful, or that even if successful we would be able to 
reach agreement to conduct larger, more extensive clinical trials required to achieve regulatory approval for a combination 
product candidate regimen. In addition, results from smaller, earlier stage clinical studies may not be representative of larger, 
controlled clinical trials that would be required in order to obtain regulatory approval of a product candidate or a combination 
of product candidates.

Each of our clinical trials requires the investment of substantial planning, expense and time and the timing of the 
commencement, continuation and completion of these clinical trials may be subject to significant delays relating to various 
causes, including scheduling conflicts with participating clinicians and clinical institutions, difficulties in identifying and 
enrolling participants who meet trial eligibility criteria, failure of participants to complete the clinical trial, delay or failure to 
obtain Institutional Review Board (“IRB”) or regulatory approval to conduct a clinical trial at a prospective site, unexpected 
adverse events and shortages of available drug supply. Participant enrollment is a function of many factors, including the size 
of the relevant population, the proximity of participants to clinical sites, the eligibility criteria for the trial, the existence of 
competing clinical trials and the availability of alternative or new treatments.

Failure by us or our CROs to conduct a clinical study in accordance with GCP standards and other applicable regulatory 
requirements could result in disqualification of the clinical trial from consideration in support of approval of a potential 
product.

We are responsible for conducting our clinical trials consistent with GCP standards and for oversight of our vendors to 

ensure that they comply with such standards. We depend on medical institutions and CROs to conduct our clinical trials in 
compliance with GCP. To the extent that they fail to comply with GCP standards, fail to enroll participants for our clinical 
trials, or are delayed for a significant time in the execution of our trials, including achieving full enrollment, we may be 
affected by increased costs, program delays or both, which may harm our business.

Clinical trials must be conducted in accordance with FDA or other applicable foreign government guidelines and are 

subject to oversight by the FDA, other foreign governmental agencies and IRBs at the medical institutions where the clinical 
trials are conducted. In addition, clinical trials must be conducted with supplies of our product candidates produced under 
GMP and other requirements in foreign countries, and may require large numbers of participants.

The FDA or other foreign governmental agencies or we ourselves could delay, suspend or halt our clinical trials of a 

product candidate for numerous reasons, including with respect to our product candidates and those of our partners in 
combination agent studies:

•

•

•

•

•

•

•

deficiencies in the trial design;

deficiencies in the conduct of the clinical trial including failure to conduct the clinical trial in accordance with 
regulatory requirements or clinical protocols;

deficiencies in the clinical trial operations or trial sites resulting in the imposition of a clinical hold;

a product candidate may have unforeseen adverse side effects, including fatalities, or a determination may be made 
that a clinical trial presents unacceptable health risks;

the time required to determine whether a product candidate is effective may be longer than expected;

fatalities or other adverse events arising during a clinical trial that may not be related to clinical trial treatments;

a product candidate or combination study may appear to be no more effective than current therapies;

23

•

•

•

•

•

•

•

•

the quality or stability of a product candidate may fail to conform to acceptable standards;

the inability to produce or obtain sufficient quantities of a product candidate to complete the trials;

our inability to reach agreement on acceptable terms with prospective CROs and trial sites, the terms of which can 
be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

our inability to obtain IRB approval to conduct a clinical trial at a prospective site;

the inability to obtain regulatory approval to conduct a clinical trial;

lack of adequate funding to continue a clinical trial, including the occurrence of unforeseen costs due to enrollment 
delays, requirements to conduct additional trials and studies and increased expenses associated with the services of 
our CROs and other third parties;

the inability to recruit and enroll individuals to participate in clinical trials for reasons including competition from 
other clinical trial programs for the same or similar indications; or

the inability to retain participants who have initiated a clinical trial but may withdraw due to side effects from the 
therapy, lack of efficacy or personal issues, or who are lost to further follow-up.

In addition, we may experience significant setbacks in advanced clinical trials, even after promising results in earlier 

trials, such as unexpected adverse events that occur when our product candidates are combined with other therapies and drugs 
or given to larger patient populations, which often occur in later-stage clinical trials, or less favorable clinical outcomes. 
Moreover, clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory 
approvals. 

Third party organizations such as patient advocacy groups and parents of trial participants may demand additional 

clinical trials or continued access to drug even if our interpretation of clinical results received thus far leads us to determine 
that additional clinical trials or continued access are unwarranted. Any disagreement with patient advocacy groups or parents 
of trial participants may require management’s time and attention and may result in legal proceedings being instituted against 
us, which could be expensive, time-consuming and distracting, and may result in delay of the program. Negative or 
inconclusive results or adverse medical events, including participant fatalities that may be attributable to our product 
candidates, during a clinical trial may necessitate that it be redesigned, repeated or terminated. Further, some of our clinical 
trials may be overseen by a Data Safety Monitoring Board (“DSMB”), and the DSMB may determine to delay or suspend 
one or more of these trials due to safety or futility findings based on events occurring during a clinical trial. Any such delay, 
suspension, termination or request to repeat or redesign a trial could increase our costs and prevent or significantly delay our 
ability to commercialize our product candidates.

HEPLISAV-B, SD-101 and most of our earlier stage programs rely on oligonucleotide TLR agonists. Serious adverse 
event data relating to TLR agonists may require us to reduce the scope of or discontinue our operations.

Most of our programs, including HEPLISAV-B and SD-101, incorporate TLR9 agonist CpG oligonucleotides. If any of 

our product candidates in clinical trials or similar products from competitors produce serious adverse event data, we may be 
required to delay, discontinue or modify many of our clinical trials or our clinical trial strategy. If a safety risk based on 
mechanism of action or the molecular structure were identified, it may hinder our ability to develop our product candidates or 
enter into potential collaboration or commercial arrangements. Rare diseases and a numerical imbalance in cardiac adverse 
events have been observed in patients in our clinical trials. If adverse event data are found to apply to our TLR agonist and/or 
inhibitor technology as a whole, we may be required to significantly reduce or discontinue our operations.

24

We rely on our facility in Düsseldorf, Germany and third parties to supply materials or perform processes necessary to 
manufacture HEPLISAV-B and our product candidates. We rely on a limited number of suppliers to produce the 
oligonucleotides we require for development and commercialization. Additionally, we have limited experience in 
manufacturing our product candidates in commercial quantities. With respect to HEPLISAV-B, we have switched to a 
pre-filled syringe presentation of the vaccine and our ability to meet future demand will depend on our ability to 
manufacture sufficient supply in this presentation.

We rely on our facility in Düsseldorf and third parties to perform the multiple processes involved in manufacturing 

HEPLISAV-B and our product candidates, including SD-101 and DV281, certain antigens, the combination of the 
oligonucleotide and the antigens, and formulation, fill and finish. The FDA approved our pre-filled presentation of 
HEPLISAV-B in 2018 and we expect such presentation will be the sole presentation for HEPLISAV-B going forward. We 
have limited experience in manufacturing and supplying this presentation, and there can be no assurance that we can 
successfully manufacture sufficient quantities of pre-filled syringes in compliance with GMP in order to meet market demand. 

We have also relied on a limited number of suppliers to produce oligonucleotides for clinical trials and a single supplier 

to produce our 1018 for HEPLISAV-B. To date, we have manufactured only small quantities of oligonucleotides ourselves 
for development purposes. If we were unable to maintain our existing suppliers for 1018 and SD-101, we would have to 
establish an alternate qualified manufacturing capability, which would result in significant additional operating costs and 
delays in developing and commercializing our product candidates, particularly HEPLISAV-B. We or other third parties may 
not be able to produce product at a cost, quantity and quality that are available from our current third-party suppliers or at all.

In countries outside of the U.S., we may not be able to comply with ongoing and comparable foreign regulations, and 

our manufacturing process may be subject to delays, disruptions or quality control/quality assurance problems. 
Noncompliance with these regulations or other problems with our manufacturing process may limit or disrupt the 
commercialization of HEPLISAV-B or our other product candidates and could result in significant expense. 

If we receive regulatory approval for our other product candidates, we will be subject to ongoing FDA and foreign 
regulatory obligations and continued regulatory review.

With respect to HEPLISAV-B and our other product candidates in development, we and our third party manufacturers 
and suppliers are required to comply with applicable GMP regulations and other international regulatory requirements. The 
regulations require that our product candidates be manufactured and records maintained in a prescribed manner with respect 
to manufacturing, testing and quality control/quality assurance activities. Manufacturers and suppliers of key components and 
materials must be named in a BLA submitted to the FDA for any product candidate for which we are seeking FDA approval. 
Additionally, third party manufacturers and suppliers and any manufacturing facility must undergo a pre-approval inspection 
before we can obtain marketing authorization for any of our product candidates. Even after a manufacturer has been qualified 
by the FDA, the manufacturer must continue to expend time, money and effort in the area of production and quality control 
to ensure full compliance with GMP. Manufacturers are subject to regular, periodic inspections by the FDA following initial 
approval. Further, to the extent that we contract with third parties for the manufacture of our products, our ability to control 
third-party compliance with FDA requirements will be limited to contractual remedies and rights of inspection.

If, as a result of the FDA’s inspections, it determines that the equipment, facilities, laboratories or processes do not 

comply with applicable FDA regulations and conditions of product approval, the FDA may not approve the product or may 
suspend the manufacturing operations. If the manufacturing operations of any of the suppliers for our product candidates are 
suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market 
demand, which would harm our business. In addition, if delivery of material from our suppliers were interrupted for any 
reason, we might be unable to ship our approved product for commercial supply or to supply our products in development for 
clinical trials. Significant and costly delays can occur if the qualification of a new supplier is required.

Failure to comply with regulatory requirements could prevent or delay marketing approval or require the expenditure of 
money or other resources to correct. Failure to comply with applicable requirements may also result in warning letters, fines, 
injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, refusal of the government 
to renew marketing applications and criminal prosecution, any of which could be harmful to our ability to generate revenues 
and our stock price.

Any regulatory approvals that we receive for our product candidates are likely to contain requirements for post-
marketing follow-up studies, which may be costly. Product approvals, once granted, may be modified based on data from 
subsequent studies or commercial use. As a result, limitations on labeling indications or marketing claims, or withdrawal 
from the market may be required if problems occur after approval and commercialization.

25

We may develop, seek regulatory approval for and market our product candidates outside the U.S., requiring a significant 
commitment of resources. Failure to successfully manage our international operations could result in significant 
unanticipated costs and delays in regulatory approval or commercialization of our product candidates.

We may seek to introduce certain of our product candidates, including HEPLISAV-B, in various markets outside the 

U.S. Developing, seeking regulatory approval for and marketing our product candidates outside the U.S. could impose 
substantial costs as well as burdens on our personnel resources in addition to potential diversion of management’s attention 
from domestic operations. International operations are subject to risk, including:

•

•

•

•

•

•

•

•

•

the difficulty of managing geographically distant operations, including recruiting and retaining qualified 
employees, locating adequate facilities and establishing useful business support relationships in the local 
community;

compliance with varying international regulatory requirements, laws and treaties;

securing international distribution, marketing and sales capabilities upon favorable terms;

adequate protection of our intellectual property rights;

obtaining regulatory and pricing approvals at a level sufficient to justify commercialization;

legal uncertainties and potential timing delays associated with tariffs, export licenses and other trade barriers;

diverse tax consequences;

the fluctuation of conversion rates between foreign currencies and the U.S. dollar; and

regional and geopolitical risks.

We withdrew our MAA for HEPLISAV-B in Europe in 2014. We may not be able to provide sufficient data or respond 
to other comments to our previously filed MAA sufficient to obtain regulatory approval in Europe in a reasonable time period 
or at all. 

Any failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory 
approval process in other jurisdictions. If we are unable to successfully manage our international operations, we may incur 
significant unanticipated costs and delays in regulatory approval or commercialization of our product candidates, which 
would impair our ability to generate revenues.

If any products we develop are not accepted by the market or if regulatory agencies limit our labeling indications, require 
labeling content that diminishes market uptake of our products or limits our marketing claims, we may be unable to 
generate significant revenues, if any.

Even if we obtain regulatory approval for our product candidates, such as the FDA approval of HEPLISAV-B in 
November 2017, and are able to commercialize them, our products may not gain market acceptance among physicians, 
patients, healthcare payors and the medical community.

The degree of market acceptance of HEPLISAV-B and any of our future approved products will depend upon a number 

of factors, including:

•

•

•

•

•

•

•

the indication for which the product is approved and its approved labeling;

the presence of other competing approved therapies;

the potential advantages of the product over existing and future treatment methods;

the relative convenience and ease of administration of the product;

the strength of our sales, marketing and distribution support;

the price and cost-effectiveness of the product; and

third-party coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the 
absence of sufficient reimbursement by third-party payors. 

The FDA or other regulatory agencies could limit the labeling indication for which our product candidates may be 

marketed or could otherwise limit marketing efforts for our products. If we are unable to achieve approval or successfully 

26

market any of our product candidates, or marketing efforts are restricted by regulatory limits, our ability to generate revenues 
could be significantly impaired.

A key part of our business strategy for products in development is to establish collaborative relationships to help fund 
development and commercialization of our product candidates. We may not succeed in establishing and maintaining 
collaborative relationships, which may significantly limit our ability to develop and commercialize our products 
successfully, if at all.

We may need to establish collaborative relationships to obtain domestic and/or international sales, marketing, research 

and distribution capabilities for those product candidates, including SD-101 and DV281. Failure to obtain a collaborative 
relationship for those product candidates or HEPLISAV-B in markets outside the U.S. requiring extensive sales efforts, may 
significantly impair the potential for those products and we may be required to raise additional capital. The process of 
establishing and maintaining collaborative relationships is difficult and time-consuming, and even if we establish such 
relationships, they may involve significant uncertainty, including:

•

•

•

•

•

•

•

•

•

•

our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, 
manufacturing issues, a change in business strategy, a change of control or other reasons;

our shortage of capital resources may impact the willingness of companies to collaborate with us; 

our contracts for collaborative arrangements are terminable at will on written notice and may otherwise expire or 
terminate and we may not have alternative funding available;

our partners may choose to pursue alternative technologies, including those of our competitors;

we may have disputes with a partner that could lead to litigation or arbitration;

we have limited control over the decisions of our partners and they may change the priority of our programs in a 
manner that would result in termination of the agreement or add significant delay in the partnered program;

our ability to generate future payments and royalties from our partners depends upon the abilities of our partners to 
establish the safety and efficacy of our drug candidates, obtain regulatory approvals and successfully manufacture 
and achieve market acceptance of products developed from our drug candidates; 

we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where 
applicable, or a party may use our proprietary information in such a way as to invite litigation that could jeopardize 
or potentially invalidate our proprietary information or expose us to potential liability;

our partners may not devote sufficient capital or resources towards our product candidates; and

our partners may not comply with applicable government regulatory requirements.

Additionally, while we have the ability to independently fund certain Phase 3 trials for SD-101, we may need to 

establish a collaborative relationship with a third party to support certain large Phase 3 studies involving SD-101 in 
combination with other cancer therapeutics. If we are unable to enter into a collaborative relationship for such a large study, 
our ability to advance SD-101 to Phase 3 in combination with certain anti-cancer drugs may be significantly harmed, and we 
may not be able to adequately fund, if at all, such a study in the absence of such a third-party partner. Despite our efforts, we 
may be unable to secure additional collaborative arrangements that are necessary for us to further develop and commercialize 
our product candidates, including SD-101 and DV281. Supporting diligence activities conducted by potential collaborators 
and negotiating the financial and other terms of a collaboration agreement are long and complex processes with uncertain 
results. Even if we are successful in entering into one or more collaboration agreements, collaborations may involve greater 
uncertainty for us, as we may have less control over certain aspects of our collaborative programs than we do over our 
proprietary development and commercialization programs, and the financial terms upon which collaborators may be willing 
to enter into such an arrangement cannot be certain. 

If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, 

manufacturing or commercialization efforts pursuant to that collaboration could be delayed or terminated, or it may be 
necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our 
collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully 
transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more of 
our product candidates, undertake development and commercialization activities at our own expense or find alternative 
sources of capital.

27

Many of our competitors have greater financial resources and expertise than we do. If we are unable to successfully 
compete with existing or potential competitors as a result of these disadvantages, we may be unable to generate revenues 
and our business will be harmed.

We compete with pharmaceutical companies, biotechnology companies, academic institutions and research 

organizations, in developing and marketing therapies to prevent or treat cancer and infectious and inflammatory diseases. For 
example, HEPLISAV-B competes in the U.S. with established hepatitis B vaccines marketed by Merck and GlaxoSmithKline 
plc (“GSK”) and if approved outside the U.S., with vaccines from those companies as well as several additional established 
pharmaceutical companies. 

Oncology is also a highly competitive market, with numerous biotechnology and pharmaceutical companies developing 
therapies for all of the targets we are pursuing. Competitors may develop more effective, more affordable or more convenient 
products or may achieve earlier approval or patent protection or commercialization of their products. These competitive 
products may render our product candidates obsolete, change the standard of care against which our products much show 
safety and efficacy or limit our ability to generate revenues from our product candidates.

Existing and potential competitors may also compete with us for qualified commercial, scientific and management 

personnel, as well as for technology that would otherwise be advantageous to our business. Our success in developing 
marketable products and achieving a competitive position will depend, in part, on our ability to attract and retain qualified 
personnel in the near-term, particularly with respect to HEPLISAV-B commercialization. If we do not succeed in attracting 
new personnel and retaining and motivating existing personnel, our operations may suffer and we may be unable to obtain 
financing, enter into collaborative arrangements, sell our product candidates or generate revenues.

The term loan agreement we entered into in February 2018 imposes significant operating and financial restrictions on us 
that may prevent us from pursuing certain business opportunities and restrict our ability to operate our business. 

In February, 2018, we entered into a term loan agreement under which we may borrow up to $175 million. We have 

borrowed $100 million under the agreement to date. Additional amounts may be borrowed only if we meet certain 
requirements. The agreement contains covenants that restrict our ability to take various actions, including, among other 
things, incur additional indebtedness, pay dividends or distributions or make certain investments, create or incur certain liens, 
transfer, sell, lease or dispose of assets, enter into transactions with affiliates, consummate a merger or sell or other dispose of 
assets. The agreement also requires us to comply with a daily minimum liquidity covenant and an annual revenue 
requirement based on the sales of HEPLISAV-B, which is $30 million for fiscal year 2019. The agreement specifies a 
number of events of default, some of which are subject to applicable grace or cure periods, including, among other things, 
non-payment defaults, covenant defaults, cross-defaults to other material indebtedness, bankruptcy and insolvency defaults, 
and non-payment of material judgments. 

Our ability to comply with these covenants will likely be affected by many factors, including events beyond our control, 

and we may not satisfy those requirements. Our failure to comply with our obligations could result in an event of default and 
the acceleration of our repayment obligation at a time when we may not have the cash to comply with that obligation, which 
could result in a seizure of most of our assets. The restrictions contained in the agreement could also limit our ability to meet 
capital needs or otherwise restrict our activities and adversely affect our ability to finance our operations, enter into 
acquisitions or to engage in other business activities that would be in our interest.

We rely on CROs and Clinical Sites and Investigators for our clinical trials. If these third parties do not fulfill their 
contractual obligations or meet expected deadlines, our planned clinical trials may be delayed and we may fail to obtain 
the regulatory approvals necessary to commercialize our product candidates.

We rely on CROs, Clinical Sites and Investigators for our clinical trials. If these third parties do not perform their 

obligations or meet expected deadlines our planned clinical trials may be extended, delayed, modified or terminated. While 
we maintain oversight over our clinical trials and conduct regular reviews of the data, we are dependent on the processes and 
quality control efforts of our third party contractors to ensure that clinical trials are conducted properly and that detailed, 
quality records are maintained to support the results of the clinical trials that they are conducting on our behalf. Any 
extension, delay, modification or termination of our clinical trials or failure to ensure adequate documentation and the quality 
of the results in the clinical trials could delay or otherwise adversely affect our ability to commercialize our product 
candidates and could have a material adverse effect on our business and operations.

28

As we are evolving from a company primarily involved in research and development to a company increasingly involved in 
commercialization, we may encounter difficulties in managing our growth and expanding our operations successfully.

As our operations expand, we expect that we will also need to manage additional relationships with various third 
parties, including sole source suppliers, distributors, wholesalers and hospital customers. Future growth, including managing 
an in-house field sales team, will impose significant added responsibilities on our organization, in particular on management. 
Our future financial performance and our ability to successfully commercialize HEPLISAV-B and to compete effectively will 
depend, in part, on our ability to manage any future growth effectively. To that end, we may not be able to manage our 
growth efforts effectively, and hire, train and integrate additional management, administrative and sales and marketing 
personnel, and our failure to accomplish any of these activities could prevent us from successfully growing our company.

If we fail to comply with the extensive requirements applicable to biopharmaceutical manufacturers and marketers under 
the healthcare fraud and abuse, anticorruption, privacy, transparency and other laws of the jurisdictions in which we 
conduct our business, we may be subject to significant liability.

Our activities, and the activities of our agents, including some contracted third parties, are subject to extensive 

government regulation and oversight both in the U.S. and in foreign jurisdictions. Our interactions with physicians and others 
in a position to prescribe or purchase our products are subject to a legal regime designed to prevent healthcare fraud and 
abuse and off-label promotion. We also are subject to laws pertaining to transparency of transfers of value to healthcare 
providers; privacy and data protection; compliance with industry voluntary compliance guidelines; and prohibiting the 
payment of bribes. Relevant U.S. laws include:

•

•

•

•

•

•

•

•

the federal Anti-Kickback Statute, which prohibits persons from, among other things, knowingly and willfully 
soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the 
referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment 
may be made under federal health care programs, such as the Medicare and Medicaid programs;

federal false claims laws, including the civil False Claims Act, and civil monetary penalty law, which prohibit 
individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for 
payment to the government or its agents that are false or fraudulent;

the Federal Food, Drug and Cosmetic Act and governing regulations which, among other things, prohibit off-label 
promotion of prescription drugs;

the federal Physician Payments Sunshine Act created under the Patient Protection and Affordable Care Act of 
2010, as amended by the Health Care and Education and Reconciliation Act of 2010 (collectively, “PPACA”) 
which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the 
Centers for Medicare & Medicaid Services (“CMS”), information related to payments and other transfers of value 
to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by 
physicians and other healthcare providers and their immediate family members; 

the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created, among other 
things, new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program 
and making false statements relating to healthcare matters;

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their 
implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission 
of individually identifiable health information; 

the Foreign Corrupt Practices Act, which prohibits the payment of bribes to foreign government officials and 
requires that a company’s books and records accurately reflect the company’s transactions; and

foreign and state law equivalents of each of the federal laws described above, such as anti-kickback and false 
claims laws which may apply to items or services reimbursed by state health insurance programs or any third party 
payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the 
pharmaceutical industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated 
by the federal government; state laws that require drug manufacturers to report information on the pricing of 
certain drugs; state and local laws that require the registration of pharmaceutical sales representatives; and state 
and foreign laws governing the privacy and security of health information, many of which differ from each other in 
significant ways and often are not preempted by HIPAA.

The Office of Inspector General for the Department of Health and Human Services, the Department of Justice, states’ 

Attorneys General and other governmental authorities actively enforce the laws and regulations discussed above. These 

29

entities also coordinate extensively with the FDA, using legal theories that connect violations of the Federal Food, Drug and 
Cosmetic Act (such as off-label promotion) to the eventual submission of false claims to government healthcare programs. 
Prosecution of such promotion cases under the federal civil False Claims Act provides the potential for private parties (qui 
tam relators, or “whistleblowers”) to initiate cases on behalf of the government and provides for significantly higher penalties 
upon conviction.

In the U.S., pharmaceutical and biotechnology companies have been the target of numerous government prosecutions 

and investigations alleging violations of law, including claims asserting impermissible off-label promotion of pharmaceutical 
products, payments intended to influence the referral of federal or state health care business, submission of false claims for 
government reimbursement, or submission of incorrect pricing information.

Violations of any of the laws described above or any other applicable governmental regulations and other similar 
foreign laws may subject us, our employees or our agents to criminal, civil and administrative penalties, including fines, civil 
monetary penalties, exclusion from participation in government health care programs (including Medicare and Medicaid), 
disgorgement, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate 
integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the restriction or 
restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial 
results. Additionally, whether or not we have complied with the law, an investigation into alleged unlawful conduct may 
cause us to incur significant expense, cause reputational damage, divert management time and attention, and otherwise 
adversely affect our business. While we have developed and instituted a corporate compliance program, we cannot guarantee 
that we, our employees, our consultants, contractors, or other agents are or will be in compliance with all applicable U.S. or 
foreign laws.

We expect there will continue to be federal and state laws and/or regulations, proposed and implemented, that could 

impact our operations and business. For example, the PPACA, among other things, imposes a significant annual fee on 
companies that manufacture or import branded prescription drug products. It also contains substantial provisions intended to 
broaden access to health insurance, reduce or constrain the growth of healthcare spending, and impose additional health 
policy reforms, any or all of which may affect our business. Some of the provisions of PPACA have yet to be fully 
implemented, and there have been legal and political challenges to certain aspects of PPACA. Since January 2017, President 
Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements 
mandated by PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of 
PPACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain 
taxes under the PPACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision 
repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by PPACA on certain individuals 
who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual 
mandate”. On January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that 
delayed the implementation of certain PPACA-mandated fees, including the so-called “Cadillac” tax on certain high cost 
employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market 
share, and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, or the BBA, 
among other things, amends the PPACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-
sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and close the coverage gap in 
most Medicare drug plans, commonly referred to as the “donut hole”. In July 2018, CMS published a final rule permitting 
further collections and payments to and from certain PPACA qualified health plans and health insurance issuers under the 
PPACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS 
uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is 
unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Act. While the 
Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no 
immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to 
repeal and replace the PPACA will impact the PPACA and on our business.

Other legislative changes have also been proposed and adopted since the PPACA was enacted. For example, the 

Budget Control Act of 2011 resulted in aggregate reductions in Medicare payments to providers of up to two percent per 
fiscal year, starting in 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in 
effect through 2027 unless additional Congressional action is taken. In addition, the American Taxpayer Relief Act of 2012, 
among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period 
for the government to recover overpayments to providers from three to five years. Such laws, and others that may affect our 
business that have been recently enacted or may in the future be enacted, may result in additional reductions in Medicare and 
other healthcare funding. 

30

In the future, there will likely continue to be additional proposals relating to the reform of the U.S. healthcare system, 
some of which could further limit coverage and reimbursement of products, including our product candidates. Any reduction 
in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private 
payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to 
generate revenue, attain profitability or commercialize our products.

The loss of key personnel, including our Chief Executive Officer, could delay or prevent achieving our objectives. In 
addition, our continued growth to support commercialization may result in difficulties in managing our growth and 
expanding our operations successfully.

We depend on our senior executive officers, as well as key scientific and other personnel. Our research, product 

development and business efforts could be adversely affected by the loss of one or more key members of our scientific or 
management staff, including our Chief Executive Officer. We currently have no key person insurance on any of our 
employees.

As our operations expand, we expect that we will need to manage additional relationships with various vendors, 
partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of 
management. Our future financial performance and our ability to successfully commercialize HEPLISAV-B and to compete 
effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to 
effectively manage our commercialization efforts, research efforts and clinical trials and hire, train and integrate additional 
regulatory, manufacturing, administrative, and sales and marketing personnel. We may not be able to accomplish these tasks, 
and our failure to accomplish any of them could prevent us from successfully growing our company and achieving 
profitability.

We face product liability exposure, which, if not covered by insurance, could result in significant financial liability.

While we have not experienced any product liability claims to date, the use of any of our product candidates in clinical 
trials and the sale of any approved products, including HEPLISAV-B, will subject us to potential product liability claims and 
may raise questions about a product’s safety and efficacy. As a result, we could experience a delay in our ability to 
commercialize one or more of our product candidates or reduced sales of any approved product candidates. In addition, a 
product liability claim may exceed the limits of our insurance policies and exhaust our internal resources. We have obtained 
limited clinical trial liability and umbrella insurance coverage for our clinical trials. This coverage may not be adequate or 
may not continue to be available in sufficient amounts, at an acceptable cost or at all. While we have obtained product 
liability insurance coverage for HEPLISAV-B, there is a risk that this coverage may not be adequate or may not continue to 
be available in sufficient amounts, at an acceptable cost or at all. We also may not be able to obtain commercially reasonable 
product liability insurance for any product approved for marketing in the future. A product liability claim, product recalls or 
other claims, as well as any claims for uninsured liabilities or in excess of insured liabilities, would divert our management’s 
attention from our business and could result in significant financial liability.

The comprehensive tax reform bill passed in 2017 could adversely affect our business and financial condition.

On December 22, 2017, President Trump signed into law legislation, known as the Tax Cuts and Jobs Act of 2017, that 

significantly revises the Internal Revenue Code of 1986, as amended. The newly enacted federal income tax law, among 
other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top 
marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings 
(except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable 
income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of 
whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate 
deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing 
many business deductions and credits. Notwithstanding the reduction in the corporate income tax rate, the overall impact of 
the new federal tax law is uncertain and our business and financial condition could be adversely affected.  

We use hazardous materials and controlled substances in our business. Any claims or liabilities relating to improper 
handling, storage or disposal of these materials and substances could be time consuming and costly to resolve.

Our research and product development activities involve the controlled storage, use and disposal of hazardous and 
radioactive materials and biological waste, and controlled substances. We are subject to federal, state and local laws and 
regulations governing the use, manufacture, storage, handling and disposal of these materials, substances, and certain waste 
products. We believe we are currently in compliance with all government permits that are required for the storage, use and 

31

disposal of these materials and controlled substances. However, we cannot eliminate the risk of accidental contamination or 
injury to persons or property from these materials, or that controlled substances will be accidentally stored or used in 
violation of relevant federal, state and local requirements. In the event of an accident related to hazardous materials or a 
violation of requirements pertaining to controlled substances, we could be held liable for damages, cleanup costs or penalized 
with fines, and this liability could exceed the limits of our insurance policies and exhaust our internal resources. We may 
have to incur significant costs to comply with future environmental laws and regulations, and laws and regulations pertaining 
to the storage and use of controlled substances.

Significant disruptions of information technology systems or breaches of data security could adversely affect our business.

Our business is increasingly dependent on critical, complex and interdependent information technology systems, 
including Internet(cid:3)based systems, to support business processes as well as internal and external communications. The size 
and complexity of our computer systems make them potentially vulnerable to breakdown, malicious intrusion and computer 
viruses that may result in the impairment of key business processes.  

In addition, our systems are potentially vulnerable to data security breaches--whether by employees or others--that may 

expose sensitive data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets or other 
intellectual property, or could lead to the public exposure of personally identifiable information (including sensitive personal 
information) of our employees, collaborators, clinical trial patients, and others. A data security breach or privacy violation 
that leads to disclosure or modification of or prevents access to patient information, including personally identifiable 
information or protected health information, could harm our reputation, compel us to comply with federal, state and/or 
international breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of 
database contents and otherwise subject us to liability under laws and regulations that protect personal data, including but not 
limited to HIPAA, similar state data protection regulations, and the E.U. General Data Protection Regulation, or GDPR (EU) 
2016/679, resulting in significant penalties, increased costs or loss of revenue. 

On June 28, 2018, California adopted the California Consumer Privacy Act of 2018 (“CCPA”). The CCPA has been 
characterized as the first “GDPR-like” privacy statute to be enacted in the United States because it mirrors a number of the 
key provisions in the GDPR. The CCPA gives California residents expanded rights to access and delete their personal 
information, opt out of certain personal information sharing, and receive detailed information about how their personal 
information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches 
that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. The 
effective date of the CCPA is January 1, 2020, however, legislators have stated that they intend to propose amendments to the 
CCPA before it goes into effect. We are continuing to analyze the CCPA in order to determine its applicability and impact to 
our business.

If we are unable to prevent such data security breaches or privacy violations or implement satisfactory remedial 
measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory 
penalties because of lost or misappropriated information, including sensitive patient data. In addition, these breaches and 
other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type 
described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data 
security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While 
we have implemented security measures to protect our data security and information technology systems, such measures may 
not prevent such events.

Such disruptions and breaches of security could have a material adverse effect on our business, financial condition and 

results of operations.

Risks Related to our Intellectual Property

We rely on licenses to intellectual property from third parties. Impairment of these licenses or our inability to maintain 
them would severely harm our business.

Our current research and development efforts depend in part upon our license arrangements for intellectual property 

owned by third parties. Our dependence on these licenses subjects us to numerous risks, such as disputes regarding the use of 
the licensed intellectual property and the creation and ownership of new discoveries under such license agreements. In 
addition, these license arrangements require us to make timely payments to maintain our licenses and typically contain 
diligence or milestone-based termination provisions. Our failure to meet any obligations pursuant to these agreements could 
allow our licensors to terminate our agreements or undertake other remedies such as converting exclusive to non-exclusive 

32

licenses if we are unable to cure or obtain waivers for such failures or amend such agreements on terms acceptable to us. In 
addition, our license agreements may be terminated or may expire by their terms, and we may not be able to maintain the 
exclusivity of these licenses. If we cannot obtain and maintain licenses that are advantageous or necessary to the development 
or the commercialization of our product candidates, we may be required to expend significant time and resources to develop 
or license similar technology or to find other alternatives to maintaining the competitive position of our products. If such 
alternatives are not available to us in a timely manner or on acceptable terms, we may be unable to continue development or 
commercialize our product candidates. In the absence of a current license, we may be required to redesign our technology so 
it does not infringe a third party’s patents, which may not be possible or could require substantial funds and time.

If third parties successfully assert that we have infringed their patents and proprietary rights or challenge our patents and 
proprietary rights, we may become involved in intellectual property disputes and litigation that would be costly, time 
consuming and delay or prevent development or commercialization of our product candidates.

We may be exposed to future litigation by third parties based on claims that our product candidates or proprietary 
technologies infringe their intellectual property rights, or we may be required to enter into litigation to enforce patents issued 
or licensed to us or to determine the ownership, scope or validity of our or another party’s proprietary rights, including a 
challenge as to the validity of our issued and pending claims. From time to time we are involved in various interference and 
other administrative proceedings related to our intellectual property which has caused us to incur certain legal expenses. If we 
become involved in any litigation and/or other significant interference proceedings related to our intellectual property or the 
intellectual property of others, we will incur substantial additional expenses and it will divert the efforts of our technical and 
management personnel.

If we or our collaborators are unsuccessful in defending or prosecuting our issued and pending claims or in defending 
potential claims against our products, for example, as may arise in connection with the commercialization of HEPLISAV-B 
or any similar product candidate, we or our collaborator could be required to pay substantial damages or be unable to 
commercialize our product candidates or use our proprietary technologies without a license from such third party. A license 
may require the payment of substantial fees or royalties, require a grant of a cross-license to our technology or may not be 
available on acceptable terms, if at all. Any of these outcomes could require us to change our business strategy and could 
materially impact our business and operations.

If the combination of patents, trade secrets and contractual provisions that we rely on to protect our intellectual property 
is inadequate, the value of our product candidates will decrease.

Our success depends on our ability to:

•

•

•

obtain and protect commercially valuable patents or the rights to patents both domestically and abroad;

operate without infringing upon the proprietary rights of others; and

prevent others from successfully challenging or infringing our proprietary rights.

We will be able to protect our proprietary rights from unauthorized use only to the extent that these rights are covered 
by valid and enforceable patents for a commercially sufficient term or are otherwise effectively maintained as trade secrets. 
We try to protect our proprietary rights by filing and prosecuting U.S. and foreign patent applications. However, in certain 
cases such protection may be limited, depending in part on existing patents held by third parties, which may only allow us to 
obtain relatively narrow patent protection. In the U.S., legal standards relating to the validity and scope of patent claims in the 
biopharmaceutical field can be highly uncertain, are still evolving and involve complex legal and factual questions for which 
important legal principles remain unresolved.

The biopharmaceutical patent environment outside the U.S. is even more uncertain. We may be particularly affected by 
this uncertainty since several of our product candidates may initially address market opportunities outside the U.S., where we 
may only be able to obtain limited patent protection.

The risks and uncertainties that we face with respect to our patents and other proprietary rights include the following:

•

•

•

we may not receive an issued patent for any of our patent applications or for any patent applications that we have 
exclusively licensed;

the pending patent applications we have filed or to which we have exclusive rights may take longer than we expect 
to result in issued patents;

the claims of any patents that are issued may not provide meaningful protection or may not be valid or enforceable;

33

•

•

•

•

•

we might not be able to develop additional proprietary technologies that are patentable;

the patents licensed or issued to us or our collaborators may not provide a competitive advantage;

patents issued to other parties may limit our intellectual property protection or harm our ability to do business;

other parties may independently develop similar or alternative technologies or duplicate our technologies and 
commercialize discoveries that we attempt to patent; and

other parties may design around technologies we have licensed, patented or developed.

We also rely on trade secret protection and confidentiality agreements to protect our interests in proprietary know-how 
that is not patentable and for processes for which patents are difficult to enforce. We cannot be certain that we will be able to 
protect our trade secrets adequately. Any disclosure of confidential data in the public domain or to third parties could allow 
our competitors to learn our trade secrets. If we are unable to adequately obtain or enforce proprietary rights, we may be 
unable to commercialize our products, enter into collaborations, generate revenues or maintain any advantage we may have 
with respect to existing or potential competitors.

Risks Related to an Investment in our Common Stock

Our stock price is subject to volatility, and your investment may suffer a decline in value.

The market prices for securities of biopharmaceutical companies have in the past been, and are likely to continue in the 

future, to be, very volatile. The market price of our common stock is subject to substantial volatility depending upon many 
factors, many of which are beyond our control, including:

•

•

•

•

•

•

•

•

•

•

•

•

•

•

progress or results of any of our clinical trials or regulatory or manufacturing efforts, in particular any 
announcements regarding the progress or results of our planned trials and BLA filing and communications, from 
the FDA or other regulatory agencies;

our ability to receive timely regulatory approval for our product candidates;

our ability to establish and maintain collaborations for the development and commercialization of our product 
candidates;

our ability to raise additional capital to fund our operations;

the success or failure of clinical trials involving our immuno-oncology product candidates and the product 
candidates of third party collaborators in combination studies;

technological innovations, new commercial products or drug discovery efforts and preclinical and clinical 
activities by us or our competitors;

changes in our intellectual property portfolio or developments or disputes concerning the proprietary rights of our 
products or product candidates;

our ability to obtain component materials and successfully enter into manufacturing relationships for our product 
candidates or establish manufacturing capacity on our own;

our ability to establish and maintain licensing agreements for intellectual property necessary for the development 
of our product candidates;

changes in government regulations, general economic conditions or industry announcements;

changes in the structure of healthcare payment systems;

issuance of new or changed securities analysts’ reports or recommendations;

actual or anticipated fluctuations in our quarterly financial and operating results; and

the volume of trading in our common stock.

One or more of these factors could cause a substantial decline in the price of our common stock. In addition, securities 
class action and shareholder derivative litigation has often been brought against a company following a decline in the market 
price of its securities. We have in the past been, and we may in the future be, the target of such litigation. Securities and 
shareholder derivative litigation could result in substantial costs, and divert management’s attention and resources, which 
could harm our business, operating results and financial condition.

34

The anti-takeover provisions of our certificate of incorporation, our bylaws, Delaware law and our share purchase rights 
plan may prevent or frustrate a change in control, even if an acquisition would be beneficial to our stockholders, which 
could affect our stock price adversely and prevent attempts by our stockholders to replace or remove our current 
management.

Provisions of our certificate of incorporation and bylaws may delay or prevent a change in control, discourage bids at a 

premium over the market price of our common stock and adversely affect the market price of our common stock and the 
voting or other rights of the holders of our common stock. These provisions include:

•

•

•

•

•

•

authorizing our Board of Directors to issue additional preferred stock with voting rights to be determined by the 
Board of Directors;

limiting the persons who can call special meetings of stockholders;

prohibiting stockholder actions by written consent;

creating a classified board of directors pursuant to which our directors are elected for staggered three year terms;

providing that a supermajority vote of our stockholders is required for amendment to certain provisions of our 
certificate of incorporation and bylaws; and 

establishing advance notice requirements for nominations for election to our Board of Directors or for proposing 
matters that can be acted on by stockholders at stockholder meetings.

In addition, we remain subject to the provisions of the Delaware corporation law that, in general, prohibit any business 
combination with a beneficial owner of 15% or more of our common stock for three years unless the holder’s acquisition of 
our stock was approved in advance by our Board of Directors.

We will continue to incur increased costs and demands upon management as a result of complying with the laws and 
regulations affecting public companies, which could affect our operating results.

As a public company, we will continue to incur legal, accounting and other expenses associated with reporting 
requirements and corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002 as well 
as new rules implemented by the Securities and Exchange Commission and the Nasdaq Stock Market LLC. We may need to 
continue to implement additional financial and accounting systems, procedures and controls to accommodate changes in our 
business and organization and to comply with new reporting requirements. There can be no assurance that we will be able to 
maintain a favorable assessment as to the adequacy of our internal control over financial reporting. If we are unable to reach 
an unqualified assessment, or our independent registered public accounting firm is unable to issue an unqualified attestation 
as to the effectiveness of our internal control over financial reporting as of the end of our fiscal year, investors could lose 
confidence in the reliability of our financial reporting which could harm our business and could impact the price of our 
common stock.

Future sales of our common stock or the perception that such sales may occur in the public market could cause our stock 
price to fall.

Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales 
might occur, could depress the market price of our common stock and could impair our ability to raise capital through the 
sale of additional equity securities. As of December 31, 2018 we had 62,862,478 shares of common stock outstanding, all of 
which shares were eligible for sale in the public market, subject in some cases to the volume limitations and manner of sale 
requirements under Rule 144 of the Securities Act of 1933, as amended. 

Under our universal shelf registration statement filed by us in August 2017, we may sell any combination of common 
stock, preferred stock, debt securities and warrants in one or more offerings, including pursuant to our 2017 At Market Sales 
Agreement with Cowen under which we can offer and sell our common stock from time to time up to aggregate sales 
proceeds of $150 million. As of December 31, 2018, we have $132.8 million remaining under this agreement. The sale or 
issuance of our securities, as well as the existence of outstanding options and shares of common stock reserved for issuance 
under our option and equity incentive plans also may adversely affect the terms upon which we are able to obtain additional 
capital through the sale of equity securities.

ITEM 1B.

UNRESOLVED STAFF COMMENTS 

None. 

35

ITEM 2.

PROPERTIES

As of December 31, 2018, we lease approximately 40,700 square feet of laboratory and office space in Berkeley, 

California. In September 2018, we entered into a new lease for 75,662 square feet of laboratory and office space located in 
Emeryville, California. The Emeryville lease expires in March 2031. In connection with our lease in Emeryville, we entered 
into a lease termination agreement to terminate the Berkeley lease effective as of the date we vacate the Berkeley premises. 
We also lease approximately 5,600 square meters of laboratory and office space in Düsseldorf, Germany under lease 
agreements expiring in March 2023. We believe that our facilities are adequate to meet our requirements for the near term.

ITEM 3.

LEGAL PROCEEDINGS 

From time to time in the ordinary course of business, Dynavax receives claims or allegations regarding various matters, 

including employment, vendor and other similar situations in the conduct of our operations.

On November 18, 2016, two substantially similar securities class action complaints were filed in the U.S. District Court 

for the Northern District of California against the Company and two of its executive officers, in Soontjens v. Dynavax 
Technologies Corporation et. al., (“Soontjens”) and Shumake v. Dynavax Technologies Corporation et al., (“Shumake”). 
The Soontjens complaint alleges that between March 10, 2014 and November 11, 2016, the Company and certain of its 
executive officers violated Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, in 
connection with statements related to HEPLISAV-B. The Shumake complaint alleges violations of the same statutes related 
to the same subject, but between January 7, 2016 and November 11, 2016. The plaintiffs in both actions are seeking an 
unspecified amount of damages and attorneys’ fees and costs. On January 17, 2017, these two actions were consolidated into 
a single case entitled In re Dynavax Technologies Securities Litigation. On January 31, 2017, the court appointed lead 
plaintiff and lead counsel. Lead plaintiff filed a consolidated amended complaint on March 17, 2017. Defendants’ filed a 
motion to dismiss the consolidated amended complaint on May 1, 2017. On September 12, 2017, the District Court granted 
Defendants’ motion to dismiss, but gave lead plaintiff an opportunity to amend his complaint. On October 3, 2017, lead 
plaintiff filed a Second Amended Complaint. Defendants filed a motion to dismiss the Second Amended Complaint on 
November 3, 2017. A hearing on Defendants’ motion to dismiss was held on May 8, 2018. On June 4, 2018, Defendants’ 
motion to dismiss was granted and the case was dismissed with prejudice. On July 3, 2018, lead plaintiff filed a notice of 
appeal to the U.S. Court of Appeals for the Ninth Circuit. Lead plaintiff’s opening appellate brief was due on November 13, 
2018. Instead of filing its opening appellate brief, plaintiff filed a motion to voluntarily dismiss its appeal with prejudice and 
the Ninth Circuit granted that motion on November 16, 2018.

On January 18, 2017, the Company was made aware of a derivative complaint that a purported stockholder of the 

Company intended to file in the Superior Court of California for the County of Alameda against certain of the Company’s 
current executive officers and directors (the “MacDonald Complaint”). The MacDonald Complaint was apparently filed on 
February 16, 2017, although the Company was not provided a copy of it until March 15, 2017. Additionally, on January 19, 
2017, another purported stockholder of the Company filed a separate derivative complaint in the Superior Court of California 
for the County of Alameda against the same officers and directors who were named in the MacDonald Complaint (the 
“Shumake Complaint”). Both complaints generally allege that the defendants caused or allowed the Company to issue 
materially misleading statements and/or omit material information regarding HEPLISAV-B and the clinical trial related 
thereto and otherwise mismanaged the clinical trial related to HEPLISAV-B. The complaints seek unspecified monetary 
damages, including restitution from defendants, corporate governance changes, attorneys’ fees and costs, and other relief. 
Defendants were never served with the Shumake Complaint. On June 23, 2017, the plaintiff voluntarily dismissed 
the Shumake Complaint without prejudice. Defendants filed a demurrer in the MacDonald case seeking to dismiss the lawsuit 
on June 19, 2017. On July 26, 2017, pursuant to a stipulation between the parties, the state court stayed the MacDonald case 
pending the final resolution of the 2016 securities class action, In re Dynavax Technologies Securities Litigation.

On December 1, 2017, the purported stockholder of the Company who filed, and then later voluntarily dismissed, the 
state court Shumake Complaint, filed a substantially similar purported stockholder derivative complaint in the U.S. District 
Court for the Northern District of California (the “Federal Shumake Action”). On February 13, 2018, pursuant to a stipulation 
between the parties, the District Court stayed the Federal Shumake Action pending the final resolution of the 2016 securities 
class action, In re Dynavax Technologies Securities Litigation.

Following lead plaintiff’s dismissal of its appeal in the securities class action, the purported stockholders who filed the 
MacDonald and Shumake actions, voluntarily moved to dismiss their lawsuits, without prejudice. On December 12, 2018, the 
District Court entered an order dismissing the Federal Shumake action and on December 17, 2018, the Superior Court 
dismissed the MacDonald lawsuit.

36

ITEM 4.

MINE SAFETY DISCLOSURE 

Not applicable.

37

PART II 

ITEM  5.

MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER 
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 

Market Information and Holders 

Our common stock is traded on the Nasdaq Capital Market under the ticker symbol “DVAX”. Public trading of our 

common stock commenced on February 19, 2004. 

As of February 22, 2019 there were approximately 50 holders of record of our common stock, one of which was Cede 
& Co., a nominee for Depository Trust Company (“DTC”). All of the shares of our common stock held by brokerage firms, 
banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and 
are therefore considered to be held of record by Cede & Co. as one stockholder. 

Dividends 

We have never paid any cash dividends on our common stock. We currently expect to retain future earnings for use in 

the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future.

In February 2018, we entered into a $175.0 million term loan agreement (“Loan Agreement”) with CRG Servicing 

LLC. The Loan Agreement restricts our ability to pay any dividend. 

Recent Sales of Unregistered Securities 

None.

Issuer Purchases of Equity Securities 

None.

38

ITEM 6.

SELECTED FINANCIAL DATA 

The following selected financial data should be read in conjunction with Management’s Discussion and Analysis of 

Financial Condition and Results of Operations, and with the Consolidated Financial Statements and Notes thereto which are 
included elsewhere in this Form 10-K. The Consolidated Statements of Operations Data for the years ended December 31, 
2018, 2017 and 2016 and the Consolidated Balance Sheets Data as of December 31, 2018 and 2017 are derived from the 
audited Consolidated Financial Statements included elsewhere in this Form 10-K. The Consolidated Statements of 
Operations Data for the years ended December 31, 2015 and 2014 and the Consolidated Balance Sheets Data as of 
December 31, 2016, 2015 and 2014 are derived from audited Consolidated Financial Statements that are not included in this 
Form 10-K. Historical results are not necessarily indicative of results to be anticipated in the future.

2018

Year Ended December 31,
2016
(In thousands, except per share data)

2015

2017

2014

Consolidated Statements of Operations Data:
Product revenue, net .......................................................... $
Other revenue ....................................................................  
Total revenues ...................................................................  
Operating expenses:

6,812    $
1,386   
8,198   

-    $

-    $

-    $

327   
327   

11,043   
11,043   

4,050   
4,050   

- 
11,032 
11,032 

Cost of sales - product ...............................................  
Cost of sales - amortization of intangible assets .......  
Research and development........................................  
Selling, general and administrative ...........................  
Restructuring .............................................................  
Unoccupied facility expense .....................................  

10,934   
10,862   
74,951   
64,770   
-   
-   
Total operating expenses ...................................................   161,517   
Loss from operations .........................................................   (153,319)  
Other income (expense):

-   
1,194   
64,988   
27,367   
2,783   
-   
96,332   
(96,005)  

-   
-   
84,493   
37,257   
-   
-   
  121,750   
  (110,707)  

-   
-   
86,943   
22,180   
-   
-   
  109,123   
  (105,073)  

- 
- 
84,580 
17,377 
- 
386 
  102,343 
(91,311)

Interest income ..........................................................  
Interest expense .........................................................  
Other (expense) income, net......................................  
Loss on extinguishment of debt ................................  

191 
(35)
433 
- 
Net loss ..............................................................................$ (158,899)   $ (95,154)   $ (112,444)   $ (106,794)   $ (90,722)
Basic and diluted net loss per share................................... $
(3.45)
Shares used to compute basic and diluted net loss per 
share................................................................................... 

755   
-   
(2,492)  
-   

205   
(572)  
317   
(1,671)  

3,828   
(9,338)  
(70)  
-   

1,337   
-   
(486)  
-   

(3.25)   $

(2.92)   $

(1.81)   $

(2.55)   $

38,506   

32,881   

62,362   

52,613   

26,289  

2018

2017

December 31,
2016
(In thousands)

2015

2014

Consolidated Balance Sheets Data:
81,415    $ 196,125    $ 122,652 
145,536    $ 191,854    $
Cash, cash equivalents and marketable securities .............$
136,331      179,430     
69,563      171,161      107,158 
Working capital ................................................................. 
210,884      218,785      109,680      216,633      138,290 
Total assets ........................................................................ 
Long-term debt .................................................................. 
9,559 
100,871     
Accumulated deficit...........................................................  (1,066,224)     (907,325)     (812,171)     (699,727)     (592,933)
89,201      187,079      100,482  
Total stockholders’ equity ................................................. 

63,065      199,549     

-     

-     

-     

39

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
    
 
    
 
    
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
       
       
       
       
 
ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS 
OF OPERATIONS 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains 
forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from 
those indicated by forward-looking statements as a result of various factors, including but not limited to, the period for which 
we estimate our cash resources are sufficient, the availability of additional funds, as well as those set forth under “Risk 
Factors” and those that may be identified from time to time in our reports and registration statements filed with the 
Securities and Exchange Commission. 

The following discussion and analysis is intended to provide an investor with a narrative of our financial results and 
an evaluation of our financial condition and results of operations. The discussion should be read in conjunction with “Item 
6—Selected Financial Data” and the Consolidated Financial Statements and the related notes thereto set forth in “Item 8—
Financial Statements and Supplementary Data.” 

Overview

We are a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and 

adaptive immune responses through toll-like receptor (“TLR”) stimulation. 

Our first commercial product, HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved by the 

United States Food and Drug Administration (“FDA”) for prevention of infection caused by all known subtypes of hepatitis 
B virus in adults age 18 years and older. We commenced commercial shipments of HEPLISAV-B in January 2018. 

Our development efforts are primarily focused on stimulating the innate immune response to treat cancer in 

combination with other immunomodulatory agents.

Our lead investigational immuno-oncology product is SD-101. SD-101 is currently being evaluated in Phase 2 clinical 

studies in melanoma, head and neck squamous cell carcinoma and neoadjuvant treatment of breast cancer. We are conducting 
a research and clinical program intended to assess potential efficacy of SD-101 in a range of tumors and in combination with 
a range of treatments, including checkpoint inhibitors and other therapies.  

Our second immuno-oncology product candidate is DV281, a novel investigational TLR9 agonist designed specifically 

for focused delivery to primary lung tumors and lung metastases as an inhaled aerosol. In October 2017, we announced 
initiation of dosing in a Phase 1b study of inhaled DV281, in combination with anti-PD-1 therapy, in patients with non-small 
cell lung cancer.

Product revenue is dependent on our ability to successfully market HEPLISAV-B and our product candidates, if they 

are approved. Prior to 2018, our revenues consisted of amounts earned from collaborations, grants and fees from services and 
licenses.

We expect to incur significant expenses and operating losses for the foreseeable future as we continue to invest in 
commercialization of HEPLISAV-B, including investment in HEPLISAV-B inventory, clinical trials and other development, 
manufacturing and regulatory activities for our immuno-oncology product candidates, discovery research and development 
and tenant improvements and ongoing occupancy costs at our new corporate headquarters. Until we can generate a sufficient 
amount of revenue from product sales, we will need to finance our operations through strategic alliance and licensing 
arrangements and/or future public or private debt and equity financings. Adequate financing may not be available to us on 
acceptable terms, or at all. If adequate funds are not available when needed, we may need to delay, reduce the scope of or put 
on hold one or more programs while we seek strategic alternatives, which could have an adverse impact on our ability to 
achieve our intended business objectives. 

40

Critical Accounting Policies and the Use of Estimates 

The accompanying discussion and analysis of our financial condition and results of operations are based upon our 

consolidated financial statements and the related disclosures, which have been prepared in accordance with U.S. generally 
accepted accounting principles. The preparation of these financial statements requires us to make estimates, assumptions and 
judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
balance sheet dates and the reported amounts of revenues and expenses for the periods presented. On an ongoing basis, we 
evaluate our estimates, assumptions and judgments described below that have the greatest potential impact on our 
consolidated financial statements, including those related to revenue recognition, research and development activities, stock-
based compensation and inventories. We base our estimates on historical experience and on various other assumptions that 
we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the 
carrying values of assets and liabilities that are not readily apparent from other sources. Accounting assumptions and 
estimates are inherently uncertain and actual results may differ materially from these estimates under different assumptions or 
conditions.

While our significant accounting policies are more fully described in Note 2 to the Consolidated Financial Statements, 

we believe the following accounting policies reflect the more critical and significant judgments and estimates used in the 
preparation of our consolidated financial statements.

Revenue Recognition 

On January 1, 2018, we adopted Accounting Standards Codification, (“ASC”) 606, Revenue from Contracts with 

Customers. Adoption of this ASC did not have a material impact on our consolidated financial statements.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an 

amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To 
determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity 
performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the 
contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; 
and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to 
contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we 
transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess 
the goods or services promised within each contract and determine those that are performance obligations, and assess whether 
each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated 
to the respective performance obligation when (or as) the performance obligation is satisfied. 

Product Revenue, Net

We sell our product to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our 
“Customers”). Revenues from product sales are recognized when we have satisfied our performance obligation, which is the 
transfer of control of our product upon delivery to the Customer. The timing between the recognition of revenue for product 
sales and the receipt of payment is not significant. Because our standard credit terms are short-term and we expect to receive 
payment in less than one-year, there is no financing component on the related receivables. Taxes collected from Customers 
relating to product sales and remitted to governmental authorities are excluded from revenues. 

Overall, product revenue, net, reflects our best estimates of the amount of consideration to which we are entitled based 
on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is 
probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If 
our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period 
of adjustment.

41

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration such 

as product returns, chargebacks, discounts, rebates and other fees that are offered within contracts between us and our 
Customers, healthcare providers, and others relating to our product sales. We estimate variable consideration using either the 
most likely amount method or the expected value method, depending on the type of variable consideration and what method 
better predicts the amount of consideration we expect to receive. We take into consideration relevant factors such as industry 
data, current contractual terms, available information about Customers’ inventory, resale and chargeback data and forecasted 
customer buying and payment patterns, in estimating each variable consideration. The variable consideration is recorded at 
the time product sales is recognized, resulting in a reduction in product revenue and a reduction in accounts receivable (if the 
Customer offsets the amount against its accounts receivable) or as an accrued liability (if we pay the amount through our 
accounts payable process). Variable consideration requires significant estimates, judgment and information obtained from 
external sources. The amount of variable consideration is included in the net sales price only to the extent that it is probable 
that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our 
estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of 
adjustment. If we were to change any of these judgments or estimates, it could cause a material increase or decrease in the 
amount of revenue that we report in a particular period.

Product Returns: Consistent with industry practice, we offer our Customers a limited right of return based on the 
product’s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may 
be returned by our Customers and record this estimate as a reduction of revenue in the period the related product revenue is 
recognized. We consider several factors in the estimation of potential product returns including expiration dates of the 
product shipped, the limited product return rights, available information about Customers’ inventory, shelf life of the product 
and other relevant factors. 

Chargebacks: Our Customers subsequently resell our product to healthcare providers. In addition to distribution 
agreements with Customers, we enter into arrangements with healthcare providers that provide for chargebacks and discounts 
with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual 
commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to Customers who 
directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the 
ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related 
revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are 
determined at the time of resale to the qualified healthcare provider by Customers, and we issue credits for such amounts 
generally within a few weeks of the Customer’s notification to us of the resale. Reserves for chargebacks consists of credits 
that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect 
will be sold to qualified healthcare providers, and chargebacks for units that our Customers have sold to healthcare providers, 
but for which credits have not been issued.

Trade Discounts and Allowances: We provide our Customers with discounts which include early payment incentives 

that are explicitly stated in our contracts, and are recorded as a reduction of revenue in the period the related product revenue 
is recognized. 

Distribution Fees: Distribution fees include fees paid to certain Customers for sales order management, data and 

distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is 
recognized.

Collaboration Revenue

We enter into collaborative arrangements with other companies. Such arrangements may include promises to customers 

which, if capable of being distinct, are accounted for as separate performance obligations. For agreements with multiple 
performance obligations, we allocate estimated revenue to each performance obligation at contract inception based on the 
estimated transaction price of each performance obligation. Revenue allocated to each performance obligation is then 
recognized when we satisfy the performance obligation by transferring control of the promised good or service to the 
customer.

Research and Development Expenses and Accruals

Research and development expenses include personnel and facility-related expenses, outside contracted services 
including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and 
non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts 
with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and 
payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements 
are capitalized and expensed as the related goods are delivered or services are performed.

42

Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts 

with clinical trial centers and clinical research organizations. We estimate our research and development expenses and the 
related accrual as of each balance sheet date based on the facts and circumstances known to us at that time. If we were to 
change any of these judgments or estimates, it could cause a material increase or decrease in the amount of research and 
development expenses that we report in a particular period.

Stock-Based Compensation 

Stock-based compensation expense for restricted stock units and stock options is estimated at the grant date based on 

the award’s estimated fair value and is recognized on a straight-line basis over the award’s requisite service period, assuming 
estimated forfeiture rates. Fair value of restricted stock units is determined at the date of grant using our closing stock price. 
Our determination of the fair value of stock options on the date of grant using an option-pricing model is affected by our 
stock price, as well as assumptions regarding a number of subjective variables. We selected the Black-Scholes option pricing 
model as the most appropriate method for determining the estimated fair value of our stock options. The Black-Scholes 
model requires the use of subjective assumptions which determine the fair value of stock options. These assumptions include, 
but are not limited to, our expected stock price volatility over the term of the awards, and projected employee stock option 
exercise behaviors. In the future, as additional empirical evidence regarding these input estimates becomes available, we may 
change or refine our approach of deriving these input estimates. These changes could impact our fair value of stock options 
granted in the future. Changes in the fair value of stock awards could materially impact our operating results. 

Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our 

stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby 
increasing stock-based compensation cost recognized in future periods. We derive the expected term assumption primarily 
based on our historical settlement experience, while giving consideration to options that have not yet completed a full life 
cycle. Stock-based compensation cost is recognized only for awards ultimately expected to vest. Our estimate of the 
forfeiture rate is based primarily on our historical experience. To the extent we revise this estimate in the future, our share-
based compensation cost could be materially impacted in the period of revision.

Inventories

Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. Our 

assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, 
including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple 
factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our 
assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or 
estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular 
period. During 2018, we recorded $1.0 million in inventory reserves, which is included in cost of sales – product.    

We primarily use actual costs to determine our cost basis for inventories. We consider regulatory approval of product 

candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval 
is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized 
as inventory but are expensed as research and development costs. We begin capitalization of these inventory related costs 
once regulatory approval is obtained. 

HEPLISAV-B was approved by the FDA on November 9, 2017, at which time we began to capitalize inventory costs 

associated with HEPLISAV-B. In March 2018, we received regulatory approval of the pre-filled syringe (“PFS”) 
presentation of HEPLISAV-B. Prior to FDA approval of HEPLISAV-B, all costs related to the manufacturing of 
HEPLISAV-B that could potentially be available to support the commercial launch of our products, were charged to research 
and development expense in the period incurred as there was no alternative future use. Prior to regulatory approval of PFS, 
costs associated with resuming operating activities at the Düsseldorf manufacturing facility were also included in research 
and development expense. Subsequent to regulatory approval of PFS, costs associated with operating activities at the 
Düsseldorf facility were included in cost of sales – product, until commercial production resumed in mid-2018 at which time 
these costs were recorded as raw materials inventory.

43

Recent Accounting Pronouncements 

Accounting Standards Update 2016-02

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 

No. 2016-02, Leases (Topic 842) which requires a lessee to recognize a right-of-use asset and corresponding lease liability, 
measured at the present value of the lease payments, for all leases with a lease term greater than 12 months. In July 2018, the 
FASB issued ASU 2018-11, Targeted Improvements, which gives the option to apply the transition provisions of ASU 2016-
02 at its adoption date instead of at the earliest comparative period presented in its financial statements.  Also in July 2018, 
the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, which clarifies certain aspects of ASU 
2016-02. We will adopt ASU 2016-02 on a modified retrospective basis on its adoption date of January 1, 2019 and elect the 
available practical expedients upon transition. We will elect the transition method that allows for the application of the 
standard at the adoption date rather than at the beginning of the earliest comparative period presented in the financial 
statements. The new standard will have a material impact on our consolidated balance sheets, but will not have an impact on 
our consolidated statement of operations.  Based on our preliminary analysis, the most significant impact will be the 
recognition of right-of-use asset and lease liabilities for operating leases ranging approximately from $34 million to $40 
million on January 1, 2019. The amount of right-of-use asset and lease liabilities primarily relates to the corporate 
headquarters operating lease entered into in September 2018.

Results of Operations 

Revenues 

Recognition of product sales as a result of commercial shipments of HEPLISAV-B commenced in January 2018. Prior 

to 2018, revenues consisted of amounts earned from collaborations, grants and fees from services and licenses and royalty 
payments. Service and license fees include revenues related to research and development and contract manufacturing services, 
license fees and royalty payments.

The following is a summary of our revenues (in thousands, except for percentages):

Year Ended December 31,
2017

2016

2018

6,812    $
1,386     
-     
-     
8,198    $

-    $
-     
295     
32     

-   
9,778   
381   
884   
327    $ 11,043   

$

$

Revenues:
Product revenue, net................ $
Collaboration revenue .............  
Grant revenue ..........................  
Service and license revenue ....  
Total revenues ......................... $

NM = Not meaningful

2018 versus 2017

Increase
(Decrease) from
2017 to 2018
    %

$
6,812   
1,386   
(295)  
(32)  
7,871   

Increase

(Decrease) from  

2016 to 2017
$

-     

(9,778)  

NM   $
NM  
NM  
NM  
NM   $ (10,716)  

(86)    
(852)    

  %  
- 
NM 
(23)%
(96)%
NM  

Product revenue, net, reflects sales of HEPLISAV-B. We commenced commercial shipments of HEPLISAV-B in 
January 2018 and deployed our field sales force in February 2018. During 2018, quarterly product revenue, net was $0.2 
million, $1.3 million, $1.5 million and $3.9 million for the three-month periods ended March 31, June 30, September 30 and 
December 31, 2018, respectively. Initial efforts during 2018 focused on ensuring market access to enable healthcare 
providers to purchase HEPLISAV-B including obtaining payor coverage and securing contracts with distributors, group 
purchasing organizations, physician buying groups and federal government entities. Sales efforts were focused on advancing 
HEPLISAV-B through the complex approval and procurement processes in large institutional accounts across the country. 
Based on progress in obtaining approvals during 2018 by several key accounts to make HEPLISAV-B available in their 
networks and our experience with the protracted time required for implementation and procurement by customers, we expect 
quarterly sales will increase during 2019 as healthcare providers complete their reviews and operational activities required to 
switch to the new 2-dose regimen provided by HEPLISAV-B and existing customers repeat orders. Collaboration revenue 
relates to services performed in 2018 under a collaboration agreement with Serum Institute of India Pvt. Ltd. There was no 
grant revenue in 2018 as the contract with the National Institutes of Health terminated.

Revenue from product sales is recorded at the net sales price which includes estimates of product returns, chargebacks, 
discounts, rebates and other fees. Overall, product revenue, net, reflects our best estimates of the amount of consideration to 
which we are entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ 

44

 
   
       
       
   
 
 
 
   
       
       
   
 
 
   
 
 
   
   
   
 
 
 
 
 
 
 
 
from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect 
net product revenue and earnings in the period such variances become known.

2017 versus 2016

No collaboration revenue was recognized in 2017 as all performance obligations under the AstraZeneca agreement 
were completed in 2016. Service and license revenue decreased in 2017 as no manufacturing services were performed on 
behalf of third parties in 2017. 

Cost of Sales - Product

Cost of sales - product reflects costs of $10.9 million for year ended December 31, 2018. Included in cost of sales - 

product are inventory reserves and certain formulation, fill, finish and overhead costs for HEPLISAV-B incurred after FDA 
approval. Cost of sales-product also includes costs at our manufacturing facility in Düsseldorf which were previously 
included in research and development expense. These charges are a result of costs incurred in 2018 associated with resuming 
operating activities at the Düsseldorf manufacturing facility after receiving regulatory approval of pre-filled syringes (“PFS”) 
of HEPLISAV-B in late March 2018. 

Prior to FDA approval of HEPLISAV-B vials, all costs related to the manufacturing of HEPLISAV-B, that could 
potentially be available to support the commercial launch of our products, were charged to research and development expense 
in the period incurred as there was no alternative future use. Our HEPLISAV-B PFS inventory also includes raw materials 
costs that were previously expensed to research and development prior to its FDA approval. We expect to use this 
HEPLISAV-B PFS inventory over approximately the next twelve months. 

Excluding the costs associated with resuming operating activities in Düsseldorf, we expect our cost of sales of 

HEPLISAV-B to increase as a percentage of net sales in future periods as we produce and then sell inventory that reflects the 
full cost of manufacturing the product. At December 31, 2018 and 2017, inventories, net were $19.0 million and $0.3 million, 
respectively.

Cost of Sales - Amortization of Intangible Assets

Cost of sales - amortization of intangible assets of $10.9 million and $1.2 million for the year ended December 31, 
2018 and 2017, respectively, consists of amortization of the intangible asset recorded as a result of a regulatory milestone and 
sublicense fees to Coley Pharmaceutical Group, Inc. (“Coley”), Merck, Sharpe & Dohme Corp. (“Merck”) and 
GlaxoSmithKline Biologicals SA (“GSK”), upon or after FDA approval of HEPLISAV-B in November 2017. At December 
31, 2018, the intangible assets related to Coley and GSK have been fully-amortized and the intangible asset related to Merck 
of $11.7 million has an estimated remaining useful life through the patent expiration date in April 2020.

Research and Development 

Research and development expense consists, primarily, of compensation and related personnel costs (which include 

benefits, recruitment, travel and supply costs), outside services, allocated facility costs and non-cash stock-based 
compensation. Outside services consist of costs associated with clinical development, preclinical discovery and development, 
regulatory filings and research, including fees and expenses incurred by contract research organizations, clinical study sites, 
and other service providers and costs of manufacturing product candidates prior to approval.  Prior to FDA approval, we 
recorded costs of acquiring, developing and manufacturing HEPLISAV-B as research and development expense.  

The following is a summary of our research and development expense (in thousands, except for percentages):

Year Ended December 31,
2018     2017     2016    

Research and Development:
Compensation and related personnel 
costs....................................................$ 30,466    $ 28,577    $ 34,333   
Outside services..................................  28,213      20,112      32,540   
8,472      10,878   
Facility costs....................................... 
Non-cash stock-based compensation . 
6,742   
7,827     
Total research and development.........$ 74,951    $ 64,988    $ 84,493   

6,668     
9,604     

45

Increase
(Decrease) from  
2017 to 2018
$

    %  

Increase
(Decrease) from  
2016 to 2017
$

    %  

$ 1,889     
$ 8,101     
$ (1,804)   
$ 1,777     
$ 9,963     

7%  
40%  
(21)% 
23%  
15%  

$ (5,756)   
  (12,428)   
(2,406)   
1,085     
$(19,505)   

(17)%
(38)%
(22)%
16%
(23)%

 
 
 
 
    
 
    
 
 
 
 
 
 
 
 
 
    
 
    
 
 
 
 
 
   
 
 
 
 
 
 
2018 versus 2017

Compensation and related personnel costs and non-cash stock-based compensation increased due to an overall increase 

in headcount to support the ongoing development of SD-101, DV281 and earlier stage oncology programs. Outside services 
increased, primarily, due to the ongoing development of SD-101. 

For the year ended December 31, 2018 and as a result of the regulatory approval of PFS of HEPLISAV-B in late March 

2018, costs incurred at our Düsseldorf facility to resume operating activities were charged to cost of sales – product, while 
costs incurred to manufacture HEPLISAV-B for commercial sale were accounted for as inventory. For the comparative prior 
year periods, facility costs, which include an overhead allocation of occupancy and related expenses, included full operating 
costs of our Düsseldorf facility. 

2017 versus 2016

Compensation and related personnel costs decreased due to implementation of organizational restructuring and cost 

reduction plans in January 2017. Outside services expense decreased primarily due to a reduction of costs related to 
HEPLISAV-B clinical trials and manufacturing activities partially offset by increased costs relating to seeking regulatory 
approval for HEPLISAV-B and the ongoing development of SD-101, DV281 and earlier stage oncology programs. Non-cash 
stock-based compensation increased due to recognition of expense related to share-based awards granted to employees in 
2017 and prior years. Facility costs, which includes an overhead allocation primarily comprised of occupancy and related 
expenses, decreased due to overall lower facility and related costs and a decrease in headcount.

We expect research and development spending to increase in 2019 in connection with the discovery, development and 

manufacturing of our product candidates, particularly SD-101 and DV281.

Selling, General and Administrative 

Selling, general and administrative expense consists primarily of compensation and related costs for our commercial 
support personnel, medical education professionals and personnel in executive and other administrative functions including 
legal, finance and information technology; costs for outside services such as costs for sales and marketing, post-marketing 
studies of HEPLISAV-B, accounting, commercial development, consulting, business development, investor relations and 
insurance; legal costs that include corporate and patent-related expenses; allocated facility costs and non-cash stock-based 
compensation.

The following is a summary of our selling, general and administrative expenses (in thousands, except for percentages):

Year Ended December 31,

Selling, General and Administrative: 2018     2017     2016    
Compensation and related personnel 
costs ......................................................$ 15,993    $ 8,685    $ 11,814   
Outside services ....................................  31,758     
7,611      14,400   
Legal costs ............................................ 
2,458   
2,777     
2,792     
Facility costs ......................................... 
1,201   
1,204     
2,466     
Non-cash stock-based compensation....  11,761     
7,384   
7,090     
Total selling, general and 
administrative ....................................... $ 64,770    $ 27,367    $ 37,257   

Increase
(Decrease) from  
2017 to 2018
$

    %  

Increase
(Decrease) from  
2016 to 2017
$

    %  

$ 7,308     
  24,147     
15     
1,262     
4,671     

84% 
317% 
1% 
105% 
66% 

$ (3,129)   
(6,789)   
319     
3     
(294)   

(26)%
(47)%
13%
0%
(4)%

$ 37,403     

137% 

$ (9,890)   

(27)%

46

 
 
   
       
       
   
 
 
 
 
   
       
       
   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
2018 versus 2017

Compensation and related personnel costs and non-cash stock-based compensation increased, primarily, due to an 
increase in employee headcount to support HEPLISAV-B commercial activities. Outside services increased due to an overall 
increase in HEPLISAV-B sales, marketing and commercial activities, including full-deployment of a contract sales force, 
post-marketing studies and consultants for commercial development services. We currently expect to convert from a contract 
sales force to a sales organization directly employed by us during the second quarter of 2019 and expect the conversion to be 
approximately cash neutral, with compensation and benefits increasing and a corresponding decrease in outside services 
related to those activities. Facility costs, which include an overhead allocation and is primarily comprised of occupancy and 
related expenses, increased due to overall higher facility-related costs and an increase in headcount and costs associated with 
the new corporate headquarters we expect to occupy in the second quarter of 2019.

2017 versus 2016

Compensation and related personnel costs and non-cash stock-based compensation decreased due to implementation of 

organizational restructuring and cost reduction plans in January 2017. Outside services decreased as 2016 included costs 
related to hiring of consultants for administrative and commercial development services for the anticipated commercial 
launch of HEPLISAV-B.

We expect selling, general and administrative spending to increase in 2019 as we continue to support our commercial 

activities and incur costs related to the occupancy of the new corporate headquarters.

Restructuring

In January 2017, we implemented organizational restructuring and cost reduction plans to align around our immuno-
oncology business while allowing us to advance HEPLISAV-B through the FDA review and approval process. To achieve 
these cost reductions, we suspended manufacturing activities, commercial preparations and other long term investment 
related to HEPLISAV-B and reduced our global workforce by approximately 40 percent. In the first quarter of 2017 we 
recorded charges of $2.8 million related to severance, other termination benefits and outplacement services. All of the $2.8 
million was paid in 2017.

Interest Income, Interest Expense and Other Expense, Net

Interest income is reported net of amortization of premiums and discounts on marketable securities and realized gains 
and losses on investments. Interest expense for the year ended December 31, 2018 includes the stated interest and accretion 
of discount and end of term fee related to our long-term debt agreement entered into in February 2018. Other expense, net 
includes gains and losses on foreign currency transactions and disposal of property and equipment. In addition, other 
expense, net for the year ended December 31, 2016 includes expenses related to an unutilized note purchase agreement which 
was terminated in December 2016.

The following is a summary of our interest income, interest expense and other expense, net (in thousands, except for 

percentages):

Year Ended December 31,
2017

2016

2018

Interest income ..............$
Interest expense .............$
Other expense, net .........$

3,828    $
(9,338)  $
(70)  $

1,337    $
-    $
(486)  $

755   
-   
(2,492) 

$
$
$

NM = Not meaningful 

2018 versus 2017

Increase

(Decrease) from  

    %  

2017 to 2018
$
2,491     
9,338   
(416)   

Increase

(Decrease) from  

2016 to 2017
$

    %  

186%  
NM 
(86)% 

$
$
$

582     
-   

(2,006)   

77%

NM 
(80)%

Interest income increased primarily due to a higher yield and higher average investment balance. We began incurring 

interest expense for the $100.0 million we borrowed on February 20, 2018 under a term loan agreement with CRG Servicing 
LLC. The change in other expense, net is primarily due to foreign currency transactions resulting from fluctuations in the 
value of the Euro compared to the U.S. dollar.

47

 
   
       
       
   
 
 
 
 
   
       
       
   
 
 
   
 
 
 
 
   
   
   
 
 
2017 versus 2016

Interest income increased due to a higher average rate of return on our investments and a higher average investment 

balance.  The change in other expense, net is primarily due to foreign currency transactions resulting from fluctuations in the 
value of the Euro compared to the U.S. dollar.

Other expense, net included expense of $5.0 million related to the settlement of securities litigation and the settlement 

of derivative complaints initiated in 2013. This expense was offset by $5.0 million in other income as the settlements were 
paid for by our insurers. For more information about our settlements, see Note 9, Commitments and Contingencies, in our 
Notes to Consolidated Financial Statements.

Liquidity and Capital Resources

As of December 31, 2018, we had $145.5 million in cash, cash equivalents and marketable securities. Since our 
inception, we have relied primarily on the proceeds from public and private sales of our equity securities, borrowings, 
government grants and revenues from collaboration agreements to fund our operations. Our funds are currently invested in 
money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We currently 
anticipate that our cash, cash equivalents and short-term marketable securities, together with the amounts remaining under 
our credit facility and anticipated revenues from HEPLISAV-B will be sufficient to fund our operations for at least the next 
12 months.

We have borrowed $100.0 million under a $175.0 million term loan agreement (“Loan Agreement”) with CRG 
Servicing LLC. Subject to our continuing satisfaction of certain market capitalization and other borrowing conditions, we 
plan to borrow the remaining $75.0 million under the Loan Agreement in the first quarter of 2019. The loans have a maturity 
date of December 31, 2023, unless prepaid earlier.

At December 31, 2018, $132.8 million of common stock remained available for sale under our At Market Sales 
Agreement with Cowen and Company, LLC (“ATM Agreement”). Subsequent to December 31, 2018 and through February 
22, 2019, we sold 1,078,901 shares of common stock for net proceeds of $11.5 million under the 2017 ATM Agreement.

We expect to incur significant expenses and operating losses for the foreseeable future as we continue to invest in 
commercialization of HEPLISAV-B, including investment in HEPLISAV-B inventory, clinical trials and other development, 
manufacturing and regulatory activities for our immuno-oncology product candidates, discovery research and development 
and tenant improvements and ongoing occupancy costs at our new corporate headquarters. Until we can generate a sufficient 
amount of revenue from product sales, we will need to finance our operations through strategic alliance and licensing 
arrangements and/or future public or private debt and equity financings. Adequate financing may not be available to us on 
acceptable terms, or at all. If adequate funds are not available when needed, we may need to delay, reduce the scope of or put 
on hold one or more programs while we seek strategic alternatives, which could have an adverse impact on our ability to 
achieve our intended business objectives. 

Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a 
number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number 
of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise 
such additional capital at a price or on terms that are favorable to us. Raising additional funds through the issuance of equity 
or debt securities could result in dilution to our existing stockholders, increased fixed payment obligations, or both. In 
addition, these securities may have rights senior to those of our common stock and could include covenants that would 
restrict our operations.

2018 versus 2017

During the year ended December 31, 2018, we used $131.3 million of cash for our operations primarily due to our net 
loss of $158.9 million, of which $39.3 million consisted of non-cash charges such as stock-based compensation, depreciation 
and amortization, amortization of intangible assets and accretion and amortization on marketable securities. During the year 
ended December 31, 2017, we used $77.5 million of cash for our operations primarily due to a net loss of $95.2 million, of 
which $18.9 million consisted of non-cash charges such as stock-based compensation, depreciation and amortization, 
amortization of intangible assets and accretion and amortization on marketable securities. Cash used in our operations during 
2018 increased by $53.8 million. Net cash used in operating activities is impacted by changes in our operating assets, and 
liabilities due to timing of cash receipts and expenditures.

During the year ended December 31, 2018, cash provided by investing activities was $55.5 million compared to $108.7 

million of cash used in investing activities for the year ended December 31, 2017. Cash provided by investing activities 

48

during the year ended December 31, 2018 included $70.7 million of net proceeds from maturities of marketable securities 
compared to $108.0 million of net purchases of marketable securities during 2017. During the year ended December 31, 2018, 
we paid $11.0 million of milestone and sublicense payments to Coley, Merck and GSK. Net cash used in the purchases of 
property plant and equipment increased by $3.5 million from 2017 to 2018. The increase is, primarily, due to the installation 
of facility improvements and purchases of laboratory equipment at our corporate headquarters and purchases of 
manufacturing equipment for our facility in Düsseldorf.

During the year ended December 31, 2018 and 2017, net cash provided by financing activities was $99.1 million and 

$187.8 million, respectively. During the year ended December 31, 2018, we received net cash proceeds of $99.0 million from 
the Loan Agreement. During the year ended December 31, 2017, we received net cash proceeds of $105.1 million from 
issuance of common stock under our ATM Agreements and $80.8 million in net proceeds from issuance of our common 
stock from our August 2017 underwritten public offering. We received net proceeds of $0.1 million and $1.9 million from 
exercises of options as well as employee purchases of our common stock under the 2014 Employee Stock Purchase Plan 
during the year ended December 31, 2018 and 2017, respectively.

2017 versus 2016

During the year ended December 31, 2017, we used $77.5 million of cash for our operations primarily due to our net 
loss of $95.2 million, of which $18.9 million consisted of non-cash charges such as stock-based compensation, depreciation 
and amortization, amortization of intangible assets and accretion and amortization on marketable securities. During the year 
ended December 31, 2016, we used $107.1 million of cash for our operations primarily due to a net loss of $112.4 million, of 
which $18.1 million consisted of non-cash charges such as stock-based compensation, depreciation and amortization, write-
off of assets in progress and accretion and amortization on marketable securities. Cash used in our operations during 2017 
decreased by $29.5 million. Net cash used in operating activities is impacted by changes in our operating assets and liabilities 
due to timing of cash receipts and expenditures.

During the year ended December 31, 2017, cash used in investing activities was $108.7 million compared to $86.2 
million of cash provided by investing activities for the year ended December 31, 2016. Cash used in investing activities 
during the year ended December 31, 2017 included $108.0 million of net purchases of marketable securities compared with 
$94.0 million of net proceeds from maturities of marketable securities during 2016. Net cash used in the purchases of 
equipment decreased by $7.1 million from 2016 to 2017 primarily due to upgrades made to our manufacturing facility during 
2016.

During the year ended December 31, 2017 and 2016, cash provided by financing activities was $187.8 million and $0.5 

million, respectively. During the year ended December 31, 2017, we received net cash proceeds of $105.1 million from 
issuance of common stock under our ATM Agreements and $80.8 million in net proceeds from issuance of our common 
stock from our August 2017 underwritten public offering. We received proceeds of $1.9 million and $0.5 million from 
exercises of options as well as employee purchases of our common stock under the 2014 Employee Stock Purchase Plan 
during the year ended December 31, 2017 and 2016, respectively.

Contractual Obligations 

The following summarizes our significant contractual obligations at December 31, 2018 and the effect those 

obligations are expected to have on our liquidity and cash flows in future periods (in thousands):  

Contractual Obligations:
Operating leases.............................................................  $
Long-term debt obligation............................................. 
Purchase commitments.................................................. 
Sublicense agreement .................................................... 
Total contractual obligations .........................................  $ 194,273    $ 22,378    $

4,839    $
-   
10,539   
7,000   

  104,808   
10,539   
14,000   

64,926    $

Total

2019

2020-
2021

2022-
2023

10,400    $ 10,164    $

  104,808   
-   

-   
-   
7,000   
17,400    $ 114,972    $

2024 and 
Thereafter 
39,523 
- 
- 
- 
39,523  

We lease our facility in Berkeley, California (“Berkeley Lease”). On September 17, 2018, we entered into an 
Office/Laboratory Lease (“Lease”), for an aggregate of 75,662 square feet of office and laboratory space located at 5959 
Horton Street, Emeryville, California. We are obligated to make lease payments totaling $61.2 million over the Lease term. 
We are also obligated to pay for operating expenses and taxes. In connection with our execution of the Lease, we entered into 
a Lease Termination Agreement to terminate the Berkeley Lease effective as of the date we vacate the Berkeley premises. 

49

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
See Note 9 in the accompanying Notes to the Condensed Consolidated Financial Statements for a description of the Lease 
and Lease Termination Agreement.  

During 2004, we established a letter of credit with Silicon Valley Bank as security for the Berkeley Lease in the 

amount of $0.4 million. The letter of credit remained outstanding as of December 31, 2018 and is collateralized by a 
certificate of deposit for $0.4 million which has been included in restricted cash in the consolidated balance sheets as of 
December 31, 2018 and 2017. Under the terms of the Berkeley Lease, if the total amount of our cash, cash equivalents and 
marketable securities falls below $20 million for a period of more than 30 consecutive days during the lease term, the amount 
of the required security deposit will increase to $1.1 million until such time as our projected cash and cash equivalents will 
exceed $20 million for the remainder of the lease term, or until our actual cash and cash equivalents remains above $20 
million for a period of 12 consecutive months. 

We also lease our facility in Düsseldorf, Germany (“Düsseldorf Lease”) under an operating lease that expires in March 

2023. During 2004, we also established a letter of credit with Deutsche Bank as security for our Düsseldorf Lease in the 
amount of 0.2 million Euros. The letter of credit remained outstanding through December 31, 2018 and is collateralized by a 
certificate of deposit for 0.2 million Euros which has been included in restricted cash in the consolidated balance sheets as of 
December 31, 2018 and 2017.

In February 2018, we entered into a $175.0 million term loan agreement. Principal amount due under the term loan 

agreement at December 31, 2018 is $101.8 million payable at maturity on December 31, 2023, unless prepaid earlier. 

In February 2018, we entered into a sublicense agreement with Merck, Sharpe & Dohme Corp. Under the agreement, 
we paid the second installment of $7 million in February 2019 and we are required to pay the third installment of $7 million 
in February 2020. 

We have entered into material purchase commitments with commercial manufacturers for the supply of HEPLISAV-B 

and SD-101. To the extent these commitments are non-cancelable, they are reflected in the above table.

In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that 

obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the 
normal course of operations, we have entered into license and other agreements and intend to continue to seek additional 
rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. 
Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of 
products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future 
events that cannot reasonably be estimated.

We also rely on and have entered into agreements with research institutions, contract research organizations and 
clinical investigators as well as clinical material manufacturers. These agreements are terminable by us upon written notice. 
Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through 
the notice period.

In conjunction with a financing arrangement with Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC 
(“Holdings”) in November 2009, we agreed to make contingent cash payments to Holdings equal to 50% of the first $50 
million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any 
third party with respect to the development and/or commercialization of cancer and hepatitis C therapies originally licensed 
to Symphony Dynamo, Inc., including SD-101. We have made no payments and have not recorded a liability as of December 
31, 2018.

Off-balance Sheet Arrangements 

We do not have any off-balance sheet arrangements as defined by rules enacted by the SEC and accordingly, no such 

arrangements are likely to have a current or future effect on our financial position. 

50

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 

Quantitative and Qualitative Disclosure about Market Risk 

Interest Rate Risk 

We are subject to interest rate risk. Our investment portfolio is maintained in accordance with our investment policy, 

which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. 
The primary objective of our investment activities is to preserve principal and, secondarily, to maximize income we receive 
from our investments without significantly increasing risk. Some of the securities that we invest in may have market risk. 
This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To 
minimize this risk, we maintain our portfolio of cash equivalents and investments in short-term money market funds, U.S. 
government agency securities, U.S. Treasuries and corporate debt securities. We do not invest in auction rate securities or 
securities collateralized by home mortgages, mortgage bank debt or home equity loans. We do not have derivative financial 
instruments in our investment portfolio. To assess our risk, we calculate that if interest rates were to rise or fall from current 
levels by 100 basis points or by 125 basis points, the pro forma change in fair value of our net unrealized loss on investments 
would be $0.8 million or $1.0 million, respectively.

Due to the short duration and nature of our cash equivalents and marketable securities, as well as our intention to hold 

the investments to maturity, we do not expect any material loss with respect to our investment portfolio. 

Foreign Currency Risk 

We have certain investments outside the U.S. for the operations of Dynavax GmbH with exposure to foreign exchange 
rate fluctuations. The cumulative translation adjustment reported in the consolidated balance sheet as of December 31, 2018 
was $1.9 million primarily related to translation of Dynavax GmbH assets, liabilities and operating results from Euros to U.S. 
dollars. As of December 31, 2018, the effect of our exposure to these exchange rate fluctuations has not been material, and 
we do not expect it to become material in the foreseeable future. We do not hedge our foreign currency exposures and have 
not used derivative financial instruments for speculation or trading purposes.

51

ITEM 8. 

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS 

Report of Independent Registered Public Accounting Firm ..........................................................................................  

   Page No.
53

Consolidated Financial Statements:

Consolidated Balance Sheets .........................................................................................................................................  

Consolidated Statements of Operations .........................................................................................................................  

Consolidated Statements of Comprehensive Loss .........................................................................................................  

Consolidated Statements of Stockholders’ Equity.........................................................................................................  

Consolidated Statements of Cash Flows ........................................................................................................................  

Notes to Consolidated Financial Statements..................................................................................................................  

54

55

55

56

57

58

52

 
 
 
  
 
 
 
 
 
 
Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Dynavax Technologies Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Dynavax Technologies Corporation (the Company) as of 
December 31, 2018 and 2017, and the related consolidated statements of operations, comprehensive loss, stockholders' equity 
and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred 
to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all 
material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and 
its cash flows for each of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted 
accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) 
(PCAOB), the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in 
Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission 
(2013 framework) and our report dated February 27, 2019 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion 
on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and 
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the 
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform 
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due 
to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial 
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included 
examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also 
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the 
overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2002
San Francisco, California
February 27, 2019

53

DYNAVAX TECHNOLOGIES CORPORATION

CONSOLIDATED BALANCE SHEETS 

(In thousands, except per share amounts) 

Assets
Current assets:

Cash and cash equivalents......................................................................................................$
Marketable securities available-for-sale ................................................................................ 
Accounts and other receivables, net....................................................................................... 
Inventories, net....................................................................................................................... 
Intangible assets, net .............................................................................................................. 
Prepaid expenses and other current assets ............................................................................. 
Total current assets ...................................................................................................................... 
Property and equipment, net........................................................................................................ 
Intangible assets, net.................................................................................................................... 
Goodwill ...................................................................................................................................... 
Restricted cash............................................................................................................................. 
Other assets.................................................................................................................................. 
Total assets ..................................................................................................................................$
Liabilities and stockholders’ equity
Current liabilities:

Accounts payable ...................................................................................................................$
Accrued research and development ....................................................................................... 
Accrued liabilities .................................................................................................................. 
Other current liabilities .......................................................................................................... 
Total current liabilities ................................................................................................................ 
Long term debt, net...................................................................................................................... 
Other long-term liabilities ........................................................................................................... 
Total liabilities............................................................................................................................. 
Commitments and contingencies (Note 9)
Stockholders’ equity:

Preferred stock: $0.001 par value; 5,000 shares authorized at December 31, 2018 and 
December 31, 2017; no shares issued and outstanding at December 31, 2018 and 
December 31, 2017 ................................................................................................................ 
Common stock: $0.001 par value; 139,000 shares authorized at December 31, 2018 and 
2017; 62,862 and 61,533 shares issued and outstanding at December 31, 2018 and 2017, 
respectively ............................................................................................................................ 
Additional paid-in capital....................................................................................................... 
Accumulated other comprehensive loss................................................................................. 
Accumulated deficit ............................................................................................................... 
Total stockholders’ equity ........................................................................................................... 
Total liabilities and stockholders’ equity ....................................................................................$

December 31,

2018

2017

49,348    $
96,188     
3,704     
19,022     
-     
6,102     
174,364     
17,064     
11,717     
2,144     
619     
4,976     
210,884    $

5,278    $
9,714     
16,041     
7,000     
38,033     
100,871     
8,915     
147,819     

26,584 
165,270 
854 
312 
1,306 
3,697 
198,023 
16,619 
- 
2,244 
629 
1,270 
218,785 

4,539 
4,359 
9,695 
- 
18,593 
- 
643 
19,236 

-     

- 

63     
1,131,241     
(2,015)    
(1,066,224)    
63,065     
210,884    $

62 
1,107,693 
(881)
(907,325)
199,549 
218,785  

See accompanying notes. 

54

 
 
 
 
   
 
   
       
 
   
       
 
 
      
  
 
      
  
 
      
  
 
      
  
DYNAVAX TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS 

(In thousands, except per share amounts) 

Year Ended December 31,
2017

2018

2016

Revenues:

Product revenue, net ........................................................................................ $
Collaboration revenue .....................................................................................  
Grant revenue ..................................................................................................  
Service and license revenue ............................................................................  
Total revenues ............................................................................................................  
Operating expenses:

6,812    $
1,386   
-   
-   
8,198   

-   
-   
295   
32   
327   

$

- 
9,778 
381 
884 
11,043 

Cost of sales - product .....................................................................................  
Cost of sales - amortization of intangible assets .............................................  
Research and development..............................................................................  
Selling, general and administrative .................................................................  
Restructuring ...................................................................................................  

10,934   
10,862   
74,951   
64,770   
-   
Total operating expenses ............................................................................................   161,517   
Loss from operations ..................................................................................................   (153,319)  
Other income (expense):

-   
1,194   
64,988   
27,367   
2,783   
96,332 
(96,005)  

Interest income ................................................................................................  
Interest expense ...............................................................................................  
Other expense, net ...........................................................................................  

1,337   
-   
(486)  
Net loss....................................................................................................................... $ (158,899)   $ (95,154)  
(1.81)  
Basic and diluted net loss per share ........................................................................... $
52,613   
Weighted average shares used to compute basic and diluted net loss per share ........  

3,828   
(9,338)  
(70)  

(2.55)   $

62,362   

- 
- 
84,493 
37,257 
- 
   121,750 
  (110,707)

755 
- 
(2,492)
$ (112,444)
(2.92)
$
38,506  

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS 

(In thousands) 

Net loss........................................................................................................................$ (158,899)
Other comprehensive (loss) income, net of tax:

2018

Year Ended December 31,
2017
 $ (95,154)

2016
 $ (112,444)

12   
Unrealized gain (loss) on marketable securities available-for-sale ....................... 
(1,146)  
Cumulative foreign currency translation adjustments ........................................... 
Total other comprehensive (loss) income ................................................................... 
(1,134)
Total comprehensive loss............................................................................................$ (160,033)

(83)  
2,826   
2,743 
 $ (92,411)

(8)
(686)
(694)
 $ (113,138)

See accompanying notes. 

55

 
 
 
   
   
 
   
   
   
   
   
 
 
 
 
 
 
 
 
 
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
   
   
   
   
   
 
 
 
 
 
  
  
DYNAVAX TECHNOLOGIES CORPORATION 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands) 

Balances at December 31, 2015.....................  

38,446     $

38     $

889,698     $

(2,930 )  

$

(699,727 )  

$

187,079  

Common Stock

Shares

  Par Amount

Additional
Paid-In Capital  

Accumulated Other
Comprehensive
(Loss) Income

Accumulated
Deficit

Total
Stockholders'
Equity

Issuance (withholding) of common stock
   upon exercise of stock options and
   restricted stock awards, net .....................  
Issuance of common stock under
   Employee Stock Purchase Plan...............  
Stock compensation expense .....................  
Total other comprehensive loss .................  
Net loss.......................................................  
Balances at December 31, 2016.....................  

Issuance of common stock upon exercise
   of stock options and restricted stock
   awards, net ..............................................  
Issuance of common stock under
   Employee Stock Purchase Plan...............  
Issuance of common stock, net of
   issuance costs ..........................................  
Stock compensation expense .....................  
Total other comprehensive income ............  
Net loss.......................................................  
Balances at December 31, 2017.....................  

Issuance (withholding) of common stock
   upon exercise of stock options and
   restricted stock awards, net .....................  
Issuance of common stock under
   Employee Stock Purchase Plan...............  
Stock compensation expense .....................  
Total other comprehensive loss .................  
Net loss.......................................................  
Balances at December 31, 2018.....................  

107    

46    
-    
-    
-    

38,599     $

262    

84    

22,588    
-    
-    
-    

61,533     $

1    

(84 )  

-    
-    
-    
-    
39     $

-    

-    

23    
-    
-    
-    
62     $

615    
14,728    
-    
-    

904,957     $

1,613    

293    

185,913    
14,917    
-    
-    

1,107,693     $

1,204    

1    

(524 )  

125    
-    
-    
-    

62,862     $

-    
-    
-    
-    
63     $

594    
23,478    
-    
-    

1,131,241     $

-    

-    
-    
(694 )  
-    
(3,624 )  

-    

-    

-    
-    
2,743    
-    
(881 )  

-    

-    
-    
(1,134 )  
-    
(2,015 )  

$

$

$

-    

(83 )

-    
-    
-    
(112,444 )  
(812,171 )  

-    

-    

-    
-    
-    
(95,154 )  
(907,325 )  

-    

-    
-    
-    
(158,899 )  
(1,066,224 )  

$

$

$

615  
14,728  
(694 )
(112,444 )
89,201  

1,613  

293  

185,936  
14,917  
2,743  
(95,154 )
199,549  

(523 )

594  
23,478  
(1,134 )
(158,899 )
63,065  

See accompanying notes. 

56

 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DYNAVAX TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS 

(In thousands) 

Year Ended December 31,
2017
(As Adjusted)

2016
(As Adjusted)

2018

Operating activities
Net loss .............................................................................................................................................$ (158,899)
Adjustments to reconcile net loss to net cash used in operating activities:

 $

(95,154)

 $ (112,444)

Depreciation and amortization ................................................................................................... 
Write-off of assets in progress.................................................................................................... 
Loss (gain) on disposal of property and equipment ................................................................... 
Accretion of discounts and amortization of premiums on marketable securities....................... 
Reversal of deferred rent upon lease amendment....................................................................... 
Cash-settled portion of stock compensation expense................................................................. 
Stock compensation expense...................................................................................................... 
Cost of sales - amortization of intangible assets ........................................................................ 
Non-cash interest expense .......................................................................................................... 

Changes in operating assets and liabilities:

Accounts and other receivables...................................................................................... 
Inventories, net ............................................................................................................... 
Prepaid expenses and other current assets...................................................................... 
Other assets .................................................................................................................... 
Accounts payable ........................................................................................................... 
Accrued liabilities and other long term liabilities .......................................................... 
Deferred revenues .......................................................................................................... 
Net cash used in operating activities ................................................................................................ 
Investing activities
Acquisition of technology licenses................................................................................................... 
Purchases of marketable securities ................................................................................................... 
Proceeds from maturities of marketable securities........................................................................... 
Purchases of property and equipment, net........................................................................................ 
Net cash provided by (used in) investing activities.......................................................................... 
Financing activities
Proceeds from long-term debt, net ................................................................................................... 
Proceeds from issuances of common stock, net ............................................................................... 
(Tax withholding) proceeds from exercise of stock options and restricted stock awards, net ......... 
Proceeds from Employee Stock Purchase Plan ................................................................................ 
Net cash provided by financing activities......................................................................................... 
Effect of exchange rate changes on cash, cash equivalents and restricted cash............................... 
Net increase (decrease) in cash, cash equivalents and restricted cash.............................................. 
Cash, cash equivalents and restricted cash at beginning of year ...................................................... 
Cash, cash equivalents and restricted cash at end of year ................................................................$
Supplemental disclosure of cash flow information
Cash paid during the year for interest...............................................................................................$
Accrual for litigation settlement and insurance recovery (Note 9) ..................................................$
Release of accrual for litigation settlement and insurance recovery (Note 9)..................................$
Return of unused development funding to AstraZeneca AB............................................................$
Milestone payment from AstraZeneca AB.......................................................................................$
Non-cash investing and financing activities:

3,621 
- 
98 
(1,559)
- 
- 
23,478 
10,862 
2,755 

(2,850)
(18,710)
(2,405)
(3,706)
3,417 
12,597 
- 
(131,301)

(11,000)
(213,804)
284,457 
(4,187)
55,466 

99,000 
- 
(523)
594 
99,071 
(482)
22,754 
27,213 
49,967 

6,583 
- 
- 
- 
- 

Disposal of fully depreciated property and equipment..................................................................$
Non-cash acquisition of technology license ..................................................................................$

199 
12,773 

3,244 
- 
(10)
(193)
(209)
- 
14,917 
1,194 
- 

488 
(312)
(1,830)
(936)
(1,915)
3,198 
- 
(77,518)

- 
(227,672)
119,638 
(669)
(108,703)

- 
185,936 
1,613 
293 
187,842 
701 
2,322 
24,891 
27,213 

- 
- 
4,975 
- 
- 

86 
- 

 $

 $
 $
 $
 $
 $

 $
 $

2,257 
862 
91 
178 
- 
602 
14,126 
- 
- 

52 
- 
560 
(103)
1,181 
(11,759)
(2,654)
(107,051)

- 
(126,754)
220,760 
(7,757)
86,249 

- 
- 
(84)
615 
531 
(259)
(20,530)
45,421 
24,891 

- 
4,975 
- 
7,200 
7,200 

2,354 
-  

 $

 $
 $
 $
 $
 $

 $
 $

See accompanying notes. 

57

 
 
 
 
 
 
 
 
   
 
    
 
    
 
   
 
    
 
    
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
 
    
 
    
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
 
    
 
    
 
  
  
  
  
  
  
  
  
  
  
   
 
    
 
    
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
 
    
 
    
 
   
 
    
 
    
 
DYNAVAX TECHNOLOGIES CORPORATION 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

1.

Organization 

Dynavax Technologies Corporation (“we,” “our,” “us,” “Dynavax” or the “Company”), is a fully-integrated 

biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through 
toll-like receptor (“TLR”) stimulation. Our first commercial product, HEPLISAV-B (Hepatitis B Vaccine (Recombinant), 
Adjuvanted), is approved by the United States Food and Drug Administration (“FDA”) for prevention of infection caused by 
all known subtypes of hepatitis B virus in adults age 18 years and older. We commenced commercial shipments of 
HEPLISAV-B in January 2018. Our development efforts are primarily focused on stimulating the innate immune response to 
treat cancer in combination with other immunomodulatory agents. Our lead investigational immuno-oncology product 
candidates are SD-101, currently being evaluated in Phase 2 clinical studies, and DV281, in a Phase 1 safety study. We were 
incorporated in California in August 1996 under the name Double Helix Corporation, and we changed our name to Dynavax 
Technologies Corporation in September 1996. We reincorporated in Delaware in 2000. 

2.

Summary of Significant Accounting Policies 

Basis of Presentation and Principles of Consolidation

The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles 

(“GAAP”) and include our accounts and those of our wholly-owned subsidiary, Dynavax GmbH located in Düsseldorf, 
Germany. All significant intercompany accounts and transactions among the entities have been eliminated from the 
consolidated financial statements. We operate in one business segment: the commercialization, discovery and development of 
biopharmaceutical products. 

Liquidity and Financial Condition 

As of December 31, 2018, we had cash, cash equivalents and marketable securities of $145.5 million. 

We expect to incur significant expenses and operating losses for the foreseeable future as we continue to invest in 
commercialization of HEPLISAV-B, including investment in HEPLISAV-B inventory, clinical trials and other development, 
manufacturing and regulatory activities for our immuno-oncology product candidates, discovery research and development 
and tenant improvements and ongoing occupancy costs at our new corporate headquarters. Until we can generate a sufficient 
amount of revenue from product sales, we will need to finance our operations through strategic alliance and licensing 
arrangements and/or future public or private debt and equity financings. Adequate financing may not be available to us on 
acceptable terms, or at all. 

Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a 
number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number 
of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise 
such additional capital at a price or on terms that are favorable to us. 

Use of Estimates 

The preparation of financial statements in conformity with GAAP requires management to make informed estimates 

and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. 
Management’s estimates are based on historical information available as of the date of the consolidated financial statements 
and various other assumptions we believe are reasonable under the circumstances. Actual results could differ materially from 
these estimates.

58

Foreign Currency Translation

We consider the local currency to be the functional currency for our international subsidiary, Dynavax GmbH. 
Accordingly, assets and liabilities denominated in this foreign currency are translated into U.S. dollars using the exchange 
rate in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the 
year. Currency translation adjustments arising from period to period are charged or credited to accumulated other 
comprehensive income (loss) in stockholders’ equity. For the years ended December 31, 2018, 2017 and 2016, we reported 
an unrealized (loss) gain of $(1.1) million, $2.8 million and $(0.7) million, respectively. Realized gains and losses resulting 
from currency transactions are included in other income (expense) in the consolidated statements of operations. For the years 
ended December 31, 2018, 2017 and 2016, we reported a gain (loss) of $0.3 million, $(0.6) million and $0.2 million, 
respectively, resulting from currency transactions in our consolidated statements of operations.

Cash, Cash Equivalents and Marketable Securities 

We consider all liquid investments purchased with an original maturity of three months or less and that can be 
liquidated without prior notice or penalty to be cash equivalents. Management determines the appropriate classification of 
marketable securities at the time of purchase. In accordance with our investment policy, we invest in short-term money 
market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We believe these types of 
investments are subject to minimal credit and market risk.

We have classified our entire investment portfolio as available-for-sale and available for use in current operations and 

accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on 
inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in 
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for 
substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive 
loss in stockholders’ equity. Realized gains and losses and declines in value, if any, judged to be other than temporary on 
available-for-sale securities are included in interest income or expense. The cost of securities sold is based on the specific 
identification method. Management assesses whether declines in the fair value of investment securities are other than 
temporary. In determining whether a decline is other than temporary, management considers the following factors: 

• whether the investment has been in a continuous realized loss position for over 12 months; 
•

the duration to maturity of our investments; 

•

•

•

our intention and ability to hold the investment to maturity and if it is not more likely than not that we will be 
required to sell the investment before recovery of the amortized cost bases; 

the credit rating, financial condition and near-term prospects of the issuer; and 

the type of investments made. 

To date, there have been no declines in fair value that have been identified as other than temporary. 

Concentration of Credit Risk and Other Risks and Uncertainties 

Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable 

securities and accounts receivable. 

Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and 

corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash 
equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, 
U.S. government agency securities and corporate debt securities. We have not experienced any losses on our cash equivalents 
and marketable securities. 

Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are 
recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts as described further below. 
We estimate our allowance for doubtful accounts based on an evaluation of the aging of our receivables. Accounts receivable 
balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have 
not recorded any allowance for doubtful accounts.

59

Our product candidates will require approval from the FDA and foreign regulatory agencies before commercial sales 

can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay 
of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, 
after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the 
drug approval process.

We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new 
technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of 
proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of 
product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.

During the year ended December 31, 2018, 2017 and 2016, 83%, 90% and 92%, respectively, of our revenues were 
earned in the United States. As of December 31, 2018 and 2017, 24% and 15%, respectively, of our long-lived assets were 
located in the United States and the remaining long-lived assets were located in Germany.

We have entered into distribution agreements with a limited number of wholesalers and specialty distributors in the 

U.S. All of our product revenue are to these customers. For the year ended and at December 31, 2018, respectively, our three 
largest customers represented approximately 68% of our product revenue and 71% of our trade receivable balance.

Inventories 

Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. Our 

assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, 
including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple 
factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our 
assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or 
estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular 
period. During 2018, we recorded $1.0 million in inventory reserves, which is included in cost of sales – product.    

We primarily use actual costs to determine our cost basis for inventories. We consider regulatory approval of product 

candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval 
is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized 
as inventory but are expensed as research and development costs. We begin capitalization of these inventory related costs 
once regulatory approval is obtained. 

HEPLISAV-B was approved by the FDA on November 9, 2017, at which time we began to capitalize inventory costs 

associated with HEPLISAV-B. In March 2018, we received regulatory approval of the pre-filled syringe (“PFS”) 
presentation of HEPLISAV-B. Prior to FDA approval of HEPLISAV-B, all costs related to the manufacturing of 
HEPLISAV-B that could potentially be available to support the commercial launch of our products, were charged to research 
and development expense in the period incurred as there was no alternative future use. Prior to regulatory approval of PFS, 
costs associated with resuming operating activities at the Düsseldorf manufacturing facility were also included in research 
and development expense. Subsequent to regulatory approval of PFS, costs associated with operating activities at the 
Düsseldorf facility were included in cost of sales – product, until commercial production resumed in mid-2018 at which time 
these costs were recorded as raw materials inventory.

Intangible Assets

We record definite-lived intangible assets related to certain capitalized milestone and sublicense payments. After 
determining that the pattern of future cash flows associated with intangible asset could not be reliably estimated with a high 
level of precision, these assets are amortized on a straight-line basis over their remaining useful lives, which are estimated to 
be the remaining patent life. We assess our intangible assets for impairment if indicators are present or changes in 
circumstance suggest that impairment may exist. No impairment of intangible assets have been identified during the years 
presented. 

60

Long-Lived Assets 

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the 
estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized and repair and 
maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the 
initial lease term or the estimated useful lives of the assets, whichever is shorter. 

We evaluate the carrying value of long-lived assets, whenever events or changes in business circumstances or our 
planned use of long-lived assets indicate, based on undiscounted future operating cash flows, that their carrying amounts may 
not be fully recoverable or that their useful lives are no longer appropriate. When an indicator of impairment exists, 
undiscounted future operating cash flows of long-lived assets are compared to their respective carrying value. If the carrying 
value is greater than the undiscounted future operating cash flows of long-lived assets, the long-lived assets are written down 
to their respective fair values and an impairment loss is recorded. Fair value is determined primarily using the discounted 
cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of 
future operating results that are used in the preparation of expected cash flows. No impairments of tangible assets have been 
identified during the years presented.  

Goodwill

Our goodwill balance relates to our April 2006 acquisition of Dynavax GmbH. Goodwill represents the excess 
purchase price over the fair value of tangible and intangible assets acquired and liabilities assumed. Goodwill is not 
amortized but is subject to an annual impairment test. In performing its goodwill impairment review, we assess qualitative 
factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, 
including goodwill. The qualitative factors include, but are not limited to macroeconomic conditions, industry and market 
considerations, and the overall financial performance of the Company. If after assessing the totality of these qualitative 
factors, we determine that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, 
then no additional assessment is deemed necessary. Otherwise, we will proceed to perform a test for goodwill impairment. 
The first step involves comparing the estimated fair value of the related reporting unit against its carrying amount including 
goodwill. If the carrying amount exceeds the fair value, impairment is calculated and recorded as a charge in the consolidated 
statements of operations. We determined that we have only one operating segment and there are no components of that 
operating segment that are deemed to be separate reporting units such that we have one reporting unit for purposes of our 
goodwill impairment testing. We evaluate goodwill for impairment on an annual basis and on an interim basis if events or 
changes in circumstances between annual impairment tests indicate that the asset might be impaired. No impairments have 
been identified for the years presented.

Revenue Recognition 

On January 1, 2018, we adopted Accounting Standards Codification, (“ASC”) 606, Revenue from Contracts with 
Customers, using the modified retrospective method applied to those contracts which were not completed as of January 1, 
2018. Under the modified retrospective method, results for the reporting period beginning January 1, 2018 are presented 
under ASC 606, while the cumulative effect of initially applying the guidance is reflected as an adjustment to the opening 
balance of retained earnings at January 1, 2018. Adoption of this ASC did not have a material impact on our consolidated 
financial statements as there were no remaining performance obligations under our license and collaboration agreements 
as of the adoption date. 

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an 

amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To 
determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity 
performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the 
contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; 
and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to 
contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we 
transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess 
the goods or services promised within each contract and determine those that are performance obligations, and assess whether 
each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated 
to the respective performance obligation when (or as) the performance obligation is satisfied.

61

Product Revenue, Net

We sell our product to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our 
“Customers”). Revenues from product sales are recognized when we have satisfied our performance obligation, which is the 
transfer of control of our product upon delivery to the Customer. The timing between the recognition of revenue for product 
sales and the receipt of payment is not significant. Because our standard credit terms are short-term and we expect to receive 
payment in less than one-year, there is no financing component on the related receivables. Taxes collected from Customers 
relating to product sales and remitted to governmental authorities are excluded from revenues.

Overall, product revenue, net, reflects our best estimates of the amount of consideration to which we are entitled based 
on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is 
probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If 
our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period 
of adjustment.

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration such 

as product returns, chargebacks, discounts, rebates and other fees that are offered within contracts between us and our 
Customers, healthcare providers, and others relating to our product sales. We estimate variable consideration using either the 
most likely amount method or the expected value method, depending on the type of variable consideration and what method 
better predicts the amount of consideration we expect to receive. We take into consideration relevant factors such as industry 
data, current contractual terms, available information about Customers’ inventory, resale and chargeback data and forecasted 
customer buying and payment patterns, in estimating each variable consideration. The variable consideration is recorded at 
the time product sales is recognized, resulting in a reduction in product revenue and a reduction in accounts receivable (if the 
Customer offsets the amount against its accounts receivable) or as an accrued liability (if we pay the amount through our 
accounts payable process). Variable consideration requires significant estimates, judgment and information obtained from 
external sources. The amount of variable consideration is included in the net sales price only to the extent that it is probable 
that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our 
estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of 
adjustment. If we were to change any of these judgments or estimates, it could cause a material increase or decrease in the 
amount of revenue that we report in a particular period. There have been no material adjustments to these estimates for the 
year ended December 31, 2018.

Product Returns: Consistent with industry practice, we offer our Customers a limited right of return based on the 
product’s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may 
be returned by our Customers and record this estimate as a reduction of revenue in the period the related product revenue is 
recognized. We consider several factors in the estimation of potential product returns including expiration dates of the 
product shipped, the limited product return rights, available information about Customers’ inventory, shelf life of the product 
and other relevant factors. 

Chargebacks: Our Customers subsequently resell our product to healthcare providers. In addition to distribution 
agreements with Customers, we enter into arrangements with healthcare providers that provide for chargebacks and discounts 
with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual 
commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to Customers who 
directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the 
ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related 
revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are 
determined at the time of resale to the qualified healthcare provider by Customers, and we issue credits for such amounts 
generally within a few weeks of the Customer’s notification to us of the resale. Reserves for chargebacks consists of credits 
that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect 
will be sold to qualified healthcare providers, and chargebacks for units that our Customers have sold to healthcare providers, 
but for which credits have not been issued.

Trade Discounts and Allowances: We provide our Customers with discounts which include early payment incentives 

that are explicitly stated in our contracts, and are recorded as a reduction of revenue in the period the related product revenue 
is recognized. 

62

Distribution Fees: Distribution fees include fees paid to certain Customers for sales order management, data and 

distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is 
recognized.

Collaboration Revenue

We enter into collaborative arrangements with other companies. Such arrangements may include promises to customers 

which, if capable of being distinct, are accounted for as separate performance obligations. For agreements with multiple 
performance obligations, we allocate estimated revenue to each performance obligation at contract inception based on the 
estimated transaction price of each performance obligation. Revenue allocated to each performance obligation is then 
recognized when we satisfy the performance obligation by transferring control of the promised good or service to the 
customer.

Research and Development Expenses and Accruals 

Research and development expenses include personnel and facility-related expenses, outside contracted services 
including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and 
non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts 
with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and 
payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements 
are capitalized and expensed as the related goods are delivered or services are performed.

We contract with third parties to perform various clinical trial activities in the on-going development of potential 
products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in 
uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain 
events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for 
clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial 
centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only 
liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be 
further responsible for termination fees and penalties. We estimate research and development expenses and the related 
accrual as of each balance sheet date based on the facts and circumstances known to us at that time. There have been no 
material adjustments to the prior period accrued estimates for clinical trial activities through December 31, 2018.

Stock-Based Compensation 

Stock-based compensation expense for restricted stock units and stock options is estimated at the grant date based on 

the award’s estimated fair value and is recognized on a straight-line basis over the award’s requisite service period, assuming 
estimated forfeiture rates. Fair value of restricted stock units is determined at the date of grant using the Company’s closing 
stock price. Our determination of the fair value of stock options on the date of grant using an option-pricing model is affected 
by our stock price, as well as assumptions regarding a number of subjective variables. We selected the Black-Scholes option 
pricing model as the most appropriate method for determining the estimated fair value-based measurement of our stock 
options. The Black-Scholes model requires the use of subjective assumptions which determine the fair value-based 
measurement of stock options. These assumptions include, but are not limited to, our expected stock price volatility over the 
term of the awards, and projected employee stock option exercise behaviors. In the future, as additional empirical evidence 
regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. 
These changes could impact our fair value of stock options granted in the future. Changes in the fair value of stock awards 
could materially impact our operating results. 

Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our 

stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby 
increasing stock-based compensation cost recognized in future periods. We derive the expected term assumption primarily 
based on our historical settlement experience, while giving consideration to options that have not yet completed a full life 
cycle. Stock-based compensation cost is recognized only for awards ultimately expected to vest. Our estimate of the 
forfeiture rate is based primarily on our historical experience. To the extent we revise this estimate in the future, our share-
based compensation cost could be materially impacted in the period of revision. There have been no material adjustments to 
these estimates during the years presented.

63

Income Taxes

The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax 
consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Tax law and 
rate changes are reflected in income in the period such changes are enacted. We include interest and penalties related to 
income taxes, including unrecognized tax benefits, within income tax expense.

Our income tax returns are based on calculations and assumptions that are subject to examination by the Internal 
Revenue Service and other tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties 
in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. 
The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it 
is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation 
processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being 
realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we 
regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for 
income taxes. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, 
income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.

Significant judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities 
and the valuation allowance recorded against our net deferred tax assets. Deferred tax assets and liabilities are determined 
using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance 
is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be 
achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and 
includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book 
income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings 
history, and reliability of forecasting.

Based on our review, we concluded that it was more likely than not that we would not be able to realize the benefit of 

our domestic and foreign deferred tax assets in the future. This conclusion was based on historical and projected operating 
performance, as well as our expectation that our operations will not generate sufficient taxable income in future periods to 
realize the tax benefits associated with the deferred tax assets within the statutory carryover periods. Therefore, we have 
maintained a full valuation allowance on our deferred tax assets as of December 31, 2018 and 2017. We will continue to 
assess the need for a valuation allowance on our deferred tax assets by evaluating both positive and negative evidence that 
may exist. Any adjustment to the net deferred tax asset valuation allowance would be recorded in the statement of operations 
for the period that the adjustment is determined to be required.

On December 22, 2017, President Trump signed U.S. tax reform legislation, commonly referred to as the Tax Cuts and 

Jobs Act (the “Tax Act”), which became effective January 1, 2018. The Tax Act significantly changed the fundamentals of 
U.S. corporate income taxation by, among many other things, reducing the U.S. federal corporate income tax rate to 21%, 
converting to a territorial tax system, and creating various income inclusion and expense limitation provisions. Also on 
December 22, 2017, The Securities and Exchange Commission staff issued Staff Accounting Bulletin (“SAB”) 118 to 
provide guidance for companies that are not able to complete their accounting for the income tax effects of the Tax Act in the 
period of enactment. SAB 118 provides for a measurement period of up to one year from the date of enactment. During the 
measurement period, companies need to reflect adjustments to any provisional amounts if it obtains, prepares or analyzes 
additional information about facts and circumstances that existed as of the enactment date that, if known, would have affected 
the income tax effects initially reported as provisional amounts. At December 31, 2018 we have completed our analysis of 
the Tax Act and there were no material changes or adjustments to the provisional amounts previously recorded.

Restructuring

Restructuring costs are comprised of severance costs related to workforce reductions. We recognize restructuring 
charges when the liability is incurred. Employee termination benefits are accrued at the date management has committed to a 
plan of termination and employees have been notified of their termination dates and expected severance payments.

64

Recent Accounting Pronouncements 

Accounting Standards Update 2016-02

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 

No. 2016-02, Leases (Topic 842) which requires a lessee to recognize a right-of-use asset and corresponding lease liability, 
measured at the present value of the lease payments, for all leases with a lease term greater than 12 months. In July 2018, the 
FASB issued ASU 2018-11, Targeted Improvements, which gives the option to apply the transition provisions of ASU 2016-
02 at its adoption date instead of at the earliest comparative period presented in its financial statements. Also in July 2018, 
the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, which clarifies certain aspects of ASU 
2016-02. We will adopt ASU 2016-02 on a modified retrospective basis on its adoption date of January 1, 2019 and elect the 
available practical expedients upon transition. We will elect the transition method that allows for the application of the 
standard at the adoption date rather than at the beginning of the earliest comparative period presented in the financial 
statements. The new standard will have a material impact on our consolidated balance sheets, but will not have an impact on 
our consolidated statement of operations. Based on our preliminary analysis, the most significant impact will be the 
recognition of right-of-use asset and lease liabilities for operating leases ranging approximately from $34 million to $40 
million on January 1, 2019. The amount of right-of-use asset and lease liabilities primarily relates to the corporate 
headquarters operating lease entered into in September 2018.

Accounting Standards Update 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of 

Credit Losses of Financial Instruments. The standard changes the methodology for measuring credit losses on financial 
instruments and the timing of when such losses are recorded. The ASU is effective for annual periods beginning after 
December 15, 2019 with early adoption permitted. We are currently evaluating the impact this standard will have on our 
consolidated financial statements.

Accounting Standards Update 2017-04

In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350), which simplifies 

the test for goodwill impairment by eliminating a previous requirement to calculate the implied fair value of goodwill to 
measure a goodwill impairment charge. The ASU is effective for annual periods beginning after December 15, 2019 with 
early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated 
financial statements.

Accounting Standards Update 2018-13

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), that eliminates, adds and 

modifies certain disclosure requirements of fair value measurements. Entities will no longer be required to disclose the 
amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but public companies will be 
required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value 
measurements. The ASU is effective for annual periods beginning after December 15, 2019 with early adoption permitted. 
The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

Accounting Standards Update 2018-15

In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other –Internal-Use Software 

(Subtopic 350-40). This ASU requires a customer in a cloud computing arrangement (i.e. hosting arrangement) that is a 
service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to 
capitalize as assets or expense as incurred. ASC 350-40 requires that certain costs incurred during the application 
development stage be capitalized and other costs incurred during the preliminary project and post-implementation stages be 
expensed as incurred. The ASU is effective for annual periods beginning after December 15, 2019 with early adoption 
permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

Accounting Standards Update 2016-18

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a 
consensus of the FASB Emerging Issues Task Force). This ASU requires that the reconciliation of the beginning-of-period 
and end-of-period amounts shown in the statement of cash flows include cash, cash equivalents and amounts generally 
described as restricted cash or restricted cash equivalents. The amendment in this update is applied using a retrospective 
transition method to each period presented. The ASU is effective for annual periods beginning after December 15, 2017. We 
adopted ASU 2016-18 on January 1, 2018 and have presented comparable prior period cash, cash equivalents and restricted 
cash balances in the consolidated statements of cash flows reflecting the retrospective impact of this ASU. See Note 4.

65

3.

Fair Value Measurements 

We measure fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit 

price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market 
participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable 
inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three 
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair 
value which are the following: 

•

•

•

Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities; 

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for 
similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be 
corroborated by observable market data for substantially the full term of the assets or liabilities; and 

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair 
value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and 
assumptions. 

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. 
We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may 
result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. There were no transfers 
between Level 1 and Level 2 during the twelve months ended December 31, 2018 and 2017.

The carrying amounts of cash equivalents, accounts and other receivables, accounts payable and accrued liabilities are 

considered reasonable estimates of their respective fair value because of their short-term nature.

As of December 31, 2018, we measured the fair value of our $7.0 million payment to Merck, Sharpe & Dohme Corp. 

(“Merck”), which is due in the first quarter of 2020, based on Level 3 inputs due to the use of unobservable inputs that cannot 
be corroborated by observable market data. We estimated the fair value of the liability using a discounted cash flow 
technique using the effective interest rate on our term loan. The liability had a fair value of $6.3 million as of December 31, 
2018. 

Recurring Fair Value Measurements 

The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable 

securities) measured at fair value on a recurring basis (in thousands): 

Level 1  

  Level 2  

  Level 3  

Total

December 31, 2018
Money market funds.....................................................................$
U.S. treasuries .............................................................................. 
U.S. government agency securities .............................................. 
Corporate debt securities .............................................................. 
Total .............................................................................................$

44,002 
- 
- 
- 
44,002 

 $

 $

- 
14,724 
42,372 
41,291 
98,387 

 $

 $

- 
- 
- 
- 
- 

December 31, 2017
Money market funds.....................................................................$
U.S. treasuries .............................................................................. 
U.S. government agency securities .............................................. 
Corporate debt securities .............................................................. 
Total .............................................................................................$

22,543 
- 
- 
- 
22,543 

 $

 $

- 
45,534 
86,820 
32,916 
165,270 

 $

 $

- 
- 
- 
- 
- 

Level 1  

  Level 2  

  Level 3  

 $

 $

 $

 $

44,002 
14,724 
42,372 
41,291 
142,389 

Total

22,543 
45,534 
86,820 
32,916 
187,813  

Money market funds are highly liquid investments and are actively traded. The pricing information on these investment 

instruments is readily available and can be independently validated as of the measurement date. This approach results in the 
classification of these securities as Level 1 of the fair value hierarchy.

66

 
 
 
   
   
   
   
   
   
   
 
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
 
 
 
   
   
   
   
   
   
   
 
  
  
  
  
  
  
  
  
  
U.S. treasuries, U.S. government agency securities and corporate debt securities are measured at fair value using Level 
2 inputs. We review trading activity and pricing for these investments as of each measurement date. When sufficient quoted 
pricing for identical securities is not available, we use market pricing and other observable market inputs for similar 
securities obtained from various third party data providers. These inputs represent quoted prices for similar assets in active 
markets or these inputs have been derived from observable market data. This approach results in the classification of these 
securities as Level 2 of the fair value hierarchy.

4.

Cash, Cash Equivalents, Restricted Cash and Marketable Securities 

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the 
consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:

Cash and cash equivalents ...............................................................................  $
Restricted cash.................................................................................................   
Total cash, cash equivalents and restricted cash shown in the consolidated 
statements of cash flows..................................................................................  $

2018

December 31
2017

2016

49,348    $
619     

26,584    $
629     

24,289 
602 

49,967    $

27,213    $

24,891  

Restricted cash balances relate to certificates of deposit issued as collateral to certain letters of credit issued as security 

to our lease arrangements. See Note 9.

Cash, cash equivalents and marketable securities consist of the following (in thousands): 

Amortized Cost    Unrealized Gains   Unrealized Losses   

Estimated
Fair Value

December 31, 2018
Cash and cash equivalents:

Cash .............................................................. $
Money market funds.....................................  
Corporate debt securities ..............................  
Total cash and cash equivalents.........................  
Marketable securities available-for-sale:

U.S. treasuries...............................................  
U.S. government agency securities ..............  
Corporate debt securities ..............................  
Total marketable securities available-for-sale ...  
Total cash, cash equivalents and marketable 
securities ............................................................ $
December 31, 2017
Cash and cash equivalents:

Cash .............................................................. $
Money market funds.....................................  
Total cash and cash equivalents.........................  
Marketable securities available-for-sale:

U.S. treasuries...............................................  
U.S. government agency securities ..............  
Corporate debt securities ..............................  
Total marketable securities available-for-sale ...  
Total cash, cash equivalents and marketable 
securities ............................................................ $

3,147   $
44,002    
2,199    
49,348    

14,732    
42,416    
39,108    
96,256    

145,604   $

4,041   $
22,543    
26,584    

45,559    
86,860    
32,931    
165,350    

191,934   $

67

-   $
-    
-    
-    

-    
-    
-    
-    

-   $

-   $
-    
-    

-    
-    
-    
-    

-   $

-    $
-     
-     
-     

(8)   
(44)   
(16)   
(68)   

3,147 
44,002 
2,199 
49,348 

14,724 
42,372 
39,092 
96,188 

(68)  $

145,536 

-    $
-     
-     

(25)   
(40)   
(15)   
(80)   

4,041 
22,543 
26,584 

45,534 
86,820 
32,916 
165,270 

(80)  $

191,854  

 
 
 
 
 
   
   
 
 
 
   
      
      
       
 
   
      
      
       
 
   
      
      
       
 
   
      
      
       
 
   
      
      
       
 
   
      
      
       
 
The maturities of our marketable securities available-for-sale are as follows (in thousands):

.

Mature in one year or less ...............................................................................................
Mature after one year through two years.........................................................................

December 31, 2018

Amortized 
Cost

Estimated
Fair Value

 $

 $

96,256 
- 
96,256 

 $

 $

96,188 
- 
96,188  

There were no realized gains or losses from the sale of marketable securities in the years ended December 31, 2018, 
2017 and 2016. All of our investments are classified as short-term and available-for-sale, as we consider them available to 
fund current operations and may not hold our investments until maturity.

5.

Inventories, net

The following table presents inventories (in thousands): 

Raw materials.................................................................................................................  $
Work-in-process............................................................................................................. 
Finished goods ............................................................................................................... 
Total ...............................................................................................................................  $

12,111    $
6,562   
349   
19,022    $

- 
312 
- 
312  

December 31

2018

2017

6.

Intangible Assets, net

Intangible assets are related to certain capitalized milestone and sublicense payments. The following table presents 

intangible assets (in thousands):

December 31,

2018

2017

Intangible assets .............................................................................................................  $
Less accumulated amortization...................................................................................... 
Total ...............................................................................................................................  $

19,773    $
(8,056)  
11,717    $

2,500 
(1,194)
1,306  

For the year ended December 31, 2018, we recorded $10.9 million in cost of sales - amortization of intangible assets 
which included amortization of $8.1 million, $1.5 million and $1.3 million related to capitalized milestone and sublicense 
payments to Merck, GlaxoSmithKline Biologicals SA (“GSK”) and Coley Pharmaceutical Group, Inc. (“Coley”), 
respectively. For the year ended December 31, 2017, we recorded $1.2 million in cost of sales - amortization of intangible 
assets related to a capitalized milestone payment to Coley. See Note 10. At December 31, 2018, the remaining intangible 
asset has an estimated remaining useful life of 16 months and will be fully amortized by April 2020. No impairment of 
intangible assets has been identified during the years presented.

68

 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.

Property and Equipment, net 

Property and equipment consist of the following (in thousands):

Manufacturing equipment .................................................................
Lab equipment ...................................................................................
Computer equipment .........................................................................
Furniture and fixtures ........................................................................
Leasehold improvements...................................................................
Assets in progress ..............................................................................

Less accumulated depreciation and amortization.............................. 
Total................................................................................................... 

Estimated Useful
Life
(In years)
5-14
5-13
3
3-13
1-5

December 31,

2018

2017

$

$

12,029   
6,938   
5,465   
1,809   
11,367   
2,605   
40,213   
(23,149)  
17,064   

$

$

12,104 
6,686 
4,760 
1,629 
10,873 
1,176 
37,228 
(20,609)
16,619  

Depreciation and amortization expense on property and equipment was $3.6 million, $3.2 million and $2.3 million for 

the years ended December 31, 2018, 2017 and 2016, respectively. 

8.

Current Accrued Liabilities and Accrued Research and Development

Current accrued liabilities and accrued research and development consist of the following (in thousands): 

Payroll and related expenses .........................................................................................$
Legal expenses .............................................................................................................. 
Revenue reserves liability ............................................................................................. 
Third party research expenses....................................................................................... 
Third party development expenses ............................................................................... 
Other accrued liabilities ................................................................................................ 
Total ..............................................................................................................................$

8,058 
151 
1,033 
7,819 
1,377 
7,317 
25,755 

 $

 $

6,180 
346 
- 
3,567 
522 
3,439 
14,054  

December 31,

2018

2017

9.

Commitments and Contingencies 

We lease our facilities in Berkeley, California (“Berkeley Lease”), Emeryville, California and Düsseldorf, Germany 

(“Düsseldorf Lease”).

On September 17, 2018, we entered into an Office/Laboratory Lease (“Lease”) for office and laboratory space located 
at 5959 Horton Street, Emeryville, California (“Premises”). Under the terms of the Lease, we will lease 75,662 square feet in 
the Premises (“Rented Area”) at the rate of $4.75 (“Base Rate”) multiplied by the Rented Area, paid on a monthly basis, 
starting on the earlier of our commencement of our business operations at the Premises or April 1, 2019 (“Commencement 
Date”). The Base Rate is subject to scheduled annual increases, and we are also responsible for certain operating expenses 
and taxes throughout the life of the Lease. In connection with the Lease, we are entitled to a tenant improvement allowance of 
up to $8.3 million. The Lease has an initial term of 12 years, following the Commencement Date with an option to extend the 
lease for two successive five-year terms.

In connection with our execution of the Lease, on September 17, 2018, we entered into a Lease Termination 

Agreement to terminate the Berkeley Lease effective as of the date we vacate the Berkeley premises. The rent payable for the 
Berkeley Lease is subject to a “hold-over” increase should we not vacate prior to July 31, 2019.   

Total net rent expense related to our operating leases for the years ended December 31, 2018, 2017 and 2016, was $4.0 
million, $2.4 million and $2.2 million, respectively. Deferred rent was $2.3 million and $0.6 million as of December 31, 2018 
and 2017, respectively.

69

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
In February 2018, we entered into a $175.0 million term loan agreement. Borrowings under the term loan agreement in 

the amount of $101.8 million is payable at maturity on December 31, 2023, unless earlier prepaid. See Note 11. 

In February 2018, we entered into a sublicense agreement with Merck. Under the agreement, we are required to make 

future payments of $7.0 million each in both February 2019 and February 2020. See Note 10.

We have entered into material purchase commitments with commercial manufacturers for the supply of HEPLISAV-B 

and SD-101. To the extent these commitments are non-cancelable, they are reflected in the table below. 

Future payments under the term loan agreement, sublicense agreement, minimum payments under the non-cancelable 

portion of our operating leases and non-cancelable purchase commitments at December 31, 2018, are as follows (in 
thousands):

Year ending December 31,
2019 .......................................................................................................................................................
2020 .......................................................................................................................................................
2021 .......................................................................................................................................................
2022 .......................................................................................................................................................
2023 .......................................................................................................................................................
Thereafter ..............................................................................................................................................
Total.......................................................................................................................................................

$

$

22,378 
12,256 
5,144 
5,212 
109,760 
39,523 
194,273  

During 2004, we established a letter of credit with Silicon Valley Bank as security for our Berkeley Lease in the 

amount of $0.4 million. The letter of credit remained outstanding as of December 31, 2018, and is collateralized by a 
certificate of deposit for $0.4 million, which has been included in restricted cash in the consolidated balance sheets as of 
December 31, 2018 and 2017. Under the terms of the Berkeley Lease, if the total amount of our cash, cash equivalents and 
marketable securities falls below $20 million for a period of more than 30 consecutive days during the lease term, the amount 
of the required security deposit will increase to $1.1 million, until such time as our projected cash and cash equivalents will 
exceed $20 million for the remainder of the lease term, or until our actual cash and cash equivalents remains above $20 
million for a period of 12 consecutive months. 

During 2004, we also established a letter of credit with Deutsche Bank as security for our Düsseldorf Lease in the 
amount of 0.2 million Euros. The letter of credit remained outstanding through December 31, 2018 and is collateralized by a 
certificate of deposit for 0.2 million Euros, which has been included in restricted cash in the consolidated balance sheets as of 
December 31, 2018 and 2017.

In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that 

obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the 
normal course of operations, we have entered into license and other agreements and intend to continue to seek additional 
rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. 
Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of 
products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future 
events that cannot reasonably be estimated.

We also rely on and have entered into agreements with research institutions, contract research organizations and 

clinical investigators. These agreements are terminable by us upon written notice. Generally, we are liable only for actual 
effort expended by the organizations at any point in time during the contract through the notice period.

In conjunction with a financing arrangement with Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC 
(“Holdings”) in November 2009, we agreed to make contingent cash payments to Holdings equal to 50% of the first $50 
million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any 
third party with respect to the development and/or commercialization of cancer and hepatitis C therapies originally licensed 
to Symphony Dynamo, Inc., including SD-101. We have made no payments and have not recorded a liability as of December 
31, 2018 and 2017.

70

 
 
   
 
 
 
 
 
 
From time to time, we may be involved in claims, suits, and proceedings arising from the ordinary course of our 
business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, 
suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the 
outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management 
resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in 
substantial damages, fines, penalties or orders requiring a change in our business practices, which could in the future 
materially and adversely affect our financial position, financial statements, results of operations, or cash flows in a particular 
period.

On September 7, 2016, we entered into a Stipulation of Settlement to settle the case entitled In re Dynavax 
Technologies Securities Litigation filed in 2013. The settlement, which was approved by the U.S. District Court for the 
Northern District of California on February 6, 2017, provided for a payment of $4.1 million by us and results in a dismissal 
and release of all claims against all defendants, including us. The settlement was paid by our insurers in February 2017. 

On October 24, 2017, we entered into a Stipulation of Settlement to settle the derivative case filed in 2013. The 
settlement provided for a payment of $0.9 million by us and results in a dismissal and release of all claims against all 
defendants, including us. The settlement was paid by our insurers in November 2017.

Amounts recorded for contingencies can result from a complex series of judgments about future events and 

uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates 
and assumptions, see Use of Estimates in Note 2.

10. Collaborative Research, Development and License Agreements 

AstraZeneca

Pursuant to a research collaboration and license agreement with AstraZeneca AB (AstraZeneca”), as amended, we 

discovered and performed initial clinical development of AZD1419, a TLR9 agonist product candidate for the treatment of 
asthma. In June 2016, all of our remaining performance obligations under our agreement with AstraZeneca were completed 
and we recognized collaboration revenue of $9.8 million. In November 2018, we were informed by AstraZeneca that initial 
results from the Phase 2a study indicate AZD1419 treatment did not meet the primary endpoint of the study. AstraZeneca is 
reviewing the full data before deciding on the next steps for the AZD1419 program.

Serum Institute of India Pvt. Ltd.

In June 2017, we entered into an agreement to provide Serum Institute of India Pvt. Ltd. (“SIIPL”) with technical 
support. In consideration, SIIPL agreed to pay us at an agreed upon hourly rate for services and reimburse certain out-of-
pocket expenses. In addition, we have rights to commercialization of certain potential products manufactured at the SIIPL 
facility. During the fourth quarter of 2018, we recognized collaboration revenue for services performed through December 
31, 2018.

Merck, Sharp & Dohme Corp.

In February 2018, we entered into a Sublicense Agreement (the “Sublicense Agreement”) with Merck. The Sublicense 

Agreement grants us, under certain non-exclusive U.S. patent rights controlled by Merck which relate to recombinant 
production of hepatitis B surface antigen, the right to manufacture, use, offer for sale, sell and import HEPLISAV-B in the 
United States and includes the right to grant further sublicenses. Under the terms of the Sublicense Agreement, we are 
obligated to pay $21.0 million in three installments. The first installment of $7.0 million was paid in February 2018 and the 
remaining two payments of $7.0 million each are due in the first quarter of each of 2019 and 2020. The payments in 2019 and 
2020 are classified on the condensed consolidated balance sheets as other current liabilities and other long-term liabilities, 
respectively. In February 2018, we recorded $19.8 million as an intangible asset. At December 31, 2018, the intangible asset, 
net balance was $11.7 million. See Note 6. The agreement continues in effect through April 2020, at which time the license 
becomes perpetual, irrevocable, fully paid-up and royalty free.

71

GlaxoSmithKline Biologicals SA

On July 12, 2018, we entered into a sublicense agreement with GSK. The GSK sublicense agreement grants us, under 

certain non-exclusive U.S. patent rights controlled by GSK, the right to manufacture, use, offer to sell, sell and import 
HEPLISAV-B in the United States and includes the right to grant further sublicenses. In consideration, we paid a $1.5 million 
license fee to GSK in July 2018 and recorded this payment as an intangible asset. At December 31, 2018, the intangible asset 
has been fully amortized. See Note 6. In addition, we were obligated to pay GSK, royalties of 13% of net sales of 
HEPLISAV-B from December 1, 2017 through July 31, 2018. For the year ended December 31, 2018, we recorded $0.2 
million of royalties in cost of sales – product in the condensed consolidated statements of operations.

Coley Pharmaceutical Group, Inc.

In June 2007, we entered into a license agreement with Coley, under which Coley granted us a non-exclusive, royalty 
bearing license to patents, with the right to grant sublicenses for HEPLISAV-B (the “Coley Agreement). We met one of the 
regulatory milestones upon FDA approval of HEPLISAV-B in November 2017 and paid $2.5 million in January 2018 to 
Coley which was recorded as an intangible asset on the consolidated balance sheets. See Note 6. The Coley Agreement 
terminated in February 2018, at which time the license became a perpetual, irrevocable, fully paid-up and royalty free license. 
As of December 31, 2018, the $2.5 million intangible asset has been fully amortized.

11. Long-Term Debt 

Long-Term Debt

On February 20, 2018, we entered into a $175.0 million term loan agreement (“Loan Agreement”) with CRG Servicing 
LLC. The Loan Agreement provides for a $175.0 million term loan facility, $100.0 million of which was borrowed at closing 
(“Initial Term Loan”) and, subject to the satisfaction of certain market capitalization and other borrowing conditions, up to an 
additional $75.0 million is available for borrowing at our option on or before July 17, 2019 (together with the Initial Term 
Loan, the “Term Loans”). Net proceeds from the Initial Term Loan were $99.0 million. The Term Loans under the Loan 
Agreement bear interest at a rate equal to 9.5% per annum. At December 31, 2018, the effective interest rate was 10.1%. At 
our option, until September 30, 2023, a portion of the interest payments may be paid in kind, and thereby added to the 
principal. Through December 31, 2018, a portion of our interest was paid in kind, which increased the principal amount of 
the Term Loans to $101.8 million. The Term Loans have a maturity date of December 31, 2023, unless earlier prepaid. The 
Term Loans and paid-in-kind interest will be entirely payable at maturity. 

The obligations under the Loan Agreement are secured, subject to customary permitted liens and other agreed upon 

exceptions, by a perfected security interest in (i) all tangible and intangible assets of the Company and any future subsidiary 
guarantors, except for certain customary excluded property, and (ii) all of the capital stock owned by the Company and such 
future subsidiary guarantors (limited, in the case of the stock of certain non-U.S. subsidiaries of the Company and certain U.S. 
subsidiaries substantially all of whose assets consist of equity interests in non-U.S. subsidiaries, to 65% of the capital stock of 
such subsidiaries, subject to certain exceptions). The obligations under the Loan Agreement will be guaranteed by each of the 
Company’s future direct and indirect subsidiaries (other than certain non-U.S. subsidiaries of the Company and certain U.S. 
subsidiaries substantially all of whose assets consist of equity interests in non-U.S. subsidiaries, subject to certain exceptions). 
The Loan Agreement contains customary covenants and requires us to comply with a $15.0 million daily minimum combined 
cash and investment balance covenant and an annual revenue requirement starting in 2019 for sales of HEPLISAV-B.

The Term Loans may be prepaid by us at any time. If the Term Loans are prepaid prior to the second anniversary of the 

initial borrowing date, we are subject to a repayment premium of up to 7.0% of the principal amount prepaid, depending on 
the date of prepayment.

We recorded $8.8 million of interest expense related to the Initial Term Loan during the year ended December 31, 2018. 

Note Purchase Agreement

In October 2016, we entered into a Note Purchase Agreement pursuant to which the Company would borrow $100.0 

million upon approval of HEPLISAV-B. The Company paid the prospective lender $1.0 million upon entering into the Note 
Purchase Agreement and incurred additional expenses of $1.6 million in securing the Note Purchase Agreement. No notes 
were ultimately sold by the Company under the Note Purchase Agreement.

72

In December 2016, the Company terminated the Note Purchase Agreement and paid a termination fee of $1.5 million. 

The $1.0 million paid upon entering in the note purchase agreement and $1.5 million termination fee are included in other 
expense in the consolidated statements of operations. The additional expenses of $1.6 million related to securing the Note 
Purchase Agreement are included in loss from operations in the consolidated statement of operations.

12. Revenue Recognition 

Our source of product revenue for the year ended December 31, 2018, consists of sales of HEPLISAV-B in the U.S. 

The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the 
year ended December 31, 2018 (in thousands):

Chargebacks, discounts 
and other fees

Returns

Total

Balance at December 31, 2017..................................  $
Provision related to current period sales .............. 
Credit or payments made during the period......... 
Balance at December 31, 2018..................................  $

-    $

4,012   
(2,276)  
1,736    $

-    $

570   
(1)  
569    $

- 
4,582 
(2,277)
2,305  

At December 31, 2018, reserves for chargebacks and discounts totaling $1.3 million were recorded as reductions of 
accounts receivable while the remaining reserves balances totaling $1.0 million were recorded as accrued liabilities in the 
condensed consolidated balance sheets.

13. Net Loss Per Share 

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares 
outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average 
number of common shares outstanding during the period and giving effect to all potentially dilutive common shares using the 
treasury-stock method. For purposes of this calculation, outstanding stock options and stock awards are considered to be 
potentially dilutive common shares and are only included in the calculation of diluted net loss per share when their effect is 
dilutive.

2018

December 31,
2017

2016

Basic and diluted net loss per share (in thousands, except per 
share amounts):
Numerator:

Net loss ...................................................................................................

 $

(158,899)

 $

(95,154)

 $

(112,444)

Denominator for basic and diluted net loss per share:

Weighted-average common shares outstanding .....................................
Basic and diluted net loss per share .............................................................

 $

62,362 
(2.55)

 $

52,613 
(1.81)

 $

38,506 
(2.92)

Outstanding stock options and stock awards were excluded from the calculation of net loss per share allocable to 

common stockholders as the effect of their inclusion would have been anti-dilutive.

Outstanding securities not included in diluted net loss per share 
calculation (in thousands):
Stock options and stock awards....................................................................

7,344 

5,981 

4,673  

2018

December 31,
2017

2016

73

 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
    
 
    
 
  
  
  
14. Common Stock 

Common Stock Outstanding

As of December 31, 2018, there were 62,862,478 shares of our common stock outstanding. 

On November 3, 2017, we entered into an At Market Sales Agreement (“2017 ATM Agreement”) with Cowen and 
Company, LLC (“Cowen”) under which we may offer and sell from time to time at our sole discretion, shares of our common 
stock having an aggregate offering price up to $150 million through Cowen as our sales agent. We pay Cowen a commission 
of up to 3% of the gross sales proceeds of any common stock sold through Cowen under the 2017 ATM Agreement. For the 
year ended December 31, 2017, we received net cash proceeds of $16.9 million resulting from sales of 840,774 shares of our 
common stock. As of December 31, 2018, we have $132.8 million remaining under the 2017 ATM Agreement. Subsequent 
to December 31, 2018 and through February 22, 2019, we sold 1,078,901 shares of common stock for net proceeds of $11.5 
million under the 2017 ATM Agreement.

In August 2017, we completed an underwritten public offering of 5,750,000 shares of our common stock, including 

750,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the 
shares were offered at a price to the public of $15.00 per share. The net proceeds to us from this offering were approximately 
$80.8 million, after deducting the underwriting discount and other estimated offering expenses payable by us.

As of December 31, 2017, we received net cash proceeds of $88.2 million from sales of 15,997,202 shares of our 

common stock under a now terminated At Market Sales Agreement.

15. Equity Plans and Stock-Based Compensation

Stock Plans 

On May 31, 2018, our stockholders approved the 2018 Equity Incentive Plan (the “2018 EIP”). The 2018 EIP is 

intended to be the successor to the Dynavax Technologies Corporation 2011 Equity Incentive Plan (the “2011 EIP”). The 
aggregate number of shares of our common stock that may be issued under the 2018 EIP (subject to adjustment for certain 
changes in capitalization) is comprised of the sum of (i) 5,000,000 newly reserved shares of common stock, (ii) 140,250 
unallocated shares of common stock remaining available for grant under the 2011 EIP as of May 31, 2018, and (iii) 7,477,619  
shares subject to outstanding stock awards granted under the 2011 EIP and the Dynavax Technologies Corporation 2017 
Inducement Award Plan that may become available from time to time as set forth in the 2018 EIP. The 2018 EIP provides for 
the issuance of up to 12,617,869 shares of our common stock to employees of the Company. The 2018 EIP is administered by 
our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the 2018 EIP have a 
term of 7 years unless earlier terminated by the Board of Directors. As of December 31, 2018, options to purchase 5,750,404 
shares of common stock remained outstanding under the 2018 EIP. As of December 31, 2018, there were 4,810,112 shares of 
common stock reserved for issuance under the 2018 EIP.

Activity under our stock plans is set forth below: 

Shares Underlying
Outstanding Options
(in thousands)

Weighted-Average Exercise
Price Per Share

Weighted-Average
Remaining
Contractual Term
(years)

Aggregate
Intrinsic Value
(in thousands)  

Balance at December 31, 2017.................
Options granted ..................................
Options exercised...............................
Options cancelled:

Options forfeited (unvested) ........
Options expired (vested) ..............
Balance at December 31, 2018.................

Vested and expected to vest at December 
31, 2018....................................................

Exercisable at December 31, 2018...........

3,555 
2,503 
(42)

(178)
(88)
5,750 

5,534 

2,975 

 $

 $

$

 $

74

19.56 
16.30 
11.80 

14.29 
29.58 
18.20 

18.28 

19.90 

5.47 

5.44 

4.87 

 $

 $

 $

651 

644 

466  

 
 
 
 
 
 
 
 
 
  
    
 
    
 
  
  
    
 
    
 
  
  
    
 
    
 
  
  
    
 
    
 
    
 
  
  
    
 
    
 
  
  
    
 
    
 
  
  
 
 
 
  
  
  
 
The total intrinsic value of stock options exercised during the years ended December 31, 2018, 2017 and 2016 was $0.2 
million, $0.9 million and $0.2 million, respectively. The total intrinsic value of exercised stock options is calculated based on 
the difference between the exercise price and the quoted market price of our common stock as of the close of the exercise 
date.

The total fair value of stock options vested during the years ended December 31, 2018, 2017 and 2016 was $8.1 

million, $13.0 million and $12.1 million, respectively. 

Our non-vested stock awards are comprised of restricted stock units granted with performance and time-based vesting 
criteria. A summary of the status of non-vested restricted stock units as of December 31, 2018, and activities during 2018 are 
summarized as follows:  

Non-vested as of December 31, 2017.................................................... 
Granted .................................................................................................. 
Vested .................................................................................................... 
Forfeited ................................................................................................ 
Non-vested as of December 31, 2018.................................................... 

2,443 
458 
(1,219)
(88)
1,594 

 $

 $

6.01 
15.98 
5.86 
9.07 
8.82  

Number of Shares
(In thousands)

Weighted-Average
Grant-Date Fair Value

Stock-based compensation expense related to restricted stock units was approximately $8.4 million for the year ended 

December 31, 2018. The aggregate intrinsic value of the restricted stock units outstanding as of December 31, 2018, based on 
our stock price on that date, was $14.6 million. 

The weighted average grant-date fair value of restricted stock units granted during the years ended December 31, 2018, 

2017 and 2016 was, $15.98, $5.34 and $12.42, respectively. The total fair value of restricted stock units vested during the 
years ended December 31, 2018, 2017 and 2016 was $19.4 million, $1.2 million and $1.0 million, respectively.

Stock-Based Compensation 

Under our stock-based compensation plans, option awards generally vest over a three-year or four-year period 
contingent upon continuous service and unless exercised, expire seven or ten years from the date of grant (or earlier upon 
termination of continuous service). The Company has also granted performance-based equity awards to certain of our 
employees. As of December 31, 2018, approximately 151,000 shares underlying stock options and approximately 12,500 
restricted stock unit awards with performance-based vesting criteria were outstanding. Vesting criteria for 5,000 of the 
awards with performance-based vesting criteria were not probable as of December 31, 2018. We recognized stock-based 
compensation expense for awards with performance-based vesting criteria during the years ended December 31, 2018, 2017 
and 2016 of $1.9 million, $0.3 million and $0.5 million, respectively.

The fair value of each option is estimated on the date of grant using the Black-Scholes option valuation model and the 

following weighted-average assumptions:

2018  
Weighted-average fair value ........................   $ 10.75 
Risk-free interest rate ...................................  
Expected life (in years) ................................  
Expected Volatility.......................................  

Stock Options
Year Ended December 31,
2017  
8.27 
 $
1.9%   
4.5 
0.9 

 $
2.5%   
4.2 
0.8 

2016  
9.54 
 $
1.4%   
4.9 
0.7 

  Employee Stock Purchase Plan  
Year Ended December 31,
2017  
3.05 
  $
1.0%   
1.2 
1.0 

2018  
8.30 
  $
2.4%   
1.3 
1.1 

2016  
7.86 
0.6%
1.2 
0.6  

Expected volatility is based on historical volatility of our stock price. The expected life of options granted is estimated 

based on historical option exercise and employee termination data. Our senior management, who hold a majority of the 
options outstanding, and other employees were grouped and considered separately for valuation purposes. The risk-free rate 
for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. 
Forfeiture estimates are based on historical employee turnover. The dividend yield is zero percent for all years and is based 
on our history and expectation of dividend payouts. 

75

 
 
 
 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
 
 
 
 
 
  
  
  
 
 
 
 
Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity 

awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods. For 
equity awards with performance-based vesting criteria, the fair value is amortized to expense when the achievement of the 
vesting criteria becomes probable. 

We recognized the following amounts of stock-based compensation expense (in thousands): 

Year Ended December 31,
2017

2018

2016

Employees and directors stock-based compensation expense ....................... 

$

23,478 

 $

14,917 

 $

14,126 

Year Ended December 31,
2017

2018

2016

Research and development............................................................................. 
Selling, general and administrative ................................................................ 
Cost of sales - product .................................................................................... 
Inventory ........................................................................................................ 
Total ............................................................................................................... 

$

$

9,604 
11,761 
1,354 
759 
23,478 

 $

 $

7,827 
7,090 
- 
- 
14,917 

 $

 $

6,742 
7,384 
- 
- 
14,126  

In addition, the cash-settled portion of stock compensation expense was $0.6 million for the year ended December 31, 

2016. No cash-settled portion of stock compensation expense was incurred during 2017 or 2018.

As of December 31, 2018, the total unrecognized compensation cost related to non-vested stock options and awards 
deemed probable of vesting, including all stock options with time-based vesting, net of estimated forfeitures, amounted to 
$26.1 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.9 years. 
Additionally, as of December 31, 2018, the total unrecognized compensation cost related to equity awards with performance-
based vesting criteria amounted to $0.3 million. 

Employee Stock Purchase Plan 

The Amended and Restated 2014 Employee Stock Purchase Plan (the “Purchase Plan”) provides for the purchase of 
common stock by eligible employees and became effective on May 28, 2014. On May 31, 2018, our stockholders approved 
an amendment to the Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance by 
600,000 shares. The purchase price per share is the lesser of (i) 85% of the fair market value of the common stock on the 
commencement of the offer period (generally, the sixteenth day in February or August) or (ii) 85% of the fair market value of 
the common stock on the exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or 
August). For the year ended December 31, 2018, employees have acquired 125,193 shares of our common stock under the 
Purchase Plan and 573,034 shares of our common stock remained available for future purchases under the Purchase Plan. 

As of December 31, 2018, the total unrecognized compensation cost related to shares of our common stock under the 

Purchase Plan amounted to $0.5 million, which is expected to be recognized over the remaining weighted-average vesting 
period of 1.6 years.

16. Employee Benefit Plan 

We maintain a 401(k) Plan, which qualifies as a deferred salary arrangement under Section 401(k) of the Internal 
Revenue Code. Under the 401(k) Plan, participating employees may defer a portion of their pretax earnings. We may, at our 
discretion, contribute for the benefit of eligible employees. The Company’s contribution to the 401(k) Plan was 
approximately $0.2 million for each of the years ended December 31, 2018, 2017 and 2016. 

17. Restructuring 

In January 2017, we implemented organizational restructuring and cost reduction plans to align around our immuno-
oncology business while allowing us to advance HEPLISAV-B through the FDA review and approval process. To achieve 
these cost reductions, we suspended manufacturing activities, commercial preparations and other long term investment 
related to HEPLISAV-B and reduced our global workforce by approximately 40 percent. In the first quarter of 2017 we 
recorded charges of $2.8 million related to severance, other termination benefits and outplacement services. All of the $2.8 
million was paid in 2017.

76

 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
  
  
 
  
  
18.

Income Taxes

Consolidated (loss) income before provision for income taxes consisted of the following (in thousands): 

U.S................................................................................................. 
Non U.S......................................................................................... 
Total .............................................................................................. 

$

$

Year Ended December 31,
2017

$

$

(95,898)  
744   
(95,154)  

$

$

2018
(160,032)  
1,133   
(158,899)  

2016
(114,484)
2,040 
(112,444)

No income tax expense was recorded for the years ended December 31, 2018, 2017 and 2016 due to our full valuation 

allowance position. The difference between the consolidated income tax benefit and the amount computed by applying the 
federal statutory income tax rate to the consolidated loss before income taxes was as follows (in thousands):

Year Ended December 31,
2017

2016

2018

Income tax benefit at federal statutory rate ................................... 
State tax ......................................................................................... 
Business credits ............................................................................. 
Deferred compensation charges .................................................... 
Change in valuation allowance...................................................... 
Rate change ................................................................................... 
Net operating loss and tax credit limitation................................... 
Other .............................................................................................. 
Total income tax expense .............................................................. 

$

$

(33,366)  
(5,591)  
(3,065)  
(1,165)  
43,134   
-   
-   
53   
-   

$

$

(32,352)  
(4,482)  
(1,960)  
3,823   
(109,165)  
86,943   
56,962   
231   
-   

$

$

(38,183)
(334)
(1,950)
3,016 
36,751 
- 
- 
700 
-  

Deferred tax assets and liabilities consisted of the following (in thousands): 

Deferred tax assets:

Net operating loss carry forwards................................................................ 
Research tax credit carry forwards .............................................................. 
Accruals and reserves .................................................................................. 
Capitalized research costs............................................................................ 
Other ............................................................................................................ 
Total deferred tax assets.......................................................................................  
Less valuation allowance ..................................................................................... 
Net deferred tax assets ......................................................................................... 
Deferred tax liabilities:

Fixed assets..................................................................................................  
Total deferred tax liabilities ................................................................................. 
Net deferred tax assets ......................................................................................... 

$

$

December 31,

2018

2017

178,730   
34,064   
10,137   
943   
1,147   
225,021   
(224,746)  
275   

(275)  
(275)  
-   

$

$

146,300 
29,658 
6,551 
1,422 
731 
184,662 
(184,388)
274 

(274)
(274)
-  

The tax benefit of net operating losses, temporary differences and credit carryforwards is required to be recorded as an 
asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is 
dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our recent history 
of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future 
tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance. The valuation 
allowance increased by $40.4 million during the year ended December 31, 2018 due to an increase in our deferred tax assets 
and decreased by $108.8 million during the year ended December 31, 2017 primarily as a result of the reduction in our 
deferred tax assets resulting from the decrease in the U.S. federal statutory tax rate. 

77

 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
 
 
 
 
 
On December 22, 2017, President Trump signed U.S. tax reform legislation, commonly referred to as the Tax Cuts and 

Jobs Act (the “Tax Act”), which became effective January 1, 2018. The Tax Act significantly changes the fundamentals of 
U.S. corporate income taxation by, among many other things, reducing the U.S. federal corporate income tax rate to 21%, 
converting to a territorial tax system, and creating various income inclusion and expense limitation provisions. 

Also on December 22, 2017, The Securities and Exchange Commission staff issued Staff Accounting Bulletin (“SAB”) 

118 to provide guidance for companies that are not able to complete their accounting for the income tax effects of the Tax 
Act in the period of enactment. SAB 118 provides for a measurement period of up to one year from the date of enactment. 
During the measurement period, companies need to reflect adjustments to any provisional amounts if it obtains, prepares or 
analyzes additional information about facts and circumstances that existed as of the enactment date that, if known, would 
have affected the income tax effects initially reported as provisional amounts.

At December 31, 2018 we have completed our analysis of the Tax Act. The Act included a re-measurement of our net 
U.S. deferred tax assets reducing the U.S. federal corporate rate to 21%, which was offset by a valuation allowance. During 
2018, this amount was finalized and no additional adjustment was required due to the change in corporate tax rate. 

The one-time transition tax is based on our total post-1986 earnings and profits that we previously deferred from U.S. 
income taxes. In 2017 we recorded a provisional amount for our one-time transition tax liability for our foreign subsidiaries. 
In 2018 the transition tax calculation was completed. The transition tax that we calculated resulted in an immaterial reduction 
income from the provisional amount recorded in 2017.

Also effective for 2018 is a new Global Intangible Low-Taxed Income inclusion (“GILTI”). The GILTI income 
inclusion did not have a material impact on our 2018 current loss or valuation allowance position. We elected to account for 
GILTI as a period cost in the year the income or tax is incurred.

As of December 31, 2018, we had federal net operating loss carryforwards of approximately $771.8 million, which will 

begin to expire in the year 2019 and federal research and development tax credits of approximately $19.9 million, which 
expire in the years 2019 through 2038. 

As of December 31, 2018, we had net operating loss carryforwards for California and other states for income tax 

purposes of approximately $229.0 million, which expire in the years 2019 through 2038, and California state research and 
development tax credits of approximately $19.1 million, which do not expire.

As of December 31, 2018, we had net operating loss carryforwards for foreign income tax purposes of approximately 

$11.9 million, which do not expire.

Uncertain Income Tax positions

The total amount of unrecognized tax benefits was $1.2 million as of each of the years ended December 31, 2018 and 

2017. If recognized, none of the unrecognized tax benefits would affect the effective tax rate. 

The following table summarizes the activity related to our unrecognized tax benefits:

Balance at December 31, 2017 ......................................................................................................... 
Tax positions related to the current year
  Additions ......................................................................................................................................... 
  Reductions....................................................................................................................................... 
Tax positions related to the prior year
  Additions ......................................................................................................................................... 
  Reductions....................................................................................................................................... 
Balance at December 31, 2018 ......................................................................................................... 

$

$

(1,229)

- 
- 

- 
- 
(1,229)

78

 
 
   
 
 
 
 
   
 
 
 
Our policy is to account for interest and penalties as income tax expense. As of December 31, 2018, there was no 
interest related to unrecognized tax benefits. No amounts of penalties related to unrecognized tax benefits were recognized in 
the provision for income taxes. We do not anticipate any significant change within 12 months of this reporting date of its 
uncertain tax positions.

The Tax Reform Act of 1986 limits the annual use of net operating loss and tax credit carryforwards in certain 
situations where changes occur in stock ownership of a company. In the event there is a change in ownership, as defined, the 
annual utilization of such carryforwards could be limited. Based on an analysis under Section 382 of the Internal Revenue 
Code, completed through December 31, 2018, we experienced ownership changes in 2008, 2009 and 2012 which limit the 
future use of its pre-change federal net operating loss carryforwards and federal research and development tax credits. We 
excluded these federal net operating loss carryforwards and federal research and development tax credits that will expire as a 
result of the annual limitations in the deferred tax assets as of December 31, 2018. A limitation calculation has not been 
performed with respect to the California net operating loss carryforwards and research and development tax credits and we 
believe that our ability to use these California net operating loss carryforwards and research and development tax credits in 
the future may be limited. 

We are subject to income tax examinations for U.S. federal and state income taxes from 1999 forward. We are subject 

to tax examination in Germany from 2017 forward and in India from 2018 forward.

19.

Selected Quarterly Financial Data (Unaudited; in thousands, except per share amounts)

Year Ended December 31, 2018

Q1

Q2

Q3

Total revenues...........................................................................   $
Net loss .....................................................................................   $
Basic and diluted net loss per share..........................................   $
Shares used to compute basic and diluted net loss per share....  

165    $
(38,958)   $
(0.63)   $

1,254    $
(39,444)   $
(0.63)   $

1,461    $
(40,528)   $
(0.65)   $

61,744   

62,346   

62,650   

Total revenues...........................................................................   $
Net loss .....................................................................................   $
Basic and diluted net loss per share..........................................   $
Shares used to compute basic and diluted net loss per share....  

148    $
(25,287)   $
(0.60)   $

105    $
(20,318)   $
(0.41)   $

53    $
(22,128)   $
(0.38)   $

41,830   

49,700   

57,650   

Year Ended December 31, 2017

Q1

Q2

Q3

Q4

5,318 
(39,969)
(0.64)
62,694 

Q4

21 
(27,421)
(0.45)
61,007  

79

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND 
FINANCIAL DISCLOSURE 

None.

ITEM 9A.

CONTROLS AND PROCEDURES 

(a) Evaluation of Disclosure Controls and Procedures 

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities 
Exchange Act of 1934 (“the Exchange Act”)) that are designed to ensure that information required to be disclosed in our 
Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and 
Exchange Commission rules and forms and that such information is accumulated and communicated to our management, 
including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow for timely decisions regarding 
required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any 
controls and procedures, no matter how well designed and operated, can only provide reasonable, not absolute, assurance of 
achieving the desired control objectives. 

Based on their evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as 

of the end of the period covered by this report, our management, with the participation of our Chief Executive Officer and our 
Chief Financial Officer, concluded that our disclosure controls and procedures are effective and were operating at the 
reasonable assurance level to ensure that information required to be disclosed by us in reports that we file or submit under the 
Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and 
Exchange Commission rules and forms. 

(b) Management’s Annual Report on Internal Control Over Financial Reporting 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as 

defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our management, with the participation of our Chief 
Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over 
financial reporting based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring 
Organizations of the Treadway Commission (2013 Framework). Based on that evaluation, our management concluded that 
our internal control over financial reporting was effective as of December 31, 2018. The Company’s independent registered 
public accountants, Ernst & Young LLP, audited the consolidated financial statements included in this Annual Report on 
Form 10-K and have issued a report on the Company’s internal control over financial reporting. The report on the audit of 
internal control over financial reporting appears below.

80

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Dynavax Technologies Corporation

Opinion on Internal Control over Financial Reporting

We have audited Dynavax Technologies Corporation’s internal control over financial reporting as of December 31, 2018, 
based on criteria established in Internal Control— Integrated Framework issued by the Committee of Sponsoring 
Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Dynavax Technologies 
Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of 
December 31, 2018, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) 
(PCAOB), the consolidated balance sheets of the Company as of December 31, 2018 and 2017, and the related consolidated 
statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period 
ended December 31, 2018 and the related notes of the Company and our report dated February 27, 2019 expressed an 
unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its 
assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s 
Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s 
internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and 
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the 
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform 
the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in 
all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material 
weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, 
and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a 
reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the 
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally 
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures 
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and 
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to 
permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and 
expenditures of the company are being made only in accordance with authorizations of management and directors of the 
company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or 
disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, 
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate 
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP

San Francisco, California
February 27, 2019

81

(c) Changes in Internal Control Over Financial Reporting 

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has 

materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 

ITEM 9B.

OTHER INFORMATION 

None.

82

PART III 

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 

Information required by this Item is incorporated by reference to the sections entitled “Proposal 1—Elections of 
Directors,” “Executive Officers,” “Corporate Governance” and “Section 16(a) Beneficial Ownership Reporting Compliance” 
in our Definitive Proxy Statement in connection with the 2019 Annual Meeting of Stockholders (the “Proxy Statement”) 
which will be filed with the Securities and Exchange Commission within 120 days after the fiscal year ended December 31, 
2018. 

We have adopted the Dynavax Code of Business Conduct and Ethics (“Code of Conduct”), a code of ethics that applies 

to our employees, including our Chief Executive Officer, Chief Financial Officer and to our non-employee directors. The 
Code of Conduct is publicly available on our website under the Investors and Media section at www.dynavax.com. This 
website address is intended to be an inactive, textual reference only; none of the material on this website is part of this report. 
If any substantive amendments are made to the Code of Conduct or any waiver granted, including any implicit waiver, from a 
provision of the Code of Conduct to our Chief Executive Officer or Chief Financial Officer, we will disclose the nature of 
such amendment or waiver on that website or in a report on Form 8-K. We will provide a written copy of the Dynavax Code 
of Conduct to anyone without charge, upon request written to Dynavax, Attention: Corporate Secretary, 2929 Seventh Street, 
Suite 100, Berkeley, CA 94710-2753, (510) 848-5100. 

ITEM 11.

EXECUTIVE COMPENSATION 

Information required by this Item is incorporated by reference to the section entitled “Executive Compensation 
Program,” “Director Compensation,” “Compensation Discussion and Analysis,” “Report of the Compensation Committee of 
the Board of Directors on Executive Compensation,” “Outstanding Equity Awards at Fiscal Year End” and “Compensation 
Committee Interlocks and Insider Participation” in the Proxy Statement. 

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND 
RELATED STOCKHOLDER MATTERS 

Information regarding security ownership of certain beneficial owners and management is incorporated by reference to 

the section entitled “Security Ownership of Certain Beneficial Owners and Management” in the Proxy Statement. 
Information regarding our stockholder approved and non-approved equity compensation plans are incorporated by reference 
to the section entitled “Equity Compensation Plans” in the Proxy Statement. 

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR 
INDEPENDENCE 

Information required by this Item is incorporated by reference to the sections entitled “Certain Transactions With” and 

“Independence of the Board of Directors” in the Proxy Statement. 

ITEM 14.

PRINCIPAL ACCOUNTING FEES AND SERVICES 

Information required by this Item is incorporated by reference to the section entitled “Audit Fees” in the Proxy 

Statement.

83

PART IV

ITEM 15.

EXHIBITS, FINANCIAL STATEMENT SCHEDULES 

(a) Documents filed as part of this report: 

1. Financial Statements 

Report of Independent Registered Public Accounting Firm 

Consolidated Balance Sheets 

Consolidated Statements of Operations 

Consolidated Statements of Comprehensive Loss 

Consolidated Statements of Stockholders’ Equity 

Consolidated Statements of Cash Flows 

Notes to Consolidated Financial Statements 

2. Financial Statement Schedules 

None, as all required disclosures have been made in the Consolidated Financial Statements and notes thereto or are not 

applicable. 

(b) Exhibits

Exhibit
Number

Document

Exhibit
Number

3.1

3.2

3.3

3.4

3.5

3.6

3.7

3.8

Sixth Amended and Restated 
Certificate of Incorporation

Amended and Restated 
Bylaws

Form of Certificate of 
Designation of Series A 
Junior Participating Preferred 
Stock

Certificate of Amendment of 
Amended and Restated 
Certificate of Incorporation

Certificate of Amendment of 
Amended and Restated 
Certificate of Incorporation

Certificate of Amendment of 
Amended and Restated 
Certificate of Incorporation

Certificate of Amendment of 
the Sixth Amended and 
Restated Certificate of 
Incorporation

Certificate of Amendment of 
the Sixth Amended and 
Restated Certificate of 
Incorporation

Incorporated by Reference

Filing

S-1/A

10-Q

Filing Date

File No.

Filed Herewith

February 5, 2004

333-109965

November 6, 
2018

001-34207

8-K

November 6, 2008

000-50577

3.1

3.8

3.3

3.1

8-K

January 4, 2010

001-34207

3.1

8-K

January 5, 2011

001-34207

3.6

8-K

May 30, 2013

001-34207

3.1

8-K

November 10, 2014

001-34207

3.1

8-K

June 2, 2017

001-34207

84

Exhibit
Number

3.9

4.1

4.2

10.01†

10.02

10.03†

10.04

10.05

10.6

10.7

Document

Certificate of Amendment of 
the Sixth Amended and 
Restated Certificate of 
Incorporation

Reference is made to Exhibits 
3.1, 3.2, 3.3, 3.4, 3.5, 3.6,  
3.7, 3.8 and 3.9 above

Form of Specimen Common 
Stock Certificate

Research Collaboration and 
License Agreement, dated 
September 1, 2006, by and 
between the Company and 
AstraZeneca AB

License Agreement, dated 
June 26, 2007, between 
Coley Pharmaceuticals 
Group, Inc. and the Company

Amendment No. 2 to the 
Research Collaboration and 
License Agreement, dated 
September 1, 2006, by and 
between the Company and 
AstraZeneca AB, dated 
February 3, 2009

Amended and Restated 
Purchase Option Agreement, 
dated November 9, 2009, 
between the Company and 
Symphony Dynamo Holdings 
LLC and Symphony Dynamo, 
Inc.

Amendment No. 3 to the 
Research Collaboration and 
License Agreement, dated 
September 1, 2006, by and 
between the Company and 
AstraZeneca AB, dated 
September 30, 2010

Lease, dated January 7, 2004, 
between the Company and 
2929 Seventh Street, LLC

First Amendment to Lease, 
dated as of May 21, 2004, 
between the Company and 
2929 Seventh Street, LLC

Incorporated by Reference

Exhibit
Number

3.1

Filing

8-K

Filing Date

File No.

Filed Herewith

July 31, 2017

001-34207

4.2

S-1/A

January 16, 2004

333-109965

10.30

10-Q

November 3, 2006

000-50577

10.2

10-Q

November 3, 
2017

001-34207

10.40

10-Q

April 30, 2009

001-34207

10.47

10-K

March 16, 2010

001-34207

10.54

8-K

October 4, 2010

001-34207

10.17

S-1/A

January 16, 2004

333-109965

10.55

8-K

October 13, 2010

001-34207

85

Exhibit
Number

10.8

10.9+

10.10+

10.11+

10.12

10.13†

10.14

10.15

10.16+

10.17+

Document

Second Amendment to Lease, 
dated as of October 12, 2010, 
between the Company and 
2929 Seventh Street, LLC

Amended and Restated 2011 
Equity Incentive Plan

Form of Restricted Stock 
Unit Award Notice and 
Restricted Stock Unit Award 
Agreement under the 2011 
Equity Incentive Plan

Form of Stock Option Grant 
Notice and Option 
Agreement under the 2011 
Equity Incentive Plan

Third Amendment to Lease, 
dated as of April 1, 2011, 
between the Company and 
2929 Seventh Street, LLC

Amendment No. 4 to the 
Research Collaboration and 
License Agreement, dated  
September 1, 2006, by and 
between AstraZeneca AB and 
the Company, dated 
September 23, 2011

Fourth Amendment to Lease, 
dated as of December 14, 
2012, between the Company 
and 2929 Seventh Street, 
LLC

Lease, dated as of December 
14, 2012, between the 
Company and 2929 Seventh 
Street, LLC

Employment Agreement, 
dated as of April 3, 2013, by 
and between Eddie Gray and 
the Company

Management Continuity and 
Severance Agreement, dated 
as of April 3, 2013, by and 
between Eddie Gray and the 
Company

Incorporated by Reference

Exhibit
Number

10.56

Filing

8-K

Filing Date

File No.

Filed Herewith

October 13, 2010

001-34207

99.1

S-8

June 1, 2016

333-211747

99.2

S-8

January 6, 2011

333-171552

99.3

S-8

January 6, 2011

333-171552

10.65

10-Q

August 3, 2011

001-34207

10.67

10-K

March 12, 2012

001-34207

10.72

10-K

March 8, 2013

001-34207

10.73

10-K

March 8, 2013

001-34207

10.78

8-K

May 3, 2013

001-34207

10.79

8-K

May 3, 2013

001-34207

86

Exhibit
Number

10.18†

10.19+

10.20+

10.21+

10.22+

10.23†

10.24

10.25+

10.26

10.27

Document

Amendment No. 5 to the 
Research Collaboration and 
License Agreement, dated 
September 1, 2006, by and 
between AstraZeneca AB and 
the Company, dated 
January 7, 2014

Employment Agreement, 
dated March 6, 2013, by and 
between David Novack and 
the Company

Employment Agreement, 
dated July 12, 2013, by and 
between Robert Janssen, 
M.D. and the Company

Employment Agreement, 
dated February 4, 2014, by 
and between David L. 
Johnson and the Company

Amended and Restated 2014 
Employee Stock Purchase 
Plan

Amendment No. 6 to the 
Research Collaboration and 
License Agreement, dated 
September 1, 2006, by and 
between AstraZeneca AB and 
the Company, effective as of 
December 8, 2014

Amendment No. 7 to the 
Research Collaboration and 
License Agreement, dated 
September 1, 2006, by and 
between AstraZeneca AB and 
the Company, effective as of 
January 13, 2016

Form of Amended and 
Restated Management 
Continuity and Severance 
Agreement between the 
Company and certain of its 
executive officers

Fifth Amendment to Lease, 
dated as of May 15, 2017, 
between the Company and 
2929 Seventh Street, LLC

Sales Agreement, dated 
November 3, 2017, between 
the Company and Cowen and 
Company, LLC

Incorporated by Reference

Exhibit
Number

10.88

Filing

10-K

Filing Date

File No.

Filed Herewith

March 10, 2014

001-34207

10.84

10-K

March 10, 2014

001-34207

10.85

10-K

March 10, 2014

001-34207

10.86

10-K

March 10, 2014

001-34207

99.4

S-8

June 1, 2016

333-211747

10.36

10-K

March 5, 2015

001-34207

10.29

10-K

March 8, 2016

001-34207

10.1

8-K

April 19, 2016

001-34207

10.2

10-Q

August 7, 2017

001-34207

10.1

10-Q

November 3, 2017

001-34207

87

Exhibit
Number

10.28†

10.29†

10.30†

10.31†

10.32†

10.33†

10.34†

10.35†

10.36

10.38

10.39

Document

Exhibit
Number

Filing

Filing Date

File No.

Filed Herewith

Incorporated by Reference

2017 Inducement Award Plan

10.1

8-K

November 30, 2017

001-34207

Master Services Agreement, 
dated January 11, 2016, 
between the Company and 
inVentiv Commercial 
Services, LLC

Project Agreement, dated 
October 31, 2017 between 
the Company and inVentiv 
Commercial Services, LLC

First Amendment to Project 
Agreement, dated October 
31, 2017 between Company 
and inVentiv Commercial 
Services, LLC

Commercial Manufacturing 
and Supply Agreement, dated 
November 22, 2013, between 
Company and Baxter 
Pharmaceutical Solutions 
LLC

Supply Agreement, dated 
November 2, 2016, between 
Company and Becton, 
Dickinson and Company

Supply Agreement, dated 
October 1, 2012, between 
Company and Nitto Denko 
Avecia, Inc.

Supply Agreement, dated 
July 27, 2016, between 
Company and West 
Pharmaceutical Services, Inc.
Amended and Restated 2004 
Non-Employee Director 
Option Program and 
Amended and Restated 2005 
Non-Employee Director Cash 
Compensation Program, as 
amended.
Sublicense Agreement, 
effective as of February 16, 
2018, by and between the 
Company and Merck, Sharpe 
& Dohme Corp.
Term Loan Agreement, dated 
as of February 20, 2018 
among the Company, certain 
Lenders party hereto and 
CRG Servicing LLC, as 
agent for the Lenders

10.30

10-K

March 8, 2018

001-34207

10.31

10-K

March 8, 2018

001-34207

10.32

10-K

March 8, 2018

001-34207

10.33

10-K

March 8, 2018

001-34207

10.34

10-K

March 8, 2018

001-34207

10.35

10-K

March 8, 2018

001-34207

10.36

10-K

March 8, 2018

001-34207

10.1

10-Q

May 9, 2018

001-34207

10.2

10-Q

May 9, 2018

001-34207

10.3

10-Q

May 9, 2018

001-34207

88

Exhibit
Number

10.40†

10.41†

10.42†

10.43

21.1

23.1

31.1

31.2

32.1*

32.2*

Document

2018 Equity Incentive Plan

Form of Restricted Stock 
Unit Award Grant Notice and 
Restricted Stock Unit Award 
Agreement under the 2018 
Equity Incentive Plan

Form of Option Grant Notice 
and Option Agreement under 
the 2018 Equity Incentive 
Plan

Office/Laboratory Lease, 
dated September 17, 2018, 
between the Company and 
Emery Station West, LLC

List of Subsidiaries

Consent of Independent 
Registered Public Accounting 
Firm

Certification of Chief 
Executive Officer pursuant to 
Section 302 of the Sarbanes-
Oxley Act of 2002

Certification of Principal 
Financial Officer pursuant to 
Section 302 of the Sarbanes-
Oxley Act of 2002

Certification of Chief 
Executive Officer to Section 
906 of the Sarbanes-Oxley 
Act of 2002

Certification of Principal 
Financial Officer pursuant to 
Section 906 of the Sarbanes-
Oxley Act of 2002

Exhibit
Number

10.1

10.2

Incorporated by Reference

Filing

Filing Date

File No.

Filed Herewith

8-K

8-K

June 1, 2018

001-34207

June 1, 2018

001-34207

10.3

8-K

June 1, 2018

001-34207

10.1

10-Q

November 6, 
2018

001-34207

X

X

X

X

X

X

XBRL Instance Document

EX—101.INS
EX—101.SCH XBRL Taxonomy Extension Schema Document
EX—101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
EX—101.DEF XBRL Taxonomy Extension Definition Linkbase
EX—101.LAB XBRL Taxonomy Extension Labels Linkbase Document
EX—101.PRE XBRL Taxonomy Extension Presentation Linkbase Document

†

+
*

We have been granted confidential treatment with respect to certain portions of this agreement. Omitted portions have 
been filed separately with the Securities and Exchange Commission. 
Indicates management contract, compensatory plan or arrangement. 
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K, are not 
deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing 
of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended 
(whether made before or after the date of this Form 10-K), irrespective of any general incorporation language contained 
in such filing.

89

 
ITEM 16.

FORM 10-K SUMMARY

None.

90

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has caused 

this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Berkeley, State of 
California. 

SIGNATURES 

Date: February 27, 2019 

Date: February 27, 2019

Date: February 27, 2019

DYNAVAX TECHNOLOGIES CORPORATION
By: 

/s/ EDDIE GRAY 
Eddie Gray
Chief Executive Officer
(Principal Executive Officer)

By: 

/s/ MICHAEL OSTRACH 
Michael Ostrach
Chief Financial Officer
(Principal Financial Officer)

By: 

/s/ DAVID JOHNSON 
David Johnson
Vice President, Chief Accounting Officer
(Principal Accounting Officer)

91

 
 
 
 
 
 
 
 
 
Signature

Title

Date

/s/ EDDIE GRAY
Eddie Gray

Chief Executive Officer
(Principal Executive Officer)

/s/ MICHAEL OSTRACH
Michael Ostrach

Chief Financial Officer
(Principal Financial Officer)

/s/ DAVID JOHNSON
David Johnson

Vice President, Chief Accounting 
Officer
(Principal Accounting Officer)

February 27, 2019

February 27, 2019

February 27, 2019

/s/ ARNOLD L. ORONSKY, PH.D.   
Arnold L. Oronsky, Ph.D.

/s/ LAURA BREGE   
Laura Brege

/s/ FRANCIS R. CANO, PH.D.   
Francis R. Cano, Ph.D.

/s/ DENNIS A. CARSON, M.D.
Dennis A. Carson, M.D.

Daniel L. Kisner, M.D.

/s/ PEGGY V. PHILLIPS
Peggy V. Phillips

/s/ NATALE S. RICCIARDI
Natale S. Ricciardi

Chairman of the Board

February 27, 2019

February 27, 2019

February 27, 2019

February 27, 2019

February 27, 2019

February 27, 2019

Director

Director

Director

Director

Director

Director

92

 
 
BOARD OF DIRECTORS

MANAGEMENT

CORPORATE HEADQUARTERS

Arnold L. Oronsky, Ph.D.
Chairman of the Board
General Partner
InterWest Partners

Laura Brege
Former President and Chief
Executive Officer
Nodality, Inc.

Francis R. Cano, Ph.D.
President and Co-Founder
Cano Biotech Corporation

Dennis A. Carson, M.D.
Former Director, Moores UCSD
Cancer Center
Professor, Department of Medicine
University of California, San Diego

Daniel L. Kisner, M.D.
Former Partner
Aberdare Ventures

Peggy V. Phillips
Former Chief Operating Officer
Immunex Corporation

Natale Ricciardi
Former Senior Vice President
Pfizer, Inc.

Eddie Gray
Chief Executive Officer and
Director

Michael S. Ostrach
Senior Vice President,
Chief Financial Officer and Chief
Business Officer

Robert L. Coffman, Ph.D.
Senior Vice President,
Chief Scientific Officer

Jeff Coon
Senior Vice President
Human Resources,
Corporate Services

Steven N. Gersten
Vice President, General Counsel
and Chief Ethics and Compliance
Officer

Robert Janssen, M.D.
Chief Medical Officer and
Senior Vice President, Clinical
Development, Medical and
Regulatory Affairs

David Johnson
Vice President,
Chief Accounting Officer

David Novack
Senior Vice President,
Operations and Quality

Dynavax Technologies Corporation
2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
U.S.A.
Tel: 510-848-5100
Fax: 510-848-1327
E-mail: contact@dynavax.com
www.dynavax.com

EUROPEAN OPERATIONS

Dynavax GmbH
Eichsfelder Str. 11
40595 Düsseldorf
Germany
Tel: +49 (0) 211 7 58 45 0

CORPORATE COUNSEL

Cooley LLP
Palo Alto, CA

TRANSFER AGENT

Computershare Inc.
P.O. Box 43070
Providence, RI 02940-3070

or

250 Royall Street
Canton, MA 02021
Tel: 800-522-6645

TDD for Hearing Impaired:
800-231-5469
Outside of the U.S.: 201-680-6578

TDD Outside of the U.S.:
201-680-6610

www.computershare.com

INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM

Ernst & Young LLP
San Francisco, CA

STOCK INFORMATION

The common stock of the company
is traded on the NASDAQ Capital
Market under the symbol DVAX